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Chapter 1
5-HT receptor classification
1.1 Events leading to the Bradley et al.(1986) 5-HT receptor classification
The presence of a vasoconstrictor substance in blood was suspected for 130 years
(Ludwig & Schmidt, 1868) and, 50 years ago, Page and associates at the Cleveland
Clinic (Cleveland, Ohio, USA) succeeded in isolating 'serotonin' from the blood
(Rapport et al., 1948).  Within the next 3 years, the chemical structure of serotonin
was deduced (Rapport, 1949) and 5-HT (5-hydroxytryptamine; for other abbreviations
see Section 16.4) synthesised (Hamlin & Fischer, 1951; Speeter t al., 1951).
Independently, during the 1930s and 40s, Erspamer and colleagues (Rome, Italy), who
were interested in characterising the substance imparting characteristic histochemical
properties to the enterochromaffin cells of the gastrointestinal mucosa, extracted a
basic gut-stimulating factor and named it "enteramine" (Erspam r, 1954).  The
chemical identity of enteramine with the natural and synthetic serotonin
(Erspamer & Asero, 1952) was soon backed by the similarity of pharmacological
profile (contraction of sheep carotid artery, guinea-pig, mouse and rabbit jejunum, rat
and cat uterus and cat nictitating membrane, triphasic blood pressure response and
antagonism by yohimbine and potentiation by cocaine of the sheep carotid artery
contraction) (Erspamer, 1954; Page, 1954).  Thus, the scene was set for the
characterisation of 5-HT receptors.
In 1957, using the guinea-pig isolated ileum, Gaddum and Picarelli (1957)
suggested that the 5-HT-induced contraction was mediated by two different receptors:
a neurotropic "M" receptor located on parasympathetic ganglia (effect blocked by
morphine and atropine) and a musculotropic "D" receptor located on smooth muscles
(effect blocked by dibenzyline, lysergide, 2-bromolysergide and dihydroergotamine).
This classification served well for three decades, although, from time to time, it was
reported that some 5-HT-induced effects, for example, the vasoconstriction in the
canine carotid arterial bed, were not mediated by "M" or "D", but by "special"
receptors (Saxena et al., 1971; Saxena, 1972), at which methysergide appeared to
behave as a partial agonist (Saxena, 1974b).
In 1974, Bennett and Aghajanian (1974)reported the first successful
radioligand binding study of 5-HT receptors using [3H]lysergide.  Further studies with
[3H]5-HT, [3H]spiperone and [3H]lysergide enabled Peroutka and Snyder (1979) to
5-HT receptor classification
12
identify two "receptors", named 5-HT1 (nM affinity for 5-HT) and 5-HT2 (nM affinity
for spiperone, but µM affinity for 5-HT); lysergide had high (nM) affinities for both.
Subsequently, 5-HT1 "receptors" (recognition sites) were subdivided into 5-HT1A and
5-HT1B subtypes on the basis of spiperone exhibiting a high and low affinity,
respectively (Pedigo et al., 1981), and 8-OH-DPAT was designated as a selective
5-HT1A ligand (Gozlan et al., 1983; Middlemiss & Fozard, 1983).   However, the most
important tool for probing 5-HT1 "receptors" proved to be 5-CT, identified by Feniuk
et al. (1981).  It was reported that 5-CT, which potently contracted the dog saphenous
vein (Feniuk et al., 1981) and inhibited noradrenaline and 5-HT release from
sympathetic and central serotonergic neurons, respectively (Feniuk et a ., 1981;
Engel et al., 1983), displayed a nM affinity for the 5-HT1 recognition sites
(Engel et al., 1983).  Furthermore, it was shown that several 5-CT-induced responses
were blocked by methiothepin and methysergide, but not by ketanserin, including
relaxation of smooth muscle (Feniuk et al., 1984), contraction of dog saphenous vein
(Feniuk et al., 1985), long-lasting hypotension in the rat (Saxena& Lawang, 1985;
Martin et al., 1987), dilatation of arterioles and contraction of arteriovenous
anastomoses in the porcine carotid bed (Saxena & Verdouw, 1985a) and tachycardia
in the cat (Saxena et al., 1985b).  These responses, thus, became associated with
5-HT1 recognition sites.
Since the 5-HT receptors were being referred to by various names ("D", "M",
5-HT1, 5-HT2, S1, S2 and others), the need for a uniform terminology was advocated
(Humphrey, 1983; Verdouw et al., 1984b).  Indeed, after several protracted but
stimulating deliberations that were aided by the synthesis of several new 5-HT-
selective agents, including neuronal "M" 5-HT receptor antagonists, MDL72222
(Fozard, 1984a) nd ICS205930 (tropisetron) (Richardson et al., 1985), it was agreed
to merge "M" and "D" (Gaddum & Picarelli, 1957) and 5-HT1 and 5-HT2
(Peroutka & Snyder, 1979) classifications.  This effort culminated in the Bradley tal.
(1986) publication, classifying 5-HT receptors as follows:  "5-HT1-like" (equivalent to
some "D" or 5-HT1), 5-HT2 (equivalent to most "D" or 5-HT2) and 5-HT3 (equivalent
to "M") receptors.  The authors clearly pointed out that this classification was meant
to be a "general framework", which will have to be regularly updated, as new
knowledge emerges.
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1.2 NC-IUPHAR Classification (1994)
In 1994, the NC-IUPHAR (Serotonin Receptor Nomenclature Committee of the
International Union of Pharmacology) reclassified 5-HT receptors into 5-HT1
("5-HT1-like", 5-HT1A, 5-HT1B, 5-HT1D, 5-ht1E and 5-ht1F), 5-HT2 (5-HT2A, 5-HT2B
and 5-HT2C), 5-HT3, 5-HT4, recombinant (5-ht5A/5B, 5-ht6, 5-ht7) and "orphan"
receptors (Hoyer et al., 1994).  This new classification was, besides the operational
characteristics (selective agonists and antagonists and ligand binding affinities), also
based on structural (molecular structure) and transductional (intracellular transduction
mechanisms) data as additional criteria.  To distinguish recombinant receptors from
native, functional receptors in whole tissues, lower case letters are used to identify
recombinant receptors (Hoyer et al., 1994).  This new classification has been updated
several times, when new information became available (Hartig et al., 1996;
Hoyer & Martin, 1997; Saxena t al., 1998b).  The 5-HT receptor classification
described below is based on these criteria for classification (see Table 1.1).
1.3 5-HT1 receptors
According to the Hoyer et al. (1994) classification scheme, all 5-HT1 receptors are by
definition negatively coupled to adenylyl cyclase and should be amenable to the
agonist action of sumatriptan.  This signal transduction system is usually associated
with contraction of smooth muscle (Randet al., 1987) and decrease in
neurotransmitter release (Langer, 1980).  At the time of the Hoyer et al. (1994)
classification, 6 subtypes were described, namely 5-HT1-like, 5-HT1A, 5-HT1B,
5-HT1D, 5-ht1E and 5-ht1F.  The 5-HT1C receptor was renamed 5-HT2C, based on
operational transductional and structural criteria (Figur 1.1; Hoyer et al., 1994).  In
view of the rather low affinity displayed by 5-CT at -ht1E and 5-ht1F receptors, the
characteristic of 5-CT being more potent than 5-HT seems no longer appropriate for
all 5-HT1 receptors.  The 5-HT1 receptor subtypes, with the exception of the
5-HT1-like receptor, have all been cloned.
5-HT receptor classification
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Table 1.1 Classification of 5-HT receptors.  For details and references, see text.
5-HT1A 5-HT1B rodent 5-HT1B 5-HT1D
Previous names- 5-HT1-like
5-HT1X
5-HT1Db
5-HT1B 5-HT1-like
5-HT1X
5-HT1Da
Selective
agonists
8-OH-DPAT
Flesinoxan
Sumatriptan CP93129 Sumatriptan
PNU109291
Selective
antagonists
WAY100635 GR127935
SB224289
GR127935
cyanopindolol
GR127935
BRL15572
Transductional
properties
Inhibition
adenylyl cyclase
Inhibition
adenylyl cyclase
Inhibition
adenylyl cyclase
Inhibition
adenylyl cyclase
Some
Responses
Behavioural
changes,
Central
hypotension
Vasoconstriction
Trigeminal
inhibition
Vasoconstriction
Auto/heterore-
ceptor
Inhibition
noradrenaline
release in human
atrium
5-HT2B 5-HT2C 5-HT3 5-HT4
Previous names5-HT2F 5-HT1C M -
Selective
agonists
BW723C86 RO600175 SR57227
m-chlorophe-
nylbiguanide
Cisapride
BIMU8
Selective
antagonists
SB204741 SB242084
RS102221
MDL72222
Ondansetron
GR113808
SB204070
Transductional
properties
Induction
inositol
phosphates
Induction
inositol
phosphates
Cation channel
opening
Stimulation
adenylyl cyclase
Some
Responses
Constriction rat
stomach fundus
Endothelium-
dependent
vasorelaxation
Regulation CSF
composition
Rat penile
erection
Neuronal
depolarisation
(e.g. von
Bezold-Jarisch
reflex)
Porcine and
human
tachycardia
Gastrokinetic
action
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Table 1.1 Continued
5-ht1E 5-HT1F 5-HT2A
Previous names- - D
5-HT2
Selective
agonists
- LY344864
LY344370
-
Selective
antagonists
- - Ketanserin
MDL100907
Transductional
properties
Inhibition
adenylyl cyclase
Inhibition
adenylyl cyclase
Induction
inositol
phosphates
Some
Responses
- Trigeminal
inhibition
Vasoconstriction
Platelet
aggregation
5-ht5A 5-ht5B 5-ht6 5-HT7
Previous names- - - 5-HT1-like
5-HT1Y
"orphan"
Selective
agonists
- - - -
Selective
antagonists
- - RO046790
RO630563
SB258719
Transductional
properties
Inhibition
adenylyl
cyclase??
- Stimulation
adenylyl cyclase
Stimulation
adenylyl cyclase
Some
Responses
- - - Vasodilatation
Feline
tachycardia
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1.3.1 5-HT1-like receptor
As described above, according to the Bradley et l. (1986) classification 5-HT
receptors were classified into three main types, namely “5-HT1-like”, -HT2 and
5-HT3.  At that time, the term “5-HT1-like” receptors was meant to be associated with
all 5-HT1 recognition sites and encompassed a broad spectrum of receptors mediating
several responses.  The operational criteria for this 5-HT1-like receptor were (i) more
potent stimulation by 5-CT than 5-HT; (ii) blockade by methiothepin and
methysergide; and (iii) resistance to blockade by selective antagonists at 5-HT2 a d
5-HT3 receptors.
It was however already recognised by Bradley et al. (1986) that the
5-HT1-like receptors were a heterogeneous group of receptors.  Indeed, with the
availability of selective ligands, several subclasses were identified, namely 5-HT1A,
5-HT1B, 5-HT1C and 5-HT1D (see Figure 1.1).  Thus, the appellation “5-HT1-like”
effectively became restricted to the remaining functional receptors (mediating
contraction or relaxation of vascular and non-vascular smooth muscle, sympathetic
neuroinhibition and feline tachycardia) and which met operational criteria for
admission into this class, but which could not be equated to the aforementioned 5-HT1
subtypes (Leff et al., 1987; Martin et al., 1987; Saxena & Ferrari, 1989;
Feniuk & Humphrey, 1990; Saxena & Villalón, 1990).    With continuing evaluation,
it became apparent that these receptors were still heterogeneous, since 5-CT was
consistently 10-100 times less potent on “5-HT1-like” receptors mediating vascular
contraction and sympathetic neuroinhibition than on “5-HT1-like” receptors mediating
vascular relaxation and tachycardia in the cat (Feniuk & Humphrey, 1990).  More
definitive pharmacological distinction was made with the introduction of sumatriptan,
which was at that time regarded as a selective “5-HT1-like” receptor agonist
(Humphrey et al., 1988; 1990).  It turned out that sumatriptan only stimulated those
“5-HT1-like” receptors mediating vascular contraction and sympathoinhibition, but
not those mediating vasodilatation.  The two types of “5-HT1-like” receptors were
therefore arbitrarily coined 5-HT1X to denote the "proconstrictor" receptor and 5-HT1Y
to denote the "prodilator" receptor (see Figure 1.1; Saxena & Ferrari, 1989;
Saxena & Villalón, 1990).  This operational differentiation was later reinforced by the
demonstration that the so-called 5-HT1X receptor was negatively coupled to adenylyl
cyclase (Sumner & Humphrey, 1990), while the so-called 5-HT1Y receptor was
positively coupled (Sumner et al., 1989, see Figure 1.1).  In 1994, the Serotonin
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Receptor Nomenclature Committee of the IUPHAR decided that the term
"5-HT1-like" should be restricted to the sumatriptan-sensitive (5HT1X) receptor, while
the sumatriptan-insensitive (5-HT1Y) receptor was transferred to the "orphan" category
(see Figure 1.1; Hoyer et al., 1994).
It is noteworthy that the high affinity of sumatriptan for 5-HT1D recognition
sites suggested that the sumatriptan-induced vasoconstriction was mediated by
5-HT1-like receptors resembling the 5-HT1D subtype (Martin, 1994).  The
NC-IUPHAR classification scheme also recognised the above similarity, yet this
5-HT1-like receptor remained a distinct entity (Hoyer etal., 1994).  The main reason
for this distinction was that metergoline, regarded as a potent 5-HT1D rec p or ligand,
was less active as an antagonist in v tro (e.g. canine, human and rabbit saphenous
vein, human pial artery and rabbit renal and cerebral arteries; Deckert t al., 1994;
Hoyer et al., 1994) and in vivo (porcine cranial arteriovenous anastomoses and canine
carotid vascular bed; Den Boer et al., 1992b; Villalón et al., 1995c) than methiothepin
or could be expected by metergoline’s affinity at the then defined 5-HT1D recognition
sites.  However, the experimental conditions used to detect 5-HT1D recognition sites
(Waeber et al., 1988) may have allowed the inclusion of, at the time unknown, 5-ht1E,
5-ht1F and 5-ht7 recognition sites.  Additionally, molecular biology studies
demonstrated the existence of two different 5-HT1D receptors, which were named
5-HT1Da and 5-HT1Db receptor (see Figure 1.1; Weinshank et al., 1992).  Moreover,
metergoline interacts with a wide variety of 5-HT receptors (see Table 10.2), displays
intrinsic efficacy at recombinant 5-HT1D receptors (Schoeffter et al., 1988;
Walsh et al., 1995) and shows variable affinity for 5-HT1D recognition sites in
different species (Waeber et al., 1988).  Thus, there was a clear need for subtype-
selective 5-HT1 receptor antagonists.  Indeed, as will be described below several
selective ligands were developed.
Apart from the implications discussed below and in the rest of this th is, it
turned out that the group of "5-HT1-like receptors", as proposed originally by Bradley
et al. (1986), consists of at least three structurally distinct receptors, the 5-HT1B,
5-HT1D and 5-HT7 receptors.  Consequently, the term "5-HT1-like receptor" has now
become redundant (see Figure1.1).
5-HT receptor classification
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Figure 1.1 The evolution of "5-HT1-like" receptors into the different sumatriptan-
sensitive 5-HT1 receptor subtypes and the sumatriptan-insensitive 5-HT7 receptor.  For
references and further explanations, see text.
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Table 1.2 Pharmacological tools to discriminate the different 5-HT1 ceptor subtypes.
5-HT1A 5-HT1B Rat
5-HT1B
5-HT1D 5-ht1E 5-HT1F
Agonists:
5-HT 9.2a 8.5b 8.6b 8.4c 8.0d 8.0d
8-OH-DPAT 8.7 (pig)e 6.6b 5.1b 7.4f 5.5d 5.8d
5-CT 10.3a 8.8b 8.9b 9.2c 5.1d 6.1d
Sumatriptan 6.4g 7.8g 7.3b 8.5g 5.8g 7.9g
L775606 7.3h 7.1h 6.1b 9.2h <5.0h 5.4h
PNU109291 6.0i 5.2i - 9.0i - -
LY344864 6.3j 6.3j - 6.2j 5.8j 8.2j
LY334370 7.8k 6.9l - 6.9l - 8.8l
CP93129 5.5 (rat)m 6.4b 8.1b 5.7 (rat)m - -
CP122288 6.5n 8.3b 6.8b 8.2n 6.4n 8.5n
Antagonists:
GR127935 7.2o 9.0o 8.8b 8.6o 5.4o 6.4o
SB224289 5.5p 8.0p - 6.2p <5.0p <5.0p
BRL15572 7.7o 6.1o - 7.9o 5.2o 6.0o
Ketanserin 5.5q 5.3r <5.1b 7.2r <5.0d <5.0d
Methiothepin 7.7q 7.6b 7.2b 7.7f 6.7d 6.2d
Metergoline 8.1 (pig)e 8.6b 8.3b 8.7f - 6.5d
Cyanopindolol 8.3 (pig)e 7.0b 9.0b - - -
(-)-Propranolol 6.8 (pig)e 5.6b 7.7b - - -
(-)-Pindolol 7.7 (pig)e <5.1b 7.6b - <5.0d <5.0d
All data are given as pKi values at human receptors, except when stated otherwise.  Data from:
a, Newman-Tancredi t al. (1997); b, Beer et al. (1998); c, Weinshank etal. (1992); d, Adham
et al. (1993); e, Hoyer, (1989); f, Pauwels et al. (1996); g, Leysen, et al. (1996); h, MacLeod
et al. (1997), values given as pIC50; i, Ennis et al. (1998); j, Phebus, et al. (1997); k, Dupuis
et al. (1998); l, Johnson et al. (1997); m, Macor et al. (1990); n, Gupta, P. (personal
communication); o, Price et al. (1997); p, Hagan et al. (1997); q, Pauwels, P.J. (personal
communication); r, Zgombick etal. (1995).
1.3.2 5-HT1A receptor
The 5-HT1A receptor site, first described by Pedigo et al. (1981), has been cloned in
several species, including human (Farginet al., 1988) and rat (Albert et al., 1990).
High densities of the 5-HT1A receptor are found in the brain, mainly in areas involved
in the modulation of emotion (see Hoyer t al., 1994).  In keeping with this, activation
5-HT receptor classification
20
of 5-HT1A receptors induces a wide variety of behavioural changes (see Hoy r t al.,
1994).  The 5-HT1A receptor is an autoreceptor, but also seems to be involved in the
central inhibition of noradrenaline release, responsible for the centrally evoked
hypotension by 5-HT1A receptor agonists (Doods et al., 1988; Dreteler et al., 1990).
5-HT1A receptors have not been detected in blood vessels (Ullmer et al., 1995).
Several selective 5-HT1A receptor agonists are available, such as 8-OH-DPAT,
flesinoxan, 5-methylurapidil, buspirone, although it should be noted that 8-OH-DPAT
also shows moderate affinity for 5-HT1B/1D receptors (see Table 1.2).  WAY100635 is
a potent and selective 5-HT1A receptor antagonist (Fletcher et al., 1996;
Hoyer & Martin, 1997).
1.3.3 5-HT1B receptor
Until recently, the 5-HT1B receptor referred to the binding site found only in rodent
brain (Pazos & Palacios, 1985; Hoyer et al., 1994).  This rodent 5-HT1B receptor was
shown to function as auto- and heteroreceptor, mediate vasoconstriction of the rat
caudal artery (Craig & Martin, 1993) and inhibit the release of noradrenaline from
sympathetic nerve terminals in the rat vena cava (Göthert et l., 1986).  In the mean
time, Weinshank et al. (1992) identified two structurally distinct genes encoding
human 5-HT1 receptors with pharmacological profiles most closely resembling the
5-HT1D receptor.  Since the operational profiles of these two new receptors were
mostly indistinguishable, they were called 5-HT1Da and 5-HT1Db.   It soon became
evident that, in spite of fundamental differences in their pharmacology (see below),
the 5-HT1Db receptor was a human homologue of the rodent 5-HT1B receptor
(Hoyer et al., 1994).  This prompted an important realignment of 5-HT receptor
nomenclature that now recognises primacy of human genome (Hartig et al., 1996).
Consequently, the 5-HT1Db receptor was renamed 5-HT1B (subsuming the rodent
5-HT1B receptor), while the 5-HT1Da nomenclature was abandoned in recognition of
the fact that this gene product encodes the 5-HT1D receptor (see Figure 1.1;
Hartig et al., 1996).  This new nomenclature for 5-HT1B and 5-HT1D receptors will be
used from this point onwards.
As described in section 1.3.1, the 5-HT1-like receptor mediating smooth
muscle contraction and inhibition of noradrenaline release showed close similarities to
the 5-HT1B and/or 5-HT1D receptors.  However, the lack of selective antagonists at the
5-HT1B/1D receptor hampered further research.  Clitherow et al. (1994) reported the
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properties of several compounds including a piperazinylbenzanilide derivative,
GR127935, which showed a high affinity for and selective antagonist activity at
5-HT1B/1D receptors (see Table 1.2).  Subsequently, Skingle et a . (1996) showed that
GR127935 potently blocked several responses elicited by sumatriptan-sensitive
5-HT1-like receptors, including: (i) contractile effects in the dog saphenous vein and
basilar artery; (ii) prejunctional sympathoinhibition in the dog saphenous vein; (iii)
(auto)inhibition of 5-HT release from slices of guinea-pig hippocampus and dorsal
raphé nucleus and (iv) hypothermic and rotational responses in the guinea-pig.
Further studies demonstrated that GR127935 potently blocked sumatriptan-induced
contractions in several blood vessels, both in vitro (see Pauwels, 1996) and in vivo
(Villalón et al., 1996).   These findings, coupled to the lack of blocking properties of
GR127935 at other 5-HT receptors, including the "orphan" receptor mediating smooth
muscle relaxation, 5-HT3 and 5-HT4 receptors (except 5-HT2A) in several preparations
(see Chapter 3), clearly reinforced the view that sumatriptan-sensitive 5-HT1-like
receptors are similar to 5-HT1B/1D receptors subtype (Figure 1.1).  Indeed, as will
discussed in this thesis, the 5-HT1-like receptor mediating vasoconstriction of the
carotid vasculature in rabbits (Chapter 3) and pigs (Chapters 4 and 6), as well as the
inhibition of sympathetic vasopressor outflow in the rat (Chapter13) were also shown
to be GR127935-sensitive.  Unfortunately, GR127935 was not capable of
distinguishing between the 5-HT1B and 5-HT1D receptor (see Table 1.2).  However,
mRNA for the 5-HT1B receptor was shown to be much more abundantly expressed on
vascular smooth muscle cells, compared to 5-HT1D receptor mRNA (Branchek et al.,
1995; Bouchelet et al., 1996; Sgard et al., 1996).  The latter was reinforced by the
demonstration of 5-HT1B, but not 5-HT1D receptor immunoreactivity in cranial blood
vessels (Longmore t al., 1997).  As described in Chapters 8 and 9, as well as by
Verheggen etal. (1998) in the isolated human temporal artery, using the recently
developed, potent and selective antagonists at either the 5-HT1B (SB224289;
Hagan et al., 1997; Gaster et al., 1998) or 5-HT1D (BRL15572; Price et al., 1997)
receptors (Table 1.2), there is now overwhelming evidence that the 5-HT1B, but not
the 5-HT1D receptor mediates the sumatriptan-induced contraction of vascular smooth
muscle.
It is important to note that, despite the 96% amino acid sequence homology in
the transmembrane regions (Adham et al., 1992), the rodent 5-HT1B receptor displays
a distinct pharmacology compared to the 5-HT1B receptor in other species
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(Hartig et al., 1996).  Thus, CP93129 is a selective agonist, whereas some
b-adrenoceptor antagonists, such as cyanopindolol, (-)-pind lol and (-)-propranolol,
are selective antagonists at the rodent 5-HT1B receptor, but not in other species (see
Table 1.2).
1.3.4 5-HT1D receptor
As shown in Table 1.2, the 5-HT1D receptor (previously called 5-HT1Da, see above) is
potently antagonised by GR127935 (Clitherow et al., 1994; Skingle et al., 1996) and
by the selective 5-HT1D receptor antagonist, BRL15572 (Priceet al., 1997).
Additionally, some 5-HT2 receptor antagonists (ketanserin and ritanserin) can
discriminate this receptor from 5-HT1B and 5-HT1F receptors (Hoyer et al., 1994),
although this is highly species dependent.  Indeed, whereas ketanserin shows a
selectivity for the 5-HT1D over the 5-HT1B receptor in the rabbit (20-fold; Bard et al.,
1996) and human (70-fold; Zgombick et al., 1995), this selectivity is absent in the dog
(Branchek et al., 1995) and guinea-pig (Zgombick et al., 1997).  In contrast to the
rodent 5-HT1B receptor (see above), the rodent 5-HT1D receptor displays similar
pharmacology compared to the 5-HT1D receptor found in other species (Hartig et al.,
1996; Saxena et al., 1998b).  Sumatriptan and the second-generation triptans (see
Chapter 2) are potent agonists at this receptor, but also interact with 5-HT1B and
5-HT1F receptors.  Some recently developed compounds, including PNU109291
(Ennis et al., 1998) and L775606 (MacLeod et al., 1997), have been reported to be
selective 5-HT1D receptor agonists (see Table1.2).  It has been demonstrated that the
5-HT1D receptor is located preferentially on neuronal, rather than vascular tissue
(Ullmer et al., 1995; Sgard et al., 1996; Longmore et al., 1997).  Operationally,
5-HT1D receptors mediate inhibition of noradrenaline release in human atrium
(Schlicker et al., 1997).  Additionally, the 5-HT1D receptor seems to be involved in the
inhibition of guinea-pig dural plasma protein extravasation (Waeber et al., 1997;
Ennis et al., 1998) and the central trigeminal inhibitory effects by some antimigraine
compounds (see Chapter 2; Mills et al., 1995; Goadsby & Knight, 1997;
Cumberbatch et al., 1998).
1.3.5 5-ht1E receptor
Little information is available on the 5-h1E receptor.  The receptor was cloned by
McAllister et al. (1992) and seems to be present in several brain regions, as
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demonstrated by homogenate-binding (Lowtheret al., 1992; Miller & Teitler, 1992)
and receptor mRNA localisation (Bruinvels et al., 1994) studies.  The 5-ht1E receptor
is not present in blood vessels (Ullmer et al., 1995).  In contrast to the other 5-HT1
subtypes, sumatriptan displays a very low affinity and, moreover, 5-CT sh ws little
interaction with the 5-ht1E receptor.  No selective agonists or antagonists are available
and there is no evidence for a physiological role for 5-ht1E receptors (Hoyer et al.,
1994; Hoyer & Martin, 1997).
1.3.6 5-HT1F receptor
The 5-HT1F receptor can be distinguished from the 5-HT1B and 5-HT1D receptors using
the potent 5-HT1F receptor agonists, LY344864 (Phebus et al., 1997) and LY334370
(Johnson et al., 1997).  Additionally, most triptans stimulate 5-HT1F receptors,
although rizatriptan (Wainscott et al., 1998) and the non-i dole compound alniditan
(Leysen et al., 1996) display low affinities (see also Table 2.2); interestingly, as will
be described in Chapter 2, the latter two drugs are at least as effective as sumatriptan
in the treatment of migraine (Goldstein et al., 1996; Kramer et al., 1998).  Presently,
no selective 5-HT1F receptor antagonists are available.  5-HT1F receptor mRNA and
the corresponding protein is preferentially expressed in the neuronal tissue rather than
vascular smooth muscle (Ullmer et al., 1995; Bouchelet et al., 1996).  Accordingly,
5-HT1F receptor agonists are devoid of vasoconstrictor properties (see Chapter 7;
Cohen et al., 1998; Bouchelet & Hamel, 1999).  The 5-HT1F receptor seems to
mediate inhibition of dural plasma protein extravasation following trigeminal ganglion
stimulation (Johnson et al., 1997; Phebus et al., 1997).  More recently, it was
demonstrated in rats that 5-HT1F receptor stimulation by LY344864 decreased the
number of capsaicin-induced C-fos-like immunoreactive cells within trigeminal
nucleus caudalis (Mitsikostas et al., 1999).  In view of the demonstration of these
functional correlates, it seems that the upper case appellation is appropriate for the
5-HT1F receptor (Figure 1.1).
1.4 5-HT2 receptors
Three different 5-HT2 receptor subtypes are known, namely 5-HT2A, 5-HT2B and
5-HT2C, which have all been cloned (Hoyer et al., 1994).  Transductionally, these
three receptors are coupled to phospholipase C, which after activation leads to the
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conversion of PIP2 into IP3 and DAG.  Ultimately, this will result in the release of
Ca2+ from the sarcoplasmatic reticulum and activation of protein kinase C.
1.4.1 5-HT2A receptor
The 5-HT2A receptor mediates contractile responses in several, mainly peripheral,
vascular and non-vascular smooth muscle preparations.  Additionally, platelet
aggregation, increased vascular permeability and several centrally mediated responses
are mediated by this receptor (Baxteret al., 1994; Hoyer t al., 1994).  No selective
5-HT2A receptor agonists are available, but ketanserin, spiperone and MDL100907
(Sorensen et al., 1993) are quite potent and selective antagonists at the 5-HT2A
receptor (Baxter et al., 1995).  DOI and a-methyl-5-HT are potent agonists, but
cannot discriminate between the three 5-HT2 r ceptor subtypes.  Similarly, ritanserin,
mianserin, metergoline, mesulergine and methiothepin are non-selective antagonists at
this receptor (see Table 10.2).
Some antimigraine drugs display affinity at 5-HT2A receptors (methysergide,
pizotifen, ergotamine, dihydroergotamine; Hoyer et al., 1994), but many other such
agents (ketanserin, cyproheptadine, mianserin, methiothepin) are not of much use in
migraine therapy (Tfelt-Hansen & Saxena, 1993).  Ketanserin is approved for the
treatment of systemic hypertension.  Indeed, it is claimed that this drug decreases
blood pressure by blocking 5-HT2A receptors mediating peripheral vasoconstriction.
However, as discussed in detail elsewhere (Sax na & Villalón, 1990), it seems that
this receptor is not involved to a significant degree in the clinical effects of the drug;
ketanserin also exhibits a potent a1-adrenoceptor antagonist activity, which can
adequately explain its antihypertensive effect.  In the complex setting of cardiac
surgery and cardiopulmonary bypass, several potent mediators are released which, in
turn, may produce systemic and/or pulmonary hypertension.  One of the mediators
may be 5-HT, released from aggregating platelets, causing vasoconstriction by
activating 5-HT2A receptors, particularly in patients with an impaired endothelial
function e.g. atherosclerosis (Reneman & Van Der Starre, 1990).  Ketanserin has also
proven effective in the treatment of postoperative pulmonary hypertension (Van Der
Starre & Reneman, 1994).  It is however far from clear whether 5-HT2A receptor
blockade is responsible for the effectiveness of ketanserin, since no selective 5-HT2
receptor antagonist has been proved to be effective.  Perhaps less questionable seems
to be the role of 5-HT2A receptors in some cases of portal hypertension, where higher
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levels of free plasma 5-HT are found in the portal venous circulation (Robertson,
1991); the above assumption is based on the fact that both ketanserin (which combines
5-HT2A with a1-adrenoceptor blockade) and ritanserin (at doses without
a1-adrenoceptor blockade) lower portal venous pressure (Lebrec, 1990).  Ketanserin
has been shown to be effective in the treatment of preeclampsia and eclampsia,
pathologies that seem to comprise local release of 5-HT from aggregating platelets in
the placental circulation (Weiner, 1990; Robertson, 1991).  Although this finding does
not establish the involvement of 5-HT2 receptors, establishing the effectiveness of
selective 5-HT2 receptor antagonists may substantiate this view.
1.4.2 5-HT2B receptor
With the exception of BW723C86 (Kennett et al., 1996a), no selective 5-HT2B
receptor agonists are available, although 5-MeO-T and a-methyl-5-HT can
moderately discriminate this receptor from the other 5-HT2 receptor subtypes
(Baxter et al., 1995); however, both compounds can interact with several other 5-HT
receptors (Hoyer et al., 1994).  SB204741 (Forbes et al., 1995) is a selective
antagonist at the 5-HT2B receptor (Baxter, 1996) and yohimbine, although able to
interact with several other receptors, also shows selectivity towards the 5-HT2B
receptor over the other two 5-HT2 receptor subtypes (Ellis et al., 1995).
The 5-HT2B receptor has been shown to mediate constriction of smooth
muscle in the rat stomach fundus; this receptor was originally named 5-HT2F
(Kursar et al., 1992).  Although at that time there was a lack of compounds
discriminating this receptor from the 5-HT2C receptor, the absence of 5-HT2C, but
presence of 5-HT2B receptor mRNA in the rat stomach fundus (Foguet et al., 1992)
resolved this issue.  The 5-HT2B receptor is also present on several blood vessels,
located on the endothelium (Ull er et al., 1995).  Activation of this endothelial
receptor has been suggested to result in the release of NO, which elicits a strong
vasorelaxant activity through activation of soluble guanylate cyclase (Ullmer et al.,
1995).  Indeed, such 5-HT2B receptor mediated endothelium-dependent vasorelaxant
responses have been described in the porcine pulmonary artery (Glusa & Roos, 1996)
and rat jugular vein (Ellis et al., 1995).  The contraction of longitudinal smooth
muscle in the human small intestine also exhibits a pharmacological profile
resembling the 5-HT2B receptor (Borman & Burleigh, 1995).
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It has been proposed that 5-HT2B/2C receptors are involved in the initiation of
migraine attacks (Fozard & Kalkman, 1994; Kalkman, 1994; Fozard, 1995).  Thus,
selective antagonism of these receptors, in particular the endothelial vasodilator
5-HT2B receptor, would be effective in migraine prophylaxis (Fozard & Kalkman,
1994; Kalkman, 1994; Fozard, 1995; Schmuck et al., 1996).  Indeed, the prophylactic
effect by the marketed drugs, pizotifen and methysergide, is claimed to involve
antagonism of the 5-HT2B receptor (Fozard, 1995).  Although the drugs are probably
effective, formal evidence is lacking (Ferrari, 1998).  Importantly, these compounds
are not selective within the 5-HT2 receptor family and methysergide is also able to
interact with 5-HT1 and 5-HT7 receptors.  Moreover, as already discussed elsewhere
(Tfelt-Hansen & Saxena, 1993; Hamel & Saxena, 1999), several 5-HT2B/2C receptor
antagonists, including mianserin and cyproheptadine, are not very effective
antimigraine agents.
1.4.3 5-HT2C receptor
RO600175 has been reported to be a selective 5-HT2C receptor agonist (Jenck et al.,
1998; Dekeyne et al., 1999); RS102221 (Bonhaus et al., 1997) and SB242084
(Bromidge t al., 1997; Kennett  al., 1997) are selective antagonists at this receptor.
Additionally, several compounds, such as SB206553 (Kennett etal., 1996b) with
antagonist properties at both 5-HT2B and 5-HT2C receptors are available.  The 5-HT2C
receptor is present in the choroid plexus and has been suggested to regulate the
composition and volume of the cerebrospinal fluid (Hoyer et al., 1994).  Moreover,
this receptor plays a role in anxiety disorders and several other psychiatric diseases
(Hoyer et al., 1994; Baxter et al., 1995).  Recently, the 5-HT2C receptor was shown to
mediate rat penile erections (Millan et al., 1997).  In contrast to the 5-HT2B receptor,
the 5-HT2C receptor is not expressed on blood vessels (Ullmer et al., 1995).
1.5 5-HT3 receptor
The 5-HT3 receptor is a ligand-gated ion channel, activation of which promotes entry
of Na+ and Ca2+ and hence neuronal depolarisation.  The receptor is localised in the
brain and in peripheral neuronal tissue (Hoyer tal., 1994).  Activation of the 5-HT3
receptor leads to bradycardia in the rat via depolarisation of cardiac afferent fibres of
the vagal nerve (Von Bezold-Jarisch reflex; see Chapter 3) and in the isolated rabbit
heart via the release of acetylcholine (Fozard, 1984b; Saxena & Villalón, 1990; 1991).
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In rabbits and dogs, 5-HT3 receptors mediate tachycardia (Saxena& Villalón, 1990;
1991).  Moreover, 5-HT3 receptors are involved in changes in intestinal tone and
secretion (Briejer et al., 1995), dermal pain and flare response (Hoy r et al., 1994).
Additionally, 5-HT3 receptors mediate the 5-HT-induced initial contraction of the
feline urinary bladder (see Chapter 3).  5-HT3 receptor antagonists are used clinically
to reduce chemotherapy-induced nausea and vomiting (Andrews et al., 1988;
Andrews & Bhandari, 1993; Gregory & Ettinger, 1998).
Some selective 5-HT3 receptor agonists have been described, such as
SR57227 (Bachy et al., 1993) and m-chlorophenylbiguanide (Hoyer et al., 1994).
Additionally, this receptor should n t be amenable to the agonist action of 5-MeO-T
(Hoyer et al., 1994).  Several potent and selective antagonists are available, including
MDL72222, granisetron, ondansetron (Hoyer et al., 1994); tropisetron also interacts
with 5-HT4 receptors.
Because no clear-cut positive antimigraine effect has been found with any of
the 5-HT3 receptor antagonists (Ferrari, 1991; Ferrari et al., 1991), this receptor does
not appear to play a major role in migraine.
1.6 5-HT4 receptor
The 5-HT4 receptor, which was cloned by Gerald et al. (1995), is coupled positively to
adenylyl cyclase.  Several splice variants have been described, which, however, are
until now pharmacologically indistinguishable (Gerald t al., 1995; Claeysen et al.,
1998).  The receptor is located in the brain (Egle et al., 1995), but also in the
gastrointestinal tract on neurones, smooth muscle and secretory cells (Hoyer et al.,
1994).  Indeed, several 5-HT4 receptor (partial) agonists have been marketed as
prokinetic drugs (Briejer et al., 1995).  Moreover, the receptor has been found in the
human and porcine cardiac atria, mediating tachycardia and positive inotropy in v tro
(Kaumann, 1990; Sanders & Kaumann, 1992) as well as in vivo (Villalón et al.,
1990b; 1991).  Since 5-HT can induce arrhythmias in the human isolated atrium, it is
proposed that 5-HT4 receptor antagonists could be useful in the treatment of cardiac
arrhythmias (Kaumann, 1994).  However, the role of 5-HT, if any, in the pathogenesis
of cardiac arrhythmias has not been established.  On the other hand, the increase in
atrial contractility by 5-HT4 receptor agonists indicated that these drugs might have
application in the therapy of heart failure.  Any such hope was dashed when it was
shown that 5-HT4 receptors are not present on human ventricles (Jahnel et al., 1992;
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Schoemaker t al., 1993).  The 5-HT4 receptor mRNA seems to be expressed on
vascular endothelium (Ullmer et al., 1995), but no 5-HT4 receptor-mediated
endothelium-dependent vasorelaxations have yet been described.  Interestingly, 5-HT4
receptors have been suggested to mediate endothelium-independent relaxation of the
isolated sheep pulmonary vein (Cocks & Arnold, 1992).
The 5-HT4 receptor is amenable to the agonist action of several compounds
(see Hoyer t al., 1994; Hoyer & Martin, 1997), including 5-MeO-T, substituted
benzamides, such as cisapride and metoclopramide, and BIMU8.  GR113808 and
SB204070 are potent and selective antagonists at this receptor (Hoyer et al., 1994;
Hoyer & Martin, 1997).
1.7 5-ht5 receptors
Two 5-ht5 receptors, 5-ht5A and 5-ht5B, have been cloned, which are pharmacologically
very similar.  The gene for the 5-ht5A receptor is found in mouse (Plassat et al., 1992),
rat (Erlander et al., 1993) and human (Rees et al., 1994) brain, whereas the 5-ht5B
receptor seems to be only present in mice and rats.  5-ht5 receptors have not been
detected in blood vessels (Ullmer et al., 1995).  5-ht5 receptors are the only class of
which little is known about the transductional properties.  Some evidence suggests
that the rat 5-ht5A receptor is negatively coupled to adenylyl cyclase (Carson et al.,
1996), but others have demonstrated that the (mouse) 5-ht5 receptor may not inhibit
adenylyl cyclase (Plassat et al., 1992).  Pharmacologically, 5-ht5 receptors display
several similarities with the 5-HT1 and 5-HT7 receptors.  Thus, 5-CT, ergotamine,
methysergide and methiothepin show high affinities at 5-ht5 recep ors (see Tables 10.1
and 10.2).  However, the structural characteristics, as well as the localisation of 5-ht5
receptors are different from these 5-HT receptor classes (Hoyer et al., 1994).
Moreover, sumatriptan displays low affinity at the 5-ht5 receptors.  No functional
correlate has been found for the 5-ht5 r ceptors and, hence, according to NC-IUPHAR
nomenclature guidelines (Hoyer et al., 1994; Hoyer & Martin, 1997), are written in
lowercase.
1.8 5-ht6 receptor
As recently reviewed by Sleight t al. (1998a), the 5-ht6 receptor has been cloned in
human (Kohen et al., 1996) and rat (Ruat et al., 1993a) and is localised in brain tissue;
5-ht6 receptor mRNA was not detected in blood vessels (Ullmer et al., 1995).  The
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5-ht6 receptor is, like the 5-HT4 and 5-HT7 receptor, positively coupled to adenylyl
cyclase (Ruat et al., 1993a; Schoeffter & Waeber, 1994).  The 5-ht6 receptor has been
suggested to be involved in several psychiatric disorders, because of its localisation in
specific brain areas and the high affinity of several antipsychotic drugs (e.g.
clozapine) displayed at this receptor (Sleight et al., 1998a).  However, because of the
lack of selective ligands, at this moment no functional correlate has been found.
Perhaps the recently developed, potent and selective antagonists, RO046790 and
RO630563 (Sleight et al., 1998b), will aid the full characterisation of this receptor.
The 5-ht6 receptor can be discerned from 5-HT1 receptors, as well as the 5-ht5 and
5-HT7 receptors by the low potency of 5-CT compared to 5-HT.  The 5-ht6 receptor is
resistant to blockade by antagonists at 5-HT2 (ketanserin), 5-HT3 (MDL72222) and
5-HT4 (tropisetron) receptors.  Moreover, mesulergine, an antagonist at 5-HT2 and
5-HT7 receptors, is devoid of interaction with 5-ht6 receptors (see Table 10.2).
1.9 5-HT7 receptor
As outlined in section 1.3.1, the appellation “5-HT1-like” was no longer regarded as
appropriate for the sumatriptan-insensitive 5-HT receptors mediating smooth muscle
relaxation and feline tachycardia.  Consequently, this receptor was transferred to the
list of "orphan" 5-HT receptors awaiting further characterisation (se  Figure 1.1;
Hoyer et al., 1994).  With the demonstration of novel recombinant receptors positively
linked to adenylyl cyclase (5-ht6 and 5-ht7), several investigators sought to determine
if the above responses mediated by "orphan" 5-HT receptors represented functional
correlates of these recombinant receptors.  One of the main obstacles that was
confronted in characterising these "orphan" receptors was that they also showed some
operational characteristics of the 5-HT1 receptor subtypes, namely, the rank order of
agonist potency of some tryptamines (5-CT>5-HT³5-MeO-T).  Fortunately, apart
from not being activated by sumatriptan, a remarkable characteristic of these receptors
is that they turned out to be resistant to the antagonist action of the 5-HT1B/1D receptor
antagonist, GR127935 (see Chapters 10-12; Terrón, 1996b; Villalón et al., 1997a).
Significantly, this pharmacological profile paralleled that reported at the cloned 5-h7
receptor, but differed from that at cloned 5-ht6 r ceptors (5-MeO-T>5-HT>5-CT).  In
agreement with these findings, methiothepin, methysergide, metergoline, mesulergine,
lisuride and clozapine, which show either high affinity (methiothepin, methysergide,
metergoline, lisuride and clozapine) or relative selectivity (mesulergine) for the cloned
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5-ht7 receptor, behaved as antagonists at the "orphan" receptors mediating relaxation
of smooth muscle (s e Chapter 10; Carter t al., 1995; Leung et al., 1996; Terrón,
1996b; Villalón et al., 1997a) and feline tachycardia (Chapter 12).  Of particular
importance is the fact that relatively low doses of mesulergine specifically
antagonised these responses, since mesulergine: (i) displays an almost 300-fold
selectivity for the cloned 5-ht7 receptor over the cloned 5-ht6 receptor; and (ii) does
not interact with the 5-HT1 receptor family.  These lines of evidence coupled to the
fact that mRNA for the putative 5-ht7 receptors, but not for 5-ht5 and 5-ht6 receptors,
has been detected in vascular smooth muscle (Ullmer et al., 1995; Schoeffter et al.,
1996), indicate that the "orphan" 5-HT receptors mediating direct smooth muscle
relaxation and tachycardia in the cat resemble recombinant 5-ht7 receptors
structurally, transductionally and operationally.  Indeed, this has been shown in
several preparations, such as guinea-pig il um (Carter et al., 1995), rabbit femoral
vein (Martin & Wilson, 1995), dog coronary artery (Terrón, 1996b), monkey jugular
vein (Leung et al., 1996), dog basilar artery (Terrón & Falcón-Neri, 1999), rabbit
pulmonary artery (Morecroft & MacLean, 1998) and the dog external carotid
vasculature (Villalón et al., 1997c).  Additionally, the 5-HT-induced late hypotensiv
response in rats and tachycardia in the cat were shown to be mediated by 5-ht7
receptors, as discussed in Chapters 10 and 12, respectively.  In view of the above, the
search for this "orphan" receptor has successfully ended and the upper case 5-HT7
receptor appellation is now clearly justified (Eglen etal., 1997; Hoyer & Martin,
1997; Saxena et al., 1998b).
Although the 5-HT7 receptor can be characterised using the above criteria, this
would be greatly facilitated by selective agonists and antagonists.  Unfortunately, no
selective agonists are as yet available, but SB258719 has been reported to be a
selective antagonists (Forbes et al., 1998; Thomas et al., 1998).
The 5-HT7 receptor has been cloned in several species, including human
(Bard et al., 1993), rat (Lovenberg et al., 1993; Ruat e al., 1993b; Shen t al., 1993),
mouse (Plassat et al., 1993) and guinea-pig (Tsou et al., 1994).  As described above
the receptor is abundantly expressed on vascular smooth muscle, but the 5-HT7
receptor is also widely distributed in the brain.  Thus, the 5-HT7 receptor has been
implicated in the regulation of the circadian rhythm (Lovenberget al., 1993),
depression (Sleight et al., 1995) and some psychiatric disorders (Roth et al., 1994).
Moreover, the 5-HT7 receptor is localised on cranial blood vessels and may play a role
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in cranial vasodilatation, thought to occur during migraine headache.  In favour of this
suggestion, lisuride (Herrmann et al., 1977; Somerville & Herrmann, 1978; Del
Bene et al., 1983) and methysergide (H rrmann et al., 1977; Silberstein, 1998) have
been reported to be of use in migraine prophylaxis (see also Section 14.6.3).  The
latter two compounds display high affinity at the 5-HT7 receptor, but, admittedly, they
are non-selective drugs.
1.10 Orphan 5-HT receptors
1.10.1 5-HT receptor mediating endothelium-dependent vasorelaxation
In several blood vessels 5-HT produces a relaxation dependent on the integrity of the
endothelium.  In most cases, the operational profile of the receptors involved does not
fulfil the current classification criteria.  In the case of the dog coronary artery the
receptor shows similarities with 5-HT1 receptors, since the response is antagonised by
methiothepin and metergoline, but not by ketanserin and MDL72222
(Houston & Vanhoutte, 1988).  A similar pharmacological profile is described in the
pig coronary artery (Schoeffter & Hoyer, 1989; Schoeffter & Hoyer, 1990) and
guinea-pig jugular vein (Gupta, 1992), where the endothelial vasorelaxant receptor
resembles the 5-HT1B/1D receptors, in view of the agonist activity of sumatriptan.
More recently, Razzaque et al. (1995), suggested that the endothelium-dependent
vasodilatation in the guinea-pig jugular vein is mediated by 5-HT1D receptors, in view
of the antagonist properties of GR127935 as well as ketanserin.  The use of SB224289
and BRL15572 may help resolve this issue.
In the rabbit jugular vein (Leffet al., 1987) and pig vena cava (Sumner,
1991), the receptor rather resembles 5-HT2B/2C receptors, since 5-CT displayed low,
while a-Me-5-HT high potency.  Moreover, ketanserin and MDL72222 were inactive,
whereas methiothepin and methysergide acted as antagonists.  A similar
pharmacological profile was demonstrated in the rat jugular vein (Bodelsson t al.,
1993) and pig pulmonary artery (Glusa & Richter, 1993).  mRNA localisation studies
and the use of selective ligands seem to indicate that 5-HT2B receptors are involved in
the latter blood vessels (Elli  et al., 1995; Ullmer t al., 1995; Glusa & Roos, 1996).
1.10.2 Novel recognition site in human brain
Castro et al. (1997) have described a binding site in human brain showing high
affinity for 5-CT.  Although 5-CT is known to be able to bind to 5-HT1, 5-ht5 and
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5-HT7 receptors, these authors describe that, after pharmacological blockade of these
receptors, there is a remaining population that is labelled by [3H]5-CT.  Under these
experimental conditions, 5-HT and 5-MeO-T bind with high potency, whereas
ergotamine also shows a moderate affinity.  Additionally, methiothepin seems to be
able to interact with this binding site.  Sumatriptan, ketanserin, GR127935,
mesulergine and ondansetron are virtually devoid of interaction.  Some results seem to
indicate that the receptor site involves G proteins in its functionality (Castro et al.,
1997), but further studies are needed to fully characterise the signal transduction.  As
will be discussed in Chapter 5, the GR127935-resistant part of the 5-HT-induced
constriction of carotid arteriovenous anastomoses seems to resemble the
pharmacological profile of this binding site, although further studies will be necessary.
1.10.3 Other responses mediated by orphan receptors
According to the Hoyer et al. (1994) 5-HT receptor classification the depolarisation in
rat motorneurons, inhibition of noradrenaline release in pig coronary artery and the
slow depolarisation of myenteric neurones are mediated by an orphan receptor.  At
this moment, no substantial progress has been made in characterising these responses.
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Chapter 2
Migraine
2.1 Epidemiology and diagnostic criteria
Migraine is a syndrome that affects a substantial fraction of world’s population, with a
higher prevalence in females (15-18%) than in males (6%; Lipton & Stewart, 1997).
Migraine is characterised by attacks of intense, pulsatile and throbbing headache,
which is typically unilateral and is accompanied by anorexia, nausea, vomiting and
photo- and/or phonophobia (see Table2.1).  In about one third of patients, the
headache is preceded by aura symptoms, consisting of certain sensory (pins and
needle feeling or numbness), motor (weakness or paralysis) and/or focal neurological
(characteristically a homonymous, spreading, scintillating scotoma) symptoms
(migraine with aura or classic migraine).  The majority of patients, however, do not
present with such symptoms (migraine without aura or common migraine, for review
see Ferrari, 1998).
2.2 Pathophysiology
Based on the clinical features of migraine, three distinct phases can be discerned: an
initiating trigger, an aura and, finally, the headache.  Although limited information is
available about the trigger phase, there is indeed now a better understanding of the
pathophysiology of migraine (e.g. Goadsby, 1997; Ferrari, 1998).  Some results
indicate that the initiating trigger, involving the brainstem as "migraine generator"
(Weiller et al., 1995), may be linked to a "familial" channelopathy (O hoff et al.,
1996; Ferrari, 1998).  The subsequent events leading to symptoms observed during the
aura and headache phases can be explained on the basis of a neurovascular hypothesis
(see Ferrari & Saxena, 1993a; Saxena, 1994; Ferrari, 1998).
Based on:
De Vries, P., Villalón, C.M. & Saxena, P.R.  (1999).  Pharmacology of triptans.
Emerg. Drugs, 4, 107-125.
De Vries, P., Villalón, C.M. & Saxena, P.R.  (1999).  Pharmacological aspects of
experimental headache models in relation to acute antimigraine therapy.  Eur. J. Pharmacol.,
375, 61-74.
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Table 2.1 Diagnostic criteria proposed by the Headache Cl ssification Committee of  the
International Headache Society (1988)
Migraine without aura
A. At least five attacks fulfilling B-D
B. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)
C. Headache has at least two of the following characteristics
1. Unilateral location
2. Pulsating quality
3. Moderate or severe intensity
4. Aggravation by walking upstairs or similar routine physical activity
D. During headache at least one of the following
1. Nausea and/or vomiting
2. Photophobia and phonophobia
Migraine with aura
A. At least two attacks fulfilling B
B. At least three of the following four characteristics
1. One or more fully reversible aura symptoms indicating focal cerebral cortical
and/or brain stem dysfunction
2. At least one aura symptom develops gradually over more than 4 min, or two or
more symptoms occur in succession
3. No aura symptoms last more than 60 min
4. Headache follows aura with a free interval of less than 60 min
As illustrated in Figure 2.1, once the "migraine generator" has been switched on,
regional cerebral blood flow decreases, possibly following a wave of cortical
spreading depression (see Read & Parsons, 1999).  In patients where cerebral blood
flow falls below a critical value, corresponding aura symptoms may appear.  The
reduced cerebral blood flow is then followed by a vasodilatation during the headache
phase, probably due to changes in the activity of the neurones innervating cranial
extracerebral large arteries and arteriovenous anastomoses (e.g. in the dura mater, base
of the skull and scalp).  Besides noradrenaline and acetylcholine,
immunohistochemical studies have demonstrated the presence of several vasodilator
transmitters in perivascular nerve fibres supplying intracranial blood vessels,
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including 5-HT, VIP, NO, substance P, neurokinin A and CGRP (for review see
Gulbenkian et al., 1999).  As discussed elsewhere (Olesen et al., 1994), NO may play
an important role in migraine pathophysiology and inhibition of its synthesis seems to
be of therapeutic relevance (Lassen et al., 1998).  In any case, cranial vasodilatation
leads to enhanced blood volume following each cardiac stroke and rapid diastolic
runoff, with a consequent augmentation in pulsations within the affected blood
vessels.  The augmented pulsations can then be sensed by "stretch" receptors in the
vessel wall and the resultant increase in perivascular (trigeminal) sensory nerve
activity provokes headache and other associated symptoms.  This stimulation of the
trigeminal nerve may also release neuropeptides, thus reinforcing vasodilatation and
perivascular sensory nerve activity (for details and references, see Saxena, 1994).
As shown in Figure 2.1, acutely-acting antimigraine drugs constrict dilated
cranial extracerebral blood vessels (Saxena& Ferrari, 1989; Humphrey & Feniuk,
1991; Ferrari & Saxena, 1993a), reduce neuropeptide release and plasma protein
extravasation across dural vessels (Moskowitz, 1992; 1993) and inhibit impulse
transmission centrally within the trigeminovascular system (Goad by t al., 1991;
Goadsby, 1997).
2.3 Acute migraine treatment: sumatriptan and the second-generation
triptans
In the last decade there has been a tremendous progress in the acute therapy of
migraine, with sumatriptan belonging to a new class of drugs (then known as
5-HT1-like receptor agonists), providing the lead (Humphrey et al., 1988; 1990).  This
seminal discovery by Humphrey and colleagues that compounds mimicking 5-HT at
craniovascular receptors should abort migraine attacks stems from the observations
that: (i) urinary excretion of 5-hydroxyindole acetic acid increases, while platelet
5-HT decreases during migraine attacks; (ii) migra ne-like symptoms can be
precipitated by reserpine and alleviated by 5-HT, which causes carotid
vasoconstriction via 5-HT1-like receptors; and (iii) ergotamine and methysergide elicit
a selective carotid vasoconstriction (at least partly via 5-HT1-like receptors), which is
confined to cephalic arteriovenous anastomoses that seem to be involved in migraine
pathophysiology (see below).  Based on the above, tryptamine derivatives were
synthesised to achieve selectivity at the craniovascular 5-HT1-like eceptor and this
culminated in the design and development of sumatriptan (Humphrey et al., 1990).
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The success of sumatriptan in migraine therapy undoubtedly resulted in heightened
research interest in the field of migraine.  This, in turn, led to a better understanding of
the pathophysiological processes involved in migraine as well as the development of
new triptans (for reviews see Ferrari, 1998; Goadsby, 1998a) and other prospective
drugs.
Despite its great utility in migraine treatment, sumatriptan has certain
limitations; e.g. low oral bioavailability, high headache recurrence, possibly due to a
short t1/2 and contra-indication in patients with coronary artery disease.  Therefore, a
number of pharmaceutical companies decided to develop newer triptans having
agonist activity at the craniovascular 5-HT1-like receptors.  Several such compounds
(zolmitriptan, rizatriptan and naratriptan) are already on the market, while others
(eletriptan, almotriptan, frovatriptan and F11356) are in different stages of clinical
development (for chemical structures, see Figure 2.2).  These compounds will be
referred to as the second-generation triptans, since they are tryptamine derivatives and
pharmacologically comparable to sumatriptan.  Zolmitriptan (Visser et al., 1996b),
rizatriptan (Gijsman et al., 1997; Kramer et al., 1998), naratriptan (Bomhof et al.,
1998) and eletriptan (Jackson, 1996; Diener, 1997) seem to be at least as effective as
sumatriptan in migraine therapy and the outcome of elaborate clinical trials with the
other triptans is awaited with interest; preliminary data indicate that frovatriptan
(Ryan & Keywood, 1997; McDaris & Hutchison, 1999) and almotriptan (Cabarrocas,
1998; Martinez t al., 1999) are also effective in migraine.  Despite the efficacy of
avitriptan (Ryan et al., 1997), BMS181885 (Yocca et al., 1997) and the non-triptan
alniditan (Goldstein et al., 1996) in the treatment of migraine, these compounds are no
longer in clinical development.
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Figure 2.1 Diagram showing putative changes in migraine and the therapeutic targets of
acutely acting antimigraine drugs.  These drugs are believed to owe their antimigraine
efficacy to direct vasoconstriction of dilated cranial blood vessels (1), inhibition of
trigeminally-induced cranial vasodilatation (2), plasma protein extravasation (3) and/or
central neuronal activity (4).  Only lipophilic, brain penetrant triptans (not sumatriptan)
exert central trigeminal inhibitory effects.  For details see text.  Based on Saxena (1994)
and De Vries et al. (1999a).  TNC, trigeminal nucleus caudalis.
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Figure 2.2 Chemical structures of sumatriptan and some second-generation triptans.
2.4 Receptor binding and pharmacokinetics of triptans
Sumatriptan as well as the second-generation triptans display high affinities at 5-HT1
receptor subtypes, mainly the 5-HT1B and 5-HT1D receptors (Table 2.2).  There are no
profound differences in affinities, although F11356 is clearly the most potent, while
sumatriptan is the weakest at the 5-HT1B receptor.  Most compounds have a
reasonable affinity at the 5-HT1A and, with the exception of F11356, at the 5-HT1F
receptor.  Some triptans display a µM affinity at the 5-HT7 rec ptor.
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The pharmacokinetic characteristics of sumatriptan and most second-
generation triptans have been studied in human volunteers and migraine patients (see
Table 2.3).  Subcutaneous sumatriptan is quickly absorbed and has a high
bioavailability.  After oral administration of therapeutic doses of sumatriptan,
however, the tmax is substantially longer and, more importantly, the bioavailability is
rather low.  Intranasal or rectal administration of sumatriptan does not seem to
improve these parameters much.  The oral bioavailability of second-generation
triptans, especially naratriptan and almotriptan, is much improved.  The latter can be
partly attributed to the more lipophilic nature of these drugs.  Int restingly, the tmax
after oral administrations of the second-generation triptans does not differ much from
that of sumatriptan.  When corrected for plasma protein binding, Cmax values of the
new drugs are lower than that of sumatriptan, which is apparently due to two main
factors: (i) lower therapeutic concentrations are needed as these drugs have a higher
affinity at 5-HT1B/1D receptors (Table 2.2); and (ii) these drugs have been better
titrated, thus reducing therapeutic penalty.  For the latter reason, low dose
formulations of sumatriptan have been marketed in some countries.  With the
exception of rizatriptan, second-generation triptans are degraded slower than
sumatriptan.  Especially frovatriptan has a plasma half- ife of 26-30 h and, in view of
the putative relation of this parameter with headache recurrence, the results of clinical
trials with frovatriptan are awaited with interest; preliminary data seem to suggest that
frovatriptan results in lower recurrence rates, although only a moderate reduction was
observed (Goldstein et al., 1999b).  In contrast to sumatriptan and naratriptan, active
metabolites have been reported for zolmitriptan, rizatriptan and eletriptan.  It is not
known, whether and if so, to what extent, the metabolites contribute towards the
amount and duration of therapeutic activity and recurrence rates.  We are not aware
whether the metabolism of almotriptan and frovatriptan results in the formation of
active metabolites.
Table 2.2 pKi values of sumatriptan and second-generation triptans at human (except when stated otherwise) 5-HT receptors.
Receptor Sumatriptan Zolmitriptan Naratriptan Rizatriptan Eletriptan Almotriptan Frovatriptan F11356
5-HT1A 6.4a
6.9b
6.0c
6.6c
6.5d
7.6b
7.1c
7.1 (rat)e
6.4c 7.4c 6.3f 7.3g 7.6h
5-HT1B 7.8a
7.4c
8.3i
7.7c
8.3d
8.1c
8.7e
6.9c
7.7j
8.1k
8.0c 8.0f 8.6g 9.4h
5-HT1D 8.5a
8.0c
8.9c
9.2d
8.4c
8.3e
7.9c
8.6k
8.9c 8.0f 8.4g 9.3h
5-ht1E 5.8a
5.8c
5.6l
7.7c
8.0k
7.7c 6.8c 7.3c <6.0g 5.9h
5-HT1F 7.9a
7.9c
7.6l
7.5c
7.2d
8.2c 6.8c 8.0c 7.0g 5.5h
5-HT2A <5.5c <5.5c <5.5c <5.5c <5.5c <5.3g 6.7h
5-HT2B 6.9m 7.2m 6.6m
5-HT2C <5.5c <5.5c <5.5c <5.5c <5.5c <5.3g
m5-HT3 <5.5c <5.5c <5.5c <5.5c <5.5c <6.0g <5.0h
gp5-HT4 <5.5c <5.5c <5.5c <5.5c <5.5c 5.7h
5-ht5A <5.5 (rat)c 6.4 (rat)c 5.5 (rat)c 5.3 (rat)c 5.8 (rat)c 6.1h
5-ht6 <5.5c <5.5c <5.5c <5.5c 6.3c 5.6h
5-HT7 5.9c 7.0c <5.5c 5.7c 6.7c <6.5f 6.7g 6.4h
Data taken from: a, Leysen et al. (1996); b, Newman-Tancredi t al. (1997); c, Napier et al. (1999); d, Martin et al. (1997);  e, Connor et al.
(1997); f, Bou et al. (1997); g, Brown et al. (1996); h, John et al. (1999); i, Beer et al. (1998); j, Wurch et al. (1997); k, Pauwels, P.J.,
personal communication; l, Adham et al. (1993); m, Gupta, P., personal communication.  m, Mouse; gp, guinea-pig.
Table 2.3 Reported pharmacokinetic parameters for sumatriptan and some second-generation triptans.
Drug Dose Tmax
(h)
Cmax
(ng ml-1)
Bio-
availa-
bility
(%)
T1/2
(h)
Area under
curve
(ng h ml-1)
Active
meta-
bolites
Plasma
protein
binding
(%)
CLR
(ml min-1)
LogDpH7.4
Sumatriptan 6 (s.c.) 0.2 72 96 2.0 90 - 14-21 220 -1.5
100 (p.o.) 1.5 54 14 2.0 158 260
10 (i.n.) 1.5 9 2.0 31
20 (i.n.) 1.5 13 16 1.8 48 210
25 (rectal) 1.5 27 19 1.8 78 200
Zolmitriptan 2.5 (p.o.) 1.5 3.3/3.8** 39 2.3/2.6** 18/21** + 25* -1.0
5 (p.o.) 1.5 10 46 3.0 42 193
10 (p.o.) 2.5 13 46 2.8 87 179
Naratriptan 2.5 (p.o.) 2.0 13 63/74** 5.5 98 - 20* 220 -0.2
Rizatriptan 10 (p.o.) 1.0 20 40 2.0 50 + 14* 414 -0.7
Eletriptan 40 (p.o.)
80 (p.o.)
1.8*
1.4
82
246
50*
50 6.3 1661
+ 85* 597* +0.5
Almotriptan 12.5 (p.o.) 2.5 50 80 3.1 266
25 (p.o.) 2.7 64 69 3.6 443 433
Frovatriptan 2.5 (p.o.)
40 (p.o.)
0.8 (i.v.)
3.0
5.0
7
53
24
30
18
100
25.7
29.7
23.6
94
881
104 132
Data taken from: Fowler et al. (1991), Duquesnoy et al. (1998), Moore et al. (1997) and Lacey et al. (1995) for sumatriptan; Dixon et al.
(1995; 1997), Seaber etal. (1998) and Peck et al. (1998) for zolmitriptan; Kempsford et al. (1997) and Fuseau et al. (1997) for naratriptan;
Lee et al. (1998), Sciberras et al. (1997) and Cheng et al. (1996) for rizatriptan; Milton et al. (1998), Hyland et al. (1998) and Morgan et al.
(1997) for eletriptan; Cabaroccas & Salva (1997), Robert et al. (1998) and Fernandez et al. (1999) for almotriptan; Buchan et l. (1998) for
frovatriptan.  *, McHarg, A., personal communication; **, Value for men and women, respectively.  CLR: renal clearance; logDpH7.4:
measure of lipophilicity with increasing numbers indicating greater lipid solubility (see Rance et al., 1997).
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2.5 Pharmacological aspects of experimental models for acutely-acting
antimigraine drugs
2.5.1 Models based on the involvement of cranial vasodilatation in migraine
These models are based on the view that cranial extracerebral vasodilatation is an
integral part of the pathophysiology of migraine and that the ergot alkaloids and
sumatriptan, which do not readily cross the blood-brain-barrier, owe their therapeutic
efficacy primarily to constriction of dilated vessels (Saxena & Ferrari, 1989;
Humphrey & Feniuk, 1991; Ferrari & Saxena, 1993a).  There are several ways to
investigate the effects of antimigraine drugs on cranial blood vessels, both in ivo and
in vitro.  Two of these models will be discussed here.
Constriction of carotid arteriovenous anastomoses in anaesthetised animals
Although the factors mediating the initiating events of migraine are still largely
unknown, the pulsatile nature of migraine headaches suggests that the pain is a result
of dilatation of cephalic blood vessels.  A simple cranial vasodilatation is, however, in
defiance of the facial paleness and coldness noticed in many migraine sufferers during
the headache phase (Drummond & Lance, 1983; 1984).  Recognising this clinical
feature, Heyck (1969) measured the O2 content of arterial and jugular venous blood
before, during, and after the headache and reported that the arterio-jugular venous O2
saturation difference (A-V SO2) was abnormally low during the headache on the
ipsilateral side.  Moreover, the ipsilateral A-V SO2 normalised after spontaneous or
drug-induced (ergotamine) alleviation of the headache.  From these results, he
suggested that arteriovenous anastomoses in the carotid vascular bed dilate during the
headache phase.
As reviewed by Hales & Molyneux (1988), arteriovenous anastomoses
(Figure 2.3) are precapillary communications between arteries and veins and are
mainly located in head skin, ears and dura mater in man (Rowbotham & Little, 1965),
as well as in pigs (Saxena & Verdouw, 1985b; Den Boer et al., 1992a).  Opening of
carotid arteriovenous anastomoses, leading to shunting of a large amount of blood
directly into the venous circulation, can indeed account for facial pallor, lowering of
facial skin temperature and increased vascular pulsations.  Furthermore, the increased
vascular pulsations may be sensed by stretch receptors, resulting in increased activity
in perivascular sensory nerve endings.  This increased activity in perivascular nerve
endings, which is probably of trigeminal origin in view of the innervation of the
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arteriovenous anastomoses by Substance P, as well as CGRP containing trigeminal
nerves fibres (Molyneux & Haller, 1988), may lead to migraine headache and its
associated symptoms (Saxena, 1994; 1995).
Figure 2.3 A schematic representation of a vascular bed containing an arteriovenous
anastomosis (AVA).  The porcine carotid AVAs are normally under a tight sympathetic
constrictor tone, but under pentobarbital anaesthesia ~80% of total carotid blood flow is
shunted through AVAs directly into the jugular venous ciculation (Den Boer et al.,
1993).  As will be described in Chapter 4, cranial AVA blood flow canbe determined
using intracarotid adminstered radioactive microspheres.
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Based on the above, we developed an animal model in which we can determine
arteriovenous anastomotic blood flow, using the radioactive microsphere technique
(Saxena, 1990; 1995).  Indeed, as will be described below and in the rest of this thesis,
5-HT as well as the antimigraine agents sumatriptan, ergotamine and
dihydroergotamine potently and selectively constrict porcine carotid arteriovenous
anastomoses (Chapters 4-6 and 9).  Due to obvious practical difficulties, the effect of
antimigraine agents on human carotid arteriovenous anastomoses has not been
investigated.  Notwithstanding, sumatriptan has been found to constrict dilated
arteriovenous anastomoses in the human forearm (Van Es et al., 1995).
The ergot alkaloids, sumatriptan as well as the newer antimigraine agents
decrease carotid blood flow in anaesthetised animals (see Chapters 3-9).  Consistent
with this, sumatriptan evokes a vasoconstrictor action on cephalic arteries during the
migraine attack in human volunteers (Friberg et al., 1991; Caekebeke t al., 1992).
As shown in Table 2.4, the apparent rank order of agonist potency in decreasing
canine carotid blood flow is: frovatriptan > zolmitriptan > eletriptan = naratriptan ³
rizatriptan = sumatriptan.  Almotriptan and F11356 potently reduce carotid blood flow
in the cat and pig, respectively.  Using radiolabelled microspheres, it has been shown
that the carotid vasoconstriction by sumatriptan (see Chapter 4), zolmitriptan and
eletriptan (see Chapter 6) is confined to arteriovenous anastomoses (Table 2.4), which
may dilate during migraine headaches (see above).  Interestingly, cerebral blood flow
does not seem to be affected, as shown with sumatriptan and even with the much more
lipophilic, brain-penetrant compounds, zolmitriptan, eletriptan and rizatriptan (see
Table 2.4).
Over the years, this vascular model, particularly with the measurement of
cephalic arteriovenous anastomotic blood flow, has proven its worth and has been
highly predictive of antimigraine activity in the clinic (Saxe a, 1995).  Another
advantage it offers is that one can simultaneously study a number of major vascular
beds in order to evaluate craniovascular selectivity of the drugs.  It must however be
realised that this model will pick up only those putative antimigraine drugs that would
be effective by constricting dilated cranial vessels, whatever the mechanism.  For
example, apart from the ergot alkaloids and triptans, NO synthase inhibitors, which
may have antimigraine activity (Olesen et al., 1994; Lassen t al., 1998), constrict
cranial arteriovenous anastomoses (Van Gelderen & Saxena, 1994) and NO donors,
which cause headache, can dilate them (Van Gelderen et al., 1995).
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For details concerning the pharmacology of the canine external carotid
vascular bed and the constriction of porcine carotid arteriovenous anastomoses, see
Chapters 4-9.
Contraction of isolated cranial blood vessels
As shown in Table 2.5, a number of isolated blood vessels from several species
contract in response to acutely acting antimigraine drugs.  This effect is undoubtedly
more marked on cranial vessels where, contrary to most peripheral arteries, 5-HT1
rather than 5-HT2 receptors are predominant (Longmore t al., 1997).  Consistent with
their binding profile, the newer triptans resemble sumatriptan in their action and
potency.  Interestingly, eletriptan and zolmitriptan seem to behave as partial agonists
in the dog (Gupta et al., 1999) and rabbit (Martin et al., 1997) saphenous vein
compared to sumatriptan.  The fact that eletriptan (s e Chapter 6; Willems et al.,
1998) and zolmitriptan (MacLennan et al., 1998) are as efficacious as sumatriptan in
contracting the carotid vasculature could be explained in terms of a larger receptor
reserve (Kenakin, 1984) in the carotid circulation compared to that in the isolated
saphenous vein.
In a number of isolated blood vessels, such as the canine basilar
(Skingle et al., 1996) and coronary (Terrón, 1996a) rteries, canine (Skingle t al.,
1996) and rabbit (Razzaque t al., 1995) saphenous vein and human middle meningeal
artery (Razzaque t al., 1997), the contractile effect of the triptans is antagonised by
selective 5-HT1B/1D receptor antagonists.  It was recently shown that sumatriptan
constricts the isolated human temporal artery via 5-HT1B, but not 5-HT1D receptors
(Verheggen et al., 1998).  Moreover, 5-HT1F receptor agonists seem to be devoid of
vasoconstrictor activity in the rabbit saphenous vein (C hen et al., 1998), as well as in
human and bovine cerebral arteries (Bouchelet & Hamel, 1999). Further studies using
selective 5-HT1B, 5-HT1D and 5-HT1F receptor agonists and antagonists are needed to
establish if the 5-HT1D and/or 5-HT1F receptor stimulation are indeed completely
devoid of vasoconstrictor action.
Table 2.4 ED50 (µg kg-1, i.v.) Values of sumatriptan and some second-generation triptans producing changes in carotid blood flow.
Sumatriptan Zolmitriptan Naratriptan Rizatriptan Eletriptan Almotriptan Frovatriptan F11356
Total (¯) 39 (dog)a
30-100 (pig)b
2.3 (dog)c
1.0 (cat)c
19 (dog)a 30 (dog)d 12 (dog)e
30-100 (pig)f
10 (cat)g 0.4 (dog)h 0.5
(pig)i
Arteriovenous
anastomotic
fraction (¯)
<30 (pig)b <10 (cat)c 30-100 (pig)f
Extracerebral
fraction
­ (pig)b ¯ (dog)c ­ (pig)f
Cerebral
fraction
= (pig)b = (dog)c = (dog)j = (pig)f
Data from: a, Connor et al. (1997); b, De Vries et al. (1996); c, MacLennan et al. (1998); d, Shepheard et al. (1995a); e, Gupta et al. (1996); f,
Willems et al. (1998); g, Bou et al. (1997); h, Parsons et al. (1997); i, John et al. (1999); j, Sperling et al. (1995).  ¯ , decrease; ­, increase; =,
no changes.
Table 2.5 pEC50 Values of sumatriptan and some second-generation triptans in producing contraction of isolated blood vessels.  If known,
the intrinsic relative to 5-HT (5-HT=1) is given between brackets.
Sumatriptan Zolmitriptan Naratriptan Rizatriptan Eletriptan Almotriptan Frovatriptan F11356
Human BA 6.93 (1.11)a 5.46b 7.86 (1.25)a
Dog BA 6.16 (0.63)c
6.44 (1.00)d
6.80 (0.89)e
6.63 (0.61)c 6.96 (1.05)d 7.20 (0.77)e
Primate BA 6.46 (0.48)f 6.92 (0.56)f
Rabbit BA 6.00g 7.20g
Dog MCA 6.73 (1.00)d
7.80 (1.08)h
7.15 (1.14)d
Human MMA 7.15 (0.66)i
7.05 (0.70)j
7.28 (0.84)k
7.37 (0.73)j 7.05 (0.83)i 7.30 (0.80)k 7.52b
Human SV 6.14 (0.54)l 5.91 (0.48)l
Dog SV 6.10 (0.85)e 6.30 (0.57)e
Rabbit SV 6.48 (0.97)f 6.79 (0.77)f 6.64 (0.90)m 7.10 (0.84)n
Human CA 6.14 (0.21)d
6.70 (0.35)f
5.80 (0.42)k
6.10 (0.24)o
6.20 (0.43)p
7.30 (0.37)f
6.32 (0.20)o
6.77 (0.33)d
6.77 (0.17)o
6.35 (0.17)o
5.99 (0.22)p
5.37 (0.33)k 7.38 (0.42)a
Data taken from: a, Parsons etal. (1998); b, Bou et al. (1997); c, Martin et al. (1996); d, Connor et al. (1997); e, Gupta et al. (1999); f, Martin
et al. (1997); g, Brown et al. (1996); h, Yocca, F.D., personal communication; i, Longmore tal. (1998); j, Razzaque et al. (1999); k,
MaassenVanDenBrink et al. (1999a); l, Van Den Broek et al. (1999); m, Beer et al. (1995); n, John et al. (1999); o, MaassenVanDenBrink
et al. (1998); p, Longmore tal. (1996).  BA, basilar artery; MCA, middle cerebral artery; MMA, middle meningeal artery; SV, saphenous
vein; CA, coronary artery.
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2.5.2 Models based on the involvement of trigeminovascular system in migraine
As described above, the contractile effects of sumatriptan and the second-generation
triptans in isolated cranial blood vessels are mediated mainly by the 5-HT1B receptor.
Given that cranial vasoconstriction is the most important therapeutic mechanism, it
implies that agonist action at the 5-HT1D (and 5-HT1F) receptor is not required for the
antimigraine action.  However, several other mechanisms, which do not seem to be
mediated solely by the 5-HT1B receptor, have also been implicated in migraine relief.
These mechanisms include inhibition of the trigemino-vascular system either
peripherally (Moskowitz, 1992; 1993) or centrally (Goadsby, 1998a).
Inhibition of plasma protein extravasation after stimulation of the trigeminal
nerve
In the rat and guinea-pig, electrical or chemical stimulation of the trigeminal ganglion
induces plasma protein extravasation in the dura mater, as measured by the increased
leakage of iodinated ([125I]) albumin (Markowitz et al., 1987).  This plasma
extravasation is suggested to be due to the antidromic release of neuropeptides, such
as substance P, neurokinin A a d CGRP, from sensory trigeminal nerve fibres (see
Figure 2.4; Moskowitz, 1992).  Indeed, tachykinin NK1 receptor antagonists, such as
GR82334 or CP99994, and the CGRP receptor antagonist aCGRP-(8-37) block this
effect (O'Shaughnessy & Connor, 1994; Shepheard t al., 1995b), although the latter
was devoid of effect in rats (O'Shaughnessy & Connor, 1994).
Sumatriptan, as well as second-generation triptans inhibit neurogenic plasma
protein extravasation (see Table 2.6).  This effect by sumatriptan is antagonised by the
5-HT1B/1D receptor antagonist GR127935 in both the rat and guinea-pig, implying the
involvement of 5-HT1B and/or 5-HT1D receptors (Yu et al., 1997).  In mice, the
receptor mediating the sumatriptan-induced effects resembles the 5-HT1B receptor,
since sumatriptan loses its activity in mice lacking this receptor (Yu et al., 1996).  On
the other hand, in the guinea-pig the selective 5-HT1D receptor agonist PNU109291
potently inhibits dural plasma extravasation (Waeber etal., 1997; Ennis et al., 1998).
In the rat, mainly based on the lower potency of CP93129 compared to that of
sumatriptan, Shepheard t al. (1997a) suggested that 5-HT1D rather than 5-HT1B
receptors mediate inhibition of plasma protein extravasation.
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Figure 2.4 Schematic representation of the trigeminal innervation of cranial
extracerebral vasculature.  Cranial blood vessels are innervated by (1) afferent sensory
fibres from the first division (ophthalmic) of the trigeminal nerve; and (2) by efferent
parasympathetic fibres from the facial nerve.  The trigeminal ganglion (TG) is
connected with the facial nerve via a brain stem reflex involving synapses in the
trigeminal nucleus caudalis (TNC), superior salivatory nucleus (SSN) and
sphenopalatine ganglion (SPG).  Redrawn with permission from Goadsby (1997).
CGRP, calcitonin gene related peptide; SP, substance P; NKA, neurokinin A; VIP,
vasoactive intestinal peptide; Ach, acetylcholine; BBB, blood brain barrier; TG,
trigeminal ganglion.
Table 2.6 ED50 (µg kg-1, i.v.) Values of sumatriptan and some second-generation triptans in producing trigeminal neuronal inhibition.
Sumatriptan Zolmitriptan Naratriptan Rizatriptan Eletriptan Almotriptan
Inhibition of plasma
protein extravasation
after trigeminal
ganglion stimulation
4 (rat)a
31 (rat)b
10-30 (guinea-
pig)c
4.1 (rat)a 31 (rat)d 30-300 (rat)e 200 (guinea-pig)f
Inhibition of CGRP
release after feline
trigeminal stimulation
Yesg Yesh
Inhibition of dural
vasodilatation after rat
trigeminal ganglion
stimulation
1000-10000b 1000-3000d
Inhibition of activity
in trigeminal nucleus
caudalis after
stimulation*
Inactive (rat)i 100 (cat)j
300-1000 (rat)k
30-100 (cat)l 1000-3000 (rat)m 500 (cat)n
Data taken from: a, Connor et al. (1997); b, Shepheard et al. (1997a); c, Martin et al. (1997); d, Williamson et al. (1997b); e, Gupta et al.
(1996); f, Bou et al. (1997); g, Goadsby & Edvinsson (1993); h, Goadsby & Edvinsson (1994); i, Shepheard et al. (1995b); j, Goadsby &
Hoskin (1996); k, Cumberbatch et al. (1998); l, Goadsby & Knight (1997); m, Cumberbatch et al. (1997); n, Goadsby & Hoskin (1999).
*, Stimulation of the superior sagittal sinus or dural meninges in rats.  No data available for frovatriptan nd F11356.
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Besides 5-HT1B and 5-HT1D receptors, inhibition of neurogenic plasma protein
extravasation can also be effected via other receptor mechanisms.  Such inhibitions by
5-CT and CP122288 are observed in 5-HT1B receptor knockout mice (Yu et al., 1996)
and are not prevented by GR127935 in guinea-pigs (Yu et al., 1997).  Moreover,
CP122288 is more than a thousand times more potent than sumatriptan in rats, which
does not correlate with its affinity at the 5-HT1B or 5-HT1D receptor (Shepheard et al.,
1997a).  A part of the action of CP122288 may be via the 5-HT1F receptor where it
displays high affinity (see Table 1.1).  Indeed, the selective 5-HT1F receptor agonists,
LY334370 and LY344864, inhibit plasma protein extravasation in the guinea-pig and
rat (Johnson et al., 1997; Phebus et al., 1997).  On the other hand, the response to
5-CT, which displays a very low affinity at this receptor (Hoyer et al., 1994), may be
mediated by a novel receptor, possibly identical to the novel receptor found in human
brain (see section 1.10.2; Castro et al., 1997) or that mediating porcine carotid
vasoconstriction (see Chapter 5).  The neurogenic plasma extravasation can also be
inhibited by the ETA/B receptor antagonist bosentan (Brändli et al., 1996) as well as a
5-HT4 receptor antagonist (Connor & Beattie, 1999).
Importantly, it should be noted that activity in this model does not necessarily
translate into effectiveness in migraine.  For example, antimigraine efficacy was not
observed with CP122288 (at doses devoid of vasoconstrictor action) (Roon et al.,
1997), the ETA/B receptor antagonist bosentan (May et al., 1996) as well as the
tachykinin NK1 receptor antagonists, lanipetant (Goldstein et al., 1997) and
RPR100893 (Diener, 1995).  The results of the trials with selective 5-HT1D or 5-HT1F
receptor agonists are also of major interest.  Interestingly, as discussed in detail in
section 14.4.1, the 5-HT1D receptor agonist PNU109291 is ineffective in the treatment
of migraine (McCall, 1999), whereas the 5-HT1F receptor agonist LY334370 did show
antimigraine properties (Goldstein et al., 1999a).  May et al. (1998) recently
questioned the involvement of plasma extravasation in migraine, based on the lack of
retinal permeability changes during migraine attacks.  Finally, it may be questioned
whether the effectiveness of triptans in this model is due to presynaptic inhibition of
neuropeptide release or via a physiological antagonism of vasodilatation
(Humphrey & Goadsby, 1994).
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Inhibition of cranial vasodilatation (carotid, dural, cortical) induced by
trigeminal stimulation
It has been shown in the cat (Lambert et al., 1984), monkey (Goadsby et al., 1986)
and guinea-pig (Beattie & Connor, 1994) that electrical stimulation of the trigeminal
ganglion decreases carotid vascular resistance.  In contrast to plasma protein
extravasation (see above), the carotid vasodilatation is not amenable to blockade by
CGRP or tachykinin receptor antagonists (Bea tie& Connor, 1994; Raval et al.,
1999).  This vasodilatation seems to involve the release of VIP, since a blockade is
observed with the VIP antagonist, [p-Cl-D-Phe6, Leu17]-VIP (Beattie & Connor,
1994), and VIP antiserum (Goadsby & MacDonald, 1985).  As depicted in Figure 2.4,
VIP can be released upon trigeminal stimulation from facial nerve parasympathetic
fibres, which are connected with the trigeminal nerve via a brain stem reflex
(Lambert et al., 1984; Goadsby, 1997).  Interestingly, the ganglion blocking agent
hexamethonium abolishes carotid vasodilatation in the cat (Lamb rt et l., 1984), but
not in the guinea-pig (Beattie & Connor, 1994).  The latter implies that the nerve
pathways differ in these two species.  In any case, as discussed by Beattie & Connor
(1994), it is unlikely that the effects in the guinea-pi  i volve sensory afferent
trigeminal fibres, in view of the lack of immunohistochemical evidence for the
presence of VIP in these neurones.  The vasodilatation within the feline carotid
vascular bed following trigeminal ganglion stimulation is inhibited by endothelin ETB
receptor antagonists, such as BQ788 (Raval etal., 1999).  Whether the latter is a result
of inhibition of the vascular effects of endogenously released endothelins or
modulation of the release of vasorelaxant neuropeptides from parasympathetic or
trigeminal sensory nerve remains to be clarified.
It is important to note that sumatriptan fails to inhibit carotid vasodilatation
evoked by trigeminal stimulation, as shown in several species (Spokes & Middlefell,
1995; Lambert & Michalicek, 1996; Raval et l., 1999).  Additionally, the endothelin
ETA/B antagonist bosentan (May et al., 1996), the tachykinin NK1 antagonists
lanipetant (Goldstein et al., 1997) and RPR100893 (Diener, 1995) are ineffective in
the acute treatment of migraine.
The dural vasculature also dilates in response to trigeminal stimulation, as
demonstrated using Doppler flowmetry in the cat (Lambert & Michalicek, 1993) and
rat (Kurosawa et al., 1995).  Recently, Shepheard et al. (1997a) have developed a
technique in the anaesthetised rat enabling them to determine dural blood vessel
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diameter through a closed cranial window.  Electrical stimulation of trigeminal
afferents through the cranial window elicits a dilatation of meningeal blood vessels
(Shepheard et al., 1997a; Williamson et al., 1997a; 1997b).  In contrast to the
neurogenically-induced increase in carotid blood flow (mainly via VIP release, see
above), this dural vasodilatation involves CGRP.  Thus, aCGRP-(8-37) potently
inhibits the effect, whereas the tachykinin NK1 receptor antagonist RP67580 is
ineffective (Williamson et al., 1997a; 1997b).  It should be noted that in this model the
increases in vessel diameter were evoked by short, low intensity electrical stimulation,
which primarily stimulate trigeminal sensory Ad-fib es containing only CGRP.  In
contrast, the dural plasma protein extravasation evoked by longer, higher intensity
stimulation, amenable to blockade by tachykinin NK1 receptor antagonists (see
above), seems to involve primarily C-f bres containing substance P (see
Shepheard et al., 1997a).  In this context, it should be noted that stimulation of the
trigeminal nerve in humans results in increased levels of CGRP as well as substance P
in jugular venous blood (Goadsby et al., 1988), but during migraine only elevated
levels of CGRP are found (Goadsby et al., 1990).  Interestingly, species differences
seem to exist, since in the cat the trigeminally-induced dural vasodilatation
predominantly involves entirely different mechanisms (Lambert et al., 1997).
The neurogenic dural vasodilatation in the rat is dose-dependently reduced by
sumatriptan and rizatriptan, probably by inhibiting the release of CGRP
(Williamson et al., 1997a; 1997b).  Sumatriptan and rizatriptan affect neither vessel
diameter per se nor the dilatation produced by exogenous CGRP or substance P
(Williamson et al., 1997a).  The 5-HT1 receptor subtype mediating this effect is likely
to be the 5-HT1B receptor, in view of the higher potency of CP93129 compared to
sumatriptan (Shepheard et al., 1997a).  Stimulation of the trigeminal ganglion also
increases blood flow to facial skin (Escottet al., 1995a) and brain (Goadsby et al.,
1997) via the release of CGRP (Goadsby, 1993; Escott et al., 1995b).  Recently, it was
demonstrated that trigeminal stimulation in the cat leads to an increase in nucleus
trigeminal caudalis blood flow, being inhibited by intravenously administered
sumatriptan (McCall, 1997).
Taken together, it appears that vasodilatation mediated via CGRP release and
involving trigeminal sensory Ad-fibres appears to be a good model for investigating
prospective antimigraine drugs.  However, it must be realised that the triptans have a
low affinity at the rodent 5-HT1B receptor.  It is, therefore, of great interest to assess
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whether this neurogenic dural vasodilatation occurs in other species and, if so, which
receptor mechanism is involved.
Central trigeminal neuronal inhibition
Goadsby and colleagues have shown that i.v. administration of zolmitriptan
(Goadsby & Hoskin, 1996), naratriptan (Goadsby & Knight, 1997) and eletriptan
(Goadsby & Hoskin, 1999) inhibits action potentials generated in the trigeminal
nucleus caudalis after superior sagittal sinus stimulation in the cat (see Table 2.6).
Similarly, in the rat rizatriptan (i.v.) inhibits such potentials evoked by dural
stimulation (Cumberbatch et al., 1997).  Thus, these drugs exhibit a central inhibitory
effect within the trigeminal system and this may partly contribute to their therapeutic
effect in migraine (see Figure 2.4).  However, due to its poor central penetration, i.v.
sumatriptan did not affect C-fos mRNA expression in the trigeminal nucleus caudalis
following trigeminal ganglion stimulation in rats (Shepheard et al., 1995b).  This
raises the question whether central trigeminal inhibition is predictive of antimigraine
potential.  On the other hand, it has been argued, though there is little evidence, that
the blood brain barrier gets disrupted during migraine.  Indeed, after disruption of
blood brain barrier by infusion of hyperosmolar mannitol, sumatriptan can inhibit
C-fos mRNA expression (Shepheard et al., 1995b).
The central trigeminal inhibitory effects of naratriptan in the cat, being
susceptible to blockade by GR127935, are mediated by 5-HT1B/1D receptors
(Goadsby & Knight, 1997).  Since ketanserin displaced zolmitriptan from its binding
sites in the cat brain stem, the involvement of 5-HT1D receptors is likely (Mills et al.,
1995).  Also, in rats the central trigeminal antinociceptive action of zolmitriptan is
mediated by 5-HT1D, but not 5-HT1B receptors (Cumberbatch et al., 1998).
Interestingly, CP99994 blocks C-fo  mRNA expression in the nucleus caudalis in the
rat (Shepheard et al., 1995b), but GR205171 does not affect the central trigeminal
activity as measured electrophysiologically or by C-f s expression in the cat
(Goadsby et al., 1998).  Since both compounds are lipophilic tachykinin NK1
antagonists, the latter results seem to indicate a species dependent involvement of
substance P in the central effects.  In any case, the non-lipophilic tachykinin NK1
receptor antagonists lanipetant (Goldstein et al., 1997) and RPR100893 (Diener,
1995) are ineffective in the acute treatment of migraine, but the clinical efficacy of
brain penetrant tachykinin NK1 receptor antagonists will hopefully provide further
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insights.  It has yet to be established whether CGRP is involved in the central
trigeminal inhibition and whether CGRP antagonists are effective in acute migraine
therapy.
2.6 Conclusion
The seminal discovery of sumatriptan led to the development of new second-
generation triptans, which show much improved pharmacokinetics (e.g. higher oral
bioavailability, longer half-life) as compared to sumatriptan and this will hopefully
contribute to a better tolerability and clinical efficacy.  The pharmacodynamics of
these second-generation triptans, however, do not seem to differ much from
sumatriptan.  Moreover, the introduction of sumatriptan has improved the
understanding of the disease pathophysiology and led to a growing number of
experimental models for migraine.  These experimental models aim at achieving drugs
that (i) counteract continued cranial extracerebral vasodilatation either by
vasoconstriction or by decreasing neuropeptide release at neurovascular synapse; and
(ii) inhibit impulse transmission within the trigeminovascular system.
The models to study direct carotid vasoconstriction, particularly involving
arteriovenous anastomoses have been highly predictive of therapeutic efficacy in
migraine (for details see Chapters 3-9).  This cannot be said for the inhibition of
neurogenic plasma protein extravasation (mainly involving antidromic release of
neurokinins), since several such compounds later proved ineffective in migraine.  At
least in the rat, triptans do inhibit neurogenic vasodilatation, involving the release of
CGRP from Ad fibres.  However, it is yet to be confirmed that CGRP antagonists are
effective in acute migraine therapy.  Similarly, the antimigraine efficacy of VIP
receptor antagonists, which block trigeminally-induced carotid vasodilatation, has not
been assessed.  Both ergot alkaloids and triptans can interfere with impulse
transmission centrally within the trigeminovascular system, but we do not yet know if
this property is linked with antimigraine efficacy.  For these reasons, detailed results
of the ongoing clinical trials with selective 5-HT1D and 5-HT1F receptor antagonists,
which are claimed to be devoid of vasoconstrictor activity, are awaited with
considerable interest (see Chapter 14).
In view of the research efforts being devoted in developing selective and
novel ligands and the use of experimental models incorporating the knowledge of the
disease pathophysiology, it is undeniable that acute migraine therapy will continue to
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evolve in the next millennium.  Selective agonists at the different 5-HT1 rec p or
subtypes will be valuable tools in probing the putative antimigraine mechanisms
clinically and provide further insights in the pathophysiology of migraine, as will be
discussed in Chapter 14.  Notwithstanding, we must also m ke efforts to advance
prophylactic drug therapy in migraine.
2.7 Aims of the thesis
Taking Chapters 1 and 2 into account the aims of the present thesis were as follows:
1. To establish the selectivity towards 5-HT1B/1D receptors of the newly developed
putative 5-HT1B/1D receptor antagonist, GR127935, in several in vivo experimental
models.
2. To investigate, using selective agonists and antagonists, whether 5-HT1B, 5-HT1D
and/or other receptors resemble the 5-HT1-like receptors mediating (i)
vasoconstriction of porcine carotid arteriovenous anastomoses; (ii) decreases in
canine external carotid blood flow; and (iii) inhibition of sympathetic vasopressor
outflow in the rat.
3. To investigate whether the 5-HT1-like or "orphan" 5-HT receptors mediating blood
pressure decreases in the rat and heart rate increases in the cat are identical to the
recombinant 5-ht7 receptor.
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Chapter 3
Interactions of GR127935, a 5-HT1B/1D receptor antagonist, with
functional 5-HT receptors
Summary GR127935 has recently been introduced as an experimental tool to
antagonise 5-HT1B/1D receptor-mediated functional responses.  The compound indeed
exhibits a very high affinity and selectivity for 5-HT1B/1D binding sites and has already
shown to antagonise a number of 5-HT1B/1D receptor-mediated responses.  The present
experiments were performed to investigate the selectivity of GR127935 against
functional responses mediated by 5-HT1-like, 5-HT2, 5-HT3, 5-HT4 or 5-HT7 receptors
in several in vivo preparations.  Intravenous (i.v.) treatment with GR127935
(300 µg kg-1) potently antagonised decreases in total carotid blood flow as well as
hypotensive responses induced by the 5-HT1-like receptor agonist, sumatriptan, in
rabbits.  I.v. bolus injections of GR127935 (up to 500 and/or 1500 µg kg-1) did not
significantly modify 5-HT-induced: (i) tachycardia in the pig (5-HT4
receptor-mediated) and cat (5-HT7 receptor-mediated); (ii) depressor effects in the rat
and cat (5-HT7 receptor-mediated); (iii) von Bezold-Jarisch reflex in the rat or the early
phase of the urinary bladder contraction in the cat (both 5-HT3 receptor-mediated).  In
contrast, high doses (500-1  µg kg-1) of GR127935 suppressed 5-HT-induced pressor
responses in the rat and cat and urinary bladder contractions (secondary phase) in the
cat as well as the DOI-induced pressor responses in the rat, which are all mediated by
5-HT2A receptors.  Lastly, 0.5mg kg-1 of GR127935 produced a methiothepin
(3 mg kg-1)-resistant vasoconstriction of carotid arteriovenous anastomoses in pigs.  In
conclusion, the present study demonstrates that GR127935 is a potent and selective
5-HT1B/1D receptor antagonist devoid of interactions at 5-HT3, 5-HT4 and 5-HT7
receptors.  However, GR127935 possesses a moderate 5-HT2A receptor blocking
property, which is consistent with its binding profile (pKi: 7.4) and seems to display
intrinsic activity in the porcine carotid vascular bed.  Lastly, in view of the potent
antagonist action of GR127935, the sumatriptan-induced hypotension in rabbits seems
to be mediated by 5-HT1B/1D receptors.
3.1 Introduction
The present decade has indisputably witnessed a remarkable progress in the
classification of 5-HT receptors; this achievement is due not only to the adoption of
structural and transductional criteria, but also to the discovery of compounds acting
selectively at 5-HT receptors (Hoyer et al., 1994; Hoyer & Martin, 1997).  For
Based on: De Vries, P., Apaydin, Ô., Villalón, C.M., Heiligers, J.P.C. & Saxena, P.R.
(1997).  Interactions of GR127935, a 5-HT1B/D receptor ligand, with functional 5-HT
receptors.  Naunyn-Schmiedeberg's Arch. Pharmacol., 355, 423-430.
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example, it is nowadays clear that the cardiovascular effects of 5-HT are mediated by
several different receptor types, including 5-HT1-like, 5-HT2, 5-HT3, 5-HT4 and, as
described recently, 5-HT7 receptors (see Chapter 1).  Notwithstanding, the exact
identity of 5-HT1-like receptor mediating vascular contraction is in debate, although
several lines of pharmacological evidence (se  Hoyer t al., 1994) suggest a close
resemblance with the 5-HT1B/1D receptor subtypes, formerly designated as 5-HT1Dß
and 5-HT1Da, respectively (Hartig et al., 1996).  This notion has been hampered
because of the lack of compounds acting selectively at 5-HT1B/1D receptor subtypes,
but the advent of GR127935, a piperazinyl-benzanilide derivative with high affinity
for and selective antagonist activity at 5-HT1B/1D receptors (Clitherow et al., 1994),
will hopefully overcome this obstacle.  Indeed, some studies already show that
GR127935 potently antagonises: (i) contralateral turning in guinea-pigs induced by
the 5-HT1B/1D receptor agonist GR56764 (Skingle et al., 1996); (ii) sumatriptan-
evoked inhibition of 5-HT release in the guinea-pig dorsal raphe nucleus
(Clitherow et al., 1994; Starkey & Skingle, 1994); and (iii) sumatriptan-induced
contraction of porcine carotid arteriovenous anastomoses (Chapter 4), canine external
carotid vessels (Villalón et al., 1996), rabbit isolated saphenous vein (Vale tin et al.,
1996) and canine basilar artery (Skingle et al., 1996).  Several of these responses have
been previously described as being mediated by 5-HT1-like receptors (see
Saxena & Villalón, 1990; 1991).
In view of the pharmacological relevance that GR127935 has been acquiring
as an experimental tool to identify functional 5-HT1B/1D receptors, we have considered
it most crucial to ascertain the selectivity of the drug.  For this purpose, the effect of
GR127935 has been studied on several functional responses mediated by different
5-HT receptors: (i)sumatriptan-i duced decrease in carotid blood flow in the rabbit
(5-HT1-like); (ii) 5-HT and/or DOI-induced pressor responses in the rat and cat as
well as the secondary phase of urinary bladder contraction in the cat (5-HT2A);
(iii) 5-HT-induced bradycardia (von Bezold-Jarisch reflex) in the rat and the early
phase of urinary bladder contraction in the cat (5-HT3); (iv) -HT-induced tachycardia
in pigs (5-HT4); and (v) 5-HT-induced hypotension in the rat and tachycardia in the
cat (5-HT7) (for references see Saxena & Villalón, 1990; 1991; Hoyer et al., 1994;
Choppin & O'Connor, 1996, Chapter 10 and 12).  Lastly, we have studied the effects
of GR127935 per se on porcine carotid haemodynamics.
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3.2 Methods
3.2.1 Experiments in rabbits
Experiments were carried out in 7 male New Zealand White rabbits (2.5-3 kg).  After
initial anaesthesia with sodium pentobarbital (45 mg kg-1, i.v.) and tracheal
cannulation, the rabbits were artificially ventilated with a mixture of oxygen and room
air using a respiratory pump (Infant ventilator MK3, HoekLoos, The Netherlands) at a
rate of 30 strokes min-1 (15 ml kg-1).  At this point a continuous infusion of
pentobarbital sodium (18 mg kg-1 h-1, i.v.) was started.  The left femoral artery and
vein were dissected free and cannulated for blood pressure measurement with a
pressure transducer (Combitrans disposable pressure transducer; Braun, Melsungen,
Germany) and the administration of drugs, respectively.  Heart rate was measured
with a tachograph (CRW, Erasmus University, Rotterdam, The Netherlands) triggered
by ECG signals.  After cutting both vagosympathetic trunks, the right common carotid
artery was dissected free.  Blood flow was measured in the right common carotid
artery with a flow probe (internal diameter: 1.4 mm) connected to a sine-wav
electromagnetic flow meter (Transflow 601-system, Skalar, Delft, The Netherlands).
Blood pressure and heart rate were continuously monitored on a polygraph (CRW,
Erasmus University, Rotterdam, The Netherlands).  After a stable haemodynamic
condition for about 30 min, all animals  received consecutive bolus injections of
sumatriptan (1, 3, 10, 30, 100 µg kg-1, i.v. every 5-15 min).  These responses were
elicited again 15 min after a bolus injection of physiological saline (0.5 ml, i.v.) and,
subsequently, 15 min after an i.v. infusion of GR127935 (300 µg kg-1) over a period
of 1 min.
3.2.2 Experiments in rats
Experiments were carried out in 39 male Wistar rats (300-350 g).  After initial
anaesthesia with ether, the trachea was cannulated and a catheter was placed in the left
external jugular vein.  At this point, ether anaesthesia was stopped and, subsequently,
the animals received i.v. bolus injections of sodium pentobarbital (30-40 mg kg-1).
Hereafter, the left carotid artery was cannulated for the recording of blood pressure,
using a pressure transducer (Combitrans disposable pressure transducer, Braun,
Melsungen, Germany) and the rats were artificially ventilated with a mixture of
oxygen and room air using a respiratory pump (Infant ventilator MK3, HoekLoos, The
Netherlands) at a rate of 40 strokes min-1 (volume: 20 ml kg-1).  Heart rate was
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measured with a tachograph (CRW, Erasmus University, Rotterdam, The Netherlands)
triggered from electrocardiogram signals.  Both blood pressure and heart rate were
recorded simultaneously on a polygraph (CRW, Erasmus University, Rotterdam, The
Netherlands).  It should be noted that three experiments were carried out
simultaneously; because of limited channels for heart rate, this variable was
determined in only one out of three rats.
At this point, the animals were divided into three groups.  In the first group
both vagus nerves were left intact (n=12), whilst the second and third group
underwent sectioning of vagosympathetic trunk bilaterally (n=12 and 15, respectively)
to avoid the bradycardia and hypotension caused by 5-HT via the von Bezold Jarisch
reflex (Paintal, 1973).  After a stable haemodynamic condition for at least 30 min,
baseline values of mean blood pressure and heart rate were determined.  Then, the first
and second group of animals received intravenous (i.v.) bolus injections of 5-HT (3,
10 and 30 µg kg-1) every 5-10 min, while the third group received i.v. bolus injections
of DOI (1, 3, 10 and 30 µg kg-1) and the changes produced in mean blood pressure and
heart rate were noted.  At this point, all groups of animals were subdivided again into
two treatment groups, which received i.v. bolus injections of either GR127935 (20,
100 and 500 µg kg-1) or the corresponding volumes of saline (control animals); at the
end, the control animals received an i.v. infusion of ritanserin (50 µg kg-1) over a
period of about 5 min to establish that the hypertensive responses were am nable to
blockade by this 5-HT2 receptor antagonist.  Before each antagonist or saline
treatment, the animals received small i.v. bolus injections of pentobarbital
(20-30 mg kg-1), necessary to establish equal baseline values of blood pressure.
Fifteen to twenty min after each antagonist or saline treatment, the responses to 5-HT
and DOI were elicited again.
3.2.3 Experiments in cats
Two cats (4 and 6 kg) were fasted overnight and anaesthetised with ketamine
(50 mg kg-1, i.m.) and sodium pentobarbital (30 mg kg-1, i.v.).  Anaesthesia was
maintained with a continuous infusion of sodium pentobarbital (15-20 mg kg-1 h-1,
i.v.).  Subsequently, the animals were artificially ventilated with a mixture of oxygen
and room air using a respiratory pump (Infant ventilator MK3, HoekLoos, The
Netherlands).  The left femoral vessels were catheterised for the i.v. injection of drugs
and measurement of arterial blood pressure with a pressure transducer (Combitrans
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disposable pressure transducer, Braun, Melsungen, Germany).  Heart rate was
measured with a tachograph (CRW, Erasmus University, Rotterdam, The Netherlands)
triggered from electrocardiogram signals.  Subsequently, the spinal cord (at the level
of C1-C2) and both vagosympathetic trunks were sectioned, as previously reported
(Saxena et al., 1985b).  Hereafter, the urinary bladder was cannulated with a suitable
polyethylene tube inserted into its cavity via a cut in the urethra.  Intravesical pressure
was monitored by connecting the bladder cannula to another pressure transducer.
Blood pressure, heart rate and intravesical pressure were continuously monitored on a
polygraph (CRW, Erasmus University, Rotterdam, The Netherlands).
After the animals had been in a stable haemodynamic condition for at least
30 min, bolus injections of 5-HT (3, 10 and 30µg kg-1, i.v.) were given at intervals of
10-15 min and the changes produced in mean blood pressure, heart rate and urinary
bladder pressure were noted.  Subsequently, GR127935 (500 µg kg-1, i.v.) was slowly
administered over a period of 5 min and the responses to 5-HT were elicited again
after 15 min.  The responses induced by 5-HT (30 µg kg-1) on the urinary bladder
pressure were also analysed after subsequent administrations of ketanserin and
MDL72222 (both 0.5 mg kg-1, i.v.) at 15 min interval.
3.2.4 Experiments in pigs
After an overnight fast, 15 domestic pigs (Yorkshire X Landrace; 10-15 kg) were
anaesthetised with azaperone (160 mg, i.m.), midazolan hydrochloride (5 mg, i.m.)
and metomidate (200 mg, i.v.), intubated and connected to a respirator (BEAR 2E,
BeMeds AG, Baar, Switzerland) for intermittent positive pressure ventilation with a
mixture of room air and oxygen.  Respiratory rate, tidal volume and oxygen supply
were adjusted to keep arterial blood gas values within physiological limits
(pH: 7.35-7.48; pCO2: 35-48 mmHg; pO2: 100-120 mmHg).  Anaesthesia was
maintained with a continuous i.v. infusion of pentobarbitone sodium at 20 mg kg-1 h-1
and both vagi and the accompanying cervical sympathetic nerves were cut to avoid
possible reflex changes.  Catheters were placed in the inferior vena cava via the left
femoral vein for the administration of drugs and in the aortic arch via the left femoral
artery for the measurement of arterial blood pressure (Combitrans disposable pressure
transducer; Braun, Melsungen, Germany).  Heart rate was measured with a tachograph
(CRW, Erasmus University, Rotterdam, The Netherlands) triggered from
electrocardiogram signals.  Blood pressure and heart rate were continuously
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monitored on a polygraph (CRW, Erasmus University, Rotterdam, The Netherlands).
During the experiment, body temperature was kept at about 37°C and the animals
were continuously infused with saline to compensate for fluid losses.
After the animals had been in a stable haemodynamic condition for at least
30 min, the first group (n=5) was given methiothepin (500 µg kg-1, i.v.) in order to
block 5-HT-induced changes in arterial blood pressure without affecting heart rate
responses (Bom et al., 1988).  After 10 min, i.v. bolus injections of 5-HT (10 and
30 µg kg-1) were administered at intervals of 10-15 min and the changes produced in
heart rate were noted (for further details see Villalón et al., 1990b; 1991).
Subsequently, GR127935 (500 µg kg-1, i.v.) was slowly administered over a 5 min
period and the responses to 5-HT were elicited again.
In the second and third groups (n=5 each) baseline values of heart rate, mean
arterial blood pressure, total carotid blood flow and its distribution into the non-
nutrient (arteriovenous anastomotic) and nutrient fractions were measured, using the
radioactive microsphere technique (for details, see Chapter 4).  Subsequently, the
second group received 3 mg kg-1 (i.v.) of methiothepin, whereas the third group
received the corresponding volume (5 ml) of physiological saline.  Thereafter, in both
groups 0.5 mg kg-1 (i.v.) of GR127935 was administered over a period of 5 min. All
haemodynamic parameters were reassessed 10 min after the administration of
GR127935.  The protocols of the investigation were approved by the joint Ethical
Committee of the Erasmus University Rotterdam and the University Hospital
Rotterdam "Dijkzigt" dealing with the use of animals in scientific experiments.
3.2.5 Data presentation and statistical evaluation
All data in the text and the illustrations are presented as the mean±s.e.mean.  The
changes and percent changes from baseline in blood pressure, heart rate and blood
flows by the different doses of the agonists/antagonists were calculated in each
experiment.  The changes from baseline values within one group by the different
doses of the drugs used were evaluated using Duncan's new multiple range test, once
an analysis of variance (randomised block design) had revealed that the samples
represented different populations (Steel & Torrie, 1980).  The changes caused by the
drugs after administration of an antagonist dose were compared to the corresponding
changes before antagonist administration by the use of Student's unpaired or paired
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t-test, where appropriate. A P-value of 0.05 or less (two-tailed) was considered
statistically significant.
3.2.6 Drugs
Apart from the anaesthetics, azaperone, metomidate (both from Janssen
Pharmaceutica, Beerse, Belgium), midazolan hydrochloride (Hoffmann La Roche b.v.,
Mijdrecht, The Netherlands) and pentobarbitone sodium (Apharmo, Arnhem, The
Netherlands), the drugs used in this study (obtained from the sources indicated) were:
GR127935 and sumatriptan succinate (both from Glaxo Group Research, Ware, UK);
5-HT creatinine sulphate (Sigma Chemical Company, St. Louis, MO, USA);
methiothepin maleate (Hoffmann La Roche b.v., Mijdrecht, The Netherlands); DOI
and ritanserin (both from RBI, Natick, USA); ketanserin tartrate (Janssen
Pharmaceutica, Beerse, Belgium); MDL72222 (Merrell Dow Research Institute,
Strasbourg, France) and heparin sodium (Leo Pharmaceutical Products, Weesp, The
Netherlands) to prevent clotting of the catheters.  GR127935 was solubilised
according to the instructions of the supplier by heating the dispersion in distilled water
to about 70ºC for 10s and then allowing to cool down to room temperature.
Ritanserin was dissolved in distilled water (30% methanol).  The other drugs were
dissolved in physiological saline.  All doses refer to the respective salts, whereas those
of 5-HT and ritanserin refer to the free base.
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3.3 Results
3.3.1 Effect of sumatriptan on total carotid blood flow, heart rate and mean arterial
blood pressure in rabbits before and after GR127935
As depicted in Figure 3.1, sumatriptan (1-100 µg kg-1, i.v.) elicited dose-d pendent
decreases in the total carotid blood flow (maximum change 32±5%; baseline
53.9±7.8 ml min-1) and concomitant increases in carotid vascular resistance
(maximum change 13±3%, baseline 1.6±0.2 mmHg ml-1 in-1).  Moreover,
sumatriptan produced dose-dependent decreases in mean arterial blood pressure
(maximum change 25±5%; baseline 74.7±2.4 mmHg); baseline heart rate
(275±16 beats min-1) was not altered by sumatriptan.  The percent changs in these
variables (pre-saline values of carotid blood flow, carotid vascular resistance and
blood pressure were 46.0±9.3 ml min-1, 1.9±0.3 mmHg ml-1 min-1 and
76.7±3.9 mmHg, respectively) induced by the same doses of sumatriptan about
15 min after the administration of physiological saline were not significantly different,
except for a small change in the response to 30 µg kg-1 sumatriptan on carotid blood
flow and arterial blood pressure.  Subsequent treatment with GR127935 (300 µg kg-1,
i.v.) potently antagonised the sumatriptan-induced changes in common carotid blood
flow  (maximum change -5±3%), vascular resistance (maximum change -1±1%) and
mean arterial blood pressure (maximum change -6±3%) (Figure 3.1).  Post-GR127935
values of carotid blood flow, carotid vascular resistance and blood pressure were
45.8±8.9 ml in-1, 1.9±0.3 mmHg ml-1 min-1 and 72.3±3.3 mmHg, respectively and,
thus, contrary to results obtained in the porcine carotid vascular bed (see below) and
some earlier reports (Pauwels & Colpaert, 1995; Watson et al., 1996), GR127935 did
not show any intrinsic activity in rabbits.
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Figure 3.1  Percentage changes from baseline values by sumatriptan in carotid blood
flow (CaBF), vascular resistance (CaVR) and mean arterial blood pressure (MAP) in
rabbits (n=7), obtained before and after treatment with saline and GR127935.  *, P<0.05
vs the corresponding dose of sumatriptan before treatments.
3.3.2 Cardiovascular effects of 5-HT in intact and vagosympathectomised rats and
of DOI in vagosympathectomised rats before and after GR127935
Baseline values
The baseline values of mean arterial blood pressure and heart rate in the three groups
of rats (see Methods section) were, respectively, 111±2, 101±2 and 86±2 mmHg and
265±13, 298±18 and 216±29 beats min-1.  These variables were not significantly
modified by the subsequent injection of GR127935 (20, 100, 500 and 1500 µg kg-1) or
the corresponding volumes of physiological saline (data not shown).
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Animals with intact vagus
As depicted in Figure 3.2, 5-HT produced a triphasic effect on arterial blood pressure
in rats with intact vagus, comprising of an initial hypotension associated with a brief,
but intense, bradycardia (not shown in the Figure) via the von Bezold-Jarisch r flex,
followed by a pressor effect and, finally, a longer-lasti  hypotension.  These
responses were reproducible and remained essentially unchanged in control animals
receiving 3 doses of saline (Figure 3.2, upper panel).  Treatment with ritanserin
(50 µg kg-1, i.v.) completely antagonised the pressor responses, while the early and
late hypotensive responses were significantly potentiated (data not shown).
GR127935 (100 and 500 µg kg-1), which showed no agonist effect,
significantly attenuated the pressor effects induced by the highest dose of 5-HT.
When compared to the respective responses in the saline-treated control animals, only
at 500 µg kg-1 of GR127935 a significant attenuation of the response to the highest
dose of 5-HT was observed.  Additionally, the pressor eff cts induced by 3 µg kg-1 of
5-HT were slightly, but significantly potentiated by GR127935 (20 and 100 µg kg-1).
Similarly, GR127935 (100 and 500 µg kg-1) slightly enhanced the late depressor
responses induced by the lowest dose of 5-HT (Figure 3.2, lower panel).
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Figure 3.2  Effects of either saline (upper panel; control; n=6) or GR127935 (lower
panel; n=6) on the triphasic blood pressure response to 5-HT in rats with intact vagi.
*, P<0.05 vs first curve to 5-HT; a, P<0.05 vs the response by corresponding dose in
control animals.
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Vagotomised animals
After section of both vagosympathetic trunks, 5-HT no longer produced bradycardia
or the associated initial hypotensive response, but the pressor responses, which
became more pronounced, and the late hypotensive responses were present.  These
responses were reproducible and remained essentially unchanged in control animals
receiving 3 subsequent doses of saline (Figure 3.3, upp r panels); after additional
treatment with ritanserin (50 µg kg-1, i.v.) the pressor response was completely
abolished, while the late depressor response was significantly potentiated (data not
shown).  As shown in the lower panel of Figure 3.3, under these experimental
conditions, GR127935 (500 and, primarily, 1500 µgkg-1) produced a significant
blockade of the pressor responses to 5-HT.
As depicted in Figure 3.4, the selective 5-HT2A receptor agonist DOI
exclusively produced dose- ep ndent pressor responses in vagosympathectomised
rats.  These responses were reproducible, but slightly (though significantly) decreased
in control animals receiving 3 subsequent doses of saline (Figure 3.4, upper panel).
The responses to DOI, particularly to 3 and 10 µg kg-1, i.v., were significantly more
attenuated by treatment with GR127935 (100 and 500 µgkg-1, i.v.) than was the case
in the saline-treated animals (Figure 3.4, lower panel).
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Figure 3.3  Effects of either saline (upper panel; control; n=6) or GR127935 (lower
panel; n=6) on the blood pressure response to 5-HT in vagotomised rats.  *, P<0.05 vs
first curve to 5-HT; a, P<0.05 vs the response by corresponding dose in control animals.
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Figure 3.4  Effects of either saline (upper panel; control; n=6) or GR127935 (lower
panel; n=6) on the pressor response to DOI in vagotomised rats.  *, P<0.05 vs first
curve to 5-HT; a, P<0.05 vs the response by corresponding dose in control animals.
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3.3.3 Effects of 5-HT on heart rate, mean arterial blood pressure and intravesical
pressure in spinal cats before and after GR127935
I.v. administration of 5-HT (3, 10 and 30 µg kg-1) produced dose-d pendent increases
in heart rate, mean arterial blood pressure and intravesical pressure.  After GR127935
(500 µg kg-1) the increases in heart rate (26, 55 and 72 beats min-1 for cat1 and 7, 31,
49 beats min-1 for cat2) remained unaltered (23, 49 and 66 beats min-1 for cat1 and 4,
30 and 47 beats min-1 for cat2), but the increases in mean arterial blood pressure (10,
21 and 42 mmHg for cat1 and 1, 15 and 40 mmHg for cat2) seemed to be attenuated
(9, 11 and 5 mmHg for cat1 and 5, 4 and 12 mmHg for cat2).
Figure 3.5  Tracings illustrating the effects by 5-HT on feline intravesical pressure
before (Control) and after 0.5 mg kg-1 of GR127935.  Note that 5-HT produced a
biphasic response and that only the secondary phase was attenuated by GR127935.
Ketanserin (0.5 mg kg-1) and MDL72222 (0.5 mg kg-1) blocked the second and third
phase, respectively.
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As has been previously reported (Saxena et al., 1985a), the contractile
responses of the cat urinary bladder induced by 5-HT (3, 10 and 30 µgkg-1) were
biphasic, consisting of an initial spike followed by a longer-lasting (secondary)
increase in intravesical pressure (Figure3.5). 0.5 mg kg-1 of GR127935 did not
modify the first phase of the increase in intravesical pressure, but seemed to attenuate
the second contractile phase.  This remaining response to 5-HT (30 µg kg-1) was
changed after the administration of ketanserin (500 µg kg-1, i.v.)  into a monophasic
(spike) response, which was then markedly antagonised by the subsequent
administration of MDL 72222 (Figure 3.5).
3.3.4 Tachycardiac responses to 5-HT in pigs
Consistent with previous findings (Villalón et al., 1990b; Villalón et al., 1991), i.v.
bolus injections of 5-HT (10 and 30 µg kg-1) resulted in dose-dependent increases in
heart rate of, respectively, 45±8 and 70±9 beats min-1.  The e tachycardiac responses
to 5-HT were not blocked after dministration of 500µg kg-1 of GR127935 (59±7 and
73±9 beats min-1, respectively).
3.3.5 Effects of GR127935 per se on carotid haemodynamic in pigs
As shown in Figure 3.6, 0.5 mg kg-1 (i.v.) of GR127935 decreased total carotid and
arteriovenous anastomotic blood flow, without significantly affecting the nutrient
fraction.  Additionally, the drug slightly decreased mean arterial blood pressure
(10±2%), heart rate (4±1%) and increased the arterio-jugular venous oxygen
saturation difference (A-V SO2) by 82±13%.  In animals pretreated with methiothepin
(3 mg kg-1), the GR127935-induced decreases in total carotid and arteriovenous
anastomotic blood flows were not modified. After methiothepin, GR127935 increased
mean arterial blood pressure (13±3%) and decreased heart rate (-8±1%; both P<0.05
vs before methiothepin; the change in A-V SO2 was not modified.
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Figure 3.6  Effect of GR127935 on total carotid, arteriovenous anastomotic (AVA) and
nutrient blood flows in pigs pretreated (i.v.) with either saline (Control) or
methiothepin.  *, P<0.05 vs baseline.
3.4 Discussion
3.4.1 General
The lack of availability of selective 5-HT1B/1D receptor antagonists has been felt as an
impediment in investigating the relationship between the 5-HT1-like and 5-HT1B/1D
receptors (see Saxena & Villalón, 1990; Den Boer et al., 1992b).  Thanks to the
advent of GR127935, it is becoming increasingly evident that sumatriptan-sensitive
5-HT1-like receptors do indeed resemble the 5-HT1B/1D subtype, with the remaining
5-HT1-like receptors resembling the pharmacological profile of the 5-ht6 or 5-HT7
receptors or even conforming the operational characteristics of "orphan" 5-HT
receptors (Hoyer et al., 1994).
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Binding studies show that GR127935 displays high affinities for human
5-HT1D, human 5-HT1B and rat 5-HT1B receptors (pKi: 8.9, 9.9 and 8.5, respectively),
moderate affinity for 5-HT2A receptors (pKi: 7.2) and very low affinity for 5-HT3,
5-HT4 and 5-ht5 receptors (pKi < 5.2) (see Pauwels, 1996).  There is only limited
information available concerning the selectivity of GR127935 in functional studies
and, therefore, the present investigation deals with this issue.  However, when
interpreting the results, one should keep in mind that the activity of GR127935 at
different 5-HT receptors is based only on binding data for human and rat 5-HT
receptors; binding data of GR127935 for the cat, pig and rabbit 5-HT receptors are, at
this moment, not available.
3.4.2 Effect of sumatriptan on total carotid blood flow, heart rate and mean arterial
blood pressure in rabbits before and after GR127935
As described by Choppin and O'Connor (1996), sumatriptan dose-dependently
decreased total carotid blood flow in anaesthetised rabbits.  These authors showed that
this effect was antagonised by methiothepin, suggestive for the involvement of
5-HT1-like receptors.  Taking into account the high affinity of sumatriptan, but also of
methiothepin for 5-HT1B/1D receptors (Beattie t al., 1994), it is argued that these
5-HT1-like receptors are identical to 5-HT1B/1D receptors.  Indeed, we have recently
shown that the sumatriptan-induced decreases in porcine carotid blood flow are
abolished by GR127935 and, therefore, mediated by 5-HT1B/1D receptors (see
Chapter 4).  In agreement with this, the present results demonstrate that the
sumatriptan-i duced reduction in the rabbit carotid blood flow, which was amenable
to blockade by GR127935, involves 5-HT1-like receptors resembling 5-HT1B/1D
receptors.  Interestingly, sumatriptan produced dose-dependent hypotensive responses
and, in view of the potent antagonist action of GR127935, the involvement of
5-HT1B/1D receptors is likely.
3.4.3 Effects of GR127935 on 5-HT-induced cardiovascular responses in the rat
As previously described by Saxena and Lawang (1985), i.v. administration of 5-HT
produced a triphasic response on the arterial blood pressure of rats with intact vagus
nerves.  This response consists of an initial hypotension associated with a brief, but
intense, bradycardia via the von Bezold-Jarisch reflex (mediated by 5-HT3 receptors),
followed by a vasopressor effect (mediated by 5-HT2A receptors) and, finally, a
Chapter 3
75
longer-lasting hypotension.  As described in detail in Chapter 10, the late hypotension
is mediated by 5-HT7 receptors, previously classified as 5-HT1-like or "orphan"
receptors ( ee Chapter 1; Saxena & Villalón, 1990; 1991).  After bilateral resection of
both vagosympathetic trunks, the initial hypotension due to reflex bradycardia was
abolished, consistent with the concept that the von Bezold-Jarisch reflex is elicited by
stimulation of 5-HT3 receptors located on sensory vagal nerve endings in the heart
(Saxena & Villalón, 1990; 1991).  Our finding that only the vasopressor response to
5-HT elicited in intact as well as vagosympathectomised rats was significantly
antagonised by 500 and 1500 µg kg-1 of GR127935, suggests that the drug produces a
moderate blockade of vascular 5-HT2A receptors.  Moreover, the use of DOI, a
compound acting selectively at 5-HT2 receptors, enabled us to study the pressor
response without the influence of the initial and late hypotensive responses.  Indeed,
GR127935 dose-dependently antagonised DOI-induced pressor responses.  The latter
blockade is in keeping with the affinity of GR127935 for 5-HT2A binding sites (see
above).  However, it may be remarked that Skingle etal. (1996) have reported that
GR127935 (1-10 mg kg-1, s.c.) did not affect wet dog shakes induced by DOI (3
mg kg-1, s.c.) in the guinea-pig, a response mediated by 5-HT2 receptors
(Skingle et al., 1991).
The fact that GR127935 failed to antagonise both the initial transient
hypotensive (in intact animals) and the late hypotensive responses to 5-HT in intact
and vagosympathectomised rats implies that the drug does not interact with,
respectively, 5-HT3 and 5-HT7 receptors.
3.4.4 Effects of 5-HT on the urinary bladder of spinal cats before and after
GR127935
Saxena et al. (1985a) have previously shown in anaesthetised cats that intra-arterial
administration of 5-HT elicits a biphasic contractile response of the urinary bladder,
consisting of an initial spike followed by a longer-lasti  increase in the intravesical
pressure.  These early and late phases of the cat urinary bladder contraction elicited by
5-HT are mediated, respectively, by 5-HT3 receptors (amenable to blockade by
MDL72222) located on parasympathetic ganglia and 5-HT2 receptors (amenable to
blockade by ketanserin, cyproheptadine or methysergide) located on smooth muscle
(Saxena et al., 1985a).  The results of the present study confirm that the contractile
response of the cat urinary bladder to 5-HT is biphasic in nature (Figure 3.5).  Since
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GR127935 did not significantly antagonise the early contractile phase, it is concluded
that the drug does not interact with 5-HT3 receptors located on parasympathetic
ganglia.  In contrast, GR127935 moderately attenuated the 5-HT-in uc d secondary
phase of urinary bladder contraction.  In conformity with its moderate affinity for
5-HT2A binding sites (Skingle et al., 1996) as well as the attenuation of pressor
responses to 5-HT and DOI (see above), these results show that high doses of
GR127935 can antagonise functional 5-HT2A receptors located on the cat urinary
bladder smooth muscle.  Indeed, for this reason we decided to confirm the
involvement of both 5-HT2 and 5-HT3 receptors by using their respective antagonists
ketanserin and MDL72222 (Figure 3.5) after treatment with GR127935.  Thus, the
fact that a monophasic response was obtained after ketanserin, and that this latter
response was markedly blocked after MDL72222 unequivocally demonstrates the
involvement of both 5-HT2 and 5-HT3 receptors.
3.4.5 Effects of 5-HT on heart rate and mean blood pressure of spinal cats before
and after GR127935
It has previously been shown that the increases in heart rate produced by 5-HT in th
cat, being mimicked by 5-carboxamidotryptamine, are mediated by 5-HT1-like
receptors (Saxena et al., 1985b; Saxena, 1988).  Recently, however, it has been
demonstrated that these 5-HT1-like receptors closely resemble the recombinant 5-HT7
receptor (Chapter 12).  Thus, our finding demonstrating that the drug fail d to
antagonise 5-HT-induced tachycardia in cats implies that GR127935 does not interact
with cardiac 5-HT7 receptors in the cat.  In keeping with this, the drug displays low
affinity (pKi: 5.5) at the 5-HT7 receptor and did not affect the late hypotensive
response in rats (see above; Chapter 10).
The antagonism of the pressor responses by GR127935 is in keeping with the
findings described above, that GR127935 displays moderate affinity for 5-HT2A
receptors.
3.4.6 Effects of GR127935 on 5-HT-induced porcine tachycardia
It has been well characterised that the 5-HT-induced tachycardia in the pig is mediated
by 5-HT4 receptors (Duncker et al., 1985; Bom et al., 1988; Villalón et al., 1990b;
1991), which are positively coupled to adenylyl cyclase (Chapter 1).  In th  present
investigation, the animals were deliberately vagosympathectomised (to avoid reflex
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bradycardia) and pretreated with methiothepin (500 µg kg-1) to block 5-HT1, 5-HT2
and 5-HT7 receptors, which may mediate vasopressor and depressor responses.  Under
these experimental conditions, i.v. bolus injections of 5-HT produced dose-d pendent
increases in heart rate which were resistant to antagonism by GR127935.  Therefore,
we conclude that GR127935 does not interact with cardiac 5-HT4 receptors in the pig.
3.4.7 The effects of GR127935 per se in the porcine carotid vascular bed
The present results demonstrate that GR127935 by itself constricts the porcine carotid
vascular bed by a selective action on the arteriovenous anastomoses.  Several studies
have described the partial agonist properties of GR127935 at h5-HT1B and h5-HT1D
receptors in vitro (Walsh et al., 1995; Pauwels, 1996; Watson e al., 1996) and, in
vivo, at (unknown) receptors mediating inhibition of neurogenic plasma extravasation
in the guinea-pig (Yu et al., 1997).  Interestingly, the 5-HT1B/1D receptors do not seem
to be involved in the porcine carotid vasculature, since this effect was resistant to the
antagonist action of methiothepin, using a dose capable of abolishing the sumatriptan-
induced carotid vascular effects (D n Boer et al., 1991b).  Therefore, it seems that the
intrinsic activity of the compound is not related to 5-HT2 or 5-HT1 receptors,
including partial agonist properties at the 5-HT1B/1D receptor subtypes and this requires
further investigation.
In conclusion, the present study demonstrates that the piperazinyl-benzanilide
derivative, GR127935, is a selective 5-HT1B/1D receptor antagonist devoid of
interactions at 5-HT3, 5-HT4 and 5-HT7 receptors.  However, GR127935 possesses
moderate 5-HT2A blocking properties which are consistent with its binding profile.
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Chapter 4
Blockade of porcine carotid vascular responses to sumatriptan by
GR127935, a selective 5-HT1B/1D receptor antagonist
Summary It has previously been shown that the antimigraine drug sumatriptan, a
putative 5-HT1B/1D receptor agonist, decreases porcine common carotid and
arteriovenous anastomotic blood flows, but slightly increases the arteriolar (nutrient)
blood flow to the skin and ears. Interestingly, such responses, being mediated by
5-HT1-like receptors, are resistant to blockade by metergoline, which, in addition to
displaying a very high affinity for (and occasionally intrinsic efficacy at) the 5-HT1B/1D
receptor subtypes, blocks (with lower potency than methiothepin) some 5-HT1B/1D
receptor-mediated vascular responses.  These findings raise doubts whether
sumatriptan-sensitive 5-HT1-like receptors mediating changes in the distribution of
porcine carotid blood flow are identical to cloned 5-HT1B/1D receptors. With the recent
advent of the potent and selective 5-HT1B/1D receptor antagonist, GR127935, the present
study has now analysed if the carotid vascular effects of sumatriptan in the pig are
amenable to blockade by GR127935.  In animals pretreated with saline, sumatriptan
(30, 100 and 300 µg kg-1, i.v.) reduced the total carotid and arteriovenous anastomotic
blood flows in a dose-dependent manner.  In contrast, sumatriptan increased blood flow
to the skin, ears and fat, although the total capillary fraction was not significantly
affected.  While GR127935 (0.25 or 0.5 mg kg-1) itself slightly reduced the total carotid
and arteriovenous anastomotic blood flows, carotid vasoconstrictor responses to
sumatriptan were either partly (0.25 mg kg-1) or completely (0.5 mg kg-1) blocked by
the compound.  In GR127935-pretreated animals, the sumatriptan-induced increases in
blood flow to the skin, ears and fat were also attenuated.  Taken together, the above
results suggest that arteriovenous anastomotic constriction and, possibly, arteriolar
dilatation in the skin, ears and fat by sumatriptan are mediated by 5-HT1B/1D receptors.
Therefore, vascular 5-HT1-like receptors in the porcine carotid bed appear to be
identical to 5-HT1B/1D receptors.
4.1 Introduction
Sumatriptan is a 5-HT1-like receptor agonist (Humphrey et al., 1988; 1990;
Hoyer et al., 1994) effective in the acute treatment of migraine headaches
(The Subcutaneous Sumatriptan I ternational Study Group, 1991; Ferrari & Saxena,
1993b).  Several studies have shown that the drug produces constriction of large
cerebral and extracerebral blood vessels (e.g. Feniuk et al., 1989; Caekebeke t al.,
1992; Villalón et al., 1995c), including porcine carotid arteriovenous anastomoses
Based on: De Vries, P., Heiligers, J.P.C., Villalón, C.M. & Saxena, P.R. (1996).  Blockade of
porcine carotid vascular response to sumatriptan by GR127935, a selective 5-HT1D r ceptor
antagonist.  Br. J. Pharmacol., 118, 85-92.
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(Den Boer et al., 1991b; 1992b), as also shown for the antimigraine drugs, ergotamine
and dihydroergotamine (Den Boer et al., 1991a; Villalón et al., 1992).  The
constriction of porcine cranial arteriovenous anastomoses by sumatriptan and, partly,
by the ergot alkaloids is mediated via the 5-HT1-like receptor because these effects are
antagonised, either partially (ergot alkaloids) or fully (sumatriptan), by methiothepin,
but not by ketanserin (Den Boer et al., 1991a; 1991b).  The 5-HT1-like receptor
mediating vasoconstriction has not yet been cloned and, therefore, its exact identity is
in debate.  In view of the high affinity (see Table 4.1) of sumatriptan, but also of
methiothepin, for 5-HT1B and 5-HT1D receptors (previously called 5-HT1Db and
5-HT1Da, respectively; see Chapter 1), it is argued that sumatriptan-induced
vasoconstriction is mediated by 5-HT1B/1D receptors (e.g. Hamel & Bouchard, 1991),
implying that 5-HT1-like and 5-HT1B/1D receptors are identical.  In contrast, the
IUPHAR 5-HT receptor classification scheme (Hoy r et al., 1994) recognises the
5-HT1-like receptor as a distinct entity, separate from any of the 5-HT1 receptor
subtypes, including 5-HT1B and 5-HT1D receptors, identified by radioligand binding
and cloning techniques.  One of the main reasons for this distinction is that
metergoline, which has an even higher affinity than methiothepin for 5-HT1B/1D
receptors (see Table 4.1), does not or only weakly antagonises sumatriptan-induced
vasoconstrictor responses, both in vivo (Villalón et al., 1990a; Perren t al., 1991;
Den Boer et al., 1992b; Villalón et al., 1995c) and in vitro (Hamel & Bouchard, 1991;
Perren et al., 1991; Bax et al., 1992a; Deckert t al., 1994).
Recently, a series of piperazinylbenzanilide derivatives with high affinity for
and antagonist activity at 5-HT1B/1D receptors has been described (Clitherow et al.,
1994).  One such derivative, GR127935, potently inhibited contralateral turning
induced by unilateral infusion of the 5-HT1 receptor agonist GR56764 into the
guinea-pig substantia nigra as well as sumatriptan-evoked inhibition of 5-HT release
in the guinea-pig dorsal raphe nucleus (Clitherow et al., 1994; Starkey & Skingle,
1994) and canine basilar artery contraction (Skingle et al., 1996).  The present study
has been designed to analyse whether the 5-HT1-lik  receptor mediating changes in
the distribution of common carotid artery blood flow by sumatriptan in the pig are
amenable to blockade by GR127935.
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Table 4.1  pKi values of sumatriptan, GR127935, methiothepin, metergoline and
ketanserin at human cloned 5-HT1 receptor subtypes.
5-HT1A 5-HT1B 5-HT1D 5-ht1E 5-HT1F
Sumatriptana 6.4 7.8 8.5 5.8 7.9
GR127935b 7.2 9.0 8.6 5.4 6.4
Methiothepin 7.7* 7.6c 7.7d 6.7e 6.2e
Metergoline 8.1f (pig) 8.6c 8.7d 6.0g 6.5e
Ketanserin 5.5* 5.3h 7.2h <5.0e <5.0e
a, Leysen et al. (1996); b, Price et al. (1997); c, Beer et al. (1998); d, Pauwels et al. (1996);
e, Adham et al. (1993); f, Hoyer (1988); g, McAllister et al. (1992); h, Adham et al. (1992).
*, P.J. Pauwels, personal communication.
4.2 Methods
4.2.1 General
After an overnight fast, 14 domestic pigs (Yorkshire X Landrace; 10-15 kg) were
anaesthetised with azaperone (160 mg, i.m.), midazolan hydrochloride (5 mg, i.m.)
and metomidate (200 mg, i.v.).  After tracheal intubation, the animals were connected
to a respirator (BEAR 2E, BeMeds AG, Baar, Switzerland) for intermittent positive
pressure ventilation with a mixture of room air and oxygen.  Respiratory rate, tidal
volume and oxygen supply were adjusted to keep arterial blood gas values within
physiological limits (pH: 7.35-7.48; pCO2: 35-48 mmHg; pO2: 100-120 mmHg).
Anaesthesia was maintained with a continuous i.v. infusion of sodium pentobarbital
(20 mg kg-1 h-1).  It may be pointed out that this anaesthetic regimen, together with
bilateral vagosympathectomy (see below), leads to an increase in heart rate and
vasodilatation of arteriovenous anastomoses due to a loss of parasympathetic and
sympathetic tone, respectively.  Indeed, basal arteriovenous anastomotic blood flow is
considerably higher in sodium pentobarbital-anaesthetised pigs (70-80% of carotid
blood flow) than in those under fentanyl/thiopental anaesthesia (~19% of carotid
blood flow) (Den Boer et al., 1993).  A high basal carotid arteriovenous anastomotic
blood flow is particularly useful for investigating the effects of drugs that constrict
arteriovenous anastomoses.
A catheter was placed in the inferior vena cava via the left femoral vein for
infusion of antagonists and sodium pentobarbital.  Another catheter was placed in the
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aortic arch via the left femoral artery for the measurement of arterial blood pressure
(Combitrans disposable pressure transducer; Braun, Melsungen, Germany) and arterial
blood withdrawal for the measurement of blood gases (ABL-510; Radiometer,
Copenhagen, Denmark).  Subsequently, the right common carotid artery and the
external jugular vein were dissected free and the accompanying vagosympathetic
trunks were cut between two ligatures in order to prevent a possible influence via
baroreceptor reflexes on agonist-induced carotid vascular responses.  Another catheter
was placed in the right external jugular vein for the withdrawal of venous blood
samples for determining blood gases (ABL-510; Radiometer, Copenhagen, Denmark).
A hub-less needle, connected to a polyethylene tube, used for the administration of
radioactive microspheres was inserted into the right common carotid artery against the
direction of blood flow for uniform mixing.  In the case of intracarotid administrations
of drugs (such as 5-HT; see Chapter 5), a second needle was placed into the right
common carotid artery.
Blood flow was measured in the right common carotid artery with a flow
probe (internal diameter: 2.5 mm) connected to a sine-wav  electromagnetic flow
meter (Transflow 601-system, Skalar, Delft, The Netherlands).  Heart rate was
measured with a tachograph (CRW, Erasmus University, Rotterdam, The Netherlands)
triggered by electrocardiogram signals.  Arterial blood pressure, heart rate and right
common carotid blood flow were continuously monitored on a polygraph (CRW,
Erasmus University, Rotterdam, The Netherlands).  During the experiment, body
temperature was kept about 37°C and the animal was continuously infused with saline
to compensate fluid losses.
4.2.2 Distribution of carotid blood flow
The distribution of common carotid blood flow was determined with 15.5±0.1 µm
(S.D.) diameter microspheres labelled with 141Ce, 113Sn, 103Ru, 95Nb or 46Sc (NEN
Dupont, Boston, USA).  For each measurement, about 200,000 microspheres, labelled
with one of the radioisotopes, were mixed and injected into the right common carotid
artery.  At the end of the experiment, the animal was killed by an overdose of sodium
pentobarbital and the heart, lungs, kidneys and all ipsilateral cranial tissues were
dissected out, weighed and put in vials.  The radioactivity in these vials was counted
for 10 min in a g-scintillation counter (Packard, Minaxi autogamma 5000), using
suitable windows to discriminate the different isotopes (141Ce: 120-167, KeV, 113Sn:
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355-435 KeV, 103Ru: 450-548 KeV, 95Nb: 706-829 KeV and 46Sc: 830-965 KeV).  All
data were processed by a set of specially designed programs (Saxena et al., 1980).
The fraction of carotid blood flow distributed to the different tissues was
calculated by multiplying the ratio of tissue and total radioactivity of each
radioisotope by the total common carotid blood flow at the time of the injection of the
microspheres labelled with the respective isotope.  Since little or no radioactivity was
detected in the heart and kidneys, all microspheres trapped in lungs reached this tissue
from the venous side after escaping via carotid arteriovenous anastomoses.  Therefore,
the amount of radioactivity in the lungs was used as an indexof the arteriovenous
anastomotic fraction of the common carotid blood flow (Saxena & Verdouw, 1982).
Vascular conductance (10-2 ml min-1 mmHg-1) was calculated by dividing blood flow
(ml min-1) by blood pressure (mmHg), multiplied by hundred.
4.2.3 Experimental protocol
The experiments were started after a stabilisation period of about 1 h.  At baseline,
heart rate, mean arterial blood pressure, carotid blood flow and its distribution as well
as arterial and jugular venous blood gases were measured.  Thereafter, the animals
were divided into three groups which received i.v. infusions of either saline (5 ml;
n=5), 0.25 mg kg-1 (n=4) or 0.5 mg kg-1 of GR127935 (n=5) over a period of 4-5 min.
All variables were reassessed about ten min after the end of the infusion.
Subsequently, all three groups of animals received cumulative i.v. doses of
sumatriptan (30, 1 0 and 300 µgk -1) every twenty min.  Fifteen min after each dose
of sumatriptan the haemodynamic variables were assessed again.
4.2.4 Data presentation and statistical analysis
All data have been expressed as the mean±s.e.mean.  The significance of the changes
induced by saline, GR127935 or the different doses of sumatriptan within one group
was evaluated with Duncan's new multiple range test, once an analysis of variance
(randomised block design) had revealed that the samples represented different
populations (Steel & Torrie, 1980).  The changes (from baseline values) caused by
sumatriptan (30, 100 or 300 µg kg-1) in the two groups of animals pretreated with
GR127935 (0.25 or 0.5 mg kg-1) were compared with the corresponding changes in
the saline-pretreated group using a Student's unpaired t-test.  Statistical significance
was accepted at P<0.05 (two-tailed).
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4.2.5 Drugs
Apart from the anaesthetics, azaperone, metomidate (both from Janssen
Pharmaceuticals, Beerse, Belgium), midazolan hydrochloride (Hoffmann La Roche
b.v., Mijdrecht, The Netherlands) and pentobarbitone sodium (Apharmo, Arnhem,
The Netherlands), the drugs used in this study were: sumatriptan succinate, GR127935
(both from Glaxo Group Research, Ware, UK) and heparin sodium (Leo
Pharmaceutical Products, Weesp, The Netherlands) to prevent clotting of the
catheters.  GR127935 was solubilised according to the instructions of the supplier by
heating the dispersion in distilled water to about 70°C for 10 s and then allowing to
cool down to room temperature.  Sumatriptan was dissolved in physiological saline.
All doses refer to the respective salts.
4.3 Results
4.3.1 Effects of GR127935
The changes in systemic and carotid haemodynamics and in arterio-jugular venous
oxygen saturation difference elicited by saline and GR127935 are shown in Table 4.2.
Pretreatment with saline did not affect any of the variables measured.  At the highest
dose (0.5 mg k -1), GR127935 slightly, but significantly, reduced heart rate (4±1%)
and mean arterial blood pressure (10±2%).  While nutrient blood flow did not change,
both doses (0.25 and 0.5 mg kg-1) of GR127935 decreased total carotid blood flow
(13±1% and 20±3%, respectively) by a selective action on its arteriovenous
anastomotic fraction, which was decreased by 22±5% and 30±6%, respectively.  The
decreases in arteriovenous anastomotic blood flow were accompanied by significant
decreases in the corresponding conductance.  In keeping with these findings, the
difference in arterial and jugular venous oxygen saturation was significantly increased
by the highest dose of GR127935.  However, it has to be remarked that the baseline
value in this group was lower than in the other two groups (Table 4.2).
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Table 4.2  Changes in heart rate (HR; beats min-1), mean arterial blood pressure (MAP;
mmHg), difference in arterial and jugular venous oxygen saturation (A-V SO2; %), total
carotid, arteriovenous anastomotic (AVA) and nutrient blood flows (ml min-1) and AVA
conductance (AVACon; 10-2 ml min-1 mmHg-1) caused by either saline or GR127935.
Saline
(5 ml; n=5)
GR127935
(0.25 mg kg-1; n=4)
GR127935
(0.5 mg kg-1; n=5)
Before After Before After Before After
HR 99±5 97±4 96±5 96±5 93±2 89±3*
MAP 105±3 102±4 97±1 99±5 103±5 93±4*
A-V SO2 8.9±3.2 8.3±3.1 8.2±3.4 9.2±3.2 5.2±1.9 9.6±3.8*
Total 132±11 133±14 121±2 106±3* 125±13 101±11*
AVA 107±12 106±16 91±6 71±7* 98±11 68±8*
Nutrient 24±4 27±4 30±4 35±4 27±3 32±5
AVACon 102±9 102±12 94±7 71±6* 96±12 73±8*
All values have been presented as the mean±s.e.mean.  *, P<0.05 vs before.
4.3.2 Systemic haemodynamic effects of sumatriptan in saline- and GR127935-
pretreated groups
Bolus injections of sumatriptan (30-300 µg kg-1, i.v.) elicited a slight, but significant,
decrease in heart rate in both saline- and GR127935-pretreated animals.  Mean arterial
blood pressure was not changed by sumatriptan, except in the animals pretreated with
0.25 mg kg-1 GR127935 where the highest dose of sumatriptan decreased arterial
pressure by 13±1% (Table 4.3).  In the saline-pretreated animals, sumatriptan (100
and 300 µg kg-1, i.v.) increased the arterio-jugular venous oxygen saturation
difference by 147±63% and 229±96%, respectively.  Table 4.3 shows that in animals
pretreated with GR127935 this effect was either markedly reduced (0.25mg kg-1) or
completely blocked (0.5mg kg-1).
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Table 4.3  Values of heart rate, mean arterial blood pressure and difference in arterial and
jugular venous oxygen saturation at baseline and after cumulative doses of sumatriptan in
animals pretreated (i.v.) with either saline (Control) or GR127935.
Sumatriptan (µg kg-1, i.v.)
Baseline 30 100 300
Heart rate (beats min-1)
Control (0.5 ml) 97±4 94±4 94±4* 92±5*
GR127935 (0.25 mgkg-1) 96±5 94±5 93±5* 92±5*
GR127935 (0.5 mg kg-1) 89±3 88±3* 86±3* 85±3*
Mean arterial blood pressure (mmHg)
Control (0.5 ml) 102±4 103±6 103±6 96±6
GR127935 (0.25 mgkg-1) 99±5 97±5 93±6 86±4*
GR127935 (0.5 mg kg-1) 93±4 91±4 91±3 87±3
Arterial-jugular venous oxygen saturation difference (%)
Control (0.5 ml) 8.3±3.1 10.7±3.2 15.9±3.2* 20.1±3.7*
GR127935 (0.25 mgkg-1) 9.2±3.2 9.8±2.1 9.6±3.2 12.5±2.4*
GR127935 (0.5 mg kg-1) 9.6±3.8 9.2±3.6 11.6±4.4 12.8±5.2
All values have been presented as the mean±s.e.mean. *, P<0.05 vs baseline.
4.3.3 Carotid haemodynamic effects of sumatriptan in saline- and GR127935-
pretreated groups
As shown in Figures 4.1 and 4.2, sumatriptan (30, 100 and 300 µg kg-1, i.v.) elicited a
dose-dependent decrease in both the total carotid and arteriovenous anastomotic blood
flows, but the total capillary fraction was not significantly increased.  The decreases in
total carotid and arteriovenous anastomotic blood flows by sumatriptan (maximal
decreases 52±6% and 76±4%, respectively) were attenuated by 0.25 mg kg-1 of
GR127935 (maximal decreases 15±2% and 27±4%, respectively) or abolished by
0.5 mg kg-1 of GR127935 (maximal decreases 9±10% and 14±12%, respectively).
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Figure 4.1  Effects of sumatriptan on the distribution of total carotid blood flow into its
arteriovenous anastomotic (AVA) and nutrient fractions in pigs pretreated with either
saline (Control; n=5) or GR127935 (0.25 or 0.5 mg kg-1; n=4 or 5, respectively).  All
values are presented as the mean±s.e.mean.  *, P<0.05 vs baseline; +, P<0.05 vs
response by corresponding dose in control animals.
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Figure 4.2  Percent changes from baseline values sumatriptan in total carotid and
arteriovenous anastomotic (AVA) blood flow in pigs pretreated with either saline
(Control) or GR127935 (0.25 or 0.5 mg kg-1).  All values are presented as the
mean±s.e.mean.  +, P<0.05 vs control.
The distribution of carotid blood flow to the head tissues in the three groups of
animals is depicted in Figure 4.3.  Sumatriptan did not significantly modify the
fraction of carotid blood flow distributed to the skeletal muscle, bone, salivary gland,
eye, tongue, brain and dura mater.  In contrast, sumatriptan markedly increased blood
flow to the skin (maximum increase 166±99%) and ears (maximum increase
234±111%) and, slightly, to the fat (maximum increase 96±42%); these effects of
sumatriptan were absent in animals pretreated with GR127935.
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Figure 4.3 Effects of sumatriptan on the distribution of total carotid blood flow to the
different cranial tissues in pigs pretreated with either saline (Control) or GR127935
(0.25 or 0.5 mg kg-1).  All values are presented as the mean±s.e.mean.  *, P<0.05 vs
baseline.
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4.4 Discussion
4.4.1 General
The mechanisms involved in vascular constriction and blood flow reduction by 5-HT
are complex and can be mediated by 5-HT1-like and/or 5-HT2 receptors depending on,
amongst other factors, the species, the blood vessel under study and the degree of
sympathetic vascular tone (Saxena & Villalón, 1990; 1991).  Unlike 5-HT,
sumatriptan, which has a negligible affinity for 5-HT2 receptors (Humphrey et al.,
1988; Peroutka & McCarthy, 1989; Humphrey et al., 1990), reduces porcine common
carotid and arteriovenous anastomotic blood flows exclusively by 5-HT1- ike
receptors (Den Boer et al., 1991b).
Previous findings obtained by the use of several 5-HT receptor agonists and
antagonists suggested that 5-HT1-like receptors were unrelated to the 5-HT1A, 5-HT1B
and 5-HT1C (now 5-HT2C) subtypes (for references see Saxena & Villalón, 1990).  In
this context it is important to note that until 1996 (Hartig et al., 1996) the 5-HT1B
receptor exclusively referred to the rodent 5-HT1B receptor, which displays a distinct
pharmacology compared to the human homologue.  Thus, the 5-HT1B receptor was
excluded to be identical to the 5-HT1-like receptors mediating constriction of porcine
carotid arteriovenous anastomoses, based on the lack of antagonism by (±)pindolol
(Bom et al., 1989b), a compound displaying high affinity at the rodent 5-HT1B
receptor (Adham et al., 1992), but not in other species (see Table 1.2).  Additionally,
Den Boer et al. (1992b) contended that the sumatriptan-sensitive 5-HT1-like receptor
mediating constriction of porcine arteriovenous anastomoses was apparently unrelated
to the 5-HT1D subtype, mainly because of the resistance to antagonism by metergoline,
which displays the highest affinity for 5-HT1D receptors (Waeber et al., 1988).
Notwithstanding, this "5-HT1D" receptor, is in fact encoded by two different receptors,
namely the 5-HT1Da and 5-HT1Db receptors (Weinshank et al., 1992).  In 1996, the
5-HT1Da and 5-HT1Db were renamed 5-HT1D and 5-HT1B receptors, respectively, based
on their molecular homologies.  These receptors are pharmacologically difficult to
distinguish, and therefore, will be termed 5-HT1B/1D in this chapter.  Although
metergoline is capable of antagonising some 5-HT1B/1D receptor-mediated vascular
responses (e.g. Schoeffter & Hoyer, 1990; Hamel & Bouchard, 1991; Bax et al.,
1992b; Jansen t al., 1993; Deckert t al., 1994; Villalón & Terrón, 1994a), it is
important to note that in these studies, the antagonist potency of metergoline did not
correlate with its affinity at 5-HT1B/1D receptors (Waeber et al., 1988) and, in some
Chapter 4
91
cases, metergoline showed a non-competitive antagonism (e.g. Hamel & Bouchard,
1991) or even intrinsic efficacy at 5-HT1B/1D receptors (Schoeffter et al., 1988;
Miller et al., 1992).  The advent of GR127935, which is a potent and selective ligand
for 5-HT1B/1D receptors and antagonises a number of responses elicited by 5-HT1B/1D
receptor agonists (Clitherow et al., 1994; Pauwels, 1996; Skingle et al., 1996), offers
us the possibility of investigating its effect on sumatriptan-induced changes.  Indeed,
in addition to the implications discussed below, our results show that GR127935
antagonised sumatriptan- nduced changes in porcine carotid haemodynamics,
implying a common site of action.
4.4.2 Effect of GR127935 on systemic and carotid haemodynamics
GR127935 elicited a slight reduction in heart rate and mean arterial blood pressure,
but we have no clear-cut explanation for it.  The compound also decreased by itself
the total carotid blood flow and, as observed with sumatriptan (see below), this
decrease was exclusively confined to the arteriovenous anastomotic fraction.  Since
these effects were observed with a concomitant decrease in the arteriovenous
anastomotic conductance (Table 4.2), GR127935 may act as an agonist at the
receptors mediating contraction of arteriovenous anastomoses.  This is supported by
the fact that in cells with human cloned receptors GR127935 can behave as an agonist
at 5-HT1B and 5-HT1D receptor subtypes (Pauwels & Colpaert, 1995; Pauwels, 1996;
Watson et al., 1996).  However, as described in Chapter 3, th  effects of GR127935
are not affected by methiothepin, at a dose capable of abolishing sumatriptan-induced
porcine carotid vascular effects.
4.4.3 Systemic haemodynamic changes after sumatriptan
As previously reported by other authors (Feniuk et al., 1989; Den Boer et al., 1991b;
1992b), sumatriptan produced a slight, but significant, decrease in heart rate; this is
likely to be an effect of the drug, since in similar experiments no changes in heart rate
were observed after four consecutive bolus injections of saline (Den Boer et al.,
1991a).  The mechanism involved in the rather small decrease in heart rate by
sumatriptan is not clear, but may be related to inhibition of sympathetic neurons
(Humphrey et al., 1988; Dreteler et al., 1989; Humphrey et al., 1990;
Saxena & Villalón, 1990; Pagniez et al., 1998).  In any case, bradycardia following
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the use of sumatriptan in patients seems to be of little clinical relevance
(Saxena & Tfelt-Hansen, 1993).
Significantly, the fact that sumatriptan did not produce important changes in
mean arterial blood pressure in the saline- or GR127935-pretreated groups (Table 4.2)
implies that the drug has a more selective vasoconstrictor action on cranial blood
vessels than, for example, ergotamine, which elicits a hypertensive response
(Den Boer et al., 1991a).
4.4.4 Carotid haemodynamic changes after sumatriptan
Sumatriptan elicited a dose- ep ndent reduction in the total carotid blood flow, which
was exclusively due to a decrease in its arteriovenous anastomotic fraction.
Consistent with this finding, sumatriptan also increased the arterio-jugular v n us
oxygen saturation difference.  The reductions in the total and arteriovenous
anastomotic blood flows as well as the accompanying increase in the arterio-jugular
venous oxygen saturation difference by sumatriptan were potently attenuated
(0.25 mg kg-1) or abolished (0.5 mg kg-1) in animals pretreated with GR127935.
Although it cannot be entirely ruled out that sumatriptan and GR127935 both act on
an "unknown" receptor, taking into account that both sumatriptan and GR127935 have
high affinities for 5-HT1B/1D receptors (Table 4.1), our results suggest that the
sumatriptan-i duced vasoconstriction of carotid arteriovenous anastomoses is
mediated by 5-HT1B/1D receptors.  Thus, these findings reinforce the view that
5-HT1-like receptors mediating vascular smooth muscle contraction are identical to
5-HT1B/1D receptors.
Nevertheless, it may be recalled that sumatriptan also displays considerable
affinity for the cloned human 5-HT1F receptor (Table 4.1).  However, the involvement
of the 5-HT1F receptor seems not very likely because (i) GR127935 has a substantially
lower affinity for 5-HT1F than for 5-HT1D or 5-HT1B receptors (Table 4.1);
(ii) sumatriptan is several folds less potent than ergotamine (not more potent as may
be expected from their affinities for the 5-HT1F receptor) on porcine arteriovenous
anastomoses (Chapter 5; Den Boer et al., 1991a; 1991b), and (iii) sumatriptan is more
potent at the 5-HT1B or 5-HT1D than at the 5-HT1F  receptor (Table 4.1).  The use of
5-HT1F receptor agonists will help confirm the latter.  Indeed, in the dog carotid
circulation, the selective 5-HT1F receptor agonist, LY344864 (Phebus et al., 1997) is
devoid of  vasoconstrictor properties (Chapter7).
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As reported earlier from our laboratory (Den Boer et al., 1991b), sumatriptan
conspicuously increased blood flows to the skin and ears, without any alteration in the
total capillary blood flow.  Although the increase in the skin and ear blood flow was
largely attenuated in animals pretreated with GR127935, it can be argued that the
dilatation of the skin and ear arterioles is an indirect consequence of the closure of
arteriovenous anastomoses by sumatriptan.  On the other hand, Schoeffter & Hoyer
(1990) have reported 5-HT receptors similar to 5-HT1B/1D receptor subtypes mediate
endothelium-dependent relaxations of porcine isolated c ronary artery.
4.4.5 Nature of 5-HT1B/1D receptors mediating constriction of porcine carotid
arteriovenous anastomoses
Based on the lack of 5-HT1D mRNA, but the abundant expression of 5-HT1B receptor
mRNA in human or bovine cerebral arteries (Hamel et al., 1993; Bouchelet et al.,
1996) it is likely that the 5-HT1B receptor mediates contractile responses in these
vessels.  The use of GR127935, which has similar affinities at 5-HT1B and 5-HT1D
receptors (Table 4.1), does not allow us to infer if one or both 5-HT receptor subtypes
are involved in the vasoconstrictor effect of sumatriptan on porcine cranial
arteriovenous anastomoses (and, possibly, in the vasodilatation of arterioles).  For a
more definitive evidence, one must await the development of subtype selective
5-HT1B/1D receptor agonists and antagonists (see Chapter 8 and 9).
In conclusion, the results of the present experiments imply that the constriction of
porcine carotid arteriovenous anastomoses by the 5-HT1-lik  receptor agonist
sumatriptan, being antagonised by the 5-HT1B/1D receptor ligand GR127935, is
mediated by 5-HT1B/1D receptors.  It would, therefore, appear that vascular 5-HT1-like
receptors, which are yet to be cloned, are identical to 5-HT1B/1D receptors.  In view of
the putative pathophysiological role of arteriovenous anastomotic dilatation in
migraine (Chapter 1), the constriction of these non-nutrient vessels by sumatriptan via
a 5-HT1B/1D receptor mechanism may be, at least partly, responsible for the therapeutic
effect of the drug in migraine.
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Chapter 5
Effects of GR127935 on the 5-HT-, ergotamine- and
dihydroergotamine-induced porcine carotid vascular changes
Summary It was previously shown that porcine cranial arteriovenous anastomoses
constrict to 5-HT, ergotamine, dihydroergotamine and sumatriptan; sumatriptan acts
exclusively via 5-HT1B/1D receptors.  The present study was devoted to establish the
contribution of 5-HT1B/1D receptors in the constriction of arteriovenous anastomoses
elicited by 5-HT (in presence of 0.5 mg kg-1 ketanserin), ergotamine and
dihydroergotamine in anaesthetised pigs.  Intracarotid infusion of 5-HT
(2 µg kg-1 min-1) and intravenous doses of ergotamine (2.5-20 µg kg-1) and
dihydroergotamine (3-100 µg kg-1) reduced arteriovenous anastomotic and increased
nutrient blood flows and vascular conductances.  The vasodilator response to 5-HT,
observed mainly in the skin and ear, was much more prominent than that of the ergot
alkaloids.  Treatment with the 5-HT1B/1D receptor antagonist GR127935 (0.5 mg kg-1,
i.v.) significantly attenuated both ergot-induced arteriovenous anastomotic constriction
and arteriolar dilatation, whereas GR127935 only slightly affected the carotid vascular
effects by 5-HT.  The results suggest that 5-HT constricts carotid arteriovenous
anastomoses primarily via receptors, which seem to differ from those (5-HT1B/1D)
stimulated by sumatriptan.  The ergot alkaloids produce arteriovenous anastomotic
constriction for a substantial part via 5-HT1B/1D receptors, but also invoke unidentified
receptors.  Both these non-5-HT1B/1D receptors may be targets for the development of
novel antimigraine drugs. The moderate vasodilator response to the ergot derivatives
seems to be mediated, at least in part, by 5-HT1B/1D receptors, whereas the arteriolar
dilatation caused by 5-HT may be mediated by other, possibly 5-HT7 receptors.
5.1 Introduction
In previous studies in vagosympathectomised, anaesthetised pigs, we have shown that
intracarotid infusions of 5-HT lead to a redistribution of carotid blood flow towards
tissue arterioles at the expense of arteriovenous anastomoses (Saxena & Verdouw,
1982; Saxena et al., 1986; Den Boer et al., 1992b).  These changes are
dose-dependent and recover within minutes of stopping 5-HT infusions
(Saxena & Verdouw, 1982).  The vasoconstrictor action of 5-HT on arteriovenous
anastomoses is mainly mediated by 5-HT1-like receptors with some contribution from
5-HT2 receptors (Saxena et al., 1986).  The constriction of porcine arteriovenous
Based on: De Vries, P., Villalón, C.M., Heiligers, J.P.C. & Saxena, P.R. (1998).
Characterisation of 5-HT receptors mediating constriction of porcine carotid arteriovenous
anastomoses; involvement of 5-HT1B/1D and novel receptors. B . J. Pharmacol., 123, 1561-
1570.
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anastomoses by the antimigraine drugs sumatriptan and, partly, by the ergot alkaloids
(ergotamine and dihydroergotamine) is also mediated by 5-HT1-like receptors,
because these effects are antagonised, either partially (ergot alkaloids) or fully
(sumatriptan), by methiothepin, but not by ketanserin (Den Bo  et al., 1991a; 1991b).
It is now recognised that the term 5-HT1-like includes several different
receptor subtypes.  The vascular 5-HT1-like receptor appears to be identical to
recombinant 5-HT1B/1D receptors, since the vasoconstrictor responses to sumatriptan,
which has a high affinity for 5-HT1B/1D receptors (Peroutka & McCarthy, 1989;
Beattie t al., 1994), are antagonised by GR127935 (see Chapter 4), a selective
5-HT1B/1D receptor antagonist (Chapter 3; Clitherow et al., 1994; Pauwels, 1996;
Skingle et al., 1996).  Using subtype selective antagonists, we have shown that the
sumatriptan-i duced cranial vasoconstriction is most probably mediated by the
5-HT1B receptor (see Chapters 8 and 9).  Indeed, mRNA for the 5-HT1B but not
5-HT1D receptor has been located in cranial blood vessels (Hamel & Bouchard, 1991;
Hamel et al., 1993; Bouchelet et al., 1996).
On the basis of above, the present investigation was undertaken to establish
the contribution of 5-HT1B/1D receptors in the reduction of porcine carotid
arteriovenous anastomotic blood flow induced by the endogenous ligand, 5-HT, and
by the ergot alkaloids, ergotamine and dihydroergotamine, both potent antimigraine
agents.  For this purpose, we analysed the carotid vasoconstrictor effects of
intracarotid infusions of 5-HT and i.v. doses of the ergot compounds before and after
treatment with GR127935 or equivalent volumes of physiological saline.  To eliminate
5-HT2 receptor-mediated arteriovenous anastomotic constriction (Verdouw et al.,
1984b), the animals receiving 5-HT were systematically pretreated with ketanserin
(0.5 mg kg-1).
5.2 Methods
5.2.1 General
The methods used for anaesthesia, surgical preparations and determination of systemic
and carotid haemodynamics are described in detail in Chapter 4.
5.2.2 Experimental protocols
After a stabilisation period of about 1 h, the animals (n=36) were divided into two
groups.  The first group (n=12) was systematically pretreated with ketanserin
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(0.5 mg kg-1, i.v.) and subsequently subdivided into two subgroups.  After measuring
baseline values of heart rate, mean arterial blood pressure, carotid blood flow and its
distribution and arterial and jugular venous blood gases, the first subgroup (n=5),
which will be referred to as the control group, received an intracarotid infusion of
5-HT (2 µg kg-1 min-1), lasting 10 min.  All variables were reassessed at the end of this
infusion and, again, 30 min after terminating the infusion (recovery).  Then, the
animals received an i.v. infusion of physiological saline (1 ml  min-1 for 5 min).
Ten min after the end of this infusion and at the end of a second 10-min 5-HT
infusion, all variables were collated again.  In the second subgroup of animals (n=7)
the same protocol was used, but instead of physiological saline, GR127935
(0.5 mg kg-1, i.v.; 1 ml min-1 for 5 min) was administered.  This dose of  GR127935
completely blocks the carotid vascular effects of sumatriptan (see Chapter 4).
The second group of animals (n=24; untreated with ketanserin) was divided
into four subgroups (n=6 each).  The first two groups received an i.v. infusion of
physiological saline (5 ml), whereas the last two groups received an i.v. infusion of
GR127935 (0.5 mg kg-1); both were administered over a period of 4-5 min.  Ten
minutes after the end of these infusions, baseline values of heart rate, mean arterial
blood pressure, carotid blood flow and its distribution, as well as arterial and jugular
venous blood gases were measured.  Then, the first and third group received
sequential i.v. bolus injections of ergotamine (2.5, 5, 10 and 20 µg kg-1), every
20 min, whereas the second and fourth group received sequential i.v. bolus injections
of dihydroergotamine (3, 10, 30 and 100 µg kg-1).  Fifteen min after each dose of
ergotamine or dihydroergotamine all haemodynamic variables were reassessed.
5.2.3 Data presentation and statistical analysis
All data have been expressed as the mean±s.e.mean.  The significance of the
difference between the variables within one group was evaluated with Duncan's new
multiple range test, once an analysis of variance (randomised block design) had
revealed that the samples represented different populations (Steel & Torrie, 1980).
Differences between variables of two groups were evaluated using Student's unpaired
t-test.  Statistical significance was accepted at P<0.05 (two-tailed).
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5.2.4 Drugs
Apart from the anaesthetics (see Chapter4), th  drugs used in this study were:
GR127935 (Glaxo Group Research, Ware, UK; courtesy Dr. H.E. Connor), 5-HT
creatinine sulphate (Sigma Chemical Company, St. Louis, MO, USA), ketanserin
tartrate (Janssen Pharmaceutica, Beerse, Belgium), ergotamine tartrate and
dihydroergotamine mesylate (both from Sandoz Pharma Ltd., Basel, Switzerland) and
heparin sodium (Leo Pharmaceutical Products, Weesp, The Netherlands) to prevent
clotting of the catheters.  Ketanserin, ergotamine and dihydroergotamine were
dissolved in distilled water; 5-HT was dissolved in physiological saline.  GR127935
was solubilised according to the instructions of the supplier by heating the dispersion
in distilled water to about 70°C for 10s and then allowing to cool down to room
temperature.  All doses refer to the respective salts whereas that of 5-HT refers t  the
free base.
5.3 Results
5.3.1 Effects of intracarotid 5-HT infusions before and after physiological saline or
GR127935 on systemic haemodynamics
The effects of 5-HT on the systemic haemodynamics are depicted in Table 5.1.
Intracarotid infusion of 5-HT (2 µg kg-1 min-1) produced a slight increase in heart rate
(7±2%, P<0.05) in control animals; mean arterial blood pressure (-5±4%, P>0.05) was
not affected.  In the second subgroup of animals also, only small changes in heart rate
(+7±2%, P<0.05) and blood pressure (-8±2%, P<0.05) were observed with the initial
5-HT infusion.  Heart rate returned to baseline values after a recovery period of
30 min, but blood pressure remained slightly lower in the second subgroup.  The
subsequent administrations of saline or GR127935 did not cause significant systemic
haemodynamic changes.  In control animals, the second infusion of 5-HT d d n t
change heart rate, but produced a slight (though significant) hypotensive effect.  In the
other subgroup, after treatment with GR127935, the hypotension was not affected, but
the tachycardia by 5-HT was attenuated.
No conspicuous changes were observed by 5-HT in the A-V SO2; in both
groups, however, the response to the second infusion of 5-HT was significantly
different compared to that by the first 5-HT infusion (Table 5.1).
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Table 5.1  Values of heart rate, mean arterial blood pressure and difference in arterial and
jugular venous oxygen saturation at baseline, during a 10-min intracarotid infusion of 5-HT,
after 30 min of recovery, after saline or GR127935 and during a second infusion of 5-HT.
5-HT Saline or 5-HT
Baseline (1st) Recovery GR127935 (2nd)
Heart rate (beats min-1)
Control 92±2 98±4* 93±3 93±3 95±4c
GR127935 93±3 100±3* 93±3 92±2 95±2bc
Mean arterial blood pressure (mmHg)
Control 106±3 101±5 102±2 97±2 88±4bc
GR127935 86±6 80±7* 81±6* 77±5 71±5b
Arterial-jugular venous oxygen saturation difference (%)
Control 6.1±1.2 4.3±0.7 7.7±1.9 9.0±2.9 12.9±4.1c
GR127935 10.1±2.3 7.9±1.8 11.3±2.2 13.9±3.5 14.5±3.7c
All values have been presented as the mean±s.e.mean. 5-HT was i fused at 2 µg kg-1 min-1;
after 30 min of recovery, 5 ml saline (n=5) or 0.5mg kg-1 of GR127935 (n=7) was
administered. *, P<0.05 vs baseline; a, P<0.05 vs recovery value; b, P<0.05 vs values after
saline or GR127935; c, P<0.05 vs first response to 5-HT.
5.3.2 Effects of intracarotid 5-HT infusions before and after physiological saline or
GR127935 on carotid haemodynamics
As shown in the upper panel of Figure 5.1, in control animals a 10-min intracarotid
infusion of 5-HT (2 µg kg-1 min-1) produced an increase in the total carotid blood flow
(31±6%), a decrease in the arteriovenous anastomotic blood flow (79±4%) and a
marked increase in nutrient (capillary) blood flow (482±71%).  These variables
returned to baseline values after a 30 min recovery period and remained unaltered
after the subsequent administration of saline.  During a second infusion of 5-HT no
changes in the total carotid blood flow were observed (P<0.05 vs first response to
5-HT), while the decrease in the arteriovenous anastomotic blood flow was more
pronounced (-93±3%; P<0.05 vs first response to 5-HT) and the increase in nutrient
blood flow was less marked (173±71%; P<0.05 vs first response to 5-HT).
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In the second subgroup of animals (Figure 5.1, low r panel) no changes in the
total carotid blood flow were observed during the initial infusion of 5-HT (P<0.05 vs
response to 5-HT in control animals), whereas 5-HT produced a decrease in
arteriovenous anastomotic blood flow (84±6%) and an increase in nutrient blood flow
(238±74%), of which the latter response was significantly less as compared to control
animals.  These variables returned to baseline values after a 30 min recovery period.
The subsequent administration of GR127935 (0.5 mg kg-1, i.v.) produced a
non-significant decrease in the total carotid blood flow (-17±3%); this change was
significantly different from that observed in control animals (-6±2%) infused with
saline.  GR127935 caused a decrease in arteriovenous anastomotic blood flow
(-27±3%; P<0.05 vs recovery and P<0.05 vs response to saline in control animals),
without changing nutrient blood flow.  In the presence of GR127935, a second
infusion of 5-HT did not change the total carotid blood flow, but decreased
arteriovenous anastomotic (-65±12%; P<0.05 vs values after GR127935) and
increased nutrient (76±26%; P<0.05 vs values after GR127935) blood flows.  Both
these 5-HT-induced changes were significantly less compared to the changes induced
by the initial infusion with 5-HT.  Compared to control animals (Figure 5.1, pper
panel), however, the decrease in arteriovenous anastomotic, as well as the increase in
nutrient blood flow, induced by the second 5-HT infusion, was not significantly
different after GR127935 treatment (Figure 5.1, low r panel).
Chapter 5
101
Figure 5.1 Distribution of total carotid blood flow into its arteriovenous anastomotic
(AVA) and nutrient fractions in ketanserin (0.5 mg kg-1, i.v.)-pretreated pigs.  Effects of
10-min intracarotid infusions of 5-HT (2 µg kg-1 min-1) before and after saline (upper
panel; n=5) or 0.5 mg kg-1 (i.v.) of GR127935 (lower panel; n=7).  *, P<0.05 vs
baseline; a, P<0.05 vs recovery value; b, P<0.05 vs values after saline or GR127935;
c, P<0.05 vs first response to 5-HT; **, P<0.05 vs response in control animals.
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Figure 5.2  Distribution of total carotid blood flow to the different cranial tissues in
ketanserin (0.5 mg kg-1, i.v.)-pretreated pigs.  Effects of 10-min intracarotid infusions of
5-HT (2 µg kg-1 min-1) before and after saline (upper panel; n=5) or 0.5 mg kg-1 (i.v.) of
GR127935 (lower panel; n=7).  *, P<0.05 vs baseline; a, P<0.05 vs recovery value;
b, P<0.05 vs values after saline or GR127935; c, P<0.05 vs first response to 5-HT;
**, P<0.05 vs response in control animals.
The distribution of carotid blood flow to the different head tissues is depicted in
Figure 5.2.  In both groups of animals, 5-HT increased blood flow significantly
towards the skin, ears, fat, and muscles and decreased blood flow to the brain;
exclusively in the control group (Figure 5.2, upper panels) significant increases were
observed in bones, eye and dural blood flow.  In keeping with the above, a marked,
sharply defined, redness of the skin and ear, confined to the ipsilateral side of the
head, was observed in all animals during the infusion with 5-HT.  These variables,
including the redness of the skin, returned to baseline values after a 30 min recovery
period and remained unaltered after the subsequent administration of saline or
GR127935.  Overall, the 5-HT-induced increases in blood flow towards the different
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head tissues were slightly, but significantly, attenuated to the same extent by treatment
with saline, as well as by GR127935; however, the increase in ear blood flow was
abolished by GR127935, while it was only partly attenuated by saline.  The decrease
in blood flow to the brain was not affected by either saline or GR127935.  The degree
of redness caused by 5-HT was not visibly different before and after GR127935 or
saline.
5.3.3 Effects of ergot alkaloids in animals pretreated with physiological saline or
GR127935 on systemic haemodynamics
As shown in Table 5.2, ergotamine (2.5-20 µg kg-1) and dihydroergotamine
(3-100 µg kg-1) did not cause major changes in heart rate or mean arterial blood
pressure; only the highest dose of dihydroergotamine produced small, but significant,
tachycardiac and hypertensive effects in control and GR127935-pretreated animals,
respectively.
In saline-treated animals, both ergot compounds produced dose-dependent
increases in the A-V SO2.  In animals pretreated with GR127935, the
ergotamine-induced increases in the A-V SO2 seemed to be attenuated, although only
at 5 µg kg-1 significance was reached.  The dihydroergotamine-induced increases in
the A-V SO2 were abolished after pretreatment with GR127935, although, compared
to saline treated animals, this was only significant at a dose of 10 µgkg-1.
5-HT receptors and porcine AVAs
104
Table 5.2  Values of heart rate, mean arterial blood pressure and difference in arterial and
jugular venous oxygen saturation at baseline and after cumulative doses of ergotamine and
dihydroergotamine in animals pretreated with either saline (Control) or GR127935
(0.5 mg kg-1).
Ergotamine (µg kg-1, i.v.)
Baseline 2.5 5 10 20
Heart rate (beats min-1)
Control 97±4 96±4 96±4 95±4 95±4
GR127935 93±4 90±4 88±4 88±4 88±4
Mean arterial blood pressure (mmHg)
Control 95±2 104±4 101±6 98±7 101±6
GR127935 93±3 97±6 98±7 97±8 102±7
Arterial-jugular venous oxygen saturation difference (%)
Control 4.1±0.7 10.0±2.9* 15.5±3.3* 17.6±2.5* 21.2±2.6*
GR127935 11.9±5.6 14.6±16.5 16.7±6.9*a 19.9±7.0* 22.6±6.2*
Dihydroergotamine (µg k -1, i.v.)
Baseline 3 10 30 100
Heart rate (beats min-1)
Control 91±3 91±3 90±3 91±2 94±3*
GR127935 94±4 94±4 93±3 94±3 98±3
Mean arterial blood pressure (mmHg)
Control 106±4 118±5 116±6 116±7 117±7
GR127935 100±2 99±1a 98±1 103±2 107±2*
Arterial-jugular venous oxygen saturation difference (%)
Control 6.2±1.5 9.4±1.6* 12.5±1.6* 14.7±1.7 16.6±2.1*
GR127935 15.5±4.9 14.8±4.3 15.4±4.0a 18.5±3.8 20.4±3.0
All values have been presented as the mean±s.e.mean. *, P<0.05 vs baseline; a, P<0.05 vs
response by corresponding dose in saline-pretreated animals.
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Table 5.3  Values of total carotid, arteriovenous anastomotic (AVA) and nutrient vascular
conductance at baseline and after cumulative doses of ergotamine and dihydroergotamine in
animals pretreated with either saline (control; n=6 each) or GR127935 (0.5 mg kg-1; n=6
each).
Ergotamine (µg kg-1, i.v.)
Baseline 2.5 5 10 20
Total carotid vascular conductance
Control 136±13 92±10* 85±9* 82±10* 71±8*
GR127935 126±8 116±9*a 103±8*a 94±9* 81±10*
AVA vascular conductance
Control 108±14 50±11* 32±8* 24±7* 13±5*
GR127935 89±6 74±9*a 61±9*a 43±7*a 25±6*a
Nutrient vascular conductance
Control 24±3 36±6* 46±6* 50±6* 49±5*
GR127935 32±3 37±4 36±3a 45±6*a 49±5*
Dihydroergotamine (µg k -1, i.v.)
Baseline 3 10 30 100
Total carotid vascular conductance
Control 113±10 86±6* 81±7* 78±8* 72±7*
GR127935 136±10 137±11a 131±10a 109±6*a 89±6*
AVA vascular conductance
Control 84±10 45±10* 30±7* 23±6* 12±3*
GR127935 102±11 94±12a 79±12*a 59±8*a 33±6*a
Nutrient vascular conductance
Control 25±3 36±7* 45±6* 50±6* 54±6*
GR127935 28±3 36±4* 43±4* 43±5* 47±3*
All values have been presented as mean±s.e.mean and expressed in 10-2 ml min-1 mmHg-1.
*, P<0.05 vs baseline; a, P<0.05 vs response by corresponding dose in control animals.
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Figure 5.3  Effects of ergotamine (left panels) and dihydroergotamine (DHE; right
panels) on the distribution of total carotid blood flow into its arteriovenous anastomotic
(AVA) and nutrient fractions in pigs pretreated with either saline (Control; n=6 each) or
GR127935 (0.5 mg kg-1; n=6 each).  All values are presented as the mean±s.e.mean.
*, P<0.05 vs baseline; +, P<0.05 vs response by c rresponding dose in control animals.
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Figure 5.4  Percent changes from baseline values (n=6 each) of total carotid,
arteriovenous anastomotic (AVA) and nutrient blood flow by ergotamine (upper panels)
and dihydroergotamine (lower panels) in pigs pretreated with either saline (Control) or
GR127935 (0.5 mg kg-1).  All values are presented as the mean±s.e.mean.  +, P<0.05 vs
control.
5.3.4 Carotid haemodynamic effects of ergot alkaloids in animals pretreated with
physiological saline or GR127935
As shown in Figures 5.3 (absolute values) and 5.4 (percent changes from baseline),
ergotamine (2.5- 0 µg kg-1), as well as dihydroergotamine (3-100µg kg-1) elicited
dose-dependent decreases in the total carotid blood flow (maximal decreases: 45±3%
and 31±2%, respectively) and in its conductance (maximal decreases: 47±4% and
37±2%, respectively; Table 5.3).  These decreases in the total carotid blood flow were
exclusively attributable to marked decreases in its arteriovenous anastomotic fraction;
the highest dose of ergotamine (20 µg kg-1) decreased arteriovenous anastomotic
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blood flow and its conductance by 88±3% and 88±4%, respectively, whereas
dihydroergotamine (100 µg kg-1) similarly decreased these variables by 86±3% and
87±2%, respectively.  Additionally, ergotamine and dihydroergotamine increased
nutrient blood flow by up to 118±17% and 152±27%, respectively, accompanied by
increases in nutrient vascular conductance (Table 5.3).  Treatment with GR127935
(0.5 mg kg-1) significantly attenuated the above ergot-induced responses.  Maximal
changes in the total carotid, arteriovenous anastomotic and nutrient blood flow
induced by ergotamine were -31±4%, -70±6% and +74±18%, respectively, while
dihydroergotamine produced changes of -30±2%, -66±3% and +89±15%,
respectively.  GR127935 (0.5mg kg-1) produced a 5.5-fold (from 0.8±0.2 to
4.4±0.8 µg kg-1) and 12.2-fold (from 1.1±0.5 to 13.4±2.3 µg kg-1) increases in the
ED30 (dose eliciting a 30% decrease in arteriovenous anastomotic conductance,
calculated using linear regression analysis) for ergotamine and dihydroergotamine,
respectively.
The ergotamine- and dihydroergotamine-induced changes in the distribution
of carotid blood flow to the different head tissues are depicted in Figure 5.5.  Both
ergot derivatives produced significant, dose-depend nt increases in blood flow to skin,
ear, fat, bone, brain and dura mater, of which only bone and brain blood flow values
were slightly, though significantly, attenuated by GR127935; exclusively in muscle
and salivary gland ergotamine-induced blood flow increases were observed, which
were slightly less in animals pretreated with GR127935.
5.4 Discussion
5.4.1 General
We have previously shown that sumatriptan-induced carotid haemodynamic responses
in pigs (see Chapter 4), as well as rabbits (Chapter 3) are mediated by 5-HT1B/1D
receptors as these responses are completely antagonised by a single i.v. dose of
0.3-0.5 mg kg-1 of GR127935.  The main aim of the present investigation in the
anaesthetised pig was to establish whether the carotid vascular responses to the
endogenous ligand (5-HT) and the antimigraine drugs, ergotamine and
dihydroergotamine, are also mediated by 5-HT1B/1D receptors.  Due to the different
pharmacological properties of 5-HT and the ergot compounds, separate protocols were
used.
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Figure 5.5  Effects of ergotamine and dihydroergotamine (DHE) on the distribution of
total carotid blood flow to the different cranial tissues in pigs pretreated with either
saline (Con; n=6 each) or GR127935 (0.5 mg kg-1; n=6 each).  All values are presented
as the mean±s.e.mean.  *, P<0.05 vs baseline; +, P<0.05 vs response by corresponding
dose in control animals.
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Firstly, as 5-HT2 receptors play a role in carotid vascular effects by 5-HT
(Saxena & Verdouw, 1982; Verdouw et al., 1984b), but not by the ergot alkaloids
(Saxena et al., 1983; Bom et al., 1989a), the animals receiving 5-HT were pretreated
with ketanserin.  Ketanserin is a potent 5-HT2A receptor antagonist and has also been
shown to possess a moderate blocking property at the h5-HT1D receptor (Table 1.2).  It
should be kept in mind, however, that in the present experiments we cannot provide
evidence that the employed dosage also blocked the porcine 5-HT1D rec ptor.
Secondly, due to the short duration of action of 5-HT, the compound was infused
directly into the carotid artery, whereas the long-acting compounds, ergotamine and
dihydroergotamine, were administered intravenously.  Moreover, the effect of
GR127935 (0.5 mg kg-1) on 5-HT-induced changes was studied within animals, while
the ergot-induced changes were studied in different groups pretreated with either
saline or GR127935.  It should be noted that the intrinsic activity of GR127935 at
receptors mediating arteriovenous anastomotic constriction (Chapter 3 and 4), also
observed in the present experiments (see Figure 5.1, lowe  panel), does not allow us to
use higher doses of the compound.
5.4.2 Systemic haemodynamics
As observed previously (Saxena & Verdouw, 1982), intracarotid infusion of 5-HT
(2 µg kg-1 min-1) produced a slight tachycardia and hypotension.  The tachycardia
could be due to an action at cardiac 5-HT4 receptors (Villalón et al., 1990b), but it
should be noted that heart rate did not increase during the second 5-HT infusi  after
treatment with physiological saline.  Therefore, the apparent attenuation of the
5-HT-induced tachycardic effect by GR127935 seems to be a non-sp cific
(tachyphylactic) effect.  The small hypotensive response caused by 5-HT may be due
to stimulation of 5-HT7 receptors (see Chapter 10).
5.4.3 Arterio-jugular venous oxygen saturation difference (A-V SO2)
5-HT did not increase the A-V SO2.  Considering the potent vasoconstriction of
cephalic arteriovenous anastomoses by 5-HT (see below), one may expect an increase
in the A-V SO2 as observed with the ergot alkaloids (present results; Den Boer et al.,
1991a) and sumatriptan (see Chapter 4; Den Boer et al., 1991b).  However, in contrast
to the latter compounds, 5-HT produces a very pronounced arteriolar dilatation,
leading to a huge increase in nutrient (capillary) blood flow.  As a consequence,
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arterial blood with high O2 saturation mixes with  jugular venous blood
("physiological shunting"), thereby decreasing the A-V SO2.
The effects of the ergot alkaloids on A-V SO2 were not potently blocked,
whereas those of sumatriptan were completely antagonised by GR127935 (see
Chapter 4).  This is in keeping with the extent of blockade of arteriovenous
anastomotic constriction by GR127935, which abolished the response to sumatriptan,
but only partly affected that to the ergot alkaloids (see below).
5.4.4 Effects of GR127935 on carotid vascular responses to 5-HT and ergot
alkaloids
In control animals, intracarotid infusions of 5-HT decreased arteriovenous
anastomotic blood flow, but caused a marked arteriolar vasodilatation; as a result the
total carotid blood flow increased.  This is in keeping with our previous reports, where
treatment with 5-HT2 receptor antagonists, such as ketanserin, cyproheptadine and
WAL1307, partly blocked 5-HT-induced arteriovenous anastomotic constriction and
enhanced arteriolar dilatation (Saxena & Verdouw, 1982; Verdouw et al., 1984b).
Surprisingly, the second 5-HT infusion, as well as the initial 5-HT infusion in the
other subgroup, did not produce significant changes in the total carotid blood flow.
We have also previously observed that, whereas the magnitude of 5-HT- nduced
decreases in arteriovenous anastomotic blood flow appears to be constant, the
magnitude of increases in nutrient blood flow is subject to variation (see
Saxena & Verdouw, 1982; Saxena & Verdouw, 1984; Verdouw et al., 1984b;
Saxena et al., 1986; Den Boer et al., 1992b).  Although we have no direct explanation
for this variable response in the arteriolar vascular bed, it is worth noticing that
differences in the degree of pre-existing sympathetic vascular tone, probably produced
by the degree of initial anaesthesia (Den Boer et al., 1993), might play a role.
As observed previously in several species (Saxena, 1974a; Mylecharane et l.,
1978; Spierings & Saxena, 1980; Den Boer et al., 1991a), both ergotamine and
dihydroergotamine dose- ependently decreased the total carotid blood flow, and this
response was exclusively caused by a selective constriction of carotid arteriovenous
anastomoses with concomitant conductance changes.
Our findings show that the arteriovenous anastomotic constriction by 5-HT
was partly attenuated after GR127935.  However, it should be noted that the observed
attenuation might be, at least in part, a result of the second 5-HT infusion starting at a
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lower level of blood flow, being related to the intrinsic activity of GR127935 itself
(see above).  Accordingly, the same minimum level of arteriovenous anastomotic
blood flow was obtained before and after GR127935 and, when compared to the
corresponding response by 5-HT in control animals, no significance was reached.
These results lead us to conclude that the 5-HT-induced carotid arteriovenous
anastomotic constriction in ketanserin-pretreated pigs is primarily mediated by
receptors not identical to the 5-HT1B/1D receptor subtypes.  As the arteriovenous
anastomotic constriction by sumatriptan was abolished by a 0.5 mgkg-1 dose of
GR127935 (Chapter 4), these findings imply that 5-HT and sumatriptan constrict
porcine arteriovenous anastomoses predominantly via distinct receptors.  In keeping
with the above, Yu et al. (1997) have recently reported that, although GR127935 was
capable of antagonising sumatriptan-induced inhibition of neurogenic plasma
extravasation in the guinea-p g, 5-CT-induced effects remained unaffected.  On the
other hand, the decrease in arteriovenous anastomotic conductance by both
ergotamine and dihydroergotamine was attenuated to a considerable degree (5.5- nd
12.2-fold shifts, respectively, in ED30 values) by GR127935 (0.5 mg kg
-1).  Den Boer
et al. (1991a) have previously shown that methiothepin (3 mg kg-1) caused 3.1- and
5.2-fold increases in ED30 values of ergotamine and dihydroergotamine, respectively.
The higher shifts in ED30 values by GR127935 are in keeping with the higher
affinities displayed by GR127935 at h5-HT1B/1D receptors compared to those exhibited
by methiothepin (see Table 4.1).  In view of the high affinities displayed at 5-HT1B
and 5-HT1D receptors by ergotamine (Table 7.1), methiothepin, as well as by
GR127935, it is suggested that both ergot compounds partly constrict porcine
arteriovenous anastomoses via 5-HT1B/1D receptors.
5.4.5 Do the GR127935-resistant receptors resemble any of the other 5-HT
receptors?
Based on the above, the greater part of the 5-HT-induced, as well as a considerable
part of the ergot-induced arteriovenous ana tomotic constriction does not seem to be
mediated by 5-HT1B/1D receptors.  Furthermore, as the arteriovenous anastomotic
constriction by 5-HT was completely blocked (Saxena et al., 1986) and that by the
ergots only partly affected (D n Boer et al., 1991a) methiothepin, it is likely that 5-HT
and the ergot compounds act via different (non-5-HT1B/1D) receptors.  In this context,
several subtypes of the 5-HT1 receptor family (5-HT1A, 5-ht1E and 5-HT1F) may be
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considered as possible candidates.  Whereas the involvement of 5-HT1A receptors has
already been excluded (Saxena & Villalón, 1990; Den Boer et al., 1992b), the
participation of 5-ht1E and 5-HT1F receptors is also unlikely because: (i) 5-CT, a
compound with little affinity at 5-ht1E and 5-HT1F receptors (Table 1.2), is a potent
agonist (Saxena & Verdouw, 1985a); (ii) the 5-HT-induced arteriovenous anastomotic
constriction was abolished by methiothepin (Saxena et al., 1986), but not by
GR127935 (present results), despite their similar affinities at the h5-ht1F receptor
(Table 4.1); and (iii) ergotamine and dihydroergotamine display low affinities (see
Table 7.1).
We have previously shown that the 5-HT- and ergot-induced arteriovenous
anastomotic constriction is not mediated by 5-HT2 or 5-HT3 receptors (Saxena et al.,
1983; Saxena et al., 1986; Bom et al., 1989a).  The pharmacological profile of the
receptors mediating ergot- or 5-HT-induced carotid vascular effects also seems to be
inconsistent with 5-HT4, 5-ht5 or 5-ht6 classification on the basis of: (i) the high
potency of 5-CT relative to 5-HT (Saxena & Verdouw, 1985a), n order which is
reversed for the 5-HT4 and 5-ht6 receptors (Hoyer et al., 1994); (ii) the potent
blockade of 5-HT-induced arteriovenous anastomotic constriction by methiothepin
(Saxena et al., 1986), which is inactive at 5-HT4 receptors (Hoyer et al., 1994); (iii)
dihydroergotamine displaying low affinity at gp5-HT4 receptors (Table 7.1) and; (iv)
the absence of mRNA for 5-ht5 receptors on blood vessels (Ullmer et al., 1995).
Similarly, 5-HT7 receptors are not likely to mediate constrictor responses on the basis
of positive coupling to adenylyl cyclase and, therefore, leading to an increase in
cAMP, which is associated with vasorelaxation (R nd et al., 1987; Hoyer t al.,
1994).  Additionally, sumatriptan, which potently constricts porcine arteriovenous
anastomoses, is inactive at 5-HT7 receptors (Hoyer et al., 1994).
Since in the dog the carotid vasoconstrictor effects by ergot-derivatives is
abolished by a combination of GR127935 and yohimbine (Chapter 7),
a2-adrenoceptors may have mediated the GR127935-resistant part of the ergot-
induced arteriovenous anastomotic constriction in the present experiments.  The latter
requires further investigation.
5.4.6 5-HT-induced arteriolar dilatation in cranial tissues
In accordance with earlier observations (Saxena & Verdouw, 1982; Verdouw et al.,
1984b; Saxena et al., 1986; Den Boer et al., 1992b), 5-HT produced arteriolar
5-HT receptors and porcine AVAs
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dilatation, which was confined to the head skin and ears.  As demonstrated in other
vascular preparations (see Chapters 10 and 12; Eglen et al., 1997; Saxena et al.,
1998b), it is possible that this carotid arteriolar dilatation may also be mediated by the
5-HT7 receptor.  This contention is supported by the fact that (i) the vasod lator
response is potently mimicked by 5-CT (Saxena & Verdouw, 1985a), but only weakly
by sumatriptan (see Chapter 4; Den Boer et al., 1991b) and (ii) methiothepin, a
compound with high affinity at cloned 5-HT7 receptors (see Table 10.2), acts as a
potent antagonist (Saxena et al., 1986).  Furthermore, in contrast to the vasodilator
effect of 5-HT (Figure 5.2), the sumatriptan-induced vasodilatation is abolished by
GR127935 (Chapter 4), implying the involvement of 5-HT1B/1D receptors, as also
shown in the porcine coronary artery (Schoeffter & Hoyer, 1990).  In view of the
attenuation of the ergot-induced (weak) arteriolar dilatation by GR127935
(Figure 5.5), their vasodilator effect also seems to b  mediated, at least in part, via
5-HT1B/1D receptors.
In conclusion, our results show that in pigs pretreated with ketanserin, 5-HT
constricts arteriovenous anastomoses primarily via a receptor type that cannot be
classified using guidelines for the current nomenclature.  Similarly, although the
present results demonstrate a substantial role for 5-HT1B/1D receptors, but yet to be
identified receptors mediate the GR127935-resistant part of the ergot-induced
arteriovenous anastomotic constriction.  Since previous reports have shown that
methiothepin completely blocks 5-HT-induced, but only partly attenuates the
ergot-induced arteriovenous anastomotic constriction, multiple receptors seem to be
involved.  In view of the putative role of cranial arteriovenous anastomotic dilatation
during migraine headache (Heyck, 1969; Saxena, 1995), as well as the high predictive
value of constriction of these structures in antimigraine therapy (Saxena, 1995), these
novel receptors could be a target for further antimigraine drug development
(Villalón et al., 1997b).
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Chapter 6
The porcine carotid and systemic haemodynamic effects of the
5-HT1B/1D receptor agonists, alniditan, BMS181885, avitriptan,
eletriptan and GMC2021; comparison with sumatriptan
Summary In previous studies, we have shown that sumatriptan potently constricts
porcine carotid arteriovenous anastomoses.  This effect seems to be of high predictive
value for antimigraine activity.   In the present experiments, we studied the effects of
several new tryptamine (BMS181885, avitriptan, eletriptan and GMC2021) as well as
non-tryptamine derivatives (alniditan) with high affinity at 5-HT1B/1D receptors on
systemic and carotid haemodynamics in anaesthetised pigs.  Intravenous
administrations of the above drugs decreased total carotid blood flow by a selective
vasoconstriction of the carotid arteriovenous anastomoses.  The apparent rank order of
potency was: alniditan > sumatriptan > avitriptan > eletriptan > GMC2021, whereas
BMS181885 seemed to have a lower intrinsic activity.  The arteriovenous anastomotic
constriction by alniditan, eletriptan and GMC2021 was potently, but not completely,
antagonised by 0.5mg kg-1 of GR127935.  After similar reductions in carotid blood
flow following a single 100 µg kg-1 intravenous dose at 30 min, the effect of
BMS181885 lasted longer than that of sumatriptan.  These results suggest that the new
triptans selectively constrict porcine carotid arteriovenous anastomoses mainly via
5-HT1B/1D receptors and should be able to abort migraine headaches.  The latter has
indeed been confirmed in initial clinical studies in man.  Lastly, the long-lasting effect
of BMS181885 may reduce the recurrence rate in migraine.
Based on:
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6.1 Introduction
The indole derivative sumatriptan was introduced several years ago (Humphreyet al.,
1988) and since then many studies have established the effectiveness of the drug in the
acute treatment of migraine (see Chapter 2).  Sumatriptan constricts several large
cranial and extracranial blood vessels, including porcine carotid arteriovenous
anastomoses, via 5-HT1-like receptors (Den Boer et al., 1991b).  Using the selective
5-HT1B/1D receptor antagonist GR127935 (see Chapter 3; Clitherow et al., 1994;
Pauwels, 1996; Skingle et al., 1996), it has been shown that the sumatriptan-sensive
5-HT1-like receptors in several tissues (Pauwels, 1996; Skingle et al., 1996;
Villalón et al., 1996), including porcine carotid arteriovenous anastomoses (see
Chapter 4), are identical to 5-HT1B/1D receptors.
The success of selective 5-HT1B/1D receptor agonists in the treatment of
migraine, combined with some shortcomings of sumatriptan (e.g. headache
recurrence, coronary artery constriction, low oral bioavailability) has prompted the
development of several new compounds acting specifically at this receptor class (see
Chapter 2).  Alniditan, BMS181885, avitriptan, eletriptan and GMC2021 are such
compounds.  Like sumatriptan, these compounds are substituted indoles, although
alniditan is a benzopyran derivative (see Figure 6.1).  As shown in Table 6.1, all
compounds display high affinities at the 5-HT1B/1D receptors, alniditan and
BMS181885 being the most potent.  Moreover, alniditan displays virtually no affinity
at the 5-HT1F receptor, but the highest at 5-HT1A receptors.  The 5-ht1E and 5-HT1F
receptor binding data have not been reported for avitriptan, BMS181885 and
GMC2021.
Isolated cerebral arteries potently and efficaciously constrict in response to
alniditan (Janssens et al., 1997), avitriptan (Yocca et al., 1995; Goggins et al., 1996)
and eletriptan (Gupta et al., 1999), whereas alniditan (Limmroth et al., 1997) and
eletriptan (Gupta et al., 1996) were also shown to block plasma extravasation evoked
by trigeminal ganglion stimulation in the rat dura mater.  BMS181885, however,
displayed weak activity (1,000-fold less potent than sumatriptan) in reducing
electrically-evoked plasma extravasation in guinea-pig dura-mater, yet the drug
potently constricted cranial blood vessels, although lower maximal contractions
compared to sumatriptan were reached (Yo ca et al., 1997).  Additionally, alniditan
(Van de Water t al., 1996), BMS181885 (Yocca et al., 1997), avitriptan
(Yocca et al., 1995) and eletriptan (Gupta et al., 1996) have shown to reduce carotid
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blood flow in the dog.  Interestingly, BMS181885 does not constrict the canine
saphenous vein, but even behaved as a competitive antagonist (Yocca et al., 1997),
whereas eletriptan behaves as a partial agonist in this blood vessel (Gupta et al.,
1999).
Table 6.1  Binding values of several antimigraine agents at human 5-HT1 receptor subtypes.
pKi
5-HT1A 5-HT1B 5-HT1D 5-ht1E 5-HT1F
Sumatriptana 6.4 7.8 8.5 5.8 7.9
Alniditana 8.4 9.0 9.4 6.6 6.4
BMS181885b 6.4 9.0 8.7 ND ND
Avitriptanc 7.2 7.7 8.4 ND ND
Eletriptand 7.4 8.0 8.9 7.3 8.0
GMC2021e 7.4 7.5 8.5 ND ND
pKi values are taken from: a, Leysen et al. (1996); b, Yocca et al. (1997); c, Yocca et al.
(1995); d, Napier et al. (1999); e, Saxena et al. (1996).  ND, not determined.
In the present study, we analysed the effects of alniditan, BMS181885, avitriptan,
eletriptan and GMC2021 in the porcine carotid vascular bed, with particular emphasis
on the arteriovenous anastomotic fraction, since constriction of cranial arteriovenous
anastomoses has previously been shown to be of high predictive value for
antimigraine activity (e.g. Saxena, 1995; Saxena et al., 1997).  Moreover, in the case
of alniditan, eletriptan and GMC2021 we established the contribution of 5-HT1B/1D
receptors using GR127935, at a dose capable of abolishing sumatriptan-induced
effects in the same experimental model (see Chapter 4).  The above effects were
compared to previous results obtained with sumatriptan, described in Chapter 4.
Lastly, in view of the slow dissociation rate of BMS181885 from 5-HT1B/1D receptors
(Yocca et al., 1997), we studied the duration of action of this drug, compared to that
of sumatriptan.
Alniditan, BMS181885, avitriptan, eletriptan and GMC2021
118
NH
S
NH
CH3
N
CH3 CH3
O O
SUMATRIPTAN
NH
S
OO
N
CH3
H
ELETRIPTAN
NH
S
NH
CH3
N
N
N
N
O
CH3
O O
AVITRIPTAN
NH
NHCH3
O O N
N
O
N
NCH3
BMS181885
H
NH
C
NH
N NH
ALNIDITAN
NH
O
S
CF3
O O N
CH3 CH3
GMC2021
Figure 6.1 Chemical structures of several compounds with antimigraine activity
6.2 Methods
6.2.1 General
The methods used for anaesthesia, surgical preparations and determination of systemic
and carotid haemodynamics are described in detail in Chapter 4.
6.2.2 Experimental protocol
After a stabilisation period of about 1 h, the animals were divided into three groups.
The first (n=42) and second group (n=19) were pretreated with saline or GR127935
(0.5 mg kg-1), respectively, given over a period of 5 min at a rate of 1 ml min-1 (i.v.).
After a waiting period of 15 min, baseline values of heart rate, mean arterial blood
pressure, carotid blood flow and its distribution, as well as arterial and jugular venous
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blood gases were measured.  Subsequently, the first group was subdivided into 6
subgroups, receiving sequential i.v. doses of either alniditan (3, 10, 30 and
100 µg kg-1; n=6), BMS181885 (10, 30, 100 and 300 µg kg-1; n=7), avitriptan (10, 30,
100 and 300 µg kg-1; n=7), eletriptan (10, 30, 100, 300 and 1000 µg kg-1; n=6, 9, 9, 8
and 3, respectively), GMC2021 (30, 100, 300 and 1000 µg kg-1; n=6) or saline (four
consecutive injections of 0.5 ml; n=7).  The second group was subdivided into 3
subgroups receiving alniditan (n=6), eletriptan (n=7) or GMC2021 (n=6), at the above
doses.  Each dose of the above agonists was given every 20 min.  Fifteen min after
each dose, all haemodynamic variables were assessed again.
After measuring the systemic and carotid haemodynamic variables at baseline,
the third group (n=12) was divided into two subgroups (n=6 each), receiving a single
i.v. dose (100 µg kg-1) of either sumatriptan or BMS181885.  All haemodynamic
parameters were reassessed 30, 60, 90 and 120 min after the drug administration.
6.2.3 Data presentation and statistical analysis
All data have been expressed as the mean±s.e.mean.  The significance of the
difference between the variables within one group was evaluated with Duncan's new
multiple range test, once an analysis of variance (randomised block design) had
revealed that the samples represented different populations (Steel & Torrie, 1980).
The changes caused by the agonists in the GR127935-pretreated groups were
compared to the corresponding responses in the saline-pretreated groups by using
Student's unpaired t-test.  Statistical significance was accepted at P<0.05 (two-tailed).
In the saline-pretreated groups, the agonist dose eliciting a 50% decrease (ED50) in
arteriovenous anastomotic vascular conductance was calculated using linear
regression analysis.
6.2.4 Drugs
Apart from the anaesthetics (see Chapter 4), the compounds used in this study were:
alniditan (Janssen Research Foundation, Belgium), BMS181885 and avitriptan (both
from Bristol-Myers Squibb, Wallingford, CT, USA), eletriptan (Pfizer Limited, UK),
GMC2021 (Department of Medicinal Chemistry, University of Groningen, The
Netherlands), sumatriptan succinate and GR127935 (Glaxo Group Research, Ware,
UK).  Heparin sodium (Leo Pharmaceutical Products, Weesp, The Netherlands) was
used to prevent clotting of the catheters.  All agonists were dissolved in physiological
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saline, whereas GR127935 was dissolved by heating the dispersion in distilled water
to about 70°C and then allowing to cool down to room temperature.  All doses refer to
the respective salts.
6.3 Results
6.3.1 Systemic haemodynamics
As shown in Table 6.2, bradycardia, hypotension and increases in the arteriovenous
oxygen saturation difference (A-V SO2) were observed (with maximum changes in
heart rate, blood pressure and A-V SO2, respectively) with alniditan (4±1, 23±5 and
252±78%), BMS181885 (6±2, 7±4 and 126±59%), avitriptan (17±4, 13±6 and
182±70%), eletriptan (11±3, 32±1 and 163±101%) and GMC2021 (5±1, 30±1 and
102±36%).  GR127935 attenuated the hypotension by eletriptan and GMC2021
(maximum decreases: 19±3 and 11±3%, respectively), as well as the decreases in
A-V SO2 by alniditan, eletriptan and GMC2021 (maximum changes: 57±14, 137±72
and 25±14%, respectively).  The infusions of saline were devoid of systemic effects.
As depicted in Table 6.3, a single dose (100 µg kg-1) of sumatriptan or
BMS181885 moderately decreased heart rate, which remained lower throughout the
observation period of 2 h; blood pressure was not affected by the drugs.  Whereas
sumatriptan did not change A-V SO2, BMS181885 increased this parameter from the
first dose onwards and this effect was evident even after 120 min.
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Table 6.2  Systemic haemodynamic effects after i.v. infusions of several 5-HT1B/1D receptor
agonists (µg kg-1) or corresponding volumes of saline (ml).
Alniditan Baseline 3 10 30 100
HR (beats min-1) 95±4 93±3* 92±4* 91±4* 91±4*
MAP (mmHg) 95±3 95±4 90±4* 80±3* 73±3*
A-V SO2 (%) 4.6±1.3 7.8±2.3 9.7±3.2* 13.1±3.4* 14.6±3.8*
BMS181885 Baseline 10 30 100 300
HR (beats min-1) 113±4 111±4 109±4* 108±4* 106±4*
MAP (mmHg) 95±4 97±5 97±4 94±5 88±6*
A-V SO2 (%) 14.6±3.2 19.1±4.2* 22.2±4.0* 24.2±3.8* 25.5±3.8*
Avitriptan Baseline 10 30 100 300
HR (beats min-1) 90±4 85±5 79±5* 77±5* 75±5*
MAP (mmHg) 93±5 91±4 90±5 88±5 80±5*
A-V SO2 (%) 4.4±0.5 5.1±1.2 6.9±1.1 9.5±1.9* 12.5±2.5*
Eletriptan Baseline 30 100 300 1000
HR (beats min-1) 101±3 97±3* 95±2* 92±3* 90±3*
MAP (mmHg) 96±3 89±2* 85±2* 80±3* 69±1*
A-V SO2 (%) 13.8±5.2 16.0±5.0 19.6±4.5 22.1±4.5* 32.8±4.5
GMC2021 Baseline 30 100 300 1000
HR (beats min-1) 94±2 93±2* 91±2* 90±2* 89±2*
MAP (mmHg) 98±3 94±4* 88±4* 79±3* 69±2*
A-V SO2 (%) 10.1±1.5 11.6±2.7 11.2±1.9 14.6±2.1 18.9±2.9*
Saline Baseline 0.5 0.5 0.5 0.5
HR (beats min-1) 98±2 97±2 96±2 96±2 95±2
MAP (mmHg) 100±3 95±3 96±3 96±2 97±3
A-V SO2 (%) 6.6±2.2 6.6±1.6 6.8±2.2 6.7±1.3 7.5±2.0
HR, heart rate; MAP, mean arterial blood pressure; A-V SO2, oxygen saturation difference
between arterial and jugular venous blood.  *, P<0.05 vs baseline.  The effects of 10 µg kg-1
of eletriptan are not shown.
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Table 6.3  Systemic haemodynamic effects at different time-points after a single i.v. infusion
of sumatriptan or BMS181885 in anaesthetised pigs.
Time (min) after 100 µg kg-1
Baseline 30 60 90 120
Sumatriptan
HR (beats min-1) 108±2 102±3* 99±3* 97±3* 95±2*
MAP (mmHg) 86±3 86±4 83±5 83±5 83±4
A-V SO2 (%) 17.7±4.5 20.9±6.3 19.1±5.9 18.6±5.9 18.2±5.4
BMS181885
HR (beats min-1) 111±4 100±4* 97±3* 95±4* 93±4*
MAP (mmHg) 83±1 85±4 84±5 84±6 83±7
A-V SO2 (%) 13.6±3.7 23.8±5.4* 23.1±6.5* 21.4±5.6* 23.6±7.5*
HR, heart rate; MAP, mean arterial blood pressure; A-V SO2, oxygen saturation difference
between arterial and jugular venous blood.  *, P<0.05 vs baseline.
6.3.2 Carotid haemodynamics
Alniditan, BMS181885, avitriptan, eletriptan and GMC2021, decreased total carotid
blood flow, which was in all cases entirely due to a decrease in its arteriovenous
anastomotic, non-nutrient fraction, as also observed with sumatriptan (Figure 6.2).
Nutrient blood flow increased in response to the agonists.  The decreases in
arteriovenous anastomotic blood flow were accompanied by reductions in carotid
arteriovenous anastomotic conductance (where the changes in blood flow are
corrected for changes in blood pressure), indicative of a vasoconstrictor action on
these blood vessels (Figure 6.3).
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Figure 6.2 The effect of several 5-HT1B/1D receptor agonists on porcine total carotid,
arteriovenous anastomotic (AVA) and nutrient blood flow.  *, P<0.05 vs baseline.  For
comparison, the effects of sumatriptan are given (data from Chapter 4).
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Figure 6.3 Percentage changes in arteriovenous anastomotic (AVA) conductance by
saline (4 consecutive infusions of 5 ml) and several 5-HT1B/1D receptor agonists in
anaesthetised pigs.  The dose producing a 50% decrease (ED50) and the maximum
percent changes (Emax) in AVA conductance are shown in the right panel.  All values
are presented as the mean±s.e.mean.  For comparison the effects of sumatriptan are
given (data from Chapter 4).
The rank order of agonist potency was: alniditan > sumatriptan > avitriptan >
eletriptan > GMC2021, whereas BMS181885 seemed to have a lower intrinsic activity
(see Figure 6.3).  As shown in Figure 6.4, the alniditan-, eletriptan- and GMC2021-
induced decreases in arteriovenous anastomotic conductances were potently, but not
completely, antagonised by 0.5 mg kg-1 of GR127935.
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Figure 6.4 Percent changes from baseline values caused by alniditan, eletriptan and
GMC2021 in carotid arteriovenous anastomotic conductance in pigs pretreated with
either saline (Control) or 0.5 mg kg-1 of GR127935.  +, P<0.05 vs control.
As depicted in Figure 6.5, the single dose of sumatriptan and BMS181885 decreased
total carotid and arteriovenous anastomotic blood flows.  BMS181885, but not
sumatriptan, also increased nutrient blood flow.  The effects of BMS181885 persisted
for the 120-min observation period.  In contrast, the effects of sumatriptan disappeared
after 30-60 min.
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Figure 6.5 The effects of a single infusion of sumatriptan or BMS181885 (both
100 µg kg-1, i.v.) at different time-points on total carotid, arteriovenous anastomotic
(AVA) and nutrient blood flow.  *, P<0.05 vs baseline.
Chapter 6
127
6.4 Discussion
6.4.1 Systemic haemodynamics
All 5-HT1B/1D receptor agonists produced a small bradycardia and a hypotension, of
which the decrease in blood pressure was especially pronounced with alniditan,
eletriptan and GMC2021.  This has also been observed with sumatriptan, although the
magnitude was rather small (see Chapter 4).  The decreases in blood pressure may be
related to an action at central or peripheral receptors mediating decreases in
sympathetic outflow (Saxena & Villalón, 1990).  It should be noted, however, that
alniditan, BMS181885 and sumatriptan are not able to cross the blood brain barrier
easily, due to their low lipophilicity (Saxena & Tfelt-Hansen, 1993;
Bonaventura et al., 1997); avitriptan, eletriptan and GMC2021 are more lipophilic
compounds (Rance et al., 1997, Svensson, K., personal communication).  In any case,
the hypotension may be related to an action at 5-HT1A receptors, in view of the lack
(alniditan, data not shown) or weak (eletriptan and GMC021, data not shown)
blockade by GR127935.  Indeed, these drugs display moderate affinities for the
5-HT1A receptor (see Table 6.1). In any case, no major systemic haemodynamic
changes were observed with alniditan (Goldstein et al., 1996), avitriptan (Couch et al.,
1996), eletriptan (Milton et al., 1998) and sumatriptan (Saxena & Tfelt-Hansen, 1993)
in clinical studies.
6.4.2 Carotid haemodynamics
The success of the 5-HT1B/1D receptor agonist sumatriptan in the treatment of migraine
has prompted the development of several new compounds acting specifically at this
receptor class (The Subcutaneous Sumatriptan I ternational Study Group, 1991;
Visser et al., 1996a), in order to overcome the shortcomings of sumatriptan, such as
the low oral bioavailability (Saxena & Tfelt-Hansen, 1993), headache recurrence
(Visser et al., 1996a) and coronary artery constriction (MaassenVanDenBrink et al.,
1998).
As depicted in Figure 6.2, all second-generation triptans (admittedly, alniditan
is a non-tryptamine derivative) potently and selectively decrease arteriovenous
anastomotic blood flow.  The latter is solely responsible for the decrease in total
carotid blood flow; in fact, all triptans slightly increase blood flow in the tissue
nutrient fraction (Figure 6.2), being most pronounced in the skin and ears (see
Chapter 4).  Since arteriovenous anastomotic conductance (where blood flow values
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are corrected for blood pressure changes) also decreased (Figure 6.3) the blood flow
changes were caused by a vasoconstriction of these vessels.  In keeping with a
vasoconstriction of the cranial arteriovenous anastomoses, all drugs increased
A-V SO2.
When using the dose of agonist that produced a 50 % decrease from baseline
values in arteriovenous anastomotic conductance (ED50) as a measure of potency, the
following rank order of potency was obtained (see Figure 6.3): alniditan > sumatriptan
³ avitriptan ³ eletriptan > GMC2021.  BMS181885 also seems to be a potent carotid
vasoconstrictor compound, but no ED50 value could be determined in view of its low
efficacy (Figure 6.3).  The above rank order of agonist potency closely correlates with
their reported binding values at 5-HT1B receptors (Table 6.1), although based on these
data a 5-HT1D receptor involvement cannot be excluded.  In keeping with the above,
the arteriovenous anastomotic constriction induced by sumatriptan (see Chapter 4),
alniditan, eletriptan and GMC2021 is strongly antagonised by the potent and selective
5-HT1B/1D receptor antagonist GR127935 (see Figure 6.4). The low expression of
5-HT1D receptor mRNA (Bouchelet et al., 1996) or even absence of the corresponding
protein (Longmore t al., 1997) in cephalic blood vessels, indicates that the 5-HT1B
receptor, which is abundantly expressed in cranial vasculature (Bou helet et al., 1996;
Longmore t al., 1997), is probably responsible for the constriction of arteriovenous
anastomoses.  More definitive evidence for the involvement of the 5-HT1B, but not
5-HT1D receptor, using subtype selective antagonists, is discussed in Chapters 8 and 9.
Although Bouchelet t al. (1996) also reported some 5-HT1F receptor transcript
expression in cranial blood vessels, this receptor is unlikely to be involved, in view of
the low affinity displayed by alniditan at this receptor (Table 6.1).  Moreover,
LY344864, a selective 5-HT1F receptor agonist (Table 1.2; Phebus et al., 1997), did
not produce canine external carotid vasoconstriction (Villalón, C.M., personal
communication) and SB224289, a selective 5-HT1B ligand with very low affinity for
5-HT1F receptors (Table 1.2), completely blocked sumatriptan-induced porcine and
canine carotid vasoconstriction (Chapter 8-9).
As 0.5 mg kg-1 of GR127935, a dose that abolished the sumatriptan-induced
arteriovenous anastomotic constriction (Chapter4), did not completely block the
carotid arteriovenous anastomotic constriction by alniditan, eletriptan and GMC2021,
it may be that receptors other than 5-HT1B/1D subtypes are involved.  Indeed, this also
seems to be the case for the ergotamine-, dihydroergotamine- and 5-HT- duced
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arteriovenous anastomotic constriction (Chapter 5).  On the other hand, it is possible
that higher doses of GR127935 may be needed for a complete blockade of the
alniditan-induced changes.  Unfortunately, the partial agonist property of GR127935
(Chapter 3) precludes the use of higher doses of this antagonist.  The mechanism of
action involved in the carotid vasoconstriction by BMS181885 and avitriptan was not
studied, but based on similar pharmacological profiles it is reasonable to assume that
mainly 5-HT1B/1D (most likely 5-HT1B) receptors were involved.
Similar to sumatriptan (see Figure 4.4), all triptans produced a dilatation in
carotid arterioles (nutrient vascular bed; Figure 6.2), which was observed in many
cranial tissues, being most pronounced in skin and ear.  This dilatation seems to be
due to activation of 5-HT1B/1D receptors, in view of the antagonism by GR127935.  It
is noteworthy that Schoeffter and Hoyer (1990) have reported of 5-HT receptors
similar to 5-HT1B/1D subtypes mediating endothelium-dependent relaxations in porcine
isolated coronary artery, although it may also be argued that the nutrient dilatation is
an indirect consequence of the closure of arteriovenous anastomoses.
Interestingly, despite the observation that eletriptan behaved as partial, but
sumatriptan as a full agonist in the dog saphenous vein (Gupta et al., 1999), eletriptan
was apparently as efficacious as sumatriptan in contracting the carotid arteriovenous
anastomoses.  Additionally, Gupta et al. (1999) showed that the maximum
vasoconstrictor effect of eletriptan was less in peripheral (dog saphenous vein) than
cranial (dog basilar artery) blood vessels, when compared to sumatriptan (see also
Table 2.5).  BMS181885 seems to display an even lower intrinsic efficacy than
eletriptan, since the drug is a competitive antagonist, devoid of intrinsic efficacy, in
dog saphenous vein, yet it behaves as a potent (partial) agonist in isolated cephalic
blood vessels (Yocca et al., 1997) and the porcine (see Figure 6.3), feline and canine
(Yocca et al., 1997) carotid vasculature.  This could be explained in terms of a larger
receptor reserve in the cranial circulation compared to that in the isolated saphenous
vein (Kenakin, 1984).  If other systemic vascular beds (e.g. coronary vasculature) also
exhibit less receptor expression, an antimigraine drug with partial agonist properties
may be able to exert a tissue selective pharmacological effect and, consequently, may
show less side-effects on peripheral vasculature.  The latter needs clinical
confirmation, but it has already been demonstrated that BMS181885 (Saxena et al.,
1998a), but not eletriptan (MaassenVanDenBrink et al., 1999a), is a partial agonist in
the human isolated coronary artery.
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The vasoconstrictor effects of BMS181885 on porcine carotid arteriovenous
anastomoses was qualitatively similar to that of sumatriptan, but the drug appears not
to reach full efficacy.  However, after similar reductions in carotid blood flow
following a single 100 µg kg-1 intravenous dose at 30 min the effect of BMS181885
lasted longer than that of sumatriptan (Figure 6.5).  Although differences in the
plasma half-li e values can explain the longer duration, an equally likely factor may be
the slow dissociation rate of BMS181885 from 5-HT1B/1D receptors (Yocca et al.,
1997).
6.4.3 Conclusions
In conclusion, our results show that in the anaesthetised pig, sumatriptan and the new
generation antimigraine agents, alniditan, GMC2021, avitriptan, BMS181885 as well
as eletriptan, potently and selectively constrict carotid arteriovenous anastomoses via
5-HT1B/1D receptors, of which the 5-HT1B receptor is the most likely candidate.  Since
constriction of porcine carotid arteriovenous anastomoses has over the years been
shown to be of high predictive value for antimigraine activity, all drugs with this
activity should be able to abort migraine headaches.  Indeed, this has been shown for
sumatriptan (The Subcutaneous Sumatriptan I ternational Study Group, 1991;
Visser et al., 1996a), avitriptan (Ryan et al., 1997; Schoenen, 1997), BMS181885
(Yocca et al., 1997), alniditan (Goldstein et al., 1996; Diener & De Beukelaar, 1997)
and eletriptan (Jackson, 1996).  Interestingly, BMS181885 was shown to only weakly
inhibit the trigeminally-evoked plasma protein extravasation in the guinea-pig
(Yocca et al., 1997).  The fact that the compound did produce porcine arteriovenous
anastomotic constriction and showed clinical efficacy, reinforces the idea that carotid
arteriovenous anastomotic constriction, but not inhibition of neurogenic inflammation,
is predictive of antimigraine potential (see also Chapter 2).  Mor over, the clinical
effectiveness of alniditan, which is, in contrast to sumatriptan, virtually devoid of
affinity at the h5-HT1F receptor, implies that an action at the 5-HT1F receptor is not
essential for antimigraine activity.  The longer duration of action of BMS181885 as
compared to sumatriptan in the present experiments suggests that potentially
BMS181885 may have less headache recurrence rates than sumatriptan.
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Chapter 7
Canine external carotid vasoconstriction to methysergide,
ergotamine and dihydroergotamine involves 5-HT1B/1D receptors
and a2-adrenoceptors, but not a1-adrenoceptors
Summary The antimigraine drugs methysergide, ergotamine and
dihydroergotamine (DHE) produce selective vasoconstriction in the external carotid
bed of vagosympathectomised dogs anaesthetised with pentobarbital and artificially
respired, but the receptors involved have not yet been completely characterised.  Since
the above drugs display affinity for several binding sites, including a-adrenoceptors
and several 5-HT1 and 5-HT2 receptor subtypes, this study has analysed the
mechanisms involved in the above responses.  Intracarotid (i.c.) infusions during 1-min
of methysergide (31-310 µg min-1), ergotamine (0.56-5.  µg min-1) or DHE
(5.6-31 µg min-1) dose-dependently reduced external carotid blood flow (ECBF) by up
to 46±4, 37±4 and 49±5%, respectively.  Blood pressure and heart rate remained
unchanged.  The reductions in ECBF by methysergide were abolished and even
reversed to increases in animals pretreated with GR127935 (10 µg kg-1, i.v.).  The
reductions in ECBF by ergotamine and DHE remained unchanged in animals pretreated
(i.v.) with prazosin (300 µg kg-1), but were partly antagonised in animals pretreated
with either GR127935 (10 or 30 µg kg-1) or yohimbine (1000 µg kg-1).  Pretreatment
with a combination of GR127935 (30 µgkg-1) and yohimbine (1000 µg kg-1) abolished
the responses to both ergotamine and DHE.  The above doses of antagonists were
shown to produce selective antagonism at their respective receptors. These results
suggest that the external carotid vasoconstrictor responses to methysergide primarily
involve 5-HT1B/1D receptors, whereas those to ergotamine and DHE are mediated by
5-HT1B/1D receptors as well as a2-adrenoceptors.
7.1 Introduction
Several lines of pharmacological evidence show that 5-HT and the antimigraine drug
sumatriptan constrict the carotid vascular bed in vagosympathectomised animals via
5-HT1-like receptors (Den Boer et al., 1991b; Villalón et al., 1995c).  Using the potent
and selective 5-HT1B/1D receptor antagonist, GR127935 (see Chapter 3;
Clitherow et al., 1994; Pauwels, 1996; Skingle et al., 1996), it was subsequently
demonstrated that the carotid vasoconstrictor 5-HT1-like receptors correspond to
Based on: Villalón, C.M., De Vries, P., Rabelo, G., Centurión, D., Sánchez-López, A. &
Saxena, P.R. (1999). Canine external carotid vasoconstriction to methysergide, ergotamine
and dihydroergotamine: role of 5-HT1B/1D receptors and a2-adrenoceptors. Br. J. Pharmacol.,
126, 585-594.
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5-HT1B/1D subtypes in the pig (Chapter 4) rabbit (Chapter 3) and dog (Villalón et al.,
1996).  Additionally, it has been previously shown that the classical antimigraine
agents methysergide, ergotamine and dihydroergotamine (DHE) exert a selective
vasoconstrictor action in the carotid vascular bed of several species, including dogs
(Saxena, 1974b; Saxena et al., 1983), pigs (see Chapter 5; Saxena & Verdouw, 1984;
Den Boer et al., 1991a), cats (Spierings & Saxena, 1980) and monkeys
(Mylecharane et al., 1978).
Surprisingly, very little is known about the receptor mechanisms involved in
the external carotid vasoconstriction induced by methysergide, ergotamine and DHE
in the dog.  In this respect, we have shown that vasoconstriction in the canine external
carotid bed may be mediated by activation of 5-HT1B/1D receptors (Villalón et al.,
1996), a1- and a2-adrenoceptors (Villalón & Terrón, 1994b; Terrón et al., 1996), but
not by 5-HT2 (Villalón et al., 1995c) or D2 receptors (Villalón & Terrón, 1994b).
Indeed, as shown in Table 7.1, ergotamine ad DHE are able to interact with a wide
variety of receptors mediating vasoconstriction, including 5-HT1/2 receptors and
a1/2-adrenoceptors, whereas methysergide seems to interact mainly with 5-HT1/2
receptors.  In the light of these findings, the present study set out to characterise the
pharmacological profile of the receptors involved in the vasoconstriction of the canine
external carotid vascular bed in response to methysergide, ergotamine and DHE, with
particular emphasis on verifying the possible involvement of the 5-HT1B/1D receptor
subtypes and a1- and a2-adrenoceptors.  For this purpose, we made use of antagonists
at 5-HT1B/1D receptor subtypes (GR127935; Skingle et al., 1996), a1- (prazosin) and
a2- (yohimbine) adrenoceptors (H ffman & Lefkowitz, 1996), after determining the
doses of these antagonists that produce selective blockade at their respective receptors.
Table 7.1 Pharmacological profile (pKi values, except when stated otherwise) of agonists and antagonists used in the
present study.
Receptor Methysergide Ergotamine DHE GR127935 Prazosin Yohimbine
5-HT1A 7.6a 8.4a 9.3b 7.2c 5.0a 6.9a
r5-HT1B 5.8a 8.7a 7.9b 8.5d 5.1a 5.5a
h5-HT1B ND 7.9* 9.2b 9.0c/9.9d ND ND
h5-HT1D ND 8.4* 8.6b 8.6c/8.9d ND ND
5-HT1B/1D 8.4a 7.6a 7.7b ND 7.1a 7.1a
5-ht1E 6.6e 6.2e 6.2b 5.4c/6.2d ND 5.9e
5-HT1F 7.5e 6.8e 7.0b 6.4c/7.3d ND 7.0e
5-HT2A 8.6a 7.7a 8.5b 7.8c/7.2d 5.0a 6.0a
5-HT2B UAf 8.2g 7.7g <6.0f ND 7.9f
5-HT2C 8.9h 7.3 7.5a/7.4b 7.0c/6.2d 4.7a 4.4a
5-ht5A 7.2h 7.3* 7.3* 5.2d ND 6.0h
5-ht5B 6.9h 8.5h ND ND ND 6.0h
5-ht6 6.4h ND 8.0b/6.8* 5.8c ND ND
5-HT7 7.9h 7.5h 7.8b/7.2* 6.2c/5.5d ND 5.6i
a1 5.6
j 8.0k 8.0b <6.0d 9.2j 6.4j
a2 5.6
j 8.2k 8.0b <6.0d 5.3j 6.8j
D2 6.7j 8.5k 7.0k <5.0d <6.0j 6.2j
a, Hoyer (1988), pKD value; b, Leysen et al. (1996); c, Price et al. (1997); d, Pauwels (1996); e, Adham et al. (1993);
f, Baxter et al. (1994), pA2 value; g, Glusa & Roos (1996), pEC50 value; h, Hoyer et al. (1994), pKD value; i, Bard et al.
(1993); j, Leysen (1985); k, Leysen & Gommeren (1984).  DHE, dihydroergotamine; UA, Unsurmountable Antagonist; ND,
Not Determined, r5-HT1B, rodent 5-HT1B; h5-HT1B and h5-HT1D human receptors, respectively (Hartiget al., 1996);
5-HT1B/1D refers to the, then called, 5-HT1D receptor binding site in calf caudate membrane, at which time the experimental
conditions allowed the inclusion of the 5-HT1B and 5-HT1D receptor sites.
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7.2 Methods
7.2.1 General
Experiments were carried out in a total of 72 dogs (15-31 k ) not selected for breed or
sex.  The animals were anaesth tised with an intravenous (i.v.) bolus injection of
sodium pentobarbitone (30 mg kg-1) and additional amounts (1 mg kg-1, i.v.) were
provided when required. All dogs were intubated with an endotracheal tube and
artificially respired with room air; for this purpose, a Palmer ventilation pump was
used at a rate of 20 strokes min-1 and a stroke volume of 13-16 ml kg-1, as previously
established by Kleinman & Radford (1964).  Catheters were placed in the inferior
vena cava via a femoral vein for the administration of antagonist drugs and in the
aortic arch via a femoral artery, connected to a Statham pressure transducer (P23 ID),
for the measurement of blood pressure. After drug administration, the venous catheter
was flushed with 3 ml of saline.  Heart ate was measured with a tachograph (7P4F,
Grass Instrument Co., Quincy, MA, U.S.A.) triggered from the blood pressure signal.
The right common carotid artery was dissected free and the corresponding internal
carotid and occipital arteries were ligated.  Thereafter, an ultrasonic flow probe (4 mm
R-Series) connected to an ultrasonic T201D flowmeter (Transonic Systems Inc.,
Ithaca, N.Y., U.S.A.) was placed around the right common carotid artery, and the flow
through this artery was considered as the external carotid blood flow (for further
details see Villalón et al., 1993b).  Bilateral cervical vagosympathectomy was
systematically performed in order to produce one of the main features of migraine, i.e.
external carotid vasodilatation (Saxena & De Vlaam-Schluter, 1974).  The agonists
were administered into the carotid artery by a Harvard model 901 pump (Harvard
Apparatus Co. Inc., Millis, MA, U.S.A.) with a catheter inserted into the right cranial
thyroid artery.  Blood pressure, heart rate and external carotid blood flow were
recorded simultaneously by a model 7D polygraph (Grass Instrument Co., Quincy,
MA, U.S.A.).  The body temperature of the animals was maintained between 37-38°C.
7.2.2 Experimental protocol
After a stable haemodynamic condition for at least 30 min, baseline values of blood
pressure, heart rate and external carotid blood flow were determined.  At this point,
the dogs were divided into two groups (n=56 and 16, respectively).  The first group
(n=56) was subdivided into three subgroups.  In the first subgroup (n=8), the effects of
sequential 1-min intracarotid (i.c.) infusions of methysergide (31, 100 and
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310 µg min-1) were analysed in animals pretreated i.v. with either saline (0.1 ml kg-1;
n=4) or GR127935 (10 µg kg-1; n=4).  In the second and third subgroups (n=24 each),
the effects of cumulative 1-min i.c. infusions of ergotamine (0.56, 1, 1.8, 3.1 and
5.6 µg min-1) or DHE (5.6, 10, 18 and 31 µg min-1), respectively, were analysed in
animals pretreated with i.v. infusions of either (n=4 each) saline (0.1 ml kg-1),
GR127935 (10 µg kg-1), GR127935 (30 µg kg-1), prazosin (300 µg kg-1), yohimbine
(1000 µg kg-1) or the combination of GR127935 (30 µg kg-1) and yohimbine
(1000 µg kg-1).  In the second group (n=16), all animals received subsequent 1-min
i.c. infusions of clonidine (1 µg min-1), phenylephrine (10µg min-1) and sumatriptan
(30 µg min-1).  Then, this group of animals was subdivided into four subgroups (n=4
each).  In these subgroups, the responses to clonidine, phenylephrine and sumatriptan
were reanalysed after i.v. administration of either prazosin (300 µg kg-1), yohimbine
(1000 µg kg-1), GR127935 (30 µg kg-1) or the combination of GR127935 (30 µg kg-1)
and yohimbine (1000 µg kg-1).  The dose-intervals between the different doses of
methysergide ranged between 5 and 10 min, as in each case we waited until the blood
flow had returned completely to baseline values.  Moreover, after the administration
of an antagonist or saline a period of about 10 min was allowed to elapse before the
responses to the respective agonists were elicited.
7.2.3 Data presentation and statistical evaluation
All data have been expressed as the mean±s.e.mean.  The peak changes in external
carotid blood flow (calculated as percent change from baseline) by methysergide,
ergotamine and DHE after pretreatment with a dose of a particular antagonist were
compared to the respective responses by these agonists in saline-pretreated animals by
Student's unpaired t-test.  Furthermore, the peak ercent changes in external carotid
blood flow by clonidine, phenylephrine and sumatriptan before and after antagonist
treatment were compared by using Student-Newman-Keuls test, once an analysis of
variance (randomised block design) had revealed that the samples represented
different populations (Steel & Torrie, 1980).  Statistical significance was accepted at
P<0.05 (two-tailed).
7.2.4 Drugs
Apart from the anaesthetic (sodium pentobarbitone), the drugs used in the present
study (obtained from the sources indicated) were the following: phenylephrine
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hydrochloride, clonidine hydrochloride and prazosin hydrochloride
(Sigma Chemical Company, St. Louis, MO, U.S.A.); GR127935 and sumatriptan
succinate (gifts from Dr. M. Skingle, Glaxo Group Research, Ware, Herts, UK and Dr.
H.E. Connor, Glaxo Group Research, Stevenage, Hertfordshire, UK, respectively);
methysergide maleate, DHE mesylate and ergotamine tartrate (gift: Sandoz A.G.,
Basel, Switzerland).  All compounds were dissolved in physiological saline.  When
needed, 5% (v v-1) propylene glycol (prazosin) was added; this vehicle had no effect
on the haemodynamic variables.  GR127935 was solubilised according to the
instructions of the supplier by heating the dispersion in bidistilled water to about 70°C
for 10 s and then allowing to cool down to room temperature.  All doses of antagonists
refer to the respective salts, whereas those of the agonists refer to the free base.
7.3 Results
7.3.1 Systemic haemodynamic variables
Baseline values of mean arterial blood pressure, heart rate and external carotid blood
flow in the 72 vagosympathectomised dogs were, respectively, 142±5 mmHg,
178±8 beats min-1 and 163±21 ml min-1.  No significant differences were observed in
the initial values between the 18 subgroups.  As depicted in Table 7.2, these
haemodynamic variables remained essentially unchanged after administrations of
saline, GR127935, yohimbine, or the combination of GR127935 and yohimbine, at all
doses tested.  Only prazosin produced a significant decrease in both mean blood
pressure and external carotid blood flow by 29±15% and 29±16%, respectively,
without affecting the corresponding carotid vascular conductance (not shown). This
prazosin-induced hypotension and the resulting decrease in external carotid blood
flow has previously been reported to be attributable to its a1-adrenoceptor blocking
properties (Terrón et al., 1996).  In any case, these effects were not accompanied by
changes in heart rate (Table 7.2), as previously shown by Massingham and Hayden
(1975).
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Table 7.2  Mean arterial blood pressure (MAP; mmHg), heart rate (HR; beats min-1) and
external carotid blood flow (ECBF; ml min-1) before and after i.v. administration of saline,
GR127935, prazosin, yohimbine or the combination of GR127935 and yohimbine.
Dose MAP HR ECBF
Treatment (µg kg-1) n Before After Before After Before After
Saline 0.11 12 152±11 152±12 176±12 173±11 151±8 153±6
GR127935 10 12 141±6 148±5 183±7 182±8 163±13 155±13
GR127935 30 8 137±5 145±6 181±5 181±7 134±12 127±9
Prazosin 300 8 143±8 101±14* 184±8 188±10 171±21122±15*
Yohimbine 1000 8 143±6 138±10 171±8 186±14 177±32 139±22
GR127935 30 8 138±5 128±7 176±9 199±18 170±19 143±18
+ +
Yohimbine 1000
All values have been presented as the mean±s.e.mean.  1, ml kg-1; *, P<0.05 vs before values.
7.3.2 Initial effects of methysergide, ergotamine and DHE on external carotid blood
flow
As shown in Figure 7.1, i.c. infusions (during 1 min) of methysergide (31, 100 and
310 µg min-1), ergotamine (0.56, 1, 1.8, 3.1 and 5.6 µg min-1) and DHE (5.6, 10, 18
and 31 µg min-1) produced dose-d pendent decreases in external carotid blood flow,
without changes in mean blood pressure or heart rate (not shown).  The above
responses, which were immediate in onset, are drug-induced as 1-min i.c. infusions of
the corresponding volumes of saline did not affect any haemodynamic parameter for
the duration of the experiments (data not shown).  The duration of action of
ergotamine and DHE could not be established, as external carotid blood flow did not
return to baseline values, as previously reported (Saxena, 1974a; Villalón et al., 1992).
In contrast, the duration of action of methysergide was 2.0±0.7, 7.0±1.2 and 9.0±1.9
min after 31, 100 and 310 µg min-1, respectively.  The apparent rank order of potency
obtained in the present experiments was ergotamine > DHE > methysergide
(Figure 7.1).
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Figure 7.1  Effects of 1-min i.c. infusions of ergotamine, dihydroergotamine (DHE) a d
methysergide (n=4 each) on external carotid blood flow in vagosympathectomised dogs.
All values have been presented as the mean±s.e.mean.
7.3.3 Effects of GR127935 on the methysergide-induced external carotid
vasoconstriction
As depicted in Figure 7.2, in animals pretreated with 10 µgkg-1 of GR127935, the
decreases in external carotid blood flow by methysergide were abolished and even
reversed to an external carotid vasodilatation.
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Figure 7.2  Effects of 1-min i.c. infusions of methysergide on externalcarotid blood
flow in dogs pretreated (i.v.; n=4 each) with either saline or GR127935.  All values
have been presented as the mean±s.e.mean.  *, P<0.05 vs response in saline-pretreated
animals.
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Figure 7.3  Effects of 1-min i.c. infusions of ergotamine on external carotid blood flow
in dogs pretreated (n=4 each) with either saline (control), GR127935, prazosin,
yohimbine or the combination of GR127935 and yohimbine (GR+Yoh).  All values
have been presented as the mean±s.e.mean.  For the sake of clarity, the responses to
ergotamine in control animals are shown in all panels. *, P<0.05 vs control.
7.3.4 Effects of GR127935, prazosin, yohimbine or the combination of GR127935
and yohimbine on the ergotamine- and DHE-induced external carotid
vasoconstriction
As shown in Figures 7.3 (ergotamine) and 7.4 (DHE), 10 µg kg-1 of GR127935 only
partly blocked the external carotid vasoconstrictor responses to ergotamine and DHE.
Interestingly, a higher dose of GR127935 (30 µg kg-1) did not produce a further
blockade.  Moreover, whereas prazosin (300 µg kg-1) did not affect the ergotamine-
and DHE-induced decreases in external carotid blood flow, yohimbine (1000 µg kg-1)
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brought about a partial blockade.  Significantly, the combination of GR127935
(30 µg kg-1) and yohimbine (1000 µg kg-1) completely blocked the external carotid
vasoconstriction induced by ergotamine (Figure 7.3) and DHE (Figure 7.4).  The
above doses of antagonists, as explained below, were shown to produce selective
antagonism at their respective receptors.
Figure 7.4  Effects of 1-min i.c. infusions of dihydroergotamine on external carotid
blood flow in dogs pretreated (n=4 each) with either saline (control), GR127935,
prazosin, yohimbine or the combination of GR127935 and yohimbine (GR+Yoh).  All
values have been presented as the mean±s.e.mean.  For the sake of clarity, the responses
to dihydroergotamine in control animals are shown in all panels. *, P<0.05 vs control.
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7.3.5 Effects of GR127935, prazosin, yohimbine and the combination of GR127935
and yohimbine on the external carotid vasoconstriction produced by
clonidine, phenylephrine and sumatriptan
As depicted in Figure 7.5, GR127935 (30 µg kg-1) selectively antagonised the
external carotid vasoconstriction to sumatriptan, as the responses to clonidine and
phenylephrine remained unaffected.  Similarly, prazosin (300 µg kg-1) exclusively
abolished the phenylephrine-induced decreases in external carotid blood flow, leaving
the clonidine- and sumatriptan-induced changes intact.  Lastly, while yohimbine
(1000 µg kg-1) abolished only the clonidine- nduced carotid vascular effects, the
combination of GR127935 (30 µg kg-1) and yohimbine (1000 µg kg-1) completely
blocked the clonidine-, as well as the sumatriptan-induced constriction of the canine
carotid vascular bed.  It should be pointed out that the external carotid vasoconstrictor
responses to phenylephrine, clonidine and sumatriptan are highly reproducible, as they
remained essentially unchanged in control animals receiving two subsequent bolus
injections of physiological saline (Villalón & Terrón, 1994b; Villalón et al., 1996).
7.4 Discussion
7.4.1 General
The major findings of the present study in vagosympathectomised dogs were that: (i)
the methysergide-induced external carotid vasoconstriction was abolished, and even
reversed to carotid vasodilatation, by the selective 5-HT1B/1D receptor antagonist,
GR127935 and (ii) the external carotid vasoconstrictor responses by ergotamine and
DHE were only partly antagonised by GR127935 or yohimbine, but were completely
blocked by the combination of GR127935 and yohimbine.  Apart from the
implications discussed below, these data indicate that the vasoconstrictor responses to
ergotamine and DHE in the external carotid vascular bed involve both 5-HT1B/1D
receptors and  a2-adrenoceptors, whereas methysergide seems to exert external carotid
vasoconstriction primarily via 5-HT1B/1D receptors.
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Figure 7.5  Effects of 1-min i.c. infusions of clonidine (Clo; 1 µg min-1), phenylephrine
(Phe; 10 µg min-1) or sumatriptan (Suma; 30 µg min-1) on canine external carotid blood
flow before and after i.v. administrations (n=4 each) of either GR127935 (30µg kg-1),
prazosin (300 µg kg-1), yohimbine (1000 µg kg-1) or the combination of GR127935 and
yohimbine (GR+Yoh; 30+1000 µg kg-1).  All values have been presented as the
mean±s.e.mean.  *, P<0.05 after vs before.
7.4.2 Receptors involved in the methysergide-induced carotid vasoconstrictor
responses
As previously observed using i.v. administrations (Villalón et al., 1996), 1 min i.c.
infusions of methysergide dose-dependently decreased external carotid blood flow, an
effect which has been suggested to be due to an agonist action of the ergot derivative
at smooth muscle 5-HT1-like receptors (Saxena & Verdouw, 1984; Martin, 1994).  As
methysergide did not affect heart rate or blood pressure, these data suggest that under
our experimental conditions methysergide induced a selective vasoconstriction in the
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external carotid circulation. A complete blockade of the methysergide- nduced carotid
vasoconstriction was observed after treatment with 10 µg kg-1 of GR127935; this dose
of GR127935 has previously been shown to abolish sumatriptan-induced external
carotid vasoconstriction without affecting that to noradrenaline or oxymetazoline
(Villalón et al., 1996).  In the present study, our results further demonstrate that doses
of GR127935 up to 30 µg kg-1 selectively abolish sumatriptan-induced canine external
carotid vasoconstriction, since the corresponding responses to phenylephrine and
clonidine remained unaltered (Figure 7.5), as expected from its binding profile (see
Table 7.1). Thus, these data show that methysergide constricts the external carotid
vasculature predominantly via the 5-HT1B/1D receptor subtypes, at which methysergide
displays high affinities (see Table 7.1).  In view of the complete blockade by
GR127935, as well as the low affinities exhibited by methysergide at a1- an
a2-adrenoceptors (see Table 7.1), we decided not to further analyse the effects of
prazosin or yohimbine on the methysergide-induced external carotid vasoconstriction.
7.4.3 Contribution of 5-HT1B/1D receptors in the carotid vasoconstrictor responses
to ergotamine and DHE
1 Min i.c. infusions of ergotamine and DHE induceddose-d pendent decreases in the
external carotid blood flow, without affecting heart rate or mean arterial blood
pressure. Thus, these findings suggest that such responses were caused by a selective
constriction in the external carotid vascular bed.  Notwithstanding, unlike
methysergide, the responses to ergotamine and DHE were of long duration, as
previously observed in vivo (Saxena, 1974a; Den Boer et al., 1991a; Villalón et al.,
1992; De Vries et al., 1998) and in vitro (Müller-Schweinitzer & Weidmann, 1978;
MaassenVanDenBrink et al., 1998).  Although there is no clear-cut explanation for
this difference, it has been suggested, albeit not categorically proven, that it may be
due to a slow dissociation from its receptors or a sequestration and subsequent
diffusion out of a local nonsaturable compartment (Müller-
Schweinitzer & Weidmann, 1978; Martin et al., 1995).
Regarding the possible receptor mechanisms involved in the vasoconstrictor
responses to ergotamine and DHE, previous results in anaesthetised dogs have shown
that the external carotid vasoconstrictor responses to ergotamine and DHE are not
mediated by 5-HT2 receptors, whereas only part of the effects seem to be mediated by
phentolamine-s nsitive a-adrenoceptors (Saxena et al., 1983).  Moreover, 5-HT1-like
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receptors are only partly involved in the ergotamine- and DHE-induced constriction of
the carotid vasculature in pigs (Den Boer et al., 1991a).  Since 5-HT1-like receptors
mediating porcine as well as canine carotid vasoconstriction are similar to the
5-HT1B/1D receptor subtypes (Chapter 4; Villalón et al., 1996), we decided to explore
the possible involvement of 5-HT1B/1D receptors in the present study.  Indeed, the
responses to ergotamine and DHE in dogs were, in contrast to the methysergide- and
sumatriptan-i duced effects, only partly antagonised by 10 µg kg-1 of GR127935; the
fact that pretreatment with a higher dose of GR127935 did not produce any further
blockade, implies that the ergotamine- and DHE-induced external carotid
vasoconstriction involves a mixed population of receptors.  Thus, we suggest that the
responses to ergotamine and DHE are partly mediated via 5-HT1B/1D receptors, but a
considerable part is mediated via GR127935-resistant receptors.  Consistent with these
findings, we have recently shown that ergotamine and DHE act, at least partly, via
GR127935-sensitive 5-HT1B/1D receptors in the porcine carotid vascular bed, but
additional receptors/mechanisms seem to be involved (Chapter 5).
7.4.4 Contribution of a1- and/or a2-adrenoceptors in the carotid vasoconstrictor
responses to ergotamine and DHE
As discussed above, a considerable part of the external carotid vasoconstriction by
both ergotamine and DHE is mediated by non-5-HT1B/1D receptors.  These
GR127935-resistant receptors may be of the a-adr noceptor class, as (i) agonists at
a1- and a2-adrenoceptors can produce potent vasoconstrictor responses in the carotid
circulation of dogs (Villalón & Terrón, 1994b; Terrón et al., 1996) and pigs
(Willems et al., 1999); and (ii) ergotamine and DHE display high affinities at a1- and
a2-adrenoceptors (Table 7.1).
Nevertheless, 300 µg kg-1 of prazosin, a dose which is three-fold higher than
that required to abolish methoxamine-induced canine external carotid vasoconstriction
(Terrón et al., 1996), did not affect the vasoconstrictor responses to either ergotamine
(Figure 7.3) or DHE (Figure 7.4). These results suggest that ergotamine and DHE do
not display a1-adrenoceptor agonist properties under our experimental conditions.
Indeed, this suggestion is strengthened by our results showing that the above dose of
prazosin produced a selective and complete blockade of the a1-adrenoc ptor-mediated
external carotid vasoconstriction induced by phenylephrine (Figure 7.5). It might still
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be argued that ergotamine and DHE could have behaved as a-adr noceptor
antagonists. Nonetheless, at such low total doses (5.6 and 31 µg for ergotamine and
DHE, respectively) these ergot derivatives did not modify the external carotid
vasoconstrictor responses to phenylephrine and clonidine (data not shown).
Contrasting with prazosin, yohimbine was capable of producing a partial
blockade of the vasoconstrictor responses to ergotamine and DHE (see Figure 7.3 and
7.4) at a dose (1000 µg kg-1) that selectively abolished clonidine-i duc d canine
external carotid vasoconstriction (Figure 7.5). Taken together, the above results imply
that a2-, but not a1-adrenoceptors, are involved, as previously suggested by other
studies (Müller-Schweinitzer & Weidmann, 1978; Kalkman, 1983; Müller-
Schweinitzer, 1984).
Nevertheless, it must be recognised that yohimbine also displays moderate
affinity for other receptors, including a1-adrenoceptors and 5-HT1B/1D receptors (see
Table 7.1); thus, it is reasonable to assume that the above dose of the drug could have
been high enough to block these, and other, receptors. Yet, lower doses of yohimbine
(100 and 300 µg kg-1, i.v.) did not completely block clonidine-i duc d external carotid
vasoconstriction and higher doses (3000 µg kg-1, i.v.) were not selective in our model
as they also blocked phenylephrine-induc d external carotid vasoconstriction (data not
shown). Indeed, other in vivo studies have shown that yohimbine displays moderate
selectivity for a2- over the a1-adrenoceptor in anaesthetised cats
(Ramage & Tomlinson, 1985) and dogs (Shepperson et al., 1981).
However, as shown in Figure 7.5, the antagonism produced by 1000 µg kg-1
of yohimbine at external carotid 2-receptors was selective, since this dose completely
blocked the clonidine-i duced carotid vascular effects without affecting those to
sumatriptan, which involve 5-HT1B/1D receptors (Villalón et al., 1996) and
phenylephrine, which involve a1-adrenoceptors (Villalón & Terrón, 1994b).  In any
case, the latter suggestion is validated by the fact that prazosin, at doses producing
selective a1-adrenoceptor antagonism (see above) did not affect the responses to
ergotamine and DHE.  Although beyond the scope of the present investigation, further
studies using highly selective agonists and antagonists will be required to ascertain
which specific subtype(s) of the a2-adrenoceptor is (are) producing vasoconstriction.
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7.4.5 Possible involvement of other receptors in the carotid vasoconstrictor
responses to ergotamine and DHE
As discussed above, the constriction of the canine carotid vascular bed by ergotamine
and DHE is likely to be mediated by 5-HT1B/1D receptors, as well as a2-adrenoceptors.
The question remains open, however, whether additional receptors and/or mechanisms
play a role in their effects.  For this reason we studied the effects of a combination of
GR127935 and yohimbine on the carotid vascular responses by the ergot alkaloids.
Indeed, after simultaneous, selective blockade of both 5-HT1B/1D receptors and
a2-adrenoceptors, the carotid vascular effects of ergotamine and DHE were abolished.
Therefore, the above results, taken collectively, suggest that the vasoconstriction
within the carotid vascular bed induced by ergotamine and DHE in
vagosympathectomised dogs is primarily mediated by both 5-HT1B/1D receptors and
a2-adrenoceptors.
On the other hand, since methysergide, ergotamine and DHE (as well as
GR127935 and yohimbine) display also moderate affinity for 5-HT1F receptors (see
Table 7.1), its potential role cannot be categorically excluded in the present study,
particularly when considering that mRNA for 5-HT1F receptors has been shown in
cranial blood vessels (Bouchelet et al., 1996). Indeed, sumatriptan, which displays
reasonable affinity for the recombinant 5-HT1F receptor (Table 1.2), also produced a
GR127935-sensitive vasoconstriction in the canine external carotid bed
(Villalón et al., 1996). Notwithstanding, two recent findings from our laboratory
apparently argue against the role of 5-ht1F receptors (and simultaneously reinforce the
role of 5-HT1B receptors): (i) 1 min i.c. infusions of LY344864 (1-3100 µg min
-1), a
selective 5-HT1F receptor agonist (Table 1.2; Phebus et al., 1997), did not
produce canine external carotid vasoconstriction (unpublished); and (ii) SB224289
(300 µg kg-1), a selective 5-HT1B ligand with very low affinity (pKi: <5.0) for 5-HT1F
receptors (Table 1.2), completely blocked 5-HT- as well as sumatriptan-induced
canine external carotid vasoconstriction (Chapter 8).
7.4.6 Possible involvement of external carotid vasodilator mechanisms by ergot
derivatives
Interestingly, after treatment with GR127935, not only was the methysergide-induced
carotid constriction abolished, but a clear vasodilator response was unmasked.  We
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have previously demonstrated that the 5-HT-induced external carotid vasodilatation in
GR127935-pretreated vagosympathectomised dogs is mediated via 5-HT7 receptors
(Villalón et al., 1997a), as shown in other vascular preparations (Saxena et al.,
1998b).  Therefore, it is tempting to suggest that methysergide could have acted via
smooth muscle relaxant 5-HT7 receptors, for which the compound displays high
affinity (see Table 7.1).  Nevertheless, this seems less likely, as methysergide behaves
as a silent antagonist at other cardiovascular 5-HT7 receptors, including those
mediating feline tachycardia (Chapter 12) and rat hypotension (Saxena & Lawang,
1985).  Alternatively, methysergide may have stimulated an endothelial receptor
resulting in the release of NO, possibly of the 5-HT2B receptor subtype, as shown
previously for other ergot derivatives in the porcine pulmonary circulation
(Glusa & Roos, 1996).  In support of this contention, the methysergide-induced
carotid dilatory response was inhibited in animals treated with the NO synthetase
inhibitor L-NAME (unpublished observations).
As opposed to methysergide, ergotamine and DHE did not induce any
vasodilator effects in the external carotid circulation, even after complete blockade of
the vasoconstrictor effects by GR127935 and yohimbine.  This seems to argue against
the possible involvement of endothelial dilatory (5-HT) receptors (see above), as these
ergot derivatives have been shown to be potent agonists at the (5-HT2B) receptors
mediating endothelium-dependent vasorelaxation of porcine isolated pulmonary
arteries (Glusa & Roos, 1996).  It should be noted, however, that yohimbine has been
shown to possess high antagonist affinity at 5-HT2B receptors (Table 7.1) and,
therefore, may have inhibited the potential ergot-induced vasorelaxant effects at these
receptors.  In this context, in view of the low affinity displayed by yohimbine at 5-HT7
receptors (Table 7.1), it is highly unlikely that 5-HT7 receptors mediate the potential
ergotamine- and DHE-induced external carotid vasodilatation.
In conclusion, our results show that in vagosympathectomised, anaesthetised dogs,
methysergide constricts the external carotid vascular bed predominantly via
GR127935-sensitive 5-HT1B/1D receptors.  After administration of GR127935, an
external carotid vasodilator (possibly endothelial) component was unmasked.
Additionally, the present results show the predominant involvement of both 5-HT1B/1D
receptors and a2-adrenoceptors, but not a1-adrenoceptors, in the external carotid
constriction by ergotamine and DHE.  The therapeutic efficacy of these classical
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antimigraine drugs is likely to be mediated by these receptors, as constriction of the
carotid vascular bed is highly predictive of antimigraine potential (Saxena et al.,
1997).  In this context, we have clearly demonstrated that the decrease in carotid blood
flow by antimigraine agents is exclusively due to vasoconstriction of carotid
arteriovenous anastomoses (for references see Saxena, 1995; Saxena et al., 1997),
which have been suggested to be in a dilated state during migraine headaches (e.g.
Heyck, 1969; Saxena, 1995).  Lastly, although we cannot categorically exclude other,
possibly novel receptors/mechanisms, as shown recently in the porcine carotid
vasculature (Chapter 5), it seems that, if present at all, these are of minor importance
in the dog external carotid vascular bed.
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Chapter 8
The canine external carotid vasoconstrictor 5-HT1 receptor:
blockade by 5-HT1B (SB224289), but not by 5-HT1D (BRL15572)
receptor antagonists
Summary In vagosympathectomised dogs pretreated intravenously (i.v.) with
mesulergine (300 µg kg-1), 1-minute (1-min) intracarotid (i.c.) infusions of
5-hydroxytryptamine (5-HT; 0.3-30 µg min-1) and sumatriptan (1-30 µg min-1)
dose-dependently decreased external carotid blood flow, without affecting mean blood
pressure or heart rate.  Treatment with the selective 5-HT1B receptor antagonist
SB224289 (30-300 µg kg-1, i.v.) produced a potent, specific and dose-dependent
blockade of this response, whereas the selective 5-HT1D receptor antagonist BRL15572
(30-300 µg kg-1, i.v.) was ineffective.  It is concluded that mainly 5-HT1B, but not
5-HT1D receptors mediate the canine external carotid vasoconstriction by 5-HT and
sumatriptan.
8.1 Introduction
We have previously reported that 1-minute (1-min) intracarotid (i.c.) infusions of
5-HT or sumatriptan produce selective vasoconstriction in the external carotid
vascular bed of vagosympathectomised dogs via 5-HT1-like receptors (Villalón et al.,
1995c).  Subsequently, it was shown that these 5-HT1-like receptors closely resemble
the 5-HT1B/1D receptor subtypes (Villalón et al., 1996), as they are highly sensitive to
the antagonist action of GR127935, a potent and selective 5-HT1B/1D receptor ligand
(Skingle et al., 1996).  Based on the presence of 5-HT1B, but not of 5-HT1D receptor
mRNA in vascular smooth muscle (Ullmer et al., 1995; Bouchelet et al., 1996), it was
suggested that the receptor mediating this response appears to be of the 5-HT1B
subtype (Villalón et al., 1996).  Notwithstanding, it remained virtually impossible to
pharmacologically attribute the external carotid vasoconstrictor responses to either the
5-HT1B or 5-HT1D receptor due to the lack of potent and selective ligands at these
subtypes.  In this context it should be emphasised that, in contrast to other species,
ketanserin cannot discriminate between the canine 5-HT1B and 5-HT1D receptor
subtypes (Branchek et al., 1995).  Considering the recent availability of potent and
Based on: De Vries, P., Sánchez-López, A., Centurión, D.,  Heiligers, J.P.C., Saxena, P.R.  &
Villalón, C.M. (1998). The canine external carotid vasoconstrictor 5-HT1 eceptor: blockade
by 5-HT1B (SB224289), but not by 5-HT1D (BRL15572) receptor antagonists. Eur. J.
Pharmacol., 362, 69-72 (Short communication).
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selective antagonists at either 5-HT1B (SB224289) or 5-HT1D (BRL15572) receptors
(Hagan et al., 1997), in the present study we decided to further analyse the 5-HT1B/1D
receptors involved in canine external carotid vasoconstrictor responses to 5-HT and
sumatriptan.
8.2 Methods
8.2.1 General
Experiments were carried out in a total of 12 dogs (16- 6 k ) not selected for breed or
sex.  The animals were anaesthetised with intravenously (i.v.) administered sodium
pentobarbitone (30 mg kg-1) and additional amounts (1 mg kg-1) were provided when
required.  All dogs were intubated with an endotracheal tube and artificially respired
with room air using a Palmer ventilation pump at a rate of 20 strokes min-1 and a
stroke volume of 13-16 ml kg-1.  Bilateral cervical vagosympathectomy was
systematically performed and mean arterial blood pressure and heart rate were
recorded.  The right femoral vein was cannulated for drug injection.  The right
common carotid artery was dissected free and the corresponding internal carotid and
occipital arteries were ligated.  The blood flow through the right common carotid
artery, measured with ultrasonic flowmetry, was considered as the external carotid
blood flow (for further details see Villalón et al., 1993b).  The agonists were
administered into the right common carotid artery with a cannula inserted into the
right cranial thyroid artery.  Body temperature was maintained between 37-38°C.
After a stable haemodynamic condition for at least 30 min, baseline values of
blood pressure, heart rate and external carotid blood flow were determined.  After i.v.
pretreatment with 300 µg kg-1 of mesulergine, in order to block 5-HT7
receptor-mediated external carotid vasodilatation (see Villalón et al., 1997a),
sequential 1-min intracarotid (i.c.) infus ons of 5-HT (0.3, 1, 3, 10 and 30 µg min-1),
sumatriptan (1, 3, 10 and 30 µgmin-1) and noradrenaline (0.1, 0.3, 1 and 3 µg min-1)
were given. The animals were then divided into 2 groups (n=6 each), where the
responses to the above agonists were reanalysed after i.v. treatment with 30, 100 and
300 µg kg-1 of either SB224289 or BRL15572.  The dose-intervals between the
different doses of agonists ranged between 5 and 20 min, as in each case we waited
until the blood flow had returned completely to baseline values.  After the
administration of an antagonist or saline a period of about 10 min was allowed to
elapse before the responses to the respective agonists were elicited.
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The drugs used in this study were: 5-HT creatinine sulphate and noradrenaline
bitatrate (Sigma Chemical Co., St. Louis, Mo., USA), sumatriptan succinate (gift:
Dr. M. Skingle, Glaxo Group Research, Ware, UK), mesulergine hydrochloride (gift:
Sandoz A.G., Basel, Switzerland) and SB224289 and BRL15572 (SmithKline
Beecham Pharmaceuticals, Harlow, Essex, UK).  All compounds were dissolved in
distilled water; when needed 20% (v v-1) propylene glycol (SB224289 and
BRL15572) was added, which did not affect any haemodynamic variable.  The peak
changes in external carotid blood flow by the agonists, expressed as percent changes
from baseline, before and after the different doses of antagonists were compared by
Student's paired t-test.  A P-value of 0.05 or less (two-tailed) was considered
statistically significant.  All data are reported as the mean±s.e.mean.
8.3 Results
8.3.1 Initial effects of 5-HT, sumatriptan and noradrenaline on external carotid
blood flow
Baseline values (n=12) of mean arterial blood pressure, heart rate and external carotid
blood flow were 125±2 mmHg, 175±3 beats min-1 and 184±5 mlin-1, respectively.
5-HT (0.3, 1, 3, 10 and 30 µg min-1), sumatriptan (1, 3, 10 and 30 µgmin-1) and
noradrenaline (0.1, 0.3, 1 and 3 µg min-1) produced dose-d pendent decreases in
external carotid blood flow in mesulergine-pretreated vagosympathectomised dog
(Figure 8.1).  The apparent rank order of agonist potency was noradrenaline>
5-HT³sumatriptan.  1-min i.c. infusions of corresponding volumes of saline did not
affect any haemodynamic parameter for the duration of the experiments (data not
shown).  Since the agonists were devoid of effects on mean arterial blood pressure and
heart rate (data not shown), a local vasoconstrictor effect in the external carotid
vasculature is implied, as previously discussed (Villalón et al., 1993b).  The
5-HT-induced decreases in external carotid blood flow were preceded by small,
non-dose-dependent increases in external carotid blood flow (see below).
8.3.2 Effects of SB224289 and BRL15572 on the external carotid vascular
responses to 5-HT, sumatriptan and noradrenaline
As shown in the upper panels of Figure 8.1, SB224289 dose-dependently antagonised
the external carotid vasoconstriction induced by 5-HT and sumatriptan, without
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affecting that to noradrenaline.  Additionally, after SB224289 the non-dose-depe dent
5-HT-induced increases in external carotid blood flow were potentiated and a
dose-dependency was unmasked.  The increases after 0.3, 1, 3, 10 and 30 µg min-1 of
5-HT were 6.6±2.7, 15.5±6.5, 17.2±10.3, 14.0±6.6 and 13.1±9.9 %, respectively
before SB224289 and 0.5±0.1, 7.2±3.5, 21.8±9.9, 43.6±14.8 and 63.2±17.4 %,
respectively after the highest dose of SB224289 (300 µg kg-1).  In contrast, BRL15572
did not inhibit the decreases in external carotid blood flow by either 5-HT,
sumatriptan or noradrenaline (Figure 8.1, lower panels); at 300 µg kg-1, BRL15572
even slightly enhanced the decrease in external carotid blood flow by 0.3 µg min-1 of
5-HT.  The small increases in the external carotid blood flow by 5-HT remained
unchanged after BRL15572 (data not given).  The doses of the antagonists used in this
study were devoid of any haemodynamic effects per se.
8.4 Discussion
We have previously shown that 5-HT and sumatriptan constrict the canine external
carotid vasculature via GR127935-sensitive 5-HT1B/1D receptors (Villalón et al.,
1996).  The recent availability of silent and selective antagonists for the 5-HT1B and
5-HT1D receptor subtypes led us to further analyse the receptors mediating these
responses.
5-HT, sumatriptan and noradrenaline produced external carotid
vasoconstriction with an apparent rank order of agonist potency
(noradrenaline>5-HT³sumatriptan), similar to that reported earlier (Villalón et al.,
1993b; 1995c; 1997a).  These effects are highly reproducible as they remain
essentially unchanged after 3 subsequent infusions of saline (Villalón et al., 1995c;
1996).  The 5-HT1B receptor ligand SB224289 (Table 9.1) dose-dependently
antagonised these responses and the highest dose of SB224289 virtually abolished
both the 5-HT- as well as sumatriptan-induced carotid vasoconstriction.  This
antagonism by SB224289 was specific, as the noradrenaline-induced effects remained
unaffected.  In contrast, the 5-HT1D receptor ligand BRL15572 (Table 9.1) did not
affect the carotid vascular effects of 5-HT, sumatriptan or noradrenaline in any way.
As SB224289 and BRL15572 display similar affinities at their respective receptors
(Table 9.1), the lack of inhibitory effects by BRL15572, combined with the potent
blockade by SB224289 at similar doses, clearly indicates that 5-HT1B, but not 5-HT1D
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receptors, are involved in the canine external carotid vasoconstriction by 5-HT and
sumatriptan.
Figure 8.1  The effects of SB224289 (upper panels) and BRL15572 (lower panels) on
the decreases in canine external carotid blood flow observed with 1-min intracarotid
(i.c.) infusions of 5-HT, sumatriptan or noradrenaline (NA).  All values are presented as
the mean±s.e.mean.  *, P<0.05 vs control.
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Admittedly, this conclusion is based on the assumption that species differences
between the binding of SB224289 and BRL15572 to canine and human 5-HT1B and
5-HT1D receptors do not play a major role.  In any case, the involvement of 5-HT1B,
but not 5-HT1D receptors is supported by the following observations: (i) the 5-HT-
induced contraction of the human isolated temporal artery is similarly antagonised by
SB224289 with a potency of 1 nM, but not by BRL15572 in doses up to 500 nM
(Verheggen et al., 1998); (ii) mRNA (Bouchelet et al., 1996; Verheggen et al., 1998)
and even the corresponding receptor protein (Longmoret al., 1997) of the 5-HT1B,
but not of the 5-HT1D receptor, has been detected in cranial blood vessels; and (iii)
high doses of ketanserin or ritanserin (potential 5-HT1D receptor antagonists) do not
display antagonism against sumatriptan-induced vasoconstriction (for reviews see
Kaumann et al., 1993; Saxena et al., 1998b).  Additionally, in view that SB224289
produced a complete blockade of the 5-HT- and sumatriptan-induced carotid vascular
effects, it seems highly unlikely that additional receptors/mechanisms play a role, if
any.
The 5-HT-induced decreases in external carotid blood flow, but not those to
sumatriptan and noradrenaline, were preceded by a small vasodilator response, which
was enhanced after blockade of the carotid vasoconstriction by SB224289, as also
previously observed with GR127935 (Villalón et al., 1996).   This carotid vasodilator
response was recently shown to be mediated by the 5-HT7 rec ptor (Villalón et al.,
1997a).  Indeed, due to the systematic pretreatment in the present experiments with
the 5-HT7 receptor ligand, mesulergine, the magnitude of the external carotid dilatory
responses was much less marked than that observed previously (Villalón et a .,
1997a).
In conclusion, using selective antagonists the present results obtained in the
canine external carotid vasculature represent the first i  vivo evidence that vascular
constriction induced by 5-HT and sumatriptan is mediated primarily via 5-HT1B, but
not 5-HT1D receptors.  Thus, SB224289 and BRL15572 seem to be excellent tools for
further investigating the pharmacology of the 5-HT1B/1D receptors.
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Chapter 9
Sumatriptan constricts porcine carotid arteriovenous
anastomoses via 5-HT1B receptors
Summary  It has previously been shown that the antimigraine drug sumatriptan
constricts porcine carotid arteriovenous anastomoses via 5-HT1-like receptors, identical
to 5-HT1B/1D receptors.  The recent availability of silent antagonists selective for the
5-HT1B (SB224289) and 5-HT1D (BRL15572) receptor led us to further analyse the
nature of receptors involved.  In pentobarbital-anaesthetised, bilaterally
vagosympathectomised pigs, sumatriptan (30, 100 and 300 µg kg-1, i.v.) dose-
dependently decreased carotid arteriovenous anastomotic conductance by up to 70±5%.
The dose-related decreases in carotid arteriovenous anastomotic conductance by
sumatriptan remained unchanged in animals treated (i.v.) with 1 mg kg-1 of BRL15572
(maximum decrease: 72±3%), but were significantly attenuated by 1 mg kg-1
(maximum decrease: 30±11%) and abolished by 3 mg kg-1 (maximum decrease: 3±7%)
of SB224289.  The highest dose of SB224289 did not attenuate the hypertension,
tachycardia or increases in carotid blood flow induced by bolus injections of
noradrenaline (0.1-3 µg kg-1, i.v.).  The results indicate that sumatriptan constricts
porcine carotid arteriovenous anastomoses primarily via 5-HT1B, but not via 5-HT1D
receptors.
9.1 Introduction
It has previously been shown in several species that 5-HT causes constriction within
the carotid vascular bed, predominantly via 5-HT1-like receptors and this effect is
potently mimicked by the antimigraine drug, sumatriptan (Den Boer et al., 1991b;
Villalón et al., 1995c).  The carotid vasoconstrictor effect of sumatriptan and other
acutely acting antimigraine agents is exclusively due to vasoconstriction of carotid
arteriovenous anastomoses (see Saxena et al., 1997; De Vries et al., 1999b), which may
open up during migraine headaches (Heyck, 1969; Saxena, 1995).  Since sumatriptan
displayed high affinity at the 5-HT1D receptor binding sites identified in calf and human
caudate membranes (Hoyer et al., 1994; Martin, 1994), it was suggested that "5-HT1D"
receptors were responsible for the sumatriptan-induced carotid vasoconstriction.
Presently, we know that the experimental conditions in the above experiments allowed
the inclusion of 5-HT1B, 5-HT1D as well as 5-HT1F receptors ( ee Saxena et al., 1998b).
GR127935, the first potent and selective antagonist at the "5-HT1D" receptor (see
Based on: De Vries, P., Willems, E.W., Heiligers, J.P.C., Villalón, C.M. & Saxena, P.R.
(1999). Investigation of the role of 5-HT1B and 5-HT1D receptors in the sumatriptan-induced
constriction of porcine carotid arteriovenous anastomoses.  Br. J. Pharmacol., 127, 405-412.
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Chapter 3; Clitherow et al., 1994; Pauwels, 1996; Skingle et al., 1996), was shown to
inhibit the sumatriptan-induced carotid vasoconstriction in pigs (see Chapter 4) and
dogs (Villalón et al., 1996).  In the mean time, it was demonstrated that the human
"5-HT1D" receptor was encoded by two structurally distinct genes, named 5-HT1Da nd
5-HT1Db (Weinshank et al., 1992).  The 5-HT1Db receptor was shown to be the human
homologue of the rat 5-HT1B receptor and, consequently, renamed 5-HT1B, while the
5-HT1Da receptor was renamed 5-HT1D receptor (see Figure 1.1).  Unfortunately,
GR127935 does not distinguish between these 5-HT1B and 5-HT1D receptors
(Table 9.1).  Recently, however, two new potent compounds were developed,
SB224289 (Hagan et al., 1997; Gaster et al., 1998) and BRL15572 (Price et al.,
1997), which show a high degree of selectivity for the 5-HT1B and 5-HT1D receptor,
respectively (Table 9.1).  Using these compounds, it was shown that sumatriptan-
induced canine external carotid vasoconstriction (Chapter 8) and human isolated
temporal artery contraction (Verheggen et al., 1998) as well as hypothermia induced
by SKF-99101H in the guinea-pig (Hagan et al., 1997) are mediated by
SB224289-sensitive 5-HT1B receptors, whereas the human atrium heteroreceptor
resembles BRL15572-sensitive 5-HT1D receptors (Schlicker et al., 1997).  In the light
of the availability of the above selective ligands, we decided to verify whether 5-HT1B
or 5-HT1D receptors are involved in the constriction of carotid arteriovenous
anastomoses in anaesthetised pigs by the antimigraine drug, sumatriptan.
9.2 Methods
9.2.1 General
The methods used for anaesthesia, surgical preparations and determination of systemic
and carotid haemodynamics are described in detail in Chapter 4.
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Table 9.1  pKi values of sumatriptan, GR127935, SB224289 and BRL15572 at human
cloned 5-HT1 receptor subtypes.
5-HT1A 5-HT1B 5-HT1D 5-ht1E 5-HT1F
Sumatriptana 6.4 7.8 8.5 5.8 7.9
GR127935b 7.2 9.0 8.6 5.4 6.4
SB224289c 5.5 8.0 6.2 <5.0 <5.0
BRL15572b 7.7 6.1 7.9 5.2 6.0
a, Leysen et al. (1996); b, Price et al. (1997); c, Hagan et al. (1997).
9.2.2 Experimental protocol
After a stabilisation period of about 1 h, baseline values of heart rate, mean arterial
blood pressure, carotid blood flow and its distribution, as well as arterial and jugular
venous blood gases were determined.  At this point the animals (n=21) were divided
into 4 groups, receiving an i.v. infusion (1 ml min-1 over a period of 5 min) of either
vehicle (distilled water, 20% propylene glycol, v v-1; n=6), SB224289 (1 mg kg-1;
n=6), SB224289 (3 mg kg-1; n=3) or BRL15572 (1 mg kg-1; n=6).  After a waiting
period of 15 min, all parameters were reassessed.  Subsequently, sequential i.v. doses
of sumatriptan (30, 100 and 300 µg kg-1) were given to all animals every 20 min.
15 Min after each dose of sumatriptan, all haemodynamic variables were assessed
again.  In the group treated with 3 mg kg-1 of SB224289, i.v. bolus injections of
noradrenaline (0.1, 0.3, 1 and 3 µg kg-1) were given at the start of the experiment
(before SB224289) and at the end of the experiment (after SB224289 and the 3 doses
of sumatriptan).
9.2.3 Data presentation and statistical analysis
All data have been expressed as the mean±s.e.mean.  The significance of the
difference between the variables within one group was evaluated with Duncan's new
multiple range test, once an analysis of variance (randomised block design) had
revealed that the samples represented different populations (Steel & Torrie, 1980).
The percent changes caused by sumatriptan in animals treated with SB224289 or
BRL15572 were compared to the corresponding responses in animals treated with
vehicle by using Student's unpaired t-test.  The peak changes induced by
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noradrenaline before and after 3 mg kg-1 of SB224289 were compared by Student's
paired t-test.  Statistical significance was accepted at P<0.05 ( wo-tailed).
9.2.4 Drugs
Apart from the anaesthetics, azaperone (Janssen Pharmaceuticals, Beerse, Belgium),
midazolan hydrochloride (Hoffmann La Roche b.v., Mijdrecht, The Netherlands) and
pentobarbitone sodium (Apharmo, Arnhem, The Netherlands), the compounds used in
this study were: sumatriptan succinate (gift from Dr. H.E. Connor, Glaxo Group
Research, Stevenage, Hertfordshire, UK), SB224289 and BRL15572 (both gifts from
Dr. A.A. Parsons, SmithKline Beecham Pharmaceuticals, Harlow, Essex, UK) and
noradrenaline bitatrate (Sigma Chemical Co., St. Louis, Mo., USA).  All compounds
were dissolved in distilled water; when needed 20% (v v-1) propylene glycol
(SB224289 and BRL15572) was added.  Heparin sodium (Leo Pharmaceutical
Products, Weesp, The Netherlands) was used to prevent clotting of the catheters.  All
doses refer to the respective salts.
9.3 Results
9.3.1 Systemic and carotid haemodynamic effects by vehicle, SB224289 or
BRL15572
The effects of the two antagonists and vehicle on systemic (mean arterial blood
pressure and heart rate) and carotid (total, arteriovenous anastomotic and nutrient
vascular conductances and the difference between oxygen saturation of arterial and
jugular venous blood; A-V SO2) are shown in Table 9.2.  Except for a moderate, but
significant increase in mean arterial blood pressure (12±2%) and decrease in carotid
arteriovenous anastomotic conductance (21±5%) after the 1 mg kg-1, i.v. dose of
SB224289, there were no changes in these variables.
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Table 9.2  The effects of (i.v.) vehicle, SB224289 and BRL15572 on heart rate (HR;
beats min-1), mean arterial blood pressure (MAP; mmHg), difference in arterial and
jugular venous oxygen saturation (A-V SO2; %), total carotid (TCa), arteriovenous
anastomotic (AVA) and nutrient (Nut) vascular conductances (VC;
10-2 ml min-1 mmHg-1).
HR MAP A-V SO2 TCa VC AVA VC Nut VC
Vehicle
before 93±3 105±1 5.6±0.8 116±6 92±7 24±4
after 93±2 103±3 5.1±0.7 118±6 89±7 29±3
SB224289 (1 mg kg-1)
before 100±2 94±2 8.5±1.8 138±10 109±10 29±3
after 101±2 105±4* 6.9±1.4 122±13 88±13* 35±3
SB224289 (3 mg kg-1)
before 101±6 89±2 10.8±3.8 201±44 149±35 51±10
after 103±7 96±6 10.0±4.7 174±29 119±20 55±10
BRL15572 (1 mg kg-1)
before 100±3 90±2 9.1±3.5 124±7 87±8 37±5
after 99±3 92±3 9.4±3.7 123±8 86±8 37±4
*, P<0.05 after vs before.
9.3.2 Systemic haemodynamic effects of sumatriptan in pigs treated with vehicle,
SB224289 or BRL15572
Systemic haemodynamic changes induced by sumatriptan in the 4 different treatment
groups are depicted in Table 9.3.  In vehicle-treated animals, sumatriptan slightly
decreased heart rate (maximum decrease: 4±1%) and blood pressure (maximum
decrease: 7±3%).  The sumatriptan-induced bradycardia was not affected by treatment
with either SB224289 (maximum decreases after 1 or 3 mg kg-1: 5±1% or 4±1%,
respectively) or BRL15572 (maximum decrease: 5±2%).  On the other hand, after
treatment with 1 mg kg-1 of SB224289, sumatriptan produced a significantly more
pronounced hypotension (maximum decrease: 19±3%).  Similarly, 3 mg kg-1
significantly potentiated the hypotension of SB224289 induced by 30 and 100 µg kg-1
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of sumatriptan.  Treatment with BRL15572 (1 mg kg-1) did not affect the
sumatriptan-i duced decrease in blood pressure (maximum decrease: 7±5%).
Table 9.3  Systemic haemodynamic effects of sequential doses of sumatriptan in pigs treated
with vehicle (n=6), SB224289 (1 or 3mg kg-1; n=6 or 3, respectively) or BRL15572 (n=6).
Sumatriptan (µg kg-1, i.v.)
Treatment Baseline 30 100 300
Heart rate (beats min-1)
Vehicle 93±2 91±2* 90±2* 89±2*
SB224289 (1 mg kg-1) 101±2 100±2 98±2* 96±2*
SB224289 (3 mg kg-1) 103±7 102±6 100±5* 99±5*
BRL15572 (1 mg kg-1) 99±3 98±3 96±3* 94±4*
Mean arterial blood pressure (mmHg)
Vehicle 103±3 103±4 103±4 97±5*
SB224289 (1 mg kg-1) 105±4 94±6*,+ 90±5*,+ 86±5*,+
SB224289 (3 mg kg-1) 96±6 88±7+ 81±3*,+ 81±2*
BRL15572 (1 mg kg-1) 92±3 92±2 90±3 85±4*
Arterial-jugular venous oxygen saturation difference (%)
Vehicle 5.1±0.8 7.0±0.8 11.4±2.6* 17.7±2.8*
SB224289 (1 mg kg-1) 6.9±1.4 12.1±2.8* 12.1±3.3* 14.9±2.2*
SB224289 (3 mg kg-1) 10.0±4.7 10.3±2.7 8.4±3.7 10.0±4.2+
BRL15572 (1 mg kg-1) 9.4±3.7 10.8±3.4 14.8±5.0* 18.6±4.8*
*, P<0.05 vs baseline; +, P<0.05 vs response by corresponding dose of sumatriptan in
animals treated with vehicle.
Sumatriptan dose-dependently increased A-V SO2 by up to 270±71%.  The increases
in A-V SO2 by sumatriptan were not significantly modified by treatment with
1 mg kg-1 of SB224289 or BRL15572 (maximum increases: 161±55 and 151±38%,
respectively), whereas after 3 mg kg-1 of SB224289 this effect was absent.
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9.3.3 Carotid haemodynamic effects of sumatriptan in pigs treated with vehicle,
SB224289 or BRL15572
Changes in carotid haemodynamics by sumatriptan in the 4 different groups are
depicted in Figures 9.1 (absolute values) and 9.2 (percent changes).  In vehicle-treated
animals, sumatriptan dose- ep ndently decreased total carotid blood flow and
conductance by up to 44±7% and 40±7%, respectively, accompanied by decreases in
arteriovenous anastomotic blood flow and conductance by up to 72±4% and 70±5%,
respectively.  Nutrient blood flow and conductance increased after sumatriptan by up
to 55±25% and 65±26%, respectively.  These effects of sumatriptan were
dose-dependently reduced by SB224289.  Thus, in animals treated with 1 mg kg-1 of
SB224289 the sumatriptan- nduced decreases in total carotid blood flow and
conductance amounted to only 32±6% and 17±7%, respectively, while carotid
arteriovenous anastomotic blood flow and conductance decreased by only up to
43±9% and 30±11%, respectively.  After the higher dose (3 mg kg-1) of SB224289,
the sumatriptan-induced maximal decreases in total carotid and arteriovenous
anastomotic blood flows (12±7% and 18±3%, respectively) and conductances (4±12%
and 3±7%, respectively) were completely blocked.  Treatment with BRL15572
(1 mg kg-1) did not affect the sumatriptan-induced decreases in total carotid and
arteriovenous anastomotic blood flows (maximum decreases: 37±3% and 74±3%,
respectively) and conductances (maximum decreases: 32±5% and 72±3%,
respectively).  Neither SB224289 nor BRL15572 significantly affected the increases
in nutrient blood flow and conductance.
5-HT1B receptors and porcine carotid AVAs
164
Figure 9.1  Values of total carotid, arteriovenous anastomotic (AVA) and nutrient blood
flows (left panels) and conductances (right panels) at baseline and after sumatriptan in
animals treated i.v. with vehicle (Veh; n=6), 1mg kg-1 of SB224289 (SB 1; n=6),
3 mg kg-1 of SB224289 (SB 3; n=3) or 1 mg kg-1 of BRL15572 (BRL1; n=6).  All
values are presented as the mean±s.e.mean.  *, P<0.05 vs baseline.  +, P<0.05 vs
response by corresponding dose in vehicle-treated animals.
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Figure 9.2  Effect of sumatriptan on total carotid, arteriovenous anastomotic (AVA) and
nutrient conductances in animals treated with vehicle (n=6), 1 mg kg-1 of SB224289
(n=6), 3 mg kg-1 of SB224289 (n=3) or BRL15572 (1 mg kg-1; n=6).  All values are
presented as mean±s.e.mean.  +, P<0.05 vs response by corresponding dose in
vehicle-treated animals.
9.3.4 Effect of SB224289 on noradrenaline-i duc d changes in heart rate, mean
arterial blood pressure and total carotid blood flow and conductance
As shown in Figure 9.3, bolus injections of noradrenaline (0.1-3 µg kg-1, i.v.)
produced dose-d pendent increases (with maximum changes) in heart rate (+82±7%),
mean arterial blood pressure (+31±2%) and total carotid blood flow (+26±5%)
without affecting total carotid vascular conductance (maximum change: +4±1%).  The
maximum changes by noradrenaline remained either unchanged (heart rate, 76±3%;
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mean arterial blood pressure, 43±4%; total carotid vascular conductance, 5±4%) or
were even enhanced (total carotid blood flow, 47±8%) after SB224289 (3 mg kg-1,
i.v.).
Figure 9.3 Effect of noradrenaline on heart rate, mean arterial blood pressure (MAP),
carotid blood flow (CaBF) and carotid vascular conductance (CaVC) before and after
SB224289 (3 mg kg-1, i.v.).  All values are presented as the mean±s.e.mean.  +, P<0.05
after vs before.
9.4 Discussion
9.4.1 General
We have previously shown that sumatriptan decreases porcine carotid blood flow by a
selective vasoconstriction of cranial arteriovenous anastomoses (Chapter 4;
Den Boer et al., 1991b).  The drug seems to exert this response via 5-HT1B/1D
receptors, since GR127935, a selective antagonist at these 5-HT1 receptor subtypes
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(see Chapter 3; Clitherow et al., 1994; Pauwels, 1996; Skingle et al., 1996), was able
to abolish the sumatriptan- nduced responses (Chapter 4).  The recent availability of
silent selective antagonists for the 5-HT1B (SB224289) and 5-HT1D (BRL15572)
receptors led us to further analyse the nature of the receptors mediating these
responses.  The present study in anaesthetised pigs clearly showed that the
sumatriptan-i duced carotid arteriovenous anastomotic constriction was potently and
specifically antagonised in a dose-dependent manner by the selective 5-HT1B receptor
antagonist SB224289, but not by the selective 5-HT1D receptor antagonist BRL15572.
Apart from the implications discussed below, these data indicate that the
vasoconstrictor response to sumatriptan on porcine carotid arteriovenous anastomoses
is mainly mediated by 5-HT1B receptors.
9.4.2 Systemic and carotid haemodynamic effects of vehicle, SB224289 and
BRL15572
Statistically significant changes were noticed only in the group that received the lower
dose (1 mg kg-1) of SB224289.  A moderate increase in mean arterial blood pressure
and a vasoconstrictor effect in the carotid vasculature, confined to the arteriovenous
anastomotic fraction, were observed.  We do not have a clear explanation for this, but
it is interesting to note that the 5-HT1B/1D receptor antagonist GR127935 also
constricts porcine arteriovenous anastomoses, but, in contrast to SB224289, decreases
blood pressure (Chapter 4).  Whereas the GR127935-induced carotid vasoconstriction
may be related to its intrinsic activity at the h5-HT1B receptor (Pauwels, 1996;
Selkirk et al., 1998), this seems unlikely in the case of SB224289, because this
compound rather behaves as an inverse agonist at this receptor (Selki k et al., 1998).
9.4.3 Systemic haemodynamic effects induced by sumatriptan in animals treated
with vehicle, SB224289 or BRL15572
Sumatriptan caused a small bradycardiac and hypotensive effect, similar to that
reported earlier (Chapter 4).  This seems to be a class effect of the drug, since several
other 5-HT1B/1D receptor agonists exert this effect (Chapter 6). Th  mechanism
involved in the hypotensive and bradycardiac action of sumatriptan is not clear, but
may involve sympathoinhibition either at the level of ganglia, neurovascular junction
(Jones et al., 1995; Villalón et al., 1998) or perhaps within the central nervous system
(Saxena & Villalón, 1990); the latter mechanism seems unlikely on the basis of poor
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central penetration of sumatriptan.  The hypotensive response to sumatriptan was
unaffected by GR127935 (Chapter 4), but potentiated by the 5-HT1B receptor
antagonist SB224289 (Table 9.3), suggesting that sumatriptan simultaneously
stimulates a systemic vasodilator and vasoconstrictor mechanism, of which the latter
is amenable to blockade by SB224289.  The sumatriptan-induced systemic dilatation
may involve sympathoinhibition mediated by the 5-HT1F receptor, for which
SB224289 displays a very low and GR127935 only a moderate affinity (see
Table 9.1); this possibility requires further investigation.  Whatever the mechanism,
this effect of sumatriptan is clinically of little relevance.  Sumatriptan
(MacIntyre t al., 1993), but also other 5-HT1B/1D receptor agonists, such as rizatriptan
(Sciberras et al., 1997), alniditan (Goldstein et al., 1996) and zolmitriptan
(Seaber et al., 1996) produce increases rather than decreases in blood pressure in
humans.
9.4.4 Carotid haemodynamics
Sumatriptan decreased total carotid blood flow, due to a potent vasoconstrictor action
on the cephalic arteriovenous anastomoses.  The effect was similar to that observed
earlier with this antimigraine agent (se  Chapter 4; Den Boer et al., 1991b).  In
animals treated with 1 mg kg-1 of the 5-HT1B receptor ligand SB224289, the
sumatriptan-i duced decreases in total carotid and carotid arteriovenous anastomotic
blood flow were not much affected; only at 300 µg kg-1 of sumatriptan a significant
attenuation was observed (see Figure 9.1).  However, as described above, in the
presence of SB224289 an enhancement of the sumatriptan-induced hypotension was
observed.  The latter will decrease the carotid perfusion pressure and, consequently,
may exaggerate decreases in blood flow, thereby masking possible inhibition of the
sumatriptan-i duced effects by SB224289.  Indeed, the decreases in total carotid and
carotid arteriovenous anastomotic conductance (where the changes in blood flow are
corrected for changes in blood pressure) were potently antagonised, although not
completely eliminated, in animals treated with 1 mgkg-1 SB224289 (Figure 9.3).  In
contrast, 1mg kg-1 of the 5-HT1D receptor antagonist BRL15572 did not affect the
carotid vascular effects of sumatriptan in any way.  As SB224289 and BRL15572
display similar affinities at their respective receptors (Table 9.1), the lack of inhibitory
effects by BRL15572, combined with the potent blockade by SB224289 at similar
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doses, clearly indicates that 5-HT1B, but not 5-HT1D receptors, are involved in the
vasoconstriction of carotid arteriovenous anastomoses.
Since a part of the sumatriptan-induced carotid arteriovenous anastomotic
constriction persisted after 1 mg kg-1 of SB224289, it may suggest that other
receptors/mechanisms may be involved.  Notwithstanding, we have previously shown
that 0.5 mg kg-1, but not 0.25 mg kg-1 of the 5-HT1B/1D receptor antagonist GR127935
was needed for a complete blockade of the sumatriptan-induced porcine carotid
vasoconstrictor effects (Chapter 4).  In view of the 10-fold higher affinity displayed at
the h5-HT1B receptor by GR127935 compared to SB224289 (Table 9.1), it can be
expected that higher doses of SB224289 are needed to bring about a complete
blockade.  Indeed, 3 mg kg-1 of SB224289 completely abolished all sumatriptan-
induced carotid vascular effects.  In keeping with this, we have previously shown that
3- to 10-fold higher concentrations of SB224289 (Chapter 8) than GR127935
(Villalón et al., 1996) were required to completely inhibit the canine external carotid
vasoconstriction by sumatriptan.
In order to ascertain the specificity of SB224289 (3 mg kg-1), we decided to
study cardiovascular responses to noradrenaline before and after administration of the
antagonist.  As expected, noradrenaline produced short-lasting increases in mean
arterial blood pressure, which were accompanied by increases heart rate, as the
baroreflex mediated bradycardia was absent due to vagotomy (Hoffman & Lefkowitz,
1996).  Moreover, noradrenaline increased carotid blood flow, which was mainly due
to the hypertensive effect, as carotid vascular conductance did not change in response
to the drug, as shown earlier (Verdouw et al., 1984a).  SB224289 did not attenuate
these effects; in fact, the noradrenaline-induced hypertension was potentiated,
probably resulting in an enhancement of the increases in carotid blood flow.
Therefore, it is concluded that 3mg kg-1 of SB224289 most likely produced a specific
antagonism against the sumatriptan-induced effects.  In keeping with this, SB224289
displays low affinities at a- and b-adrenoceptors (Gaster et al., 1998).
Taking the above into account, the present results imply that sumatriptan
constricts porcine arteriovenous anastomoses via the 5-HT1B receptor, which in
contrast to the 5-HT1D receptor is abundantly expressed on vascular smooth muscle
(Ullmer et al., 1995; Bouchelet et al., 1996; Longmore et al., 1997).  Moreover, the
results obtained in this study imply that the so-called 5-HT1-like receptor mediating
vascular smooth muscle contraction (Saxe a et al., 1998b), including porcine carotid
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arteriovenous anastomotic constriction (Den Boer et al., 1991b), is identical to the
5-HT1B receptor.  This is also shown in the isolated human temporal artery
(Verheggen et al., 1998) and the canine external carotid vascular bed (Chapter 8).
Additionally, in view of the complete blockade by SB224289 and the highly selective
nature of the compound, it seems unlikely that the other known 5-HT1 subtypes
(5-HT1A, 5-ht1E and 5-HT1F) are involved in the sumatriptan-induced carotid vascular
effects.  Thus, intracarotid infusions of LY344864 (1-3100 µg min-1), a selective
5-HT1F receptor agonist (Phebus et al., 1997), does not produce vasoconstriction in the
canine external carotid vascular bed (Chapter 7).  Also, mRNAs for 5-HT1A and 5-ht1E
receptor have not been detected in the vascular smooth muscle (Ullmer et al., 1995).
In conclusion, the results of the present experiments show that the constriction of
porcine carotid arteriovenous anastomoses by the 5-HT1 rec ptor agonist sumatriptan,
being antagonised by the selective 5-HT1B receptor antagonist SB224289, but not by
the 5-HT1D receptor ligand BRL15572, is mediated by 5-HT1B receptors.  In view of
the putative pathophysiological role of arteriovenous anastomotic dilatation in
migraine (Heyck, 1969; Saxena, 1995), the constriction of these non-nutrient vessels
by sumatriptan via a 5-HT1B receptor mechanism may be, at least partly, responsible
for the therapeutic effect of the drug in migraine.
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Chapter 10
Nature of 5-HT1-like receptors mediating depressor responses in
vagosympathectomised rats; close resemblance to the cloned 5-ht7
receptor
Summary It has been suggested that the late hypotensive response to 5-HT i
vagosympathectomised rats is mediated by 5-HT1-like receptors since this effect is
mimicked by 5-CT, is not modified by cyproheptadine, ketanserin or MDL72222, but it
is blocked by methysergide.  The present study was set out to reanalyse this suggestion
in terms of the classification schemes proposed in 1994 and 1996 by the NC-IUPHAR
subcommittee on the classification and nomenclature of 5-HT receptors.  I.v. bolus
injections of 5-CT (0.01-0.3 µg kg-1), 5-HT (1-30 µg kg-1) and 5-MeO-T (1-30 µg kg-1)
produced dose-d pendent hypotensive responses with a rank order of agonist potency:
5-CT >> 5-HT ³ 5-MeO-T with sumatriptan (30-10 0 µg kg-1) inactive.  The depressor
responses to 5-HT and 5-CT were not attenuated by i.v. GR127935 (300-3000 µg kg-1)
or equivalent volumes of saline.  In contrast, lisuride, methiothepin, mesulergine,
metergoline and clozapine dose-dependently antagonised the responses to 5-HT and
5-CT; the rank order of apparent pA2 values against 5-HT and 5-CT, respectively, was:
lisuride (7.7; 7.8) > methiothepin (6.8; 7.0) ³ mesulergine (6.4; 6.6) > clozapine (5.7;
5.8); metergoline displayed variable potencies (5.6; 6.4).  Except for lisuride, which
also affected  isoprenaline-induced hypotension, the antagonism by the other drugs was
specific.  Based upon the above rank order of agonist potency, the blockade by a series
of drugs showing high affinity for the cloned 5-ht7 r ceptor and the lack of blockade by
GR127935, our results indicate that the 5-HT receptor mediating hypotension in
vagosympathectomised rats is operationally similar to other putative 5-ht7 receptors
mediating vascular and non-vascular responses (e.g. relaxation of the rabbit femoral
vein, canine coronary and external carotid arteries and guinea-pig ileum as well as
feline tachycardia).
10.1 Introduction
First noticed by Page and McCubbin (1953) and later further characterised
(Kalkman et al., 1984; Saxena & Lawang, 1985; Martin et al., 1987), i.v.
administration of 5-HT produces a triphasic blood pressure response in anaesthetised
rats with intact vagus; this response consists of an initial hypotension associated with
Based on: De Vries, P., Villalón, C.M., Heiligers, J.P.C. & Saxena, P.R. (1997). Nature of
5-HT1-like receptors mediating depressor responses in vagosympathectomized rats; close
resemblance to the cloned 5-ht7 receptor. Naunyn-Schmiedebergs's Arch. Pharmacol., 356,
90-99.
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a brief, but intense, bradycardia via the von Bezold-Jarisch reflex (mediated by 5-HT3
receptors located on afferent vagal fibres), followed by a vasopressor effect (mediated
by vascular 5-HT2A receptors) and, finally, a longer-lasting hypotension (see
Chapter 3; Saxena & Villalón, 1990; 1991).  After bilateral vagosympathectomy and
5-HT2 receptor blockade, using ritanserin, in a dose proven to be sufficient to block
the pressor phase (Chapter 3), 5-HT exclusively produces the late depressor response.
This latter response, also observed in the cat (Saxen e al., 1985b; Connor et al.,
1986), has previously been ascribed to an action at vascular 5-HT1-like eceptors
(Saxena & Lawang, 1985; Saxena & Villalón, 1990; 1991), on the basis of agonism
by 5-HT, being mimicked by 5-CT, potent antagonism by the mixed 5-HT1/2 receptor
antagonists (methiothepin and methysergide) and the lack of inhibitory action by
5-HT2 (ketanserin and cyproheptadine) and 5-HT3 (MDL7222) receptor antagonists.
Notwithstanding, it has been recommended that the receptor involved should be
referred to as an atypical 5-HT1-like or even "orphan" 5-HT receptor (Hoyer et al.,
1994), mainly on the basis of the lack of agonist effect of the 5-HT1-like receptor
agonist sumatriptan (Feniuk et al., 1989; Perren t al., 1989) and contradictory
transductional properties.  Thus, according to current nomenclature, members of the
5-HT1 family are negatively coupled to adenylyl cyclase, leading to a decrease in
cAMP which is usually associated with vasoconstrictor rather than vasodilator and
concomitant hypotensive responses (Rand t al., 1987; Hoyer t al., 1994).  In keeping
with this, evidence has emerged that sumatriptan-sensitive 5-HT1-like receptors
mediating vasoconstriction resemble 5-HT1B/1D receptors  (Chapter 4; Villalón et al.,
1996), of which the 5-HT1B receptor seems to be primarily involved (see
Chapters 8 and 9; Verheggen t al., 1998).  On the other hand, the recently cloned
5-ht7 receptor (e.g. Bard et al., 1993; Ruat e al., 1993b) seems to be a suitable
candidate for responses mediated by the atypical, sumatriptan-insensitive 5-HT1-like
receptors.  Indeed, the cloned 5-ht7 receptor is coupled positively to adenylyl cyclase
and binding studies show that, as for 5-HT1-like receptors, the rat 5-h7 receptor
displays high affinity for 5-HT and 5-CT as well as for methiothepin, but low affinity
for sumatriptan and ketanserin (see Tables 10.1 and 10.2).
Therefore, in the present study, we have further characterised the late
hypotensive response to 5-HT in vagosympathectomised rats, with particular emphasis
on verifying if these receptors are operationally similar to the cloned 5-ht7 re eptor.
Although, until now, no selective 5-ht7 receptor ligands are available, we made use of
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several compounds that, according to current literature, display high affinity for, and
in some cases relative selectivity at cloned rat 5-ht7 receptors (see Tables 10.1 and
10.2).
Table 10.1  pKi values at human (except when stated otherwise) 5-HT receptors of the
agonists used in the present study.
5-CT 5-HT 5-MeO-T Sumatriptan
5-HT1A 10.3
a 9.2a 8.0b (pig) 6.4c
5-HT1B 8.9
d (rat)
8.8d
8.6d (rat)
8.5d
8.2d (rat)
8.2d
7.3d/ 6.3e (rat)
8.1d/ 7.8c
5-HT1D 9.2
f 8.4f 8.3f 8.5c
5-ht1E 5.1
g 8.0g 5.5g 5.8c/5.6g
5-HT1F 6.1
g 8.0g 5.9g 7.9c/7.6g
5-HT2A 4.7
b (rat) 5.5b (rat) 5.5b (rat) <5.5h
5-HT2B 8.0
i (rat) 8.6i (rat) 8.8i (rat) <4.5i (rat)
6.9*
5-HT2C 6.2
b (pig) 7.5b (pig) 7.6b (pig) <5.5h
5-HT3 Inactive
j (rat) 6.7j (rat) Inactivej (rat) <5.5h (mouse)
5-HT4 <5.0
k (rat) 6.8k (rat) 6.4k (rat) <5.5h (guinea-pig)
5-ht5A 9.5
j (rat) 8.1j (rat) <5.5h (rat)
5-ht5B 7.4
j (rat) 6.6j (rat)
5-ht6 6.1
l (rat) 6.8l (rat) 7.4l (rat) <5.5h
5-HT7 9.5
m (rat) 8.7m (rat) 8.7m (rat) 5.9h
*, Gupta, P, personal communication.  a, Newman-Tancredi t al. (1997); b, Hoyer (1989);
c, Leysen et al. (1996); d, Beer et al. (1998); e, Adham et al. (1992); f, Weinshank etal.
(1992); g, Adham et al. (1993); h, Napier et al. (1999); i, Baxter et al. (1994), pEC50 values;
j, Hoyer et al. (1994); k, Gerald et al. (1995); l, Monsma et al. (1993); m, Shen et al. (1993).
Table 10.2  pKi values at human (except when stated otherwise) 5-HT rec ptors of the antagonists used in the present study.
Lisuride Mesulergine Metergoline Methiothepin Clozapine GR127935
5-HT1A 9.7
a 6.8b (rat) 8.1f (pig) 7.7* 6.9d (rat) 6.9e (rat)
5-HT1B 6.7
f (rat) 5.9b (rat) 8.3g (rat)
8.6g
7.2g (rat)
7.6g
6.2d (rat)
6.2d
8.5e (rat)
9.9e
5-HT1D 8.7
h 7.7h 6.4d 8.9e
5-ht1E 6.0
i 6.7j 6.4d 6.2e
5-HT1F <5.0
j 6.5j 6.2j 6.9d 7.3e
5-HT2A 8.3
f (rat) 9.1c** (rat) 8.5c** (rat) 9.0c** (rat) 8.5d (rat) 7.2e (rat)
5-HT2B 7.9
k (rat) <6.0k (rat)
5-HT2C 7.7
f (pig) 9.1c** (pig) 10.6c** (pig) 8.2c** (pig) 7.9d (pig) 6.2e (pig)
5-HT3 <5.0
b (rat) 7.0d (mouse) 5.2e (rat)
5-HT4 Inactive
c (rat) Inactivec (rat) <5.0e
(guinea-pig)
5-ht5A <6.0
c (rat) <6.0c (rat) 7.0c (rat) 5.2e
5-ht5B <6.0
c (rat) <6.0c (rat) 7.8c (rat)
5-ht6 8.1
c (rat) 5.8c (rat) 7.5c (rat) 8.7c (rat) 8.4d (rat) 5.8l
5-HT7 9.1
m (rat) 7.7m (rat) 8.2m (rat) 9.4m (rat) 7.4m (rat) 6.2l
*, Pauwels, P.J., personal communication; **, pKB value.  a, Newman-Tancredi t al. (1997); b, Van Wijngaarden t al. (1990);
c, Hoyer et al. (1994); d, Schotte t al. (1996); e, Pauwels (1996); f, Hoyer (1989); g, Beer et al. (1998); h, Pauwels et al. (1996); i,
McAllister et al. (1992); j, Adham et al. (1993); k, Baxter et al. (1994), pA2 value; l, Price et al. (1997); m, Shen et al. (1993).
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10.2 Methods
10.2.1 General
Experiments were carried out in 98 male Wistar rats (300-350 g).  After initial
anaesthesia with ether, the trachea was cannulated and a catheter was placed in the
right external jugular vein.  At this point, ether anaesthesia was stopped and,
subsequently, the animals received i.v. bolus injections of sodium pentobarbital
(30-40 mg kg-1).  Hereafter, both vagus nerves and accompanying cervical
sympathetic trunks were cut to avoid the bradycardia and hypotension via the
von Bezold-Jarisch reflex (Paintal, 1973).  The right carotid artery was cannulated for
the recording of blood pressure, using a pressure transducer (Combitrans disposable
pressure transducer, Braun, Melsungen, Germany).  The rats were artificially
ventilated with a mixture of oxygen and room air using a respiratory pump (Infant
ventilator MK3, HoekLoos, The Netherlands) at a rate of 40 strokes min-1 (volume:
20 ml kg-1).  Heart rate was measured with a tachograph (CRW, Erasmus University,
Rotterdam, The Netherlands) triggered from electrocardiogram signals.  Both blood
pressure and heart rate were recorded simultaneously on a polygraph (CRW, Erasmus
University, Rotterdam, The Netherlands).  It should be noted that three experiments
were carried out simultaneously; because of limited channels for heart rate, this
variable was determined in only some experiments.
10.2.2 Experimental protocols
After a stabilisation period of about 30 min, baseline values of arterial blood pressure
and heart rate were determined.  Then the animals received consecutive i.v. bolus
injections, every 5-10 min, of either 5-HT (1, 3 and 10 µg kg-1; n=44, of which 17
animals received an additional dose of 30 µg kg-1), 5-CT (0.01, 0.03, 0.1 and
0.3 µg kg-1; n=42), 5-MeO-T (1, 3, 10 and 30  µg kg-1; n=6) or sumatriptan (10, 30,
100, 300 and 1000 µg kg-1; n=6) and the peak changes in mean arterial blood pressure
and heart rate were noted.
The animals receiving 5-HT were pretreated with ritanserin (50 µg kg-1, i.v.)
in order to block pressor responses.  Additionally, after each curve to 5-HT,
consecutive bolus injections of isoprenaline (0.01, 0.03 and 0.1 µg kg-1, i.v.) were
given.  For the sake of clarity, the results with isoprenaline are shown separately.
Subsequently, this group of animals was subdivided into seven treatment groups
receiving (over a 1-2 min period) either physiological saline (0.5 ml three times; n=5),
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lisuride (10, 30 and 100 µg kg-1; n=6), mesulergine (100, 300, 1000 and 3000µg kg-1;
n=6), metergoline (100, 300, 1000 and 3000 µg kg-1; n=6), methiothepin (100, 300
and 1000 µg kg-1; n=9), clozapine (300, 1000 and 3000 µg kg-1; n=6) or GR127935
(300, 1000 and 3000 µg kg-1; n=6).  Before each antagonist or saline treatment, the
animals received small i.v. bolus injections of pentobarbital (20-30 mg kg-1),
necessary to establish equal baseline values of blood pressure.  The responses to 5-HT
and isoprenaline were elicited again about 10 min after each dose of saline and
antagonists.
Similarly, the animals receiving 5-CT were subdivided into 7 treatment
groups (n=6 each) as specified above, except that the doses of lisuride used were 3, 10
and 30 µg kg-1, those of mesulergine 30, 100, 300 and 1000 µg kg-1 and those of
methiothepin were 30, 100 and 300 µg kg-1.
10.2.3 Calculation of agonist ED30 and apparent antagonist pA2 values
Hypotensive responses produced by each dose of 5-HT and 5-CT before and after
each antagonist dose were subjected to linear regression analysis to calculate ED30
values (i.e. the dose needed to decrease mean arterial blood pressure by 30 mmHg).
With the baseline dose-ratio value set to 1, agonist dose ratios after the different
antagonist doses were computed in each experiment. The conversion of the drug doses
into nmol kg-1 allowed us to perform Schild analysis to determine apparent pA2 values
of antagonists.
10.2.4 Data presentation and statistical analysis
All data in the text and illustrations are presented as the mean±s.e.mean.  The changes
from baseline in blood pressure caused by 5-HT, 5-CT and isoprenaline before and
after the different doses of antagonists were compared by the use of Duncan's new
multiple range test, once an analysis of variance (randomised block design) had
revealed that the samples represented different populations (Steel & Torrie, 1980).  A
P-value of 0.05 or less (two-tailed) was considered statistically significant.
10.2.5 Drugs
Apart from the anaesthetics, ether (Lab-scan, Dublin, Ireland) and pentobarbitone
sodium (Apharmo, Arnhem, The Netherlands), the drugs used in this study were:
GR127935 and sumatriptan succinate (GlaxoWellcome Research Ltd., Stevenage,
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UK); 5-HT creatinine sulphate (Sigma Chemical Company, St. Louis, MO, USA);
5-MeO-T hydrochloride, 5-CT maleate, ritanserin and R(+)lisuride hydrogen maleate
(all from RBI, Natick, USA); mesulergine hydrochloride and clozapine (Sandoz
Pharma Ltd., Basel, Switzerland); methiothepin maleate (Hoffman La Roche b.v.,
Mijdrecht, The Netherlands); metergoline (Farmitalia, Milan, Italy); isoprenaline
sulphate (Pharmacy Department, Erasmus University, Rotterdam, The Netherlands)
and heparin sodium (Leo Pharmaceuticals, Weesp, The Netherlands) to prevent
clotting of the catheters.  GR127935 was solubilised according to the instructions of
the supplier by the dispersion in distilled water to about 70°C for 10 s and then
allowing to cool down to room temperature.   The other antagonists were dissolved in
distilled water with the following additives: 30% methanol (ritanserin and lisuride),
30% ethanol (metergoline), 4% ascorbic acid (clozapine), 25% propylene glycol
(methiothepin); these vehicles had no effect on the haemodynamic variables or
agonist-induced responses.  The agonist drug  were dissolved in physiological saline.
All doses refer to the respective salts, whereas those of 5-HT, 5-MeO-T and 5-CT
refer to the free base.
10.3 Results
10.3.1 Blood pressure and heart rate responses to 5-HT, 5-CT, 5-MeO-T,
sumatriptan and isoprenaline
Baseline values of mean arterial blood pressure and heart rate were 106±1 mmHg
(n=98) and 361±9 beats min-1 (n=27), respectively.  As depicted in Figure 10.1 (pper
panel), i.v. bolus injections of 5-HT, 5-CT, 5-MeO-T and isoprenaline, but not of
sumatriptan, produced dose-dependent decreases in mean arterial blood pressure.  The
blood pressure effects, except with the highest dose of 5-CT, lasted 5-10 min.  The
rank order of agonist potency was 5-CT >> -HT ³ 5-MeO-T, with sumatriptan being
inactive.  Heart rate was increased by isoprenaline, but no consistent changes were
observed with the other four agonists (Figure 10.1; lower panel).  Heart rate changes
were not analysed further.
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Figure 10.1  Peak changes in mean arterial blood pressure (MAP) and heart rate (HR;
with group sizes for MAP and HR changes in brackets) by i.v. bolus injections of 5-CT
(n=42 and 7), 5-HT (n=44 and 12), sumatriptan (n=6 and 2), isoprenaline (n=44 and 12)
and 5-MeO-T (n=6 and 6) in vagosympathectomised, anaesthetised rats.  Animals
receiving 5-HT and isoprenaline were pretreated with 50 µg kg-1 of ritanserin (i.v.).
10.3.2 Hypotensive responses to 5-HT, 5-CT and isoprenaline in animals treated
with physiological saline
As shown in Figure 10.2, the hypotensive responses induced by 5-HT and 5-CT were
not much affected by treatment with physiological saline, although after the third
administration of saline the changes induced by the lower doses of 5-CT wer  slightly,
but significantly, attenuated.  The isoprenaline-induced changes in blood pressure
were significantly attenuated, especially after the third administration of saline.
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Figure 10.2  Hypotensive responses to 5-HT (n=5), 5-CT (n=6) and isoprenaline (n=5)
before (Control) and after 3 i.v. administrations of 0.5 ml of saline in
vagosympathectomised, anaesthetised rats.  Animals receiving 5-HT and isoprenaline
were pretreated with 50 µg kg-1 of ritanserin (i.v.).  *, P<0.05 vs control.
10.3.3 Effects of saline or 5-HT receptor antagonists per se on systemic
haemodynamics
While three consecutive i.v. administrations of saline (0.5 ml) or GR127935 (300-
3000 µg kg-1) did not produce any changes in blood pressure or heart rate, lisuride,
mesulergine, metergoline, methiothepin and clozapine elicited a variable pressor
response only in animals receiving 5-CT (data not given).  This increase in blood
pressure is apparently related to the antagonism of the long-lasting hypotensive effect
of the highest dose (0.3 µg kg-1) of 5-CT injected before the antagonists, since such an
increase was not observed in animals receiving 5-HT or those treated with GR127935,
which did not antagonise the effects of 5-CT (see below).
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Figure 10.3  Hypotensive responses to 5-HT before (Control) and after different doses
of 5-HT receptor antagonists (n=6 each, except for methiothepin n=9) in
vagosympathectomised, anaesthetised rats, pretreated with 50 µg kg-1 of ritanserin (i.v.).
*, P<0.05 vs control.  All the graphs after the starred (*) graph are also significantly
different from control.
10.3.4 Effects of several antagonists on the 5-HT-induced hypotensive responses
As shown in Figure 10.3, the responses to 5-HT were antagonised to varying degrees
by lisuride, mesulergine, metergoline, methiothepin and clozapine, but the 5-HT1B/D
receptor antagonist GR127935 enhanced 5-HT-in uced responses. The rank order of
antagonist potency of the different ligands against 5-HT wa : lisuride > methiothepin
³ mesulergine > clozapine =  metergoline, with GR127935 inactive (Table 10.3).
Table 10.3  Effect of saline or several antagonists (i.v.) on the dose of 5-HT ne ded to decrease blood pressure by
30 mmHg (ED30).  Dose ratios, with baseline values set to 1, are given in brackets.
Dose Salinea Lisuride Mesulergine Metergoline Methiothepin Clozapine GR127935
(µg kg-1)
Baseline 5.8±0.7
(1)
2.3±0.2
(1)
3.0±0.5
(1)
4.9±0.9
(1)
3.8±0.6
(1)
7.8±1.7
(1)
4.9±0.3
(1)
10 4.3±1.3
(0.7±0.3)
5.3±0.8*
(2.3±0.4)
- - - - -
30 4.6±1.0
(0.8±0.2)
45.5±13.2*
(17.8±3.9)
- - - - -
100 4.7±0.8
(0.8±0.1)
175.9±50.3*
(82±29.3)
4.3±0.8
(1.5±0.2)
4.9±0.7
(1.1±0.0)
11.8±2.4*
(4.1±0.9)
- -
300 - - 7.6±0.5*
(3.1±0.6)
6.5±1.7
(1.3±0.3)
28.4±6.3*
(9.9±2.6)
7.8±1.1
(1.1±0.2)
5.1±0.4
(1.1±0.1)
1000 - - 10.6±0.9*
(4.4±1.1)
7.3±1.4*
(1.6±0.1)
128.1±31.8*
(34.8±9.3)
11.9±1.6
(1.8±0.4)
4.7±0.3
(1.0±0.1)
3000 - - 32.6±4.4*
(12.3±1.9)
51.6±15.9*
(12.1±3.1)
- 22.8±3.1*
(3.5±0.6)
4.4±0.2
(0.9±0.1)
"pA2" - 7.7±0.1 6.4±0.2 5.6±0.1 6.8±0.2 5.7±0.2 -
Values are presented as the mean±s.e.mean.  *, P<0.05 vs Control.  a, 3 consecutive infusions of saline (0.5 ml)
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Figure 10.4  Hypotensive responses to 5-CT before (Control) and after different doses
of 5-HT receptor antagonists (n=6 each) in vagosympathectomised, anaesthetised rats.
*, P<0.05 vs control.  All the graphs after the starred (*) graph are also significantly
different from control.
10.3.5 Effects of several antagonists on the 5-CT-induced hypotensive responses
As shown in Figure 10.4, the responses to 5-CT were antagonised by lisuride,
mesulergine, metergoline, methiothepin and clozapine, whereas GR127935 only
slightly attenuated the effects of the highest dose of 5-CT.  The rank order of
antagonist potency against 5-CT was: lisuride > methiothepin ³ mesulergine =
metergoline > clozapine (Table 10.4).
Table 10.4  Effect of saline or several antagonists (i.v.) on the dose of 5-CT ne ded to decrease blood pressure by
30 mmHg (ED30).  Dose ratios, with baseline values set to 1, are given in brackets.
Dose Salinea Lisuride Mesulergine Metergoline Methiothepin Clozapine GR127935
(µg kg-1)
Baseline 0.06±0.01
(1)
0.06±0.01
(1)
0.07±0.01
(1)
0.06±0.00
(1)
0.12±0.02
(1)
0.08±0.01
(1)
0.05±0.00
(1)
3 0.07±0.01
(1.2±0.2
0.05±0.01
(0.9±0.1)
- - - - -
10 0.09±0.01*
(1.7±0.3)
0.2±0.03*
(6.2±2.7)
- - - - -
30 0.09±0.01*
(1.7±0.2)
2.79±1.04*
(48.3±17.7)
0.07±0.00
(1.1±0.1)
- 0.28±0.04*
(2.8±0.6)
- -
100 - - 0.16±0.01*
(2.6±0.4)
0.09±0.01*
(1.6±0.2)
0.47±0.05*
(4.7±1.0)
-
300 - - 0.36±0.02*
(5.9±0.8)
0.19±0.02*
(3.3±0.3)
1.97±0.22*
(19.3±2.7)
0.12±0.01*
(1.5±0.1)
0.05±0.00
(1.1±0.1)
1000 - - 1.63±0.2*
(26.1±4.3)
0.56±0.05*
(9.6±1.0)
- 0.30±0.02*
(4.2±0.5)
0.05±0.00
(1.0±0.1)
3000 - - - 2.08±0.26*
(36.0±4.9)
- 0.86±0.09*
(12.4±2.3)
0.04±0.00
(1.0±0.1)
"pA2" - 7.8±0.1 6.6±0.1 6.4±0.1 7.0±0.1 5.8±0.1 -
Values are presented as the mean±s.e.mean.  *, P<0.05 vs Control.  a, 3 consecutive infusions of saline (0.5 ml)
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Figure 10.5  Hypotensive responses to isoprenaline before (Control) and after different
doses of 5-HT receptor antagonists (n=6 each, except for methiothepin n=9) in
vagosympathectomised, anaesthetised rats, pretreated with 50 µg kg-1 of ritanserin (i.v.).
*, P<0.05 vs control.  All the graphs after the starred (*) graph are also significantly
different from control.
10.3.6 Effects of several antagonists on the isoprenaline-induced hypotensive
responses
As shown in Figure 10.5, the isoprenaline-induced hypotensive responses were clearly
attenuated only by lisuride; the other drugs, except for a slight reduction (at one
agonist and antagonist dose) by methiothepin and clozapine, did not cause any
reduction in the responses elicited by isoprenaline.  As was the case with 5-HT,
isoprenaline-induced responses were also slightly enhanced by GR127935.
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10.4 Discussion
10.4.1 Effect of 5-HT receptor agonists on mean arterial blood pressure
As described earlier (Kalkman et al., 1984; Saxena & Lawang, 1985; Martin et al.,
1987), the present results show that 5-HT receptor agonists dose- ep ndently decrease
blood pressure; these responses were reproducible as they remained essentially
unchanged in control animals receiving saline.  The apparent rank order of potency
was: 5-CT >> 5-HT ³ 5-MeO-T.  This characteristic is in keeping with the
involvement of 5-HT1-like receptors (see Table 10.1), which have been proposed to
mediate depressor responses (Kalkman et al., 1984; Saxena & Lawang, 1985;
Martin et al., 1987). Notwithstanding, it was already recognised before
(Saxena & Lawang, 1985; Martin et al., 1987), that the responses mediated by
5-HT1-like receptors could be subdivided into at least two operationally distinct
receptors, mainly on the basis of their differential sensitivity to the action of
5-HT1-like receptor agonists, such as 8-OH-DPAT, indorenate, RU24969 and/or
sumatriptan (e.g. Saxena & Villalón, 1990; Den Boer et al., 1991b; Villalón et al.,
1993b; 1995a; 1995c).  Interestingly, recent studies have provided evidence that
several of these 5-HT1-like receptor-mediated responses are, in fact, identical to the
5-HT1B receptor.  The latter is mainly based on the agonism by sumatriptan and potent
antagonism by the selective 5-HT1B/1D receptor ligand, GR127935 and the 5-HT1B
receptor antagonist, SB224289, but lack of effect by the 5-HT1D rec ptor antagonist
BRL15572 (see Chapters 4, 8 and 9; Villalón et al., 1996).  In marked contrast, the
present experiments show that sumatriptan did not mimic nor did it antagonise (data
not shown) the effects of 5-HT and 5-CT, thereby excluding the involvement of
5-HT1B/1D receptors.  Notwithstanding, the agonists in the present study display a
pharmacological profile that closely parallels that of cloned 5-ht7 rec ptors (see
Table 10.1).
As shown in Chapter 3, 50 µg kg-1 of ritanserin proved to be sufficient to
prevent the 5-HT-induced pressor responses.  We have decided not to administer
ritanserin to the animals receiving 5-CT, as the latter compound does not produce
pressor responses in rats (Saxena & Lawang, 1985; Saxena & Villalón, 1990).
However, in view of the appreciable affinity (pKi: 7.2) displayed by ritanserin at 5-ht7
receptors (Lovenberg et al., 1993), theoretically this compound could have affected
the 5-HT-induced dose-r sponse curves.  Notwithstanding, this does not seem to be
the case, since (i) 100 µg kg-1 of ritanserin did not affect the 5-ht7 receptor-mediated
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dilatation of the canine external carotid vasculature by 5-HT, 5-CT and 5-MeO-T
(Villalón et al., 1997a), and (ii) 50 µg k -1 of ritanserin did not affect rat hypotensive
responses induced by 1, 3, 10 and 30 µg kg-1 of 5-MeO-T (4.2±1.1, 8.0±1.3, 18±0.6
and 28.8±3.6 mmHg before and 4.2±1.1, 5.2±0.5, 14.5±1.9 and 31.5±4.1 mmHg after
ritanserin, respectively; Villalón, unpublished).
10.4.2 Do rat depressor responses involve any of the known 5-HT1 receptor
subtypes?
Although the above agonist profile already excludes sumatriptan-sensitive 5-HT1-like
as well as 5-HT1B/1D receptors (see above), the 5-HT1 receptor family includes several
other subtypes (5-HT1A, 5-ht1E and 5-HT1F, see Chapter 1).  However, the involvement
of the above 5-HT1 subtypes in the present study is not likely because 5-CT (with a
very high potency), but not sumatriptan, mimicked 5-HT in eliciting hypotension,
whereas 5-CT and sumatriptan display low and high affinities at the 5-ht1F receptor
(Table 10.1).  This suggestion is reinforced when considering that: (i) mesulergine and
clozapine, which specifically antagonised the responses to 5-HT and 5-CT in our
experiments, do not bind potently to the 5-HT1 receptor subtypes (Table 10.2) and (ii)
the 5-HT1 family is, by definition, negatively coupled to adenylyl cyclase
(Hoyer et al., 1994), leading to a decrease in cAMP, which is usually associated with
vasoconstriction and hypertension, not hypotension (Rand et al., 1987).
10.4.3 Lack of resemblance of the rat 5-HT receptor mediating hypotension with
either 5-HT2, 5-HT3, 5-HT4, 5-ht5 or 5-ht6  receptors
The pharmacological profile of the 5-HT receptors mediating hypotension i  the
vagosympathectomised, ritanserin-treated rat also seems to be inconsistent with a
5-HT2, 5-HT3, 5-HT4 or 5-ht6 classification on the basis of: (i) the high potency of
5-CT relative to 5-HT (present results; Saxena & Lawang, 1985), an order which is
reversed for the aforementioned types (Table 10.1); (ii) insensitivity to antagonism by
high doses of the 5-HT2 receptor antagonists ketanserin, cyproheptadine
(Saxena & Lawang, 1985) and ritanserin (De Vries et al., 1997a); (iii) resistance to
antagonism by MDL72222  (Dalton et al., 1986) at doses that block the 5-HT3
receptor-mediated von Bezold-Jarisch reflex; (iv) the ability of 5-MeO-T to induce
depressor responses in rats, a compound that is inactive at 5-HT3 r ceptors
(Table 10.1); (v) the antagonism of hypotensive responses by methiothepin,
Chapter 10
187
mesulergine and metergoline, which are inactive at 5-HT4 r ceptors (see Table 10.2);
(vi) the potent blockade by mesulergine, a compound displaying low affinity for 5-ht6
receptors as compared to 5-ht7 receptors (Table 10.2).
Interestingly, 5-CT (Table 10.1) and methiothepin (Table 10.2) display a
relatively high affinity for the recombinant 5-ht5A and 5-ht5B receptors.  This,
therefore, raises the question whether the cloned 5-ht5 receptors are related to the
5-HT receptors mediating depressor responses in the rat.  However, the potent
antagonism by mesulergine and metergoline, which do not seem to interact with 5-ht5A
and 5-ht5B receptors (see Table 10.2), does not support this possibility.  Consistent
with the above, it is worthy of note that no mRNA expression for 5-HT1A, 5-HT1D,
5-HT1F, 5-HT2C, 5-HT4, 5-ht5A/B and 5-ht6 receptors was detected in rat blood vessels.
In contrast, 5-ht7 receptor mRNA, as well as that of 5-HT1B, 5-HT2A/B receptors, was
strongly expressed (Ullmer et al., 1995).
10.4.4 Resemblance of the rat 5-HT receptor mediating hypotension to cloned 5-ht7
receptors
In keeping with the agonist profile found in the present study, and the unlikely
involvement of 5-HT1-5ht6 receptors (see above), the different antagonists displayed a
pharmacological profile against the 5-HT- and 5-CT-induced depressor responses that
is consistent with the involvement of functional 5-ht7 receptors.  Indeed, all
compounds used in the present study, displaying high affinities at cloned 5-ht7
receptors, antagonised the depressor responses.  Furthermore, we calculated apparent
pA2 values for the antagonists against 5-CT- and 5-HT-induced depressor responses.
Admittedly, to apply Schild analysis to in vivo data, we had to assume equilibrium
conditions of the compounds under study, for which we cannot provide supporting
evidence in the present experimental set-up.  However, recognising the limitations of
calculating pA2 values in an i  vivo setting, we believe that it is still an appropriate
and illustrative approximation, which provides a useful apparent rank order of
antagonist potency.  The rank order of antagonist potency (with apparent pA2 values
against 5-HT- and 5-CT-induced depressor responses, respectively) obtained in the
present study was lisuride (7.7; 7.8) > methiothepin (6.8; 7.0) ³ mesulergine (6.4; 6.6)
> clozapine (5.7; 5.8), while metergoline displayed variable potencies (5.6; 6.4) and
GR127935 was inactive.  This order of potency resembles the order of pKi valu s
against cloned rat 5-ht7 receptors, which is: methiothepin (9.4) ³ lisuride (9.1) >
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metergoline (8.2) > mesulergine (7.7) ³ clozapine (7.4) >> GR127935 (6.2).   Since
the potencies of these compounds were almost equal in groups of animals receiving
5-HT or 5-CT, a common site of action is implied.  However, metergoline seemed to
be a more potent antagonist against 5-CT than it was against 5-HT-induced depressor
responses (apparent pA2 values of 6.4 and 5.6, respectively).  Although we have no
direct explanation for this, it should be noted that the reported pKi values for
metergoline against rat cloned 5-ht7 receptors also vary (7.2-8.2) (Lovenberg et al.,
1993; Ruat et al., 1993b; Shen t al., 1993).
Except for lisuride, which attenuated isoprenaline-induced decreases in blood
pressure, all compounds acted as specific antagonists.  GR127935, a selective
5-HT1B/1D receptor antagonist (Table 10.2), was devoid of blocking properties against
the depressor responses.  Combined with the lack of agonism by sumatriptan, this
property clearly shows that the hypotensive responses are not mediated by
5-HT1-like/1B/1D receptors.  Interestingly, GR127935 potentiated the depressor responses
induced by 5-HT, most probably due to the moderate blocking properties of this
compound at rat vasopressor 5-HT2 receptors (Chapter 3).  Although the rats were
systematically pretreated with ritanserin, a part of the pressor response, though
present, may have been overshadowed by the hypotensive effect.  Admittedly, a
(small, but significant) potentiating effect was also observed with isoprenaline, but to
a much lesser extent.  In keeping with the above explanation, GR127935 did not
modify hypotensive responses induced by 5-CT, a compound devoid of interactions
with 5-HT2A receptors.
In the light of the above lines of pharmacological evidence, the involvement
of putative 5-ht7 receptors mediating the late hypotensive response to 5-HT in
vagosympathectomised rats is substantiated, as recently shown for other functional
5-ht7 receptors, both in in vitro (Carter et al., 1995; Martin & Wilson, 1995;
Leung et al., 1996; Hirst e al., 1997) as well as in in vivo (see Chapter 12;
Villalón et al., 1997a; 1997c) studies.
10.4.5 Considerations of other possible mechanisms involved in the 5-HT-i duc d
late hypotensive response in vagosympathectomised rats
In the present experiments we deliberately made use of an intact rat model; only
bilateral vagosympathectomy was performed to avoid the von Bezold-Jarisch reflex
(Paintal, 1973).  The advantage of this preparation, compared to the frequently utilised
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pithed rat model, is that a more physiological (normotensive) condition is
approximated.  On the other hand, the main disadvantage is that several mechanisms
could contribute simultaneously to the hypotensive action of 5-HT receptor agonists.
Indeed, four major mechanisms are believed to play a role in 5-HT rec ptor-mediated
vasorelaxation and hypotension, namely (i) inhibition of central vasomotor loci, (ii)
endothelial NO release, (iii) prejunctional inhibition of sympathetic outflow, and (iv)
direct vascular smooth muscle relaxation (Saxena & Villalón, 1990).  Nevertheless, as
5-HT,  5-MeO-T and 5-CT are not able to cross readily the blood-brain barrier, the
first of these mechanisms can be excluded in the present experimental set-up.  The
second mechanism is similarly unlikely to play a major role, as the NO synthetase
inhibitor L-NAME does not attenuate 5-HT- or 5-CT-induced depressor responses in
pithed rats (Van Gelderen & Saxena, 1992).  Additionally, the 5-HT receptors found
to be involved in endothelium dependent vasorelaxation (Martin et al., 1987;
Schoeffter & Hoyer, 1990; Glusa & Richter, 1993) display different pharmacological
profiles, compared to the one found in the present study.  Thirdly, the inhibition of
sympathetic vasopressor responses in pithed rats by 5-HT is mediated via
prejunctional 5-HT1-like receptors probably resembling 5-HT1A/1B/1D receptors, on the
basis of agonism by sumatriptan, as well as antagonism of this response by GR127935
(Chapter 13) and, consequently, this mechanism does not se m to be involved in
dilatation of the rat systemic vasculature either.  Taking the above into account, it is
suggested that the hypotensive response to 5-HT in vagosympathectomised,
normotensive rats is predominantly mediated directly via vascular smooth muscle
receptors, that closely resemble cloned 5-ht7 receptors.  This suggestion is
strengthened when considering that (i) the receptor mediating vasorelaxation in
endothelium denuded blood vessels displays similar pharmacological profiles as
obtained in the present study (Martin et al., 1987; Martin & Wilson, 1995;
Leung et al., 1996) and, most significantly (ii) 5-ht7 receptor mRNA is strongly
expressed in vascular smooth muscle cells (Ullmer et al., 1995).  Finally, it is
interesting to note that the fall in systemic peripheral resistance during this putative
5-ht7 receptor-mediated hypotension is almost exclusively confined to the skeletal
muscle vascular beds (Chapter 11).
In conclusion, on the basis of the results presented in this study, the late depressor
response in vagosympathectomised, normotensive rats, previously described to be
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mediated by 5-HT1-like receptors (Saxena & Lawang, 1985; Martin et al., 1987),
appear to be mediated by 5-ht7 receptors, most probably located on vascular smooth
muscle.  Our findings are in agreement with other in vivo studies, where functional
5-ht7 receptors have been described, including tachycardia in cats (Chapter 12) and
canine external carotid vasodilatation (Villalón et al., 1997a), responses that were
previously attributed to 5-HT1-like receptors.  Since these responses represent
functional correlates of the 5- t7 gene product, the 5-HT7 (upper case) receptor
appellation is reinforced.
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Chapter 11
Changes in systemic and regional haemodynamics during 5-HT7
receptor mediated depressor responses in rats
Summary The 5-HT-induced late depressor response in rats is mainly mediated by
vascular 5-HT7 receptors.  The present study was devoted to determine the systemic
and regional haemodynamic changes during this response, with particular emphasis on
localising vascular beds that may contribute to the increase in total systemic vascular
conductance.  In vagosympathectomised, pentobarbital anaesthetised rats pretreated
with the 5-HT2 receptor antagonist ritanserin (50 µg kg-1, i.v.), 5-HT (1, 3 and
10 µg kg-1 min-1 during 10 min; i.v.) produced a dose-dependent decrease in mean
arterial blood pressure by up to 46±3%.  This decrease was accompanied by increases
in systemic vascular conductance by up to 83±15%; cardiac output was unaffected.
5-HT increased regional vascular conductance in skeletal muscle, carcass,
mesentery/pancreas and adrenals by up to 740±141, 117±18, 135±26 and 88±22%,
respectively, but decreased "lung" (mainly arteriovenous anastomotic) conductance by
up to 81±2%.  Pretreatment with R(+)lisuride (100 µg kg-1, i.v.) abolished all
5-HT-induced systemic and regional haemodynamic effects.  In contrast, i.v.
pretreatment with S(-)lisuride (100 µg kg-1) or GR127935 (300 µg kg-1) did not affect
the 5-HT-induced systemic haemodynamic changes.  The above results suggest that
hypotension induced via 5-HT7 receptor activation was exclusively caused by
vasodilatation of the systemic vasculature, confined to skeletal muscle, carcass,
mesentery/pancreas and adrenal vascular beds.  Furthermore, this study shows that
blockade of vasorelaxant 5-HT7 receptors by lisuride is stereoselective.
11.1 Introduction
The complexity of cardiovascular effects (bradycardia or tachycardia, hypotension or
hypertension and vasodilatation or vasoconstriction) produced by 5-HT has een
explained by its capacity to interact with specific receptors (se  Saxena & Villalón,
1990; 1991; Martin, 1994; Jones et al., 1995).  These receptors include 5-HT1
(5-HT1A, 5-HT1B and/or 5-HT1D subtypes), 5-HT2 (5-HT2A, 5-HT2B/2C), 5-HT3, 5-HT4
as well as 5-HT7 receptors (see Chapter 1).
The cardiovascular response induced by 5-HT in the rat serves as an example
to illustrate the above complexity.  Thus, i.v. administration of 5-HT produces a
triphasic blood pressure response in anaesthetised rats with intact vagus nerves.  This
Based on: De Vries, P., De Visser, P.A., Heiligers, J.P.C., Villalón, C.M., & Saxena, P.R.
(1999).  Changes in systemic and regional haemodynamics during 5-HT7 receptor mediated
depressor responses in rats.  Br. J. Pharmacol., 359, 331-338.
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response consists of an initial hypotension associated with a brief, but intense,
bradycardia via the von Bezold-Jarisch reflex (mediated by 5-HT3 receptors located
on cardiac vagal afferents), followed by a vasopressor effect (mediated by vascular
5-HT2A receptors) and, finally, a longer-lasting hypotension (see Chapter 3;
Kalkman et al., 1984; Saxena & Lawang, 1985).  After bilateral vagosympathectomy
and pretreatment with ketanserin, ritanserin or cyproheptadine (5-HT2A rec ptor
antagonists), 5-HT exclusively produces the late depressor response (see
Chapters 3 and 10; Saxena & Lawang, 1985).  Although this 5-HT-induced
hypotensive response had initially been ascribed to an action at vascular 5-HT1-like
receptors (Martin et al., 1987; Saxena & Villalón, 1990), it was subsequently
concluded that these receptors closely resemble the pharmacological profile of the
5-HT7 receptors (Chapter 10).  This conclusion was based, amongst other findings, on:
(i) the inactivity of the 5-HT1B/1D receptor agonist, sumatriptan; (ii) the blockade by
mesulergine and clozapine, compounds that do not interact with the 5-HT1 receptor
family (see Table 10.2); and (iii) the resistance to blockade by GR127935, a selective
5-HT1B/1D receptor antagonist (Skingle et al., 1996).  In the light of these findings, the
present study was designed to further analyse this late hypotensive response, with
particular emphasis on ascertaining the regional blood flows responsible for the
5-HT-induced increase in systemic vascular conductance in the rat.  For this purpose,
the distribution of cardiac output to the different tissues during 5-HT-induced increase
in systemic vascular conductance was determined using the radioactive microsphere
technique (Saxena et al., 1980).  In order to confirm the involvement of 5-HT7
receptors, we decided to use: (i) the stereoisomers of lisuride [R(+) and S(-)], to
investigate whether the blockade of 5-HT7 receptors by this ergot derivative is
stereoselective; and (ii) GR127935, which fails to antagonise 5-HT-induced
hypotension in rats (Chapter 10).
11.2 Methods
11.2.1 General
Experiments were carried out in 26 male Wistar rats (300-330 g).  After initial
anaesthesia with ether, the trachea was cannulated and a catheter was placed in the
right external jugular vein.  At this point, ether anaesthesia was stopped and the
animals received i.v. bolus injections of pentobarbital (30-40 mg kg-1).  Subsequently,
the rats were artificially ventilated with a mixture of oxygen and room air using a
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respiratory pump (Infant ventilator MK3, Hoekloos, The Netherlands) at a rate of 40
strokes min-1 (volume: 20 ml kg-1).  Bilateral vagosympathectomy was performed to
avoid the bradycardia and hypotension caused by the von Bezold-Jarisch reflex
(Paintal, 1973).  The right common carotid artery was exposed and a catheter,
connected to a pressure transducer (Combitrans disposable pressure transducer, Braun,
Melsungen, Germany), was guided through the carotid artery into the left ventricle.
The presence of the tip of the catheter in the left ventricle was confirmed by the
observation of the sudden switch from an arterial to a ventricular pressure profile.
Additionally, a catheter was placed into the left femoral artery and connected to
another pressure transducer for the recording of blood pressure and for the withdrawal
of reference blood samples.  Heart rate was measured with a tachograph (CRW,
Erasmus University, Rotterdam, The Netherlands) triggered from electrocardiogram
signals.  Both blood pressure and heart rate were recorded simultaneously on a
polygraph (CRW, Erasmus University, Rotterdam, The Netherlands).  The right
external jugular vein was used for the administration of drugs.
11.2.2 Distribution of cardiac output
The distribution of aortic blood flow was determined with 15.5±0.1 (S.D.) µm
diameter microspheres labelled with 141Ce, 113Sn, 103Ru or 46Sc (NEN Dupont, Boston,
USA).  For each measurement about 200,000 microspheres, suspended in 0.2 ml
physiological saline and labelled with one of the isotopes, was mixed and injected into
the left ventricle over a 15 sec period; the catheter was thoroughly flushed with 0.5 ml
saline.  Starting 10 sec before microsphere injection and lasting 70 sec, an arterial
reference blood sample was drawn from the left femoral artery at a constant rate of
0.5 ml min-1, using a withdrawal pump (Model 55, Harvard Apparatus, Natick, USA).
At the end of the experiment the animal was sacrificed with an overdose of
pentobarbital and all tissues and organs were dissected out, weighed and put in vials.
The following tissues were studied: skeletal muscle, carcass (consisting of bone with
skeletal muscle residue, fat, tail, eyes and urogenital tract), mesentery/pancreas (for
practical reasons, these two tissues were not studied separately), adrenals, lungs,
kidneys, skin, heart, liver, brain, gastrointestinal tract and spleen.  The radioactivity in
the reference blood samples and the tissues were counted for 5min in a g-scintillation
counter (Packard, Minaxi Auto-Gamma 5000 series), using suitable windows
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discriminating different isotopes.  All data were processed by a set of specially
designed computer programs (S xena et al., 1980).
The cardiac output was calculated by multiplying the ratio of total and arterial
blood sample radioactivity by the withdrawal rate of the arterial reference blood
sample (0.5 ml min-1).  Accordingly, tissue blood flow was calculated by multiplying
the ratio of tissue and total radioactivity by cardiac output (Saxena et al., 1980).
Conductances were calculated as blood flow divided by the mean arterial blood
pressure multiplied by hundred and expressed as 10-2 ml mmHg-1 min-1.
11.2.3 Experimental protocols
The experiments were started after a stabilisation period of about 30 min.  At this
point, all animals were systematically pretreated with ritanserin (50 µg kg-1, .v.),
which has been shown to be sufficient to block 5-HT2A receptor-mediated vasopressor
responses (Chapter 3 and 10).  The animals were then divided into 5 groups.  In the
first group (n=6), the effects of 3 consecutive 10-min i.v. infusions of vehicle
(physiological saline; 0.1 ml min-1) were studied to ascertain the stability of the
preparation.  The second group (control) received sequential 10-min i.v. infusions (at
a rate of 0.1 ml min-1) of 5-HT (1, 3 and 10 µg kg-1 min-1; n=5), after pretreatment
with saline (0.5 ml).  In the last 3 groups (n=5 each), the effects of the above infusions
of 5-HT were analysed in animals pretreated (i.v.) with either R(+)lisuride
(100 µg kg-1), S(-)lisuride (100 µg kg-1) or GR127935 (300 µg kg-1).
Fifteen min after respective pretreatments, baseline values of heart rate, mean
arterial blood pressure, cardiac output and its distribution were determined.
Subsequently, 10 min after the start of each of the infusions of vehicle or 5-HT all
variables were reassessed.  Between the different infusions, the animals were given
about 15 min to recover.  During this recovery period, the 5-HT-induced hypotension
recovered completely (data not shown).
11.2.4 Data presentation and statistical analysis
All data are presented as the mean±s.e.mean.  The changes induced by the different
infusions of vehicle or agonists were calculated in each experiment.  Data were
compared to baseline values by the use of Duncan’s new multiple range test, once an
analysis of variance (randomised block design) had revealed that the samples
represented different populations (Steel & Torrie, 1980).  The changes caused by
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5-HT in the R(+)lisuride-, S(-)lisuride- or GR127935-pretreated groups were
compared to those in the control group by using Student's unpaired t-te t.  Statistical
significance was accepted at P<0.05 (two-tailed).
11.2.5 Drugs
Apart from the anaesthetics, ether (Lab-scan, Dublin, Ireland) and pentobarbital
(Apharmo, Arnhem, The Netherlands), the drugs used in this study were: GR127935
(Glaxo Group Research, Ware, UK; courtesy Dr. H.E. Connor); 5-HT creatinine
sulphate (Sigma Chemical Company, St. Louis, MO, USA); ritanserin, S(-)lisuride
and R(+)lisuride hydrogen maleate (RBI, Natick, USA); and heparin sodium (Leo
Pharmaceuticals, Weesp, The Netherlands) to prevent clotting of the catheters.
GR127935 was dissolved according to the instructions of the supplier by heating the
dispersion in distilled water to about 70°C and then allowing to cool down to room
temperature.  All compounds were dissolved in physiological saline.  When needed,
30% (v v-1) methanol was added to dissolve ritanserin, S(-)lisuride and R(+)lisuride;
this vehicle had no effect on the haemodynamic variables or the 5-HT-induced
responses.  All doses refer to the respective salts, whereas that of 5-HT refers to the
free base.
11.3 Results
11.3.1 Baseline values of systemic and regional haemodynamic variables
Baseline values of systemic haemodynamic variables in the 26 vagosympathectomised
rats pretreated with ritanserin were: heart rate, 231±5 beatsmin-1; cardiac output,
111±5 ml min-1; mean arterial blood pressure, 75±1 mmHg; diastolic arterial blood
pressure, 56±1 mmHg; stroke volume, 0.48±0.02 ml; and systemic vascular
conductance, 148±6 10-2 ml min-1 mmHg-1.   No significant differences were observed
in these values between the 5 experimental groups.  Furthermore, the i.v. pretreatment
with ritanserin (50 µg kg-1) as well as the subsequent i.v. administration of
physiological saline (0.5 ml), R(+)lisuride (100 µg kg-1), S(-)lisuride (100 µg kg-1) or
GR127935 (300 µg kg-1) did not produce significant changes in these variables (data
not shown).
Baseline values (n=26) of regional blood flow (ml min-1; with the
corresponding percentage of cardiac output in brackets) were: 15.4±1.6 (13.7±1.3%)
for skeletal muscle, 26.2±1.5 (23.4±0.8%) for carcass, 1.6±0.1 (1.5±0.1%) for
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mesentery, 0.16±0.01 (0.14±0.01%) for adrenals, 6.0±0.9 (5.3±0.7%) for lungs,
11.4±0.7 (10.6±0.8%) for kidneys, 8.1±0.4 (7.4±0.3%) for skin, 9.3±0.6 (8.3±0.4%)
for heart, 2.4±0.2 (2.2±0.2%) for liver, 1.9±0.1 (1.7±0.1%) for brain, 27.1±1.6
(24.5±1.0%) for gastrointestinal tract (GIT) and 1.0±0.1 (0.9±0.1%) for spleen.  No
profound differences were observed in these values between the 5 experimental
groups.
11.3.2 Effects of vehicle on systemic and regional haemodynamics
Three consecutive 10-min infusions of vehicle (saline; 0.1 mlmin-1) did not produce
any changes in the systemic haemodynamic variables (Figure 11.1).  Mo over, exc pt
for some decreases in the skin (data not shown) and skeletal muscles, vehicle infusion
did not affect regional haemodynamics (Figure 11.1).
11.3.3 Effects of R(+)lisuride, S(-)lisuride and GR127935 on 5-HT-induced systemic
haemodynamic changes
The effects of three consecutive 10-min i.v. infusions of 5-HT on systemic
haemodynamics in the different experimental groups are depicted in Figure 11.2.
5-HT slightly decreased (P<0.05) heart rate (maximum change: -16±6%) and
increased (P<0.05) stroke volume by up to 17±4%.  These moderate changes were not
significantly modified by pretreatment with R(+)lisuride, S(-)lisuride or GR127935.
Cardiac output remained unchanged in all groups.
5-HT decreased mean and diastolic arterial blood pressures by up to 46±3%
and 46±3%, respectively, and increased systemic vascular conductance (maximum
change: 83±15%).  These 5-HT-induced decreases in blood pressure and concomitant
increases in systemic vascular conductance were essentially similar in animals
pretreated with S(-)lisuride and GR127935, but, remarkably, were absent in animals
pretreated with R(+)lisuride.
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Figure 11.1  Effects of 3 consecutive 10-min i.v. infusions of vehicle (saline;
0.1 ml min-1) on heart rate (HR; beats min-1), cardiac output (CO; ml min-1), mean
arterial blood pressure (MAP; mmHg), diastolic arterial blood pressure (DAP; mmHg),
stroke volume (SV; 10-2 ml), systemic vascular conductance (SVC;
10-2 ml mmHg-1 min-1) (upper panel) and skeletal muscle (Mus), carcass (Car),
mesentery/pancreas (M+P), adrenal (Adr), lung and kidney (Kid) vascular conductances
(10-2 ml mmHg-1 min-1) (lower panel) in anaesthetised rats systematically pretreated
with ritanserin (50 µg kg-1, i.v.).  *, P<0.05 vs baseline.  For the sake of clarity, adrenal
vascular conductance values have been multiplied by a factor of 10.
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Figure 11.2  Effects of 10-min i.v. infusions of 5-HT on heart rate (HR), cardiac output
(CO), mean arterial blood pressure (MAP), diastolic arterial blood pressure (DAP),
stroke volume (SV) and systemic vascular conductance (SVC) in anaesthetised rats
pretreated i.v. with either (n=5 each) saline (Control; 0.5 ml), R(+)lisuride (RL;
100 µg kg-1), S(-)lisuride (SL; 100 µg kg-1) or GR127935 (GR; 300 µg kg-1).  *, P<0.05
vs baseline.  +, P<0.05 vs response by corresponding dose of 5-HT in control animals.
All animals were systematically pretreated with ritanserin (50 µg kg-1, i.v.).
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Figure 11.3 Effects of 10-min i.v. infusions of 5-HT on regional blood flow in
anaesthetised rats pretreated i.v. with either (n=5 each) saline (Control; 0.5 ml),
R(+)lisuride (RL; 100 µg kg-1), S(-)lisuride (SL; 100 µg kg-1) or GR127935 (GR;
300 µg kg-1).  *, P<0.05 vs baseline.  +, P<0.05 vs response by corresponding dose of
5-HT in control animals.  All animals were systematically pretreated with ritanserin
(50 µg kg-1, i.v.).
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11.3.4 Effects of R(+)lisuride, S(-)lisuride and GR127935 on 5-HT-induced regional
haemodynamic changes
The effects of three consecutive 10-min infusions (i.v.) of 5-HT (1, 3 and
10 µg kg-1 min-1) on regional blood flows to a number of tissues in animals with or
without (control) antagonist pretreatment are depicted in Figure 11.3.  In control
animals, 5-HT increased blood flows to skeletal muscle (maximum change: 346±67%)
and carcass (maximum change: 47±19%), but decreased those to lungs (maximum
change: 90±1%) and kidneys (maximum change: 53±6%).  The increase in skeletal
muscle blood flow by 5-HT may have been underestimated, since vehicle infusion by
itself lowered skeletal muscle blood flow (see Figure 11.2).  Blood flow changes
elicited by 5-HT were potently blocked by pretreatment with R(+)lisuride, but
remained essentially unchanged in animals pretreated with S(-)lisuride or GR127935.
The changes effected by 5-HT in vascular conductances in the above
mentioned tissues are shown in Figure 11.4.  5-HT increased vascular conductance in
the skeletal muscles (maximum change: 740±141%), carcass (maximum change:
117±18%), mesentery/pancreas (maximum change: 135±26%) and adrenals
(maximum change: 88±22%).  On the other hand, vascular conductance in the lungs
(maximum change: 81±2%) and, to some extent, kidneys (23±4% at 3 µg kg-1 min-1)
was decreased by 5-HT.  These 5-HT-induced changes in vascular conductances were
substantially reduced or even abolished after pretreatment with R(+)lisuride.  In
contrast, pretreatment with S(-)lisuride, the 5-HT-induced changes in the skeletal
muscles (maximum change: 250±120%) and mesentery/pancreas (maximum change:
50±23%) vascular conductances were slightly less, whereas the responses in carcass
(maximum change: 107±16%), adrenals (maximum change: 96±13%) and lungs
(maximum change: 68±5%) were not significantly modified.  Pretreatment with
GR127935 slightly attenuated the increase in muscle conductance (maximum change:
232±65%) without affecting the 5-HT-induced effects in carcass, mesentery/pancreas,
adrenals and lungs (maximum changes: 94±21%, 190±50% and 126±43% and
73±3%, respectively).
Additionally, decreases in blood flow were observed in skin, heart,
gastrointestinal tract, brain, spleen and liver, but the respective vascular conductance
values remained unchanged, as the corresponding hypotensive responses were
quantitatively similar (data not shown).
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Figure 11.4  Effects of 10-min i.v. infusions of 5-HT on regional vascular conductance
in anaesthetised rats pretreated i.v. with either (n=5 each) saline (Control; 0.5 ml),
R(+)lisuride (RL; 100 µg kg-1), S(-)lisuride (SL; 100 µg kg-1) or GR127935 (GR;
300 µg kg-1).  *, P<0.05 vs baseline.  +, P<0.05 vs response by corresponding dose of
5-HT in control animals.  All animals were systematically pretreated with ritanserin
(50 µg kg-1, i.v.).
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11.4 Discussion
11.4.1 General
It has previously been shown that i.v. bolus injection of 5-HT produces a triphasic
blood pressure response in anaesthetised rats (Kalkmanet al., 1984;
Saxena & Lawang, 1985), of which exclusively a long lasting decrease in blood
pressure persists after bilateral vagosympathectomy and 5-HT2A receptor blockade
(Chapter 3).  The receptor mediating this 5-HT-induced hypotension has recently been
shown to resemble the 5-HT7 receptor (Chapter 10).  Thus, 5-HT-induced hypotension
was: (i) mimicked, in decreasing order of agonist potency, by 5-CT, 5-HT and
5-MeO-T; sumatriptan (30-1000 µg kg-1) was inactive; (ii) antagonised, in decreasing
order of potency, by R(+)lisuride, methiothepin, mesulergine and metergoline, in
agreement with their affinities at the 5-HT7 receptor (see Table 10.2); and (iii)
resistant to blockade by the 5-HT1B/1D receptor antagonist, GR127935 (Skingle et al.,
1996), at doses that block 5-HT1B/1D receptor-mediated cardiovascular responses (see
Chapter 4; Villalón et al., 1996).  Undoubtedly, this pharmacological profile is
identical to that displayed by other 5-HT7 receptors mediating cardiovascular
responses in vitro and in vivo (see Chapter 12; Eglen et al., 1997; Villalón et al.,
1997a; 1997c; Saxena et al., 1998b).  It must be recognised, however, that
5-HT-induced hypotension and/or vasodilatation may also involve secondary
mechanisms (e.g. endothelial NO release, sympathoinhibition) which could have been
overshadowed by the much more prominent effect on musculotropic 5-HT7 receptors, as
previously shown by several lines of evidence (Ullmer tal., 1995; De Vries et al.,
1997b; Eglen et al., 1997; Saxena et al., 1998b).  These considerations led us to
choose lisuride (although, admittedly, a non-selective ligand; see Table 10.2) as
antagonist of the 5-HT-induced hypotensive responses in the present study.  This drug
displays: (i) very high affinity (pKi=9.1) at 5-HT7 receptors; and (ii) the highest
potency in blocking cardiovascular responses following 5-HT7 receptor activation (see
Chapter 10; Villalón et al., 1997a; 1997c).
Apart from the implications discussed below, the major findings of the present
study in vagosympathectomised rats were that: (i) the 5-HT-induced hypotension was
exclusively attributable to an increase in systemic vascular conductance, mediated by
a lisuride-sensitive (most probably 5-HT7) receptor; and (ii) the 5-HT-induced
increase in systemic vascular conductance was confined to skeletal muscle,
mesentery/pancreas, adrenal and carcass vascular beds.
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11.4.2 Systemic haemodynamic changes induced by 5-HT
Only with its highest dose (10 µg kg-1 min-1, i.v. for 10 min), 5-HT produced a slight
bradycardia, for which we do have no clear-cut xplanation.  In our previous
experiments, we reported that bolus injections of 5-HT (1-10 µg kg-1) did not affect
heart rate in vagosympathectomised, ritanserin-tre ted rats (Chapter 10), suggesting
that the mode of administration (10-min infusions) could have played a role.  In any
case, 5-HT did not change cardiac output, as the 5-HT-induced bradycardia was
accompanied by a compensatory increase in stroke volume.  Additionally, 5-HT
produced a dose-dependent decrease in blood pressure, which was exclusively caused
by a dilatation of systemic vasculature, as cardiac output remained unaffected.  The
present results confirm previous reports, that this hypotension was mediated by 5-HT7
receptors, as demonstrated in Chapter 10.  Thus, R(+)lisuride completely blocked this
response, whereas GR127935 hardly affected the 5-HT-induced hypotension.  This
suggestion is reinforced by the fact that 10-min i.v. infusions of 5-CT decreased blood
pressure, with a higher potency than 5-HT (Saxena & Lawang, 1985).  Moreover, the
weak, if any, blockade by S(-)lisuride seems to indicate that this stereoisomer displays
moderate affinity at the rodent 5-HT7 receptor mediating hypotension.
11.4.3 Regional haemodynamic changes
In vagosympathectomised, ritanserin-pretreated, pentobarbital anaesthetised rats, the
5-HT7 receptor-mediated decrease in blood pressure was solely caused by systemic
vasodilatation.  This vasodilatation was confined to the skeletal muscles,
mesentery/pancreas, carcass and adrenals.  As a result of the prominent vasodilatation
in these vascular beds, cardiac output was redistributed, leading to an under-perfusion
("steal") in the other tissues/organs.  Indeed, these decreases in regional blood flow,
with the clear exception of lungs (see below), were due only to the corresponding
decreases in blood pressure, as the respective conductance values remained essentially
unmodified.  Additionally, carcass vascular conductance increased in response to
5-HT, which most likely reflects changes in residual skeletal muscles, although a
dilator action in fat, bone or urogenital tract vasculature cannot be excluded.  Taking
into account that skeletal muscle received the larger part of cardiac output, it is
reasonable to assume that the dilatation in skeletal muscle arterioles contributed most
to the dilatation of the total systemic vasculature, leading to hypotension.  In keeping
with this suggestion, the receptor mediating the dilatation to 5-HT in skeletal muscle
5-HT7 receptors and the rat systemic vasculature
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vasculature seems to resemble the pharmacological profile of the receptor mediating
the hypotension to 5-HT.  Thus, the 5-HT-induced skeletal muscle vasodilatation, as
well as the concomitant decrease in blood pressure was abolished by R(+)lisuride, but
not much affected by GR127935.  On the same grounds, 5-HT7 receptors seem to be
primarily involved in the vasodilatation induced by 5-HT in the carcass,
mesentery/pancreas, as well as adrenal vascular beds.
Contractile responses in several blood vessels, including the renal artery
(Choppin & O'Connor, 1994; Whiting & Cambridge, 1995), cerebral artery
(Deckert et al., 1994; Skingle et al., 1996) and gastrointestinal vasculature
(Choppin & O'Connor, 1996), have been described to be mediated by 5-HT1-like -
most likely 5-HT1B/1D – receptors (Saxena et al., 1998b).  Interestingly, however, little
or no vasoconstrictor responses were observed in the corresponding vascular beds in
the saline-pretreated animals.  Similarly, although 5-HT7 receptor mRNA has been
shown to be abundantly expressed in renal and coronary arteries (Ullmer e al., 1995)
and 5-HT7 receptor-mediated vasorelaxant responses have been described in isolated
coronary artery rings (Cushing et al., 1996), no dilator effects were observed in these
tissues (heart and kidneys; see Figure 11.3).  The absence of these vascular responses
could be explained in terms of: (i)the presence of counter-regulatory mechanisms,
such as tissue autoregulation (Saxena & Bolt, 1986); (ii) the fact that changes in tissue
vascular conductance are mainly mediated by changes in smaller, more distal
arterioles than those used in in v tro experiments; and (iii)a species difference.
Admittedly, it is also possible that vasoconstrictor 5-HT1B/1D and vasodilator 5-HT7
receptors were simultaneously activated by 5-HT, producing, as a consequence, an
apparent lack of effect.  However, this seems unlikely, as treatment with the 5-HT1B/1D
receptor antagonist, GR127935, was not capable of unmasking a dilator effect.
In agreement with previous findings in rabbits, cats and pigs
(Forsyth & Saxena, 1978; Saxena et al., 1978; Saxena & Verdouw, 1982;
Den Boer et al., 1992b), 5-HT produced a dose-dependent decrease in lung vascular
conductance values.  This effect is representative of constriction of peripheral
arteriovenous anastomoses (Saxena & Verdouw, 1982), as bronchial blood flow is
only 1-1.5% of cardiac output (Baile et al., 1982).  Interestingly, in the presence of
ritanserin, this response was not much affected by GR127935, ruling out a major role
for 5-HT1B/1D or 5-HT2 receptors.  Although it is tempting to attribute this effect to a
novel (5-HT?) receptor, as recently shown in the porcine carotid circulation
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(Chapter 5) and human brain (Castro et al., 1997), we cannot categorically exclude the
influence of baroreceptor-reflex-mediated increase in sympathetic activity (Saxena,
1986b).
In conclusion, the present investigation shows that 10-min i.v. infusions of 5-HT
produce decreases in mean arterial blood pressure, exclusively caused by an increase
in systemic vascular conductance.  This systemic vasodilatation, confined to skeletal
muscle, carcass, mesentery/pancreas and adrenal vascular beds, was mediated
primarily by lisuride-sensitive 5-HT7 receptors.  Furthermore, this study confirms and
extends our previous findings by showing that blockade of vasorelaxant 5-HT7
receptors by lisuride is stereoselective.   The present results may eventually be helpful
in the future development of drugs producing local or systemic vasodilatation
(Villalón et al., 1997b).  In this context, it has been shown that chronic administration
of 5-CT in spontaneous hypertensive rats produced a sustained antihypertensive effect
(Balasubramaniam et al., 1993).
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Chapter 12
Characterisation of putative 5-HT7 receptors mediating
tachycardia in the cat
Summary It has been suggested that the tachycardic response to 5-HT in the
spinal-transected cat is mediated by 5-HT1-like receptors since this effect, being
mimicked by 5-CT, is not modified by ketanserin or MDL72222, but it is blocked by
methiothepin, methysergide or mesulergine.  The present study was set out to reanalyse
this suggestion in terms of the IUPHAR 5- T receptor classification schemes proposed
in 1994 and 1996.  Intravenous (i.v.) bolus injections of the tryptamine derivatives,
5-CT (0.01-30 µg kg-1), 5-HT (3-30 µg kg-1) and 5-MeO-T (3-30 µg kg-1) as well as the
atypical antipsychotic drug, clozapine (1000 and 3000 µg kg-1) resulted in
dose-dependent increases in heart rate, with a rank order of agonist potency of 5-CT >>
5-HT > 5-MeO-T >> clozapine.  The tachycardic effects of 5-HT and 5-MeO-T were
dose-dependently antagonised after i.v. administration of lisuride (30 and 100 µg kg-1),
ergotamine (100 and 300 µg kg-1) or mesulergine (100, 300 and 1000 µg kg-1); the
highest doses used of these antagonists also blocked the tachycardic effects of 5-CT.
Clozapine (1000 and 3000 µg kg-1) did not affect the 5-HT-induced tachycardia, but
attenuated, with its highest dose, the responses to 5-MeO-T and 5-CT; however, these
doses of clozapine as well as the high doses of ergotamine (300 µg kg-1) and
mesulergine (300 and 1000 µg kg-1) also attenuated the tachycardic effects of
isoprenaline.  In contrast, 5-HT-, 5-MeO-T- and 5-CT-induced tachycardia were not
significantly modified after i.v. administration of physiological saline (0.1 and
0.3 ml kg-1), the 5-HT1B/1D receptor antagonist, GR127935 (500 µg kg-1) or the 5-HT3/4
receptor antagonist, tropisetron (3000 µg kg-1).  I.v. injections of the 5-HT1 receptor
agonists, sumatriptan (30, 100 and 300 µg kg-1) and indorenate (300 and 1000 µg kg-1)
or the 5-HT4 receptor (partial) agonist cisapride (100, 300 and 1000 µg kg-1) were
devoid of effects on feline heart rate pe se and failed to significantly modify
5-HT-induced tachycardic responses.  Based upon the above rank order of agonist
potency, the failure of sumatriptan, indorenate or cisapride to produce
cardioacceleration and the blockade by a series of drugs showing high affinity for the
cloned 5-ht7 receptor, the present results indicate that the 5-HT rec ptor mediating
tachycardia in the cat is operationally similar to other putative 5-HT7 receptors
mediating vascular and non-vascular responses.  Since these responses represent
functional correlates of the 5- t7 gene product, the 5-HT7 receptor appellation is
reinforced.  Therefore, the present experimental model, which is not complicated by the
presence of other 5-HT receptors, can be utilised to characterise and develop new drugs
with potential agonist and antagonist properties at functional 5-HT7 receptors.
Based on: Villalón, C.M., Heiligers, J.P.C., Centurión, D., De Vries, P. & Saxena, P.R.
(1997).  Characterization of putative 5-HT7 receptors mediating tachycardia in the cat.  Br.
J. Pharmacol., 121, 1187-1195.
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12.1 Introduction
5-HT elicits complex changes in the cardiovascular system comprising bradycardia or
tachycardia, hypotension or hypertension and vasodilatation or vasoconstriction (for
reviews see Saxena & Villalón, 1990; 1991; Saxena et al., 1998b).  In most species,
bradycardia induced by 5-HT is mediated by 5-HT3 receptors, via the activation of the
von Bezold Jarisch reflex; in marked contrast, 5-HT-induced tachycardia is
notoriously species-d pendent and is mediated, directly or indirectly, either by
5-HT1-like (cat), 5-HT2 (rat, dog), 5-HT3 (rabbit, dog) and 5-HT4 (pig, human)
receptors or by tyramine-like (guinea-pig) or unidentified mechanisms (Saxena,
1986a; Saxena & Villalón, 1990; 1991).
The so called 5-HT1-like receptors mediating tachycardia in the cat are
potently stimulated by 5-CT and blocked by methiothepin and methysergide
(Saxena et al., 1985b; Saxena, 1988).  However, it is noteworthy that these receptors
do not satisfactorily fulfil some classification requirements for the 5-HT1 type,
including insensitivity to stimulating doses of RU24969 and 8-OH-DPAT at typical
5-HT1-like receptor-mediated responses ( .g. constriction of porcine carotid
arteriovenous anastomoses; Saxena & Villalón, 1990), blockade by mesulergine
(Saxena, 1988), an ergoline devoid of interactions with the 5-HT1 r ceptor family
(see Table 10.2), and inconsistency with a negative coupling to adenylyl cyclase
(Hoyer et al., 1994).  These cardiac receptors, consequently, are different from the
typical 5-HT1-like receptors mediating vasoconstriction, a response usually associated
with a decrease in cyclic AMP (Sumner et al., 1992), but are similar to those
mediating direct relaxation of vascular and non-vascular smooth muscle, a response
that involves an increase in cyclic AMP (for references see Saxena & Villalón, 1990;
Martin, 1994).
While evidence is emerging that sumatriptan-sensitive 5-HT1-like receptors
mediating vasoconstriction resemble 5-HT1B receptors (see Chapters 8 and 9), the
recently cloned 5-ht7 receptor (e.g. Bard et al., 1993; Ruat e al., 1993b) seems to be a
suitable candidate for responses mediated by the atypical, sumatriptan-insensitive
5-HT1-like receptors.  Indeed, the cloned 5-ht7 receptor is positively coupled to
adenylyl cyclase (Chapter 1) and binding studies show that the cloned 5-ht7 receptor
displays high affinities for 5-CT, 5-HT, methiothepin, mesulergine and methysergide,
but relatively low affinities for RU 24969, 8-OH-DPAT and sumatriptan (see
Tables 10.1 and 10.2).
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In the light of these findings, the present study was set out to investigate the
operational characteristics of the 5-HT receptors mediating tachycardia in the spinal
cat, with particular emphasis on verifying if these receptors display the
pharmacological profile of the cloned 5-ht7 receptor.  Hence, the drugs employed
included agonists and/or antagonists at 5-HT1, 5-HT2, 5-HT3 and 5-HT4 receptors, as
well as some compounds with high affinity for the cloned 5-ht5, 5-ht6 and/or 5-ht7
receptors (see Tables 10.1 and 10.2).
12.2 Methods
12.2.1 General
Forty one cats, not selected for breed or sex (2.5-4.0 kg) and fasted overnight, were
initially anaesthetised with sodium pentobarbitone (30 mg kg-1, i.v.).  Left femoral
vein and artery were cannulated for, respectively, drug injections and the
measurement of aortic blood pressure using a Statham pressure transducer (P23 ID).
Heart rate was obtained by triggering a tachograph (Grass Instruments Co., Quincy,
MA, USA; model 7P4) with the ECG signals.  Blood pressure and heart rate were
recorded simultaneously by a model 7D Grass polygraph (Grass Instrument Co.,
Quincy, MA, USA).  The animals were then given an additional dose of pentobarbital
(10-15 mg kg-1, i.v.) and intubated with an endotracheal tube for artificial ventilation
with room air, using a Palmer ventilation pump (rate: 20 strokes min-1; stroke volume:
13-16 ml kg-1).  Subsequently, both vagosympathetic trunks and the spinal cord (at the
level of C1-C2) were sectioned in all animals, as previously reported (Saxena et al.,
1985b; Saxena, 1988).
12.2.2 Experimental protocols
After the cats had been in a stable haemodynamic condition for at least 60 min,
baseline values of blood pressure and heart rate were determined.  Then, the animals
were divided into two groups.
The first group (n=34) received consecutive i.v. bolus injections, every 5 to
10 min, of 5-HT (3, 10 and 30 µg kg-1), 5-MeO-T (3, 10 and 30 µg kg-1) and
isoprenaline (0.01, 0.03 and 0.1 µgkg-1) and the changes produced in blood pressure
and heart rate were noted.  At this point, the animals were divided into six subgroups.
Four subgroups were treated, using a cumulative dose schedule, with either
physiological saline (0.1 and 0.3 ml kg-1; n=5), lisuride (30 and 100 µg kg-1; n=6),
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ergotamine (100 and 300 µg kg-1; n=6) or mesulergine (100, 300 and 1000 µg kg-1;
n=6).  The fifth subgroup (n=6) was given clozapine (1000 and 3000 µgkg-1)
following a sequential (not cumulative) dosing because it produced an immediate
short-lasting tachycardic response by itself.  The sixth subgroup (n=5) was treated
with GR127935 (500 µg kg-1) and, subsequently, with tropisetron (3000 µgkg-1).  The
responses to i.v. injections of 5-HT, -MeO-T and isoprenaline, at the doses and
sequence listed above, were elicited again 10min after each dose of physiological
saline or the above compounds.
The second group (n=7) received consecutive i.v. injections of 5-HT (3, 10
and 30 µg kg-1) and isoprenaline (0.01, 0.03 and 0.1 µg kg-1) and the changes in blood
pressure and heart rate were noted.  The animals were then divided into two
subgroups.  The first subgroup (n=4) was given, sequentially, i.v. injections of the
5-HT1 receptor agonist, indorenate (300 and 1000 µg kg
-1 spaced by 5 min) followed
by the 5-HT4 receptor (partial) agonist, cisapride (300 and 1000µg kg
-1 spaced by
5 min) and the second subgroup (n=3) was treated with sequential i.v. injections of the
5-HT1 receptor agonist, sumatriptan (30, 100 and 300 µg kg
-1 spaced by 5 min).  After
each treatment and dose, the responses to 5-HT and isoprenaline were reanalysed.
Subsequently, each of the above 8 subgroups received, at the end of their
corresponding protocol, i.v. injections of 5-CT at cumulative total dose levels of 0.03,
0.1, 0.3, 1, 3, 10 and 30 µg kg-1 every 5-7 min.  The  changes in heart rate and blood
pressure, produced after each dose of 5-CT, were noted.  Lastly, in at least three cats
of each of the above eight subgroups (see Results section), the highest dose used of
saline or the corresponding drug was administered once again in an attempt to
investigate which compounds could reverse the tachycardia elicited by the highest
dose of 5-CT (30 µg kg-1), as previously described for methysergide (Saxena t al.,
1985b).
With the exception of 5-CT (see above), the dose-intervals between the
different doses of agonists ranged between 1 and 10 min, as in each case we waited
until the heart rate had returned to baseline values.  For the antagonists, as well as for
indorenate, cisapride and sumatriptan, a period of 10 m n was allowed to elapse before
the dose-response curves for the agonists were elicited again.  The dosing with 5-HT,
5-MeO-T, isoprenaline, sumatriptan, indorenate, cisapride and clozapine was
sequential, whilst that for 5-CT and the rest of antagonists was cumulative.
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12.2.3 Data presentation and statistical analysis
All data in the text and figures are presented as the mean±s.e.mean and these were
analysed using a computer program (Saxena, 1985).  The agonist-induced increases in
heart rate just before and after a particular dose of saline or antagonist drug within one
group of animals were compared by Student Newman-Keuls' test, once an analysis of
variance (randomised block design) had revealed that the samples represented
different populations (Steel & Torrie, 1980). Furthermore, the increases in heart rate
by 5-HT and isoprenaline before and after sumatriptan (430 µg kg-1), indorenate
(1300 µg kg-1) or cisapride (1300 µg kg-1), given cumulatively, were compared by
using Student's paired t-test.  Finally, the tachycardic responses to 5-CT in the
different groups of animals were compared by using Student's unpaired t- est.
A P-value of 0.05 or less (two-tailed) was considered statistically significant.
12.2.4 Drugs
Apart from the anaesthetic (sodium pentobarbitone), the drugs used in the present
study (obtained from the sources indicated) were the following: 5-HT creatinine
sulphate (Sigma Chemical Company, St. Louis, MO, USA); lisuride hydrogen
maleate, isoprenaline hydrochloride, 5-MeO-T hydrochloride and 5-CT maleate
(Research Biochemicals Int., Natick, MA, USA); sumatriptan succinate (gift:
Prof. Dr. P.P.A. Humphrey, Glaxo Institute of Applied Pharmacology, Cambridge,
UK); GR127935 (gift: Dr. M. Skingle, Glaxo Group Research Limited, Ware, Herts,
UK); tropisetron, clozapine base, mesulergine hydrochloride and ergotamine tartrate
(gift: Sandoz A.G., Basel, Switzerland); indorenate (gift: Prof. Dr. E. Hong,
CINVESTAV-IPN, Mexico City, Mexico); and cisapride (gift: Janssen
Pharmaceutica, Beerse, Belgium). All compounds were dissolved in distilled water.
When needed, 4% (w v-1) ascorbic acid (clozapine) or 5% (v v-1) DMSO (lisuride) was
added; these vehicles had no effect on the haemodynamic variables or the
agonist-induced responses.  The doses mentioned in the text refer to the salts of
substances, except in the case of all agonists and clozapine, where they refer to the
free base.
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12.3 Results
12.3.1 Initial blood pressure and heart rate changes by 5-HT receptor agonists
Baseline values of mean arterial blood pressure and heart rate in the forty one cats
were, respectively, 84±3 mmHg and 184±35 beats min-1.  The changes induced in
mean arterial blood pressure by the agonist drugs were: 5-HT (-2±1, +3±4 and
+15±5 mmHg after 3, 10 and 30 µg kg-1, respectively; n=41), 5-MeO-T (-1±2, +7±4
and +23±4 mmHg after 3, 10 and 30 µg kg-1, respectively; n=34), 5-CT (-1±17, -13±5,
-17±6 and -20±7 mmHg after 0.03, 0.1, 0.3 and 1 µg kg-1, with 3, 10 and 30 µg kg-1
producing no subsequent change; n=5, i.e. saline-treated animals), sumatript n
(-12±12, +17±9, +3±2 mmHg after 30, 100 and 300 µg kg-1, respectively; n=3),
indorenate (-5±7 and -3±5 mmHg after 300 and 1000 µg kg-1, respectively; n=4),
cisapride (-1±2 and -7±3 mmHg after 300 and 1000 µg kg-1, respectively; n=4) and
clozapine (-9±5 and -18±5 mmHg after 1000 and 3000µg kg-1, respectively; n=6).  It
should be pointed out that these effects were not evaluated further because in spinal
cats the baseline blood pressure is low and, consequently, the hypotensive responses
produced by the above agonists were smaller and not strictly dose-dependent (see
above).
The onset of the increases in heart rate induced by the agonists under study
was immediate.  Figure 12.1 shows that isoprenaline, 5-CT, 5-HT, 5-MeO-T and
clozapine caused dose-dependent increases in heart rate; in contrast, sumatriptan,
indorenate and cisapride, at the doses tested, failed to increase feline heart rate.
Isoprenaline was about 1.5 log units more potent than 5-CT, which was itself
distinctly more potent (~1.5 log units) than 5-HT and 5-MeO-T; clozapine was the
least potent.  Thus, the apparent rank order of agonist potency was: isoprenaline >>
5-CT >> 5-HT > 5-MeO-T >> clozapine.
The duration of tachycardic effects of agonist drugs (except 5-CT) was
relatively short: isoprenaline (3.9±0.2, 4.8±0.2 and 6.2±0.2 min after 0.01, 0.03 and
0.1 µg kg-1, respectively), 5-HT (2.6±0.2, 4.6±0.2 and 7.0±0.3 min after 3, 10 and
30 µg kg-1, respectively), 5-MeO-T (2.3±0.2, 3.5±0.2 and 5.2±0.2 min after 3, 10 and
30 µg kg-1, respectively) or clozapine (2.1±1.0 and 3.0±1.0 after 1000 and
3000 µg kg-1, respectively). Furthermore, the 5-CT-induced tachycardia has been
shown to last longer than 1 h (Saxena et al., 1985b; Saxena, 1988) and, therefore, as
expected, no recovery was observed with 5-CT during the dosing intervals (5-7 min)
or for at least 10 min after the last dose.
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Figure 12.1 Comparative effects of i.v. bolus injections of isoprenaline (n=41),
5-CT (n=5), 5-HT (n=41), 5-MeO-T (n=34), clozapine (n=6), sumatriptan (n=3),
indorenate (n=4) and cisapride (n=4) on heart rate in vagosympathectomised spinal cats.
12.3.2 Effect of physiological saline and 5-HT receptor antagonists on the
tachycardic responses induced by 5-HT, 5-MeO-T and isoprenaline
The effects of physiological saline or lisuride on the tachycardic responses induced by
5-HT, 5-MeO-T and isoprenaline are depicted in Figure 12.2.  No evidence of
tachyphylaxis was observed since the responses to these agonists, at the doses and
time intervals (330 min) used in the present study, were reproducible and
remained essentially unchanged in control animals receiving two doses (0.1 and
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0.3 ml kg-1, i.v.) of physiological saline (Figure 12.2, upper panels). In contrast, the
administration of low doses (30 and 100 µg kg-1, i.v.) of lisuride potently and
dose-dependently antagonised the tachycardic responses induced by 5-HT and
5-MeO-T; this blockade was specific as lisuride did not alter isoprenaline- nduced
tachycardia (Figure 12.2, lower panels).
Figure 12.2 Effects of i.v. bolus injections of physiological saline (upper panels; n=5)
or lisuride (lower panels; n=6) on tachycardic responses to 5-HT, 5-MeO-T and
isoprenaline in vagosympathectomised spinal cats.  *, P<0.05 vs the corresponding
control response.
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Figure 12.3 Effects of i.v. bolus injections of ergotamine (upper panels; n=6) or
mesulergine (lower panels; n=6) on tachycardic responses to 5-HT, 5-MeO-T and
isoprenaline in vagosympathectomised spinal cats.  *, P<0.05 vs the corresponding
control response.
Ergotamine (100 and 300 µg kg-1) and mesulergine (100, 300 and 1000 µg kg-1) also
produced a dose-dependent blockade of the tachycardic responses to 5-HT and
5-MeO-T (Figure 12.3).  However, the blockade produced by the high doses of
ergotamine (300 µg kg-1) and mesulergine (300 and 1000 µg kg-1) was not specific as
they also attenuated the tachycardic effects of isoprenaline (Figure 12.3).  Moreover,
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the atypical antipsychotic drug, clozapine (1000 and 3000 µg kg-1), did not affect
5-HT-induced tachycardia, but significantly blocked, with its highest dose, the
responses to 5-MeO-T; however, these doses of clozapine also attenuated the
tachycardic effects of isoprenaline (Figure 12.4, pper panels).
The apparent order of potency for blockade of both 5-HT- and
5-MeO-T-induced tachycardic responses was ergotamine ³ lisurid  > mesulergine >
clozapine.  Finally, as shown in Figure 12.4 (lower panels), the tachycardic responses
to 5-HT, 5-MeO-T and isoprenaline were not significantly modified after
administration of the selective 5-HT1B/1D receptor antagonist, GR127935 or by the
subsequent administration of tropisetron which, at 3000 µg kg-1, is a 5-HT3 and 5-HT4
receptor antagonist (Chapter 1).
Except for an immediate and sustained increase in mean blood pressure by
ergotamine (from 103±9 to 134±13 mmHg, after its highest dose; P<0.05), the values
of mean blood pressure and heart rate before and 10 min after the administration of
physiological saline or the above 5-HT receptor antagonists were not significantly
different (data not shown).
12.3.3 Tachycardic effects of 5-HT before and after administration of indorenate,
cisapride or sumatriptan
Since the 5-HT receptor agonists, indorenate, cisapride and sumatriptan, failed to
mimic 5-HT in increasing heart rate (see Figur  12.1), we decided to investigate these
compounds (1300 µg kg-1 each of  indorenate and cisapride in one subgroup and
430 µg kg-1 of sumatriptan in another subgroup) as potential antagonists of the
tachycardic responses to 5-HT.  5-HT (3, 10 and 30µg kg-1) elicited a dose-d pendent
tachycardia (first subgroup: 5±2, 26±10 and 46±11 beats min-1, n=4, respectively;
second subgroup:7±2, 17±6 and 43±7 beats min-1, n=3, respectively).  These
responses as well as the tachycardia elicited by isoprenaline (0.01, 0.03 and
0.1 µg kg-1) remained unaffected after administration of the above compounds (data
not shown).
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Figure 12.4 Effects of i.v. bolus injections of clozapine (u per panels; n=6) or
GR127935 followed by tropisetron  (lower panels; n=5) on tachycardic responses to
5-HT, 5-MeO-T and isoprenaline in vagosympathectomised spinal cats.  *, P<0.05 vs.
the corresponding control response.
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Figure 12.5 Effects of a number of drugs acting on 5-HT receptors on tachycardic
responses to 5-CT in vagosympathectomised spinal cats.  The cumulative doses of
various drugs used were: saline (0.3 ml kg-1; n=5), lisuride (100 µg kg-1; n=6),
ergotamine (300 µg kg-1; n=6), clozapine (4000 µg kg-1; n=6) in the l ft panel;
mesulergine (1000 µg kg-1; n=6), GR127935 (500 µg kg-1) + tropisetron (3000 µg kg-1;
GR+Trop; n=5), indorenate (1300µg kg-1) + cisapride (1300 µg kg-1; Indo+Cisa; n=4)
and sumatriptan (430 µg kg-1; n=3) in the right panel.  *, P<0.05 vs the corresponding
control response in animals treated with saline, indicated in both panels.
12.3.4 Tachycardic effects of 5-CT after physiological saline or some compounds
acting at 5-HT receptors
Figure 12.5 shows the comparative effects of different doses of 5-CT obtained in cats
pretreated with cumulative doses of either saline (0.3ml kg-1), lisuride (100 µg kg-1),
ergotamine (300 µg kg-1), clozapine (4000 µg kg-1), mesulergine (1000 µg kg-1),
GR127935 (500 µg kg-1) plus tropisetron (3000 µg kg-1), indorenate (1300 µg kg-1)
plus cisapride (1300 µg kg-1) or sumatriptan (430 µg kg-1).  Only lisuride,
mesulergine, ergotamine and clozapine produced a significant blockade of the
responses to 5-CT, with an apparent order of antagonist potency of ergotamine ³
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lisuride > mesulergine > clozapine.  In addition, indorenate + cisapride slightly
- though significantly - attenuated the response to the highest dose of 5-CT
(30 µg kg-1).  The remaining compounds produced no significant effect (Figure 12.5).
After the tachycardic response to 30 µg kg-1 of 5-CT (given cumulatively) had
been stable for at least 10 min, a subsequent administration of the same dose of saline,
GR127935 + tropisetron, indorenate + cisapride or sumatriptan (n=3 each) in the
corresponding subgroups produced no further change in heart rate (data not shown).
In contrast, 5-CT-induced tachycardia was significantly (P<0.05) decreased from the
prevailing values after i.v. administration of the same dose of lisuride (-17±1%; n=4),
ergotamine (-8±2%; n=4), clozapine (-22±4%; n=3) or mesulergine (-25±2%; n=6).
12.4 Discussion
12.4.1 General
In previous studies, Saxena et al. (1985b) had proposed that the tachycardia induced
by 5-HT in the cat, being potently mimicked by 5-CT and blocked by methysergide, is
mediated by 5-HT1-like receptors on the basis of the resistance to blocking doses of
antagonists at 5-HT2 (ketanserin, ritanserin) and 5-HT3 (MDL72222) receptors.
However, it is noteworthy that, in contrast to its constrictor effects via vascular
5-HT1-like receptors ( ee Saxena & Villalón, 1990), methysergide did not show any
agonist activity at the feline cardiac 5-HT1-like receptors.  Subsequently, Saxena
(1988) showed that these atypical cardiac receptors were unrelated to the 5-HT1A,
5-HT1B, 5-HT1C (now 5-HT2C) and 5-HT1D subtypes based on: (i) the blockade, in
decreasing order of potency, by methiothepin, mesulergine and metergoline, an order
which does not match with their corresponding affinities for these receptors (see
Table 10.2); (ii) the low agonist potency of the 5-HT1A receptor agonist, 8-OH-DPAT;
and (iii) the lack of activity of 5-HT1A/1B receptor agonist, RU 24969.
Certainly, the approach established by the IUPHAR 5-HT receptor
classification scheme (Hoyer et al., 1994) lead us to conclude that the appellation
5-HT1-like is no longer regarded as appropriate for the 5-HT receptors mediating
tachycardia in the cat.  The operational approach of the present study strengthens this
view as the feline cardiac 5-HT receptors were not stimulated by sumatriptan or
indorenate, which are both agonists at typical 5-HT1-like receptors mediating
vasoconstrictor responses (Saxena & Villalón, 1990; Villalón et al., 1990a;
Hoyer et al., 1994) and could be blocked by a series of drugs showing high affinity for
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cloned 5-ht7 receptors.  Thus, these cardiac receptors resemble those mediating
smooth muscle relaxation and elevation of cyclic AMP in neonatal porcine vena cava
(Trevethick et al., 1986; Sumner et al., 1989), hypotension in anaesthetised rats
(Chapter 10) and cats (Connor et al., 1986) and vasodilatation in the canine external
carotid bed (Villalón et al., 1997a).  Apart from the implications discussed below,
these data suggest that the 5-HT receptors mediating tachycardia in the cat may
represent a functional correlate of the recombinant 5-ht7 receptor.
12.4.2 Agonist action of some tryptamine derivatives on the feline heart 5-HT
receptor
Admittedly, the rank order of agonist potency (5-CT >> -HT > 5-MeO-T) observed
in our study is similar to that reported for the prejunctional sympatho-inhibitory
5-HT1B/1D receptors mediating canine external carotid vasodilatation
(Villalón & Terrón, 1994a).  Nevertheless, at these prejunctional 5-HT1B/1Dreceptors,
indorenate and sumatriptan behaved as agonists (Villalón et al., 1993a;
Villalón & Terrón, 1994a), as previously reported for other 5-HT1B/1D receptors
(Saxena & Villalón, 1990; Villalón et al., 1990a; De Vries et al., 1996; 1996).
Contrasting with this 5-HT1B/1D receptor operational profile, our results in the cat heart
clearly show that sumatriptan and indorenate id not behave as agonists (or
antagonists).  The above rank order of agonist potency, therefore, closely resembles
the pharmacological properties of the cloned 5-ht7 r ceptor subtype; pKi values
reported for recombinant 5-ht7 receptors for 5-CT, 5-HT, 5-MeO-T and sumatriptan
are 9.5, 8.7, 8.7 and 6.2, respectively (see Table  10.1).
12.4.3 Do feline heart 5-HT receptors correlate with any subtype of the 5-HT1
receptor family?
Although the above rank order of agonist potency with indorenate and sumatriptan
inactive already excludes the involvement of 5-HT1A, -HT1B/1D and
sumatriptan-sensitive 5-HT1-like receptors, it is well known that the 5-HT1 receptor
family includes two additional subtypes, namely, the cloned 5-ht1E a d 5-HT1F
receptors (Chapter 1).  However, the involvement of these subtypes in the present
study is not likely because (i) 5-CT and 5-MeO-T, which display very low affinity for
the recombinant 5-ht1E and 5-HT1F receptors (see Table 10.1), potently mimicked
5-HT in eliciting tachycardia; (ii) the tachycardic responses to 5-CT, 5-HT and
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5-MeO-T were antagonised by mesulergine and clozapine, which do not interact with
any subtype of the 5-HT1 receptor family (see Table 10.2); (iii) these tachycardic
responses were not antagonised by GR127935 at doses that are high enough to block
5-HT1B/1D receptors (De Vries et al., 1996; Skingle et al., 1996; Villalón et al., 1996)
and (iv) the 5-HT1 receptor family is, by definition, negatively coupled to adenylyl
cyclase (Hoyer et al., 1994), a signal transduction system usually associated with
vasoconstriction and bradycardia, not tachycardia (Ran et al., 1987;
Saxena & Villalón, 1990; 1991; Sumner et al., 1992).
12.4.4 Lack of resemblance of the feline heart 5-HT eceptor with either 5-HT2,
5-HT3, 5-HT4, 5-ht5 or 5-ht6 receptors
The 5-HT receptors mediating tachyc rdia in the cat also seem to differ from the
5-HT2, 5-HT3, 5-HT4 and 5-ht6 receptor types on the basis of: (i) the high potency of
5-CT relative to 5-HT, an order which is reversed for the aforementioned types (see
Table 10.1); (ii) insensitivity to antago ism by high doses of 5-HT2 (ketanserin,
ritanserin or cyproheptadine) and 5-HT3 (MDL72222) receptor antagonists
(Saxena et al., 1985b); (iii) the inactivity (as agonist or antagonist) of cisapride, a
benzamide with partial agonist properties at the 5-HT4 r ceptors mediating
tachycardia in the pig (Villalón et al., 1991); (iv) resistance to antagonism by
tropisetron at doses (3000 µg kg-1) that block 5-HT3 and 5-HT4 receptors
(Villalón et al., 1990b; 1991) and (v) the potent blockade by mesulergine, a compound
showing selectivity for the cloned 5-ht7 receptor (pKi=7.7) over the cloned 5-ht6
receptor (pKi=5.8) (see Table 10.2).  Furthermore, based on the above, the ability of
5-MeO-T to induce tachycardia in the cat, which is, in its own right, an additional
criterion to exclude the participation of 5-HT3 receptors (see Table 10.1), cannot be
attributed to its agonist properties at 5-HT4 receptors (Villalón et al., 1991).
Interestingly, 5-CT, methiothepin and ergotamine display a relatively high
affinity for the recombinant 5-ht5A and 5-ht5B receptors (see Tables 10.1 and 10.2).
This, therefore, raises the question whether the cloned 5- t5A/5B receptors are related to
the 5-HT receptors mediating tachycardia in the cat.  However, this does not seem
very likely because: (i) ergotamine failed to increase heart rate in the cat and
(ii) methiothepin, which has a ten-fold lower affinity than ergotamine for 5-ht5A/5B
receptors (see above), was more potent (not less potent as may be expected from their
affinities for 5-ht5A/5B receptors) than ergotamine in blocking 5-HT-induced feline
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tachycardia (present results; Saxena, 1988). Moreover, the antagonism by mesulergine
and metergoline (Saxena, 1988), both with pKi values of <6.0 at cloned 5-ht5A/5B
receptors (see table 10.2), also points against these receptors mediating the
5-HT-induced tachycardia in the cat.
12.4.5 Resemblance of the feline heart 5-HT receptor to putative 5-HT7 receptors
Since the involvement of 5-HT1-5-ht6 receptors seems improbable, the possibility has
finally to be discussed that the 5-HT receptors mediating tachycardia in the cat
resemble the cloned 5-ht7 receptor.  Indeed, the rank order of agonist potency of 5-CT
>> 5-HT > 5-MeO-T >> clozapine to produce tachycardia in the cat, wit  sumatriptan
and indorenate inactive parallels that reported at the mouse (Plassat t al., 1993), rat
(Lovenberg et al., 1993; Ruat e al., 1993b; Shen t al., 1993) and human (Bard et al.,
1993) cloned 5-ht7 receptors (5-CT > 5-MeO-T ³ 5-HT). Significantly, the above rank
order of agonist potency is practically identical to that reported in other preparations
where the relaxant effects of 5-HT have been ascribed to stimulation of musculotropic
5-HT7 receptors.  Some of these preparations include the rabbit femoral vein
(Martin & Wilson, 1995), the Cynomolgus monkey isolated jugular vein (L u g et al.,
1996), the guinea-pig ileum (Carter et al., 1995) and the canine coronary (Terrón,
1996b), external carotid (Villalón et al., 1997a) arteries and rat systemic vasculature
(Chapter 10).
This suggestion gains weight when considering that the tachycardia induced
by the 5-HT in the cat was blocked in previous studies (Saxena, 1988) by
methiothepin, methysergide and metergoline, compounds that display high affinities
for cloned 5-ht7 receptors (see Table 10.2).  On this basis, in the present study, we
deliberately selected ergotamine, lisuride, clozapine and mesulergine as potential
antagonists because they show either high affinity (the former three) or relative
selectivity (the latter) for the cloned 5-ht7 receptor (see Hoyer et al., 1994).
Accordingly, all of these compounds blocked the 5-CT-, 5-HT- and 5-MeO-T-induced
tachycardic responses, though this blockade appeared to be highly specific only for
lisuride.  Indeed, ergotamine, lisuride, mesulergine or clozapine have been reported to
antagonise smooth muscle relaxant responses mediated by other functional 5-HT7
receptors ( ee Chapter 10; Carter t al., 1995; Martin & Wilson, 1995; Terrón, 1996b;
Villalón et al., 1997a).
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Admittedly, there are no selective agonists and antagonists at cloned 5-ht7
receptors available so far.  Thus, although we recognise that the antagonists blocking
5-HT-induced feline tachycardia display varying degrees of affinity for receptors other
than 5-HT, including a (a1 and a2)-adrenoceptors, H2 histaminergic and muscarinic
receptors (Leysen, 1985), the agonists used in the present study do not interact with
these receptors; most significantly, these and other mechanisms in 5-HT-induced
feline tachycardia (including stimulation of cardiac b-ad enoceptors and the indirect
release of catecholamines) have already been excluded (Saxena et al., 1985b).
In conclusion, it is suggested that the tachycardic effect of 5-HT in the cat is mediated
by a receptor similar to the cloned 5-ht7 subtype.  Since this cardiac 5-HT receptor
represents another functional correlate of the 5-ht7 gene product, the change of the
appellation 5-ht7 into 5-HT7 is favoured (Eglen et al., 1997; Saxena et al., 1998b).
Although species variations should not be dismissed (Saxena & Villalón, 1991), the
present findings in the cat seem to be the first to show a tachycardic effect being
mediated by the 5-HT7 receptor.  This in vivo experimental model, which is not
complicated by the presence of other 5-HT receptors, can be utilised to characterise
and develop, including the possibility of studying oral absorption, new drugs with
potential agonist and antagonist properties at functional 5-HT7 receptors.
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Chapter 13
The 5-HT1-like receptors mediating inhibition of sympathetic
vasopressor outflow in the pithed rat: operational correlation
with the 5-HT1A, 5-HT1B and 5-HT1D subtypes
Summary It has been suggested that the inhibition of sympathetically-induced
vasopressor responses produced by 5-HT in pithed rats is mediated by 5-HT1-like
receptors. The present study has reanalysed this suggestion considering the
classification schemes recently proposed by the NC-IUPHAR subcommittee on 5-HT
receptors.  Intravenous (i.v.) continuous infusions of 5-HT and the 5-HT1 receptor
agonists, 8-OH-DPAT (5-HT1A), indorenate (5-HT1A), CP93129 (5-HT1B) and
sumatriptan (5-HT1B/1D), resulted in a dose-dependent inhibition of
sympathetically-induced vasopressor responses.  The sympatho-inhibitory responses
induced by 5-HT, 8-OH-DPAT, indorenate, CP93129 or sumatriptan were analysed
before and after i.v. treatment with blocking doses of the putative 5-HT receptor
antagonists, WAY100635 (5-HT1A), cyanopindolol (5-HT1A/1B) or GR127935
(5-HT1B/1D).  Thus, after WAY100635, the responses to 5-HT and indorenate, but not to
8-OH-DPAT, CP93129 and sumatriptan, were blocked. After cyanopindolol, the
responses to 5-HT, indorenate and CP93129 were abolished, whilst those to
8-OH-DPAT and sumatriptan (except at the lowest frequency of stimulation) remained
unaltered. In contrast, after GR127935, the responses to 5-HT, CP93129 and
sumatriptan, but not to 8-OH-DPAT and indorenate, were abolished.  In additional
experiments, the inhibition induced by 5-HT was not modified after 5-HT7 receptor
blocking doses of mesulergine.  The above results suggest that the 5-HT1-like rec ptors,
which inhibit the sympathetic vasopressor outflow in pithed rats, display the
pharmacological profile of the 5-HT1A, 5-HT1B and 5-HT1D, but not that of 5-HT7,
receptors.
13.1 Introduction
The complexity of cardiovascular effects produced by 5-HT, including bradycardia or
tachycardia, hypotension or hypertension and vasodilatation or vasoconstriction, has
been explained by the capability of the monoamine to interact with specific receptors
in the central nervous system (CNS), on the autonomic ganglia and postganglionic
nerve endings, on vascular smooth muscle and endothelium and on the cardiac tissue
(see Saxena & Villalón, 1990; 1991; Martin, 1994; Jones et al., 1995); in addition, the
Based on: Villalón, C.M., Centurión, D., Rabelo, G., De Vries, P., Saxena, P.R. & Sánchez-
López, A. (1998). The 5-HT1-like receptors mediating inhibition of sympathetic vasopressor
outflow in the pithed rat: operational correlation with the 5-HT1A, 5-HT1B and 5-HT1D
subtypes.  Br. J. Pharmacol., 124, 1001-1011.
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advent of selective 5-HT receptor agonists and antagonists has revealed that the
cardiovascular effects of 5-HT may be mediated by 5-HT1 (including the 5-HT1A,
5-HT1B and/or 5-HT1D subtypes), 5-HT2, 5-HT3, 5-HT4 and 5-HT7 receptors (see
Villalón et al., 1997b; Saxena et l., 1998b).
With respect to the capability of 5-HT to interfere with sympathetic
transmission, it has been shown that the monoamine inhibits, via prejunctional
5-HT1-like receptors, the contractile responses to adrenergic nerve stimulation in
several blood vessels including, amongst others, the canine (Humphrey et al., 1988)
and human (Göthert et al., 1990) saphenous veins, the canine external carotid bed
(Villalón & Terrón, 1994a) nd the rat vena cava (Molderings et al., 1987). The
subsequent pharmacological analysis of these prejunctional 5-HT1-like receptors (see
Hoyer et al., 1994; Hartig et al., 1996) shows a correlation with either the 5-HT1B
subtype (cyanopindolol-sensitive) in the case of rodents (e.g. Molderings et al., 1987)
or the 5-HT1B/1D subtypes (GR127935-sensitive) in the case of non-rodent speci s
(e.g. Molderings et al., 1990).  These studies, however, do not prove if the above
sympatho-inhibitory receptors are operative in the systemic vasculature; in this
respect, we have shown, producing selective stimulation of the sympathetic
vasopressor outflow in pithed rats, that 5-HT does indeed inhibit the sympathetically-
induced vasopressor responses, but not those by exogenous noradrenaline
(Villalón et al., 1995b).  Since this sympatho-inhibitory response to 5-HT, being
potently mimicked by 5-CT, is not modified by ritanserin, MDL72222 or tropisetron,
but it is blocked by methysergide, we suggested the involvement of
sympatho-inhibitory 5-HT1-like receptors (Villalón et al., 1995a).
Nevertheless, the functional 5-HT1-like receptors (see Hoyer et al., 1994) can,
at present, be reclassified into 5-HT1B/1D receptors (stimulated by 5-CT and
sumatriptan; blocked by GR127935, but not by mesulergine) and 5-HT7 receptors
(potently stimulated by 5-CT, but not by sumatriptan; blocked by mesulergine, but not
by GR127935) (see Eglen et al., 1997; Saxena et al., 1998b).  On this basis, the
present study was carried out to reanalyse the pharmacological profile of the above
sympatho-inhibitory 5-HT1-like receptors.  Hence, the drugs employed included, in
addition to the endogenous ligand (5-HT), agonists and/or antagonists at 5-HT1A,
5-HT1B, 5-HT1D and 5-HT7 receptors.
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13.2 Methods
13.2.1 General
Experiments were carried out in a total of 164 male Wistar rats (250-300 g).  After
anaesthesia with ether and cannulation of the trachea, the rats were pithed by inserting
a stainless steel rod through the orbit and foramen magnum into the vertebral foramen
(Shipley & Tilden, 1947).  The animals were artificially ventilated with room air using
an Ideal Palmer pump (56 strokes min-1; volume: 20 ml kg-1).  Subsequently, the
pithing rod was replaced by an electrode, enamelled except for 1 cm length 9 cm from
the tip, so that the uncovered segment was situated at T7-T9 of the spinal cord to
stimulate the thoracic sympathetic nerves supplying the systemic vasculature
(Gillespie t al., 1970).  After bilateral vagotomy, catheters were placed in the left and
right femoral veins, for the infusion of agonists and for the administration of
antagonists respectively, and the left carotid artery, connected to a Statham pressure
transducer (P23 ID), for the recording of arterial blood pressure.  Heart rate was
measured with a tachograph (7P4F, Grass Instrument Co., Quincy, MA, USA)
triggered from the blood pressure signal.  Both blood pressure and heart rate were
recorded simultaneously by a model 7D Grass polygraph (Grass Instrument Co.,
Quincy, MA, USA).  Prior to electrical stimulation, the animals received gallamine
(25 mg kg-1, i.v.) to avoid electrically-induced muscular twitching.
Since the sympatho-inhibitory effects of 5-HT are particularly more
pronounced at lower frequencies of stimulation, all animals were systematically
pretreated with 50 µg kg-1 (i.v.) of desipramine (to block reuptake of noradrenaline)
before each stimulus-response curve (S-R curve).  Under these conditions, as
previously reported (Villalón et al., 1995a; 1995b): (i) the resulting vasopressor
responses to lower frequencies of stimulation are greater in magnitude when
compared to those elicited in rats without desipramine; and (ii) the potentiating effect
of desipramine on the sympathetically-induced vasopressor responses does not wear
off with time during the experiment.
13.2.2 Experimental protocol
After a stable haemodynamic condition for at least 30 min, baseline values of diastolic
blood pressure and heart rate were determined.  The sympathetic vasopressor outflow
was stimulated by applying trains of 10 sec, consisting of monophasic rectangular
pulses of 2ms duration and 50 V, at increasing frequencies (0.03, 0.1, 0.3, 1 and
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3 Hz); the S-R curve was completed in about 30 min.  Then, one group of 20 animals
(out of the 164) was subdivided intofive subgroups (n=4 each) which received,
respectively, i.v. continuous infusions of 5-HT (1.8, 3.0 and 5.6 µg kg-1 min-1),
8-OH-DPAT, indorenate, CP93129 and sumatriptan (10, 30 and 100 µg kg-1 min-1
each) by a Harvard model 901 pump (Harvard Apparatus Co. Inc., Millis, MA, USA).
Twenty min after the start of each infusion, a S-R curve was elicited as described
above during the infusion of each agonist dose.
The remaining 144 animals were divided into 6 groups (see Figure 13.1)
which received continuous i.v. infusions of physiological saline (0.01 ml min-1; n=27),
5-HT (5.6 µg kg-1 min-1; n=29), 8-OH-DPAT (30 µg kg-1 min-1; n=20), indorenate
(30 µg kg-1 min-1; n=20), CP93129 (100 µg kg-1 min-1; n=24) or sumatriptan
(100 µg kg-1 min-1; n=24) using the aforementioned pump.  Twenty min after the start
of the infusion, a S-R curve was elicited as previously described during the infusion of
saline or the corresponding agonist.  Once the S-R curve was completed
(about 30 min), the infusions were stopped, except for the group receiving the infusion
of 8-OH-DPAT, which was continuous until the end of the experiment (see Results
section).  Thus, in the 5 groups, where the infusion was stopped immediately after
completing the S-R curve, the total period of infusion was of 50 min.  At this point,
the six groups were subsequently subdivided on the basis of treatment with
antagonists (see Figure 13.1).
The first group, infused with saline, was subdivided into 5 treatment groups
(see Figure 13.1) comprising i.v. bolus injections of: saline (0.3, 1, 3 and 10 ml kg-1;
n=7), WAY100635 (3, 10, 30 and 100 µg kg-1; n=6), cyanopindolol (100, 300 and
1000 µg kg-1; n=6), GR127935 (100, 300 and 1000 µg kg-1; n=4) or mesulergine
(300 µg kg-1; n=4) in order to analyse their effects on the sympathetically-induc d
vasopressor responses per e.  Ten min after each dose of saline or the corresponding
antagonist, a S-R curve was elicited again.  The second group, infused with 5-HT, was
similarly subdivided into 5 treatment groups (see Figure 13.1) comprising i.v. bolus
injections of: saline (0.3, 1 and 3 ml kg-1; n=7), WAY100635 (10 µg kg-1; n=6),
cyanopindolol (100 µg kg-1; n=6), GR127935 (100 µg kg-1; n=6) or mesulergine
(300 µg kg-1; n=4); ten min after each treatment, a S-R curve was elicited again.
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Figure 13.1 Experimental protocols showing the number of animals used in the 6 main
groups (receiving infusions of physiological saline or agonist infusions) and the different
subgroups (receiving i.v. bolus injections of physiological saline or antagonists).
As shown in Figure 13.1, each of the other four groups, infused with 8-OH-DPAT,
indorenate, CP93129 or sumatriptan, was systematically subdivided into 4 treatment
subgroups comprising, respectively, i.v. bolus injections of saline (0.3, 1 and
3 ml kg-1), WAY100635 (10 µg kg-1 and, in some cases, 30 µg kg-1 when the
preceding dose failed to block the sympatho-inhibi ion induced by the corresponding
agonist), cyanopindolol (100 µg kg-1) or GR127935 (100 µg kg-1).  Ten min after each
treatment a S-R curve was elicited again (for number of experiments, see Figure 13.1).
The reason for giving three or, as in the case of the first group, four different dose
volumes of physiological saline as controls is that a single concentration of antagonist
solution was used, so that increasing dose volumes were used to increase the dose of
antagonist rather than using a fixed dose volume and increasing concentrations of
antagonist solution.
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The doses of 5-HT, indorenate, CP93129 or sumatriptan were infused at a rate
of 0.01 ml min-1 during a total period of 50 min, at which time the corresponding
S-R curve had already been completed.  The dose of 8-OH-DPAT, although infused at
the same rate, was continuous until the end of the experiment because in preliminary
studies (not shown) we observed that the interruption of the infusion abolished the
sympatho-inhibition produced by 8-OH-DPAT. The doses of 5-HT, 8-OH-DPAT,
indorenate, CP93129 and sumatriptan were selected on the basis of results obtained
from preliminary experiments, in which reproducible and consistent inhibitory effects
on the S-R curves were elicited with no changes in baseline diastolic blood pressure or
heart rate (Villalón et al., 1995a; 1995b).  The dosing with all compounds used was
sequential.
13.2.3 Drugs
Apart from the anaesthetic (diethyl ether), the drugs used in the study (obtained from
the sources indicated) were: 5-HT creatinine sulphate and gallamine triethiodide
(Sigma Chemical Co., St. Louis, MO, USA); indorenate hydrochloride (gift:
Prof. Enrique Hong, CINVESTAV-IPN, Mexico City, Mexico); CP93129 (gift:
Pfizer Inc., Groton, USA); 8-OH-DPAT, WAY100635 and desipramine hydrochloride
(Research Biochemicals Int., Natick, MA, USA); GR127935 and
sumatriptan succinate (gifts: Dr. Simon Lister and Dr. Helen Connor,
GlaxoWellcome, Stevenage, Hertfordshire, UK); cyanopindolol and mesulergine
hydrochloride (gifts: Sandoz AG, Basel, Switzerland).  All compounds were dissolved
in distilled water.  When needed, 1% (w v-1) ascorbic acid (CP93129) was added; this
vehicle had no effect on baseline diastolic blood pressure or heart rate.  The doses
mentioned in the text refer to the salts of substances except in the case of 5-HT,
8-OH-DPAT, indorenate, CP93129 and sumatriptan, where they ref  to the free base.
13.2.4 Data presentation and statistical analysis
All data in the text and figures are presented as the mean±s.e.mean.  The peak changes
in diastolic blood pressure produced by electrical stimulation in saline- and
agonist-infused animals were determined.  The difference between the changes in
diastolic blood pressure within one subgroup of animals was evaluated with
Student-Newman-Keuls' test, once an analysis of variance (randomised block design)
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had revealed that the samples represented different populations (Steel & Torrie, 1980).
A P-value of 0.05 or less (two-tailed) was considered statistically significant.
13.3 Results
13.3.1 Systemic haemodynamic variables
The baseline values of diastolic blood pressure and heart rate in the 164 rats were,
respectively, 59.9±0.3 mmHg and 290±3.4 beats min-1.  Following the first i.v. bolus
injection of desipramine (50 µg kg-1) these values were transiently increased, but after
8 min they did not significantly differed from the baseline values (i.e. 61.2±0.6 mmHg
and 292±3.3 beats min-1, respectively).
The latter values in desipramine-pretr ated rats were not significantly
modified (data not shown) by: (i) the continuous infusion of physiological saline
(0.01 ml min-1), 5-HT (1.8, 3.0 and 5.6 µg kg-1 min-1), 8-OH-DPAT, indorenate,
CP93129 or sumatriptan (10, 30 and 100 µg kg-1 min-1 each);  (ii) the i.v. bolus
injections of saline (0.3, 1, 3 and 10 ml kg-1), WAY100635 (3, 10, 30 and
100 µg kg-1), GR127935 (100, 300 and 1000 µg kg-1) or mesulergine (300 µg kg-1); or
(iii) the subsequent treatments with desipramine (50 µg kg-1 each).
In contrast, the administration of cyanopindolol (100, 300 and 1000 µg kg-1,
i.v.) to the control animals infused with saline (0.01 ml min-1) resulted in changes in
heart rate of, respectively, +20±7, +34±8 and -2±3 beats min-1, but diastolic blood
pressure was not significantly modified. Similarly, in the animals infused with the
agonists at the above rat s, cyanopindolol (100 µg kg-1, i.v.) produced an increase in
heart rate of, respectively, 37±2 (5-HT), 30±9 (8-OH-DPAT), 22±3 (indorenate), 28±5
(CP93129) and 22±8 (sumatriptan) beats min-1.
13.3.2 Initial effects produced by electrical stimulation of the preganglionic (T7-T9)
sympathetic nerves on blood pressure and heart rate
The onset of the responses induced by stimulation of the sympathetic vasopressor
outflow was immediate and resulted in frequency-d pendent increases in diastolic
pressure (see Figures 13.2-13.5). These vasopressor responses are due to selective
stimulation of the systemic vasculature since only negligible (if any) changes in heart
rate were observed, as reported by other authors (e.g. Gille pie t al., 1970;
Flavahan et al., 1985; Grant & McGrath, 1988).
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13.3.3 Effect of 5-HT and the 5-HT1 receptor agonists, 8-OH-DPAT, indorenate,
CP93129 or sumatriptan, on the sympathetically-indu ed vasopressor
responses
Figure 13.2 shows that continuous infusions of 5-HT (1.8, 3.0 and 5.6 µg kg-1 min-1)
produced a dose-dependent inhibition on sympathetically-induced vasopressor
responses, as previously observed (Villalón et al., 1995b).  This sympatho-inhibitory
response to 5-HT was dose-dependently mimicked by the continuous infusions of the
5-HT1 receptor agonists, 8-OH-DPAT, indorenate, CP93129 and sumatriptan (10, 30
and 100 µg kg-1 min-1 each; see Figure 13.2). This inhibition was, in all cases,
significantly more pronounced at lower frequencies of stimulation (0.03-1 Hz).
Comparatively, 5-HT was about 1 log unit more potent than the abov gonists in its
ability to produce sympatho-inhibition.
Figure 13.2 Increases in diastolic blood pressure (D DBP) produced by electrical stimulation of the sympathetic vasopressor
outflow in pithed rats before (control) and during the i.v. continuous infusions of 5-HT, 8-OH-DPAT, indorenate, CP93129 and
sumatriptan. *, P<0.05 vs. control. All the other graphs after the starred (*) graph are also significantly different from control.
5-HT1 receptors and inhibition of sympathetic outflow
234
13.3.4 Effect of physiological saline, WAY100635, cyanopindolol, GR127935 or
mesulergine on the sympathetically-induced vasopressor responses per se and
on the inhibition of sympathetically-induced vasopressor responses produced
by 5-HT
Figure 13.3 (upper panels) hows the effects of i.v. bolus injections of physiological
saline or the 5-HT receptor antagonists on the sympathetically-indu ed vasopressor
responses per se in animals infused with saline (0.01 ml min-1 i.v. during 50 min).
After stopping the infusion of saline, these vasopressor responses, which remained
essentially unchanged in control animals receiving four subsequent i.v. bolus
injections of saline (0.3, 1, 3 and 10 ml kg-1), were not significantly modified by either
the lower doses of WAY100635 (3, 10 and 30 µg kg-1), cyanopindolol (100 and
300 µg kg-1) or all doses tested of GR127935 (100, 300 and 1000 µg kg-1) and
mesulergine (300 µg kg-1).  In contrast, the highest doses of WAY100635
(100 µg kg-1) and cyanopindolol (1000 µg kg-1) produced a significant inhibition on
the S-R curves which was, coincidentally, more pronounced at lower frequencies of
stimulation (Figure 13.3, upper panels).
Figure 13.3 (lower panels) hows the effects produced by i.v. bolus injections
of physiological saline (0.3, 1 and 3 ml kg-1), WAY100635 (10 µg kg-1),
cyanopindolol (100 µg kg-1), GR127935 (100 µg kg-1) and mesulergine (300 µg kg-1)
on the inhibition of sympathetically-induced vasopressor responses produced by the
infusion of 5-HT (5.6 µg kg-1 min-1 i.v. during 50 min). Under these experimental
conditions, the sympatho-in ibition induced by the infusion of 5-HT was reproducible
since even after stopping the infusion, the corresponding S-R curves remained without
significant changes when the animals received three subsequent bolus injections of
physiological saline (Figure 13.3, lower panels). In contrast, when analysing the
effects of antagonists, the response to 5-HT was practically abolished after
administration of WAY100635, cyanopindolol or GR127935, but was unaffected by
mesulergine (Figure 13.3, lower panels).
Figure 13.3 Effects of i.v. bolus injections of saline, WAY 100635, cyanopindolol, GR127935 or mesulergine on either: (upper pa els) the increases
in diastolic blood pressure by stimulation of the sympathetic vasopressor outflow in animals infused (i.v.) with saline (during 50 min); or (low r
panels) the corresponding inhibition by the i.v. infusion of 5-HT (during 50 min) of sympathetically-induced vasopressor responses. The above doses
of antagonists (or saline) were injected after stopping the infusion of saline (upper panels) or 5-HT (lower panels) and the S-R curves were elicited
after each dose. *, P<0.05 vs control. All the other graphs after the starred (*) graph are also significantly different from control.
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13.3.5 Effect of physiological saline, WAY100635, cyanopindolol or GR127935 on
the inhibition of sympathetically-induced vasopressor responses produced by
some 5-HT1 receptor agonists
Figures 13.4 and 13.5 show the effects of physiological saline (0.3, 1 and 3 ml kg-1),
WAY100635 (10 and/or 30 µg kg-1), cyanopindolol (100 µg kg-1) or GR127935
(100 µg kg-1) on the inhibition of sympathetically-induced vasopressor responses
induced by 8-OH-DPAT (30 µg kg-1 min-1; Figure 13.4, upper panels), indorenate
(30 µg kg-1 min-1; Figure 13.4, lower panels), CP93129 (100 µg kg-1 min-1; Figure
13.5, upper panels) and sumatriptan (100 µg kg-1 min-1; Figure 13.5, lower panels).
As previously observed with 5-HT, the sympatho-inhibition produced by the
continuous infusion (during 50 min) of indorenate, CP93129 and sumatriptan was
reproducible since even after stopping the infusion, the corresponding S-R curves
remained without significant changes when the animals received three subsequent
bolus injections of physiological saline.
In the case of the inhibition produced by 8-OH-DPAT (Figure 13.4, upper
panels), there was an important difference in the experimental protocol because in
preliminary experiments (not shown) we observed that the infusion of 8-OH-DPAT, in
contrast to that of the other agonists, produced a short-lasting sympatho-inhibition
which was simply abolished when interrupting the infusion. That is why the infusion
of 8-OH-DPAT had to be kept continuous until the end of the experiments. Under
these conditions, the response to 8-OH-DPAT was reproducible since the
corresponding S-R curves remained without significant changes when the animals
received three subsequent bolus injections of physiological saline (Figure 13.4, upper
panels).
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Figure 13.4 Effects of i.v. bolus injections of saline, WAY 100635, cyanopindolol or
GR127935 on the inhibition of sympathetically-induced vasopressor responses induced
by: (upper panels) 8-OH-DPAT (infused uninterruptedly); and (lower panels)
indorenate (during 50 min).  The above doses of antagonists (or saline) were injected
either after concluding each S-R during the infusion of 8-OH-DPAT (upper panels) or
after stopping the infusion of indorenate (lower panels); the S-R curves were elicited
after each dose. *, P<0.05 vs control response. All the other graphs after the starred (*)
graph are also significantly different from control.
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Figure 13.5 Effects of i.v. bolus injections of saline, WAY100635, cyanopindolol or
GR127935 on the inhibition of sympathetically-induced vasopressor responses induced
by the i.v. continuous infusion (during 50 min) of: (upper panels) CP93129; and (lower
panels) sumatriptan. The above doses of antagonists (or saline) were injected after
stopping the infusion of CP93129 or sumatriptan, and the S-R curves were elicited after
each dose. *, P<0.05 vs control. All the other graphs after the starred (*) graph are also
significantly different from control.
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When analysing the effects of the antagonists, differential effects were observed on
the sympatho-inhibition produced by each agonist.  Thus, Figure 13.4 (upper panels)
shows that the sympatho-inhibition produced by 8-OH-DPAT was practically resistant
to blockade by WAY100635 (10 and 30 µg kg-1), cyanopindolol (100 µg kg-1) and
GR127935 (100 µg kg-1). Similarly, in additional experiments (not reported for the
sake of clarity in the experimental protocol and in the figures), the inhibition by
8-OH-DPAT was not significantly modified after administration of the
a2-adrenoceptor antagonist, rauwolscine (1000 µgkg-1 i.v.), either alone (n=6) or in
combination with WAY100635 (30 µg kg-1 i.v., n=4).
In contrast, the response to indorenate (Figure 13.4, lower panels) was
virtually abolished by WAY100635 (10 µg kg-1) and cyanopindolol (100 µg kg-1), but
not by GR127935 (100 µg kg-1).  With respect to the sympatho-inhibition produced by
CP93129 and sumatriptan, it is evident that the responses to CP93129 (Figure 13.5,
upper panels) and sumatriptan (Figure 13.5, lower panels) were blocked by
GR127935 (100 µg kg-1), but remained unchanged after WAY100635 (10 and
30 µg kg-1).  Furthermore, after cyanopindolol, the responses to CP93129 were
abolished and those to sumatriptan were blocked only at 0.03 Hz, but remained
unaffected at the other frequencies studied (0.1-3 Hz).
13.4 Discussion
The aim of this study was to re-analyse the pharmacological profile of the
"5-HT1-like" receptors mediating the inhibition of sympathetically-induced
vasopressor responses in pithed rats considering the classification schemes proposed
by the NC-IUPHAR subcommittee on 5-HT receptors (see Hoyer et al., 1994;
Hartig et al., 1996; Saxena et al., 1998b). Within this framework, we have to admit
that our study did not measure sympathetic nerve activity directly, but the
electrically-induced neurotransmitter release could be estimated indirectly by
measurement of the evoked vasopressor response. Under these experimental
conditions, the responses to 5-HT were considered to be (sympatho)-inhibitory on the
basis that the monoamine is capable of inhibiting the vasopressor responses induced
by preganglionic stimulation (T7-T9) of the sympathetic vasopressor outflow, but not
those by exogenous noradrenaline (Vil alón et al., 1995b).
Thus, our study shows that the inhibition of sympathetically-induced
vasopressor responses induced by 5-HT: (i) can be mimicked by agonists at 5-HT1A,
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such as indorenate and 8-OH-DPAT (Dompert et al., 1985; Hoyer t al., 1994),
5-HT1B (CP93129; Macor et al., 1990) and 5-HT1B/1D (sumatriptan; Hoyer et al.,
1994) receptors; and (ii)can be blocked by antagonists at 5-HT1A (WAY100635),
5-HT1A/1B (cyanopindolol) or 5-HT1B/1D (GR127935) receptors, but not by antagonists
at cardiovascular 5-HT7 (mesulergine) receptors (Hoyer et al., 1994; Fletcher et al.,
1996; Skingle et al., 1996; Villalón et al., 1997b).
Apart from the implications discussed below, the present results suggest that
the 5-HT-induced inhibition of sympathetically-induced vasopressor responses in
pithed rats could be mediated by "5-HT1-like" receptors the pharmacological profile of
which correlates with some subtypes (5-HT1A/1B/1D) of the 5-HT1 receptor family, but
not with the 5-HT7 receptor.
With respect to our experimental model, some features deserve further
consideration. Thus, though we produced selective stimulation of the sympathetic
vasopressor outflow, propranolol has been recommended to eliminate vasodilatation
due to catecholamine release from the adrenal medulla (Flavahan et al., 1985).
However, we deliberately avoided using propranolol since it has affinity for some
5-HT1 binding sites (Hoyer, 1988) and, indeed, blocks some "5-HT1-like"
receptor-mediated functional responses in the rat (Martin, 1994), as we have shown
with another ß-adrenoceptor antagonist (cyanopindolol) in the present study.
Moreover, the possible influences arising from the CNS via 5-HT mechanisms can be
ruled out, since pithed rats were used.
13.4.1 Systemic haemodynamic changes
Considering the short bursts of activity which characterize sympathetic nerves in vivo,
our results showing the potentiation of sympathetic vasopressor responses after
desipramine (compare Flavahan et al., 1985; Bulloch & McGrath, 1988;
Villalón et al., 1995a; Villalón et al., 1995b) have relevance for the purpose of the
present study, since the prejunctional inhibitory effects of 5-HT (and of any other
agonist drug) are, coincidentally, more pronounced at lower frequencies of stimulation
(Langer, 1980; Göthert et al., 1990).
Hence, it could be alternatively argued that the marked inhibitory effects of
5-HT, 8-OH-DPAT, indorenate, CP93129 and sumatriptan may be due to
tachyphylaxis of the sympathetically-induced vasopressor responses.  However, this
seems unlikely since such responses remained essentially unchanged when the
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animals received three subsequent i.v. bolus injections of physiological saline
(Figures 13.2, 13.3 and 13.4), as previously reported for 5-HT (Villalón et al., 1995a;
Villalón et al., 1995b).
On the other hand, it is interesting to note that higher doses of WAY100635
(100 µg kg-1) and cyanopindolol (1000 µg kg-1) produced a significant inhibition on
the S-R curves per se (Figure 13.3, upper panels).  Since this inhibitory effect was,
coincidentally, more pronounced at lower frequencies of stimulation, as previously
reported for 5-HT (Villalón et al., 1995a; 1995b) and other 5-HT1 receptor agonists
(see Figure 13.2), it is tempting to suggest that at higher doses these compounds may
have stimulated the 5-HT1 receptors mediating (sympatho)-inhibition. Admittedly,
further experiments will be required to document and evaluate this possibility.
13.4.2 Possible involvement of (sympatho)-inhibitory 5-HT1A receptors
The possible correlation of the (sympatho)-inhibitory 5-HT1-like receptors with the
5-HT1A receptor subtype is established, in the first instance, by the use of
WAY100635, a highly potent and selective 5-HT1A receptor antagonist
(Fletcher et al., 1996) and cyanopindolol, a putative 5-HT1A/1B receptor antagonist
(Hoyer et al., 1994).  At doses devoid of effects on sympathetically-indu ed
vasopressor responses per e (Figure 13.3, upper panels), these compounds were
capable of blocking the (sympatho)-inhibition induced by both 5-HT (the endogenous
ligand; Figure 13.3, lower panels) and indorenate (Figure 13.4, lower panels), a
5-HT1A receptor agonist (Dompert et al., 1985).  Accordingly, the (sympatho)-
inhibition by indorenate being resistant to blockade by GR127935, an antagonist at
5-HT1B/1D receptors (previously described as, respectively, the 5-HT1Dß/1Da subtypes of
the 5-HT1D receptor) (Hartig et al., 1996) may be explained in terms of its low affinity
for 5-HT1A receptors (Skingle et al., 1996).  It must be emphasized that the doses of
the 5-HT receptor antagonists, WAY100635, cyanopindolol and GR127935 used in
the present study were higher than those required to abolish functional responses
mediated by their respective receptors (see Martin, 1994; Fletcher et al., 1996;
Skingle et al., 1996; Villalón et al., 1996).
8-OH-DPAT, another 5-HT1A receptor agonist (Hoyer et al., 1994),
presumably also produced (sympatho)-inhibition in the pithed rat (Figure 13.4, upper
panels), but this response, interestingly, was not blocked by WAY100635,
cyanopindolol or GR127935.  Although this finding, apparently, does not support the
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involvement of 5-HT1A (and 5-HT1B/1D) receptors, it is tempting to consider that
8-OH-DPAT, unlike indorenate, behaves as a partial agonist at the a-adrenoc ptors
mediating vasopressor responses in the pithed rat (Castillo et al., 1994). Thus, it could
be argued that the agonist properties of 8-OH-DPAT, particularly at
sympatho-inhibitory a2-adrenoceptors (Borton et al., 1991) might have masked its
agonist properties at 5-HT1A receptors; however, our preliminary findings showing the
failure of the a2-adrenoceptor antagonist, rauwolscine, either alone or in combination
with WAY100635, to antagonize the inhibition by 8-OH-DPAT (see Results section)
does not support this hypothesis.
In view that the inhibition by 8-OH-DPAT was resistant to blockade by all the
antagonists investigated in the present study, it is prudent to keep in mind that
8-OH-DPAT, in contrast to the other agonists, had to be infused continuously until the
end of the experiments because its inhibitory response was abolished when
interrupting the infusion (see Results section). Thus, it seems more likely that under
conditions of an uninterrupted infusion, the level of 8-OH-DPAT in the biophase was
so high that it may have overshadowed any potential antagonism towards 5-HT1A (and
probably also 5-HT1B/1D and/or a2) receptors. In any case, the pharmacological
properties of 8-OH-DPAT emphasize the importance of being cautious when
characterizing the operational profile of prejunctional autonomic 5-HT receptors,
particularly in rats.
13.4.3 Possible involvement of (sympatho)-inhibitory 5-HT1B receptors
Evidence for the involvement of 5-HT1B receptors stems from the capability of
cyanopindolol, a putative 5-HT1A/1B receptor antagonist (Hoyer et al., 1994), to block
the (sympatho)-inhibition induced by 5-HT (Figure 13.3, lower panels) and by the
selective rodent 5-HT1B receptor agonist, CP93129 (Macor et al., 1990, Figure 13.5,
upper panels).  Thus, the (sympatho)-inhibition by CP93129, being resistant to
blockade by WAY100635 (at doses even higher than those required to block the
(sympatho)-inhibition by 5-HT and indorenate; Figure 13.5, upper panels), confirms
the high selectivity of the latter as a 5-HT1A receptor antagonist (Fletcher et al., 1996).
A relevant finding was also the blockade of CP93129-induced (sympatho)-inhibition
by GR127935 since this compound is now apparently considered as an antagonist at
non-rodent 5-HT1B/1D receptors (Hartig et al., 1996; Villalón et al., 1997b).
Notwithstanding, binding data show that GR127935 has similar affinities for 5-HT1Da
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(pKi: 8.9; non-rodent 5-HT1D), 5-HT1Dß (pKi: 9.9; non-rodent 5-HT1B) and 5-HT1B
(pKi: 8.5; rodent 5-HT1B) receptors (Skingle et al., 1996).  Thus, the simplest
interpretation suggests that the blockade of CP93129-induced (sympatho)-inhibition
by GR127935 may be due to the high affinity of the latter for rodent 5-HT1B receptors.
13.4.4 Possible involvement of (sympatho)-inhibitory 5-HT1D , 5-ht1E and/or 5-ht1F
receptors
Taking into consideration the classification criteria for 5-HT1B/1D eceptors in rodent
and non-rodent species (Hartig et al., 1996), our results with the 5-HT1B/1D receptor
agonist, sumatriptan, suggest that rodent 5-HT1D receptors could also be involved, as
previously implied by Shepheard et l. (1997b).  In keeping with this suggestion, the
(sympatho)-inhibition produced by sumatriptan (see Figure 13.5, lower panels) was
resistant to blockade by WAY100635 (at doses even higher than those required to
block 5-HT and indorenate), a finding that excludes an action via 5-HT1A receptors.
Conversely, the 5-HT1B/1D receptor antagonist, GR127935, practically abolished the
response to sumatriptan at all frequencies analysed (0.03-3 Hz), while cyanopindolol,
which has a pKD of 6.85 at 5-HT1D compared with 8.28 at the 5-HT1B receptor (Hoyer,
1988), had no significant effect at most of the frequencies studied (0.1-3 Hz).
Although it is possible that, at this infusion rate (100 µg kg-1 min-1), sumatriptan could
have had a small effect, if any, at 5-HT1B receptors, this was cyanopindolol-sensitive
only at 0.03 Hz (Figure 13.5, lower panels).
In contrast with the above findings, the involvement of 5-ht1E and 5-ht1F
receptors, although not categorically excluded due to the lack of potent and selective
agonists and antagonists, seems unlikely on the basis of: (i) the relatively low affinity
of WAY100635, cyanopindolol and GR127935 for these receptors (se  Adham et al.,
1993; Fletcher t al., 1996; Skingle et al., 1996); and (ii) the rank order of
(sympatho)-inhibitory agonist potency of 5-CT>>5-HT>8-OH-DPAT (present results;
Villalón et al., 1995a; 1995b).  Except for 5-HT, which has the highest affinity for
both these receptors, 5-CT and 8-OH-DPAT have very low affinity for 5-ht1E or 5-ht1F
receptors (Adham et al., 1993).
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13.4.5 Operational and transductional evidence against the involvement of 5-HT7
receptors
Although there is no direct evidence that the inhibition produced by 5-HT,
8-OH-DPAT, indorenate, CP93129 and sumatriptan in our experiments involves
inhibition of adenylyl cyclase, it is important to emphasize that all 5-HT1 receptor
subtypes are, by definition, negatively coupled to adenylyl cyclase (Hoyer et al.,
1994), and this is a signal transduction system usually associated with the decrease in
noradrenaline release from sympathetic neurones (Langer, 1980; Rand et al., 1987).
Notwithstanding, given the above rank order of (sympatho)-inhibitory agonist potency
of 5-CT>>5-HT>8-OH-DPAT, and the capability of methysergide, an antagonist at
cardiovascular 5-HT1 and 5-HT7 receptors (Villalón et al., 1997b), to block the
(sympatho)-inhibition induced by 5-HT (Villalón et al., 1995a), it could still be argued
that 5-HT7 receptors might be involved, as previously suggested for other
cardiovascular 5-HT7 receptors (De Vries et al., 1997b; Villalón et al., 1997a; 1997c).
However, this is unlikely since mesulergine, an ergoline derivative devoid of
interactions with the 5-HT1 receptor family (Hoyer et al., 1994), at doses that are high
enough to block cardiovascular 5-HT7 receptors (De Vries et al., 1997b;
Villalón et al., 1997a; 1997c), failed to antagonize the inhibition by 5-HT (Figure
13.3, lower panels).  Consistent with this finding, the cardiovascular 5-HT7 receptors,
unlike 5-HT1A/1B/1D receptors are: (i)resistant to blockade by GR127935 and
cyanopindolol and to the agonist action of indorenate, CP93129 and sumatriptan
(De Vries et al., 1997b; Villalón et al., 1997a; 1997c); and (ii) positively coupled to
adenylyl cyclase (Plassat et al., 1993), and this is a signal transduction system
associated with an increase (not decrease) in the release of noradrenaline from
sympathetic neurones (Langer, 1980; Rand et al., 1987).
13.4.6 Possible locus of the (sympatho)-inhibitory 5-HT1A, 5-HT1B and 5-HT1D
receptors
Lastly, we would like to speculate upon the possible locu of the 5-HT1A, 5-HT1B and
5-HT1D receptors that mediate 5-HT-induced inhibition of sympathetically-induced
vasopressor responses. In this context, although central mechanisms are not operative
in our experimental model, we cannot categorically exclude an action of 5-HT nd
related agonists at both the sympathetic ganglia (Foz rd, 1984b) and postganglionic
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sympathetic neurons (Saxena & Villalón, 1990) which have modulatory 5-HT
receptors.
Indeed, some studies suggest that 5-HT1 receptors may be mediating
inhibition (5-HT- and 5-CT-induced hyperpolarisation) of the sympathetic ganglionic
transmission (Ireland & Jordan, 1987; Jones et al., 1995).  These inhibitory ganglionic
5-HT1 receptors closely resemble the 5-HT1A subtype in rats (blocked by spiperone,
cyanopindolol and 8-OH-DPAT) (Ireland & Jordan, 1987) or the 5-HT1B/1D, but not
the 5-HT1A, subtypes in cats (blocked by GR127935, but resistant to WAY100635)
(Jones et al., 1995). Although this apparent discrepancy may be due to a species
difference, it must be highlighted that the possible role of inhibitory ganglionic
5-HT1B/1D receptors in rats will be unequivocally proven by the use of agonists (e.g.
CP93129 and sumatriptan) and antagonists (e.g. cyanopindolol and GR127935) at
these receptor subtypes.
Furthermore, the lines of pharmacological evidence available thus far have
shown the existence of inhibitory 5-HT1B/1D (previously called 5-HT1-like), but not
5-HT1A, receptor subtypes on vascular sympathetic nerves (see Saxena & Villalón,
1990; Hoyer t al., 1994; Martin, 1994; Saxena et al., 1998b). With respect to the
5-HT1B/1D receptor subtypes (blocked by GR127935), one must keep in mind that
species homologues of the same receptor can show major pharmacological
differences.
For example, the rodent 5-HT1B receptor (96% homology in the
transmembrane region with the human 5-HT1B receptor) displays the distinct
pharmacology that has long been associated with the 5-HT1B appellation (agonist:
CP93129; antagonists: cyanopindolol and SDZ21009) (Hoyer et al., 1994;
Hartig et al., 1996). Thus, on the basis of the moderate ability of ketanserin to
discriminate between 5-HT1B (ketanserin-resistant) and 5-HT1D (ketanserin-sensitive)
receptors, the inhibition of noradrenaline release from sympathetic neurons in human
tissues has been attributed to both 5-HT1B (e.g. the saphenous vein; Göthert et al.,
1996) and 5-HT1D (e.g. the right atrium; Molderings t al., 1996) receptors.
In contrast, in rat blood vessels, only 5-HT1B receptors have been shown thus
far to mediate the above inhibition of noradrenaline release (e.g. the vena cava;
Molderings et al., 1987; Hoyer t al., 1994); to the best of our knowledge, there are no
formally recognized functional roles for the 5-HT1D receptor subtype on rat
postganglionic sympathetic neurons.  Hence, subtype-selective 5-HT1B and 5-HT1D
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receptor ligands (see Saxena et al., 1998b) become crucial probes to explore whether
or not sympathetic neuronal effects in the rat are mediated by the 5-HT1D subtyp .
In conclusion, we suggest that the 5-HT-induced inhibition of sympathetically-
induced vasopressor responses in the pithed rat is primarily mediated by 5-HT1
receptors that resemble the pharmacological profile of the 5-HT1A, 5-HT1B and 5-HT1D
receptor subtypes, but not that of the 5-HT7 r ceptor.
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Chapter 14
General discussion
14.1 Nature of 5-HT receptors mediating porcine and canine carotid
vasoconstrictor effects and sympathoinhibition in the rat in vivo
It has previously been demonstrated that 5-HT is able to induce a vasoconstriction
within the external carotid vascular bed of the dog (Sax na et al., 1971; Saxena, 1972;
Villalón et al., 1993b).  Similarly, 5-HT constricts the porcine carotid vasculature.
The resulting decrease in the carotid blood flow is exclusively confined to the
arteriovenous anastomotic fraction (Saxena & Verdouw, 1982; Verdouw et al.,
1984b).  This 5-HT-induced cranial vasoconstriction in the dog and pig, but also the
inhibition of sympathetically-induced blood pressure increases in the rat, were shown
to be primarily mediated by sumatriptan-sensitive 5-HT1-like receptors (Saxena et al.,
1986; Den Boer et al., 1991b; Villalón et al., 1995a; 1995c).  Although these
5-HT1-like receptors showed some pharmacological resemblance to the 5-HT1B/1D
receptor subtypes, this could not be substantiated mainly because of a lack of subtype
selective agonists and/or antagonists.  The development of selective 5-HT1B/1D
receptor antagonists, in particular GR127935 (Clitherowet al., 1994; Pauwels, 1996;
Skingle et al., 1996), proved to be of great importance.  Indeed, the results of the
experiments described in Chapter 3 clearly show that GR127935 is a potent antagonist
at (5-HT1) receptors mediating carotid vasoconstriction in the rabbit, but is devoid of
interactions with functional 5-HT3, 5-HT4 or 5-HT7 receptors.  Consistent with its
binding profile, however, GR127935 moderately interacts with 5-HT2 receptors.  As
shown in Chapter 4, GR127935 completely antagonised the sumatriptan-induced
vasoconstriction of porcine carotid arteriovenous anastomoses.  Villalón et al. (1996)
obtained similar results with GR127935 against the sumatriptan-induced decreases in
canine external carotid blood flow.  Therefore, these results imply that the
sumatriptan-sensitive 5-HT1-like receptors mediating cranial vasoconstriction are
identical to the 5-HT1B/1D receptor subtypes.  Additionally, GR127935 potently
antagonised the porcine carotid vascular effects by the newer antimigraine agents,
alniditan, eletriptan and GMC2021 (Chapter 6).
Subsequently, we showed that the receptors in the canine (Chapter 8) as well
as porcine (Chapter 9) carotid vasculature were pharmacologically similar to the
5-HT1B receptor, but not the 5-HT1D receptor.  This conclusion was based on the
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findings that the selective 5-HT1B receptor antagonist, SB224289 (Hagan et al., 1997),
produced a complete blockade, whereas the selective 5-HT1D receptor antagonist,
BRL15572 (Schlicker et al., 1997), was devoid of effect.  In keeping with the latter,
5-HT1B receptors are abundantly expressed on vascular smooth muscle, whereas this is
not the case for the 5-HT1D receptor (Longmore t al., 1997; 1998).  These findings
represent the first n vivo evidence showing that vascular constriction induced by
sumatriptan is mediated primarily via 5-HT1B, but not 5-HT1D receptors.  Thus,
SB224289 and BRL15572 seem to be excellent tools for further investigating the
pharmacology of the 5-HT1B/1D receptors.  Additionally, in view of the complete
blockade by SB224289 and the highly selective nature of the compound, it seems
unlikely that the other known 5-HT1 subtypes (5-HT1A, 5-ht1E and 5-HT1F) are
involved in the sumatriptan- nduced carotid vascular effects.  Accordingly,
LY344864, a selective 5-HT1F receptor agonist (Phebus et al., 1997), does not produce
vasoconstriction in the canine external carotid vascular bed (Chapter 7) or in isolated
cranial arteries (Bouchelet & Hamel, 1999).
As described in Chapter 5, however, GR127935 did not completely block the
ergotamine- or dihydroergotamine-induced constriction of porcine carotid
arteriovenous anastomoses.  In the dog carotid vasculature, we clearly show that the
constriction induced by the above ergot derivatives is mediated by a combination of
GR127935-sensitive 5-HT1B/1D receptors, as well as yohimbine-sensitive
a2-adrenoceptors (Chapter 7).  These a2-adrenoceptors may also have been involved
in the GR127935-resistant part of the ergot-induced porcine carotid vascular effects.
Indeed, Willems et al. (1999) have recently shown that stimulation of both a1- and
a2-adrenoceptors results in potent vasoconstriction of porcine cranial arteriovenous
anastomoses.
Interestingly, in Chapter 5 it was shown that 5-HT-induced constriction of
porcine carotid arteriovenous anastomoses was not much affected by GR127935,
using a dose that was capable of abolishing sumatriptan-induced effects.  These results
led us to conclude that 5-HT and sumatriptan act primarily via different receptor
mechanisms.  Thus, whereas sumatriptan causes cranial vasoconstriction via 5-HT1B
receptors, the receptor responsible for the effect of 5-HT cannot be classified using the
current 5-HT receptor nomenclature scheme.  This GR127935-insensitive receptor
may correspond to the novel 5-HT receptor site found in human brain (see Chapter 1;
Castro et al., 1997); obviously, this needs further investigation.  In any case, since the
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constriction of carotid arteriovenous anastomoses is of high predictive value for
antimigraine efficacy (Chapter 2), the a-adrenoceptors, as well as the atypical receptor
stimulated by 5-HT, may be considered as targets for future antimigraine drugs.
The sumatriptan-sensitive 5-HT1-like receptors mediating inhibition of
sympathetically-induced vasopressor responses in the rat also seem to resemble
5-HT1B/1D receptors, in view of the antagonism displayed by GR127935 (Chapter 1 ).
In contrast to the vasoconstrictor 5-HT1-like receptors (which appear to be identical
exclusively to the 5-HT1B receptor, see above), this sympathoinhibitory effect may
also involve 5-HT1A and 5-HT1D receptors (Chapter 13).
14.2 Nature of 5-HT receptors mediating vasodilatation of the rat systemic
vasculature and feline tachycardia
It has been demonstrated previously that 5-HT produces smooth muscle relaxation in
several vascular and non-vascular preparations.  Originally, these responses were
ascribed to an action at vascular 5-HT1-like receptors, which were also shown to be
involved in the 5-HT-induced feline tachycardia (S xena et al., 1985b;
Saxena & Villalón, 1990; 1991).  Notwithstanding, the IUPHAR Receptor
Nomenclature Committee recommended that the receptor involved should be referred
to as an atypical 5-HT1-like or even "orphan" 5-HT receptor (Hoyer et al., 1994),
mainly on the basis of the lack of agonist effect of the 5-HT1-like receptor agonist
sumatriptan and contradictory transductional properties (for details see Chapter 1).  As
described above, the sumatriptan-sensitive (vasoconstrictor) 5-HT1-like receptors
mainly resemble 5-HT1B receptors.  For several reasons, we considered the
recombinant 5-ht7 receptor site a suitable candidate for responses mediated by the
atypical, sumatriptan-insensitive 5-HT1-like receptors.  The cloned 5-ht7 receptor is
coupled positively to adenylyl cyclase, a transductional system generally associated
with smooth muscle relaxation and tachycardia (Langer, 1980; Rand et al., 1987).
Moreover, binding studies show that the rat 5- t7 receptor displays high affinity for
5-HT and 5-CT as well as for methiothepin, but low affinity for sumatriptan and
ketanserin (see Chapter 1).
Indeed, we have shown that the pharmacological profile of the sumatriptan-
insensitive 5-HT1-like or "orphan" receptor mediating decreases in blood pressure in
the rat (Chapter 10) and tachycardia in the cat (Chapter 12) is similar to that of the
cloned 5-ht7 receptor.  The 5-ht7 receptor was also shown to mediate 5-HT-induced
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carotid vasodilatation in the anaesthetised dog (Villalón et al., 1997a), relaxation of
isolated canine cerebral arteries (Terrón & Falcón-Neri, 1999), as well as of several
vascular and non-vascular smooth muscle preparations (see Chapter 1).  These lines of
evidence, coupled to the fact that mRNA for the 5-ht7 receptors has been detected in
vascular smooth muscle (Ul mer et al., 1995; Schoeffter et al., 1996), indicate that the
"orphan" 5-HT receptors mediating direct smooth muscle relaxation and tachycardia
in the cat resemble recombinant 5-ht7 receptors structurally, transductionally and
operationally.  Therefore, the search for the "orphan" has successfully ended and the
upper case 5-HT7 receptor appellation is now clearly justified, although, admittedly,
there are no selective agonists for 5-HT7 receptors thus far.  The recent availability of
the selective 5-HT7 receptor antagonists, SB258719 (Forbes et al., 1998;
Thomas et al., 1998), which displays an at least 100 fold selectivity over other 5-HT
receptors, will help the further characterisation of this 5-HT receptor class.
14.3 5-HT1-like receptors: a time to bid goodbye
The present decade has indisputably witnessed a remarkable progress in the
classification of 5-HT receptors.  This achievement is due to several factors,
including: (i) the discovery of new recombinant receptors, using molecular biology
techniques; (ii) the possibility to express these recombinant receptors in cell lines,
enabling the characterisation of their pharmacological profile; and (iii) the increasing
knowledge concerning the receptor transductional properties.  Additionally, the
discovery of compounds acting selectively at 5-HT receptors proved to be of great
importance.  Accordingly, the findings discussed in this thesis show that the family of
“5-HT1-like” receptors, originally proposed by Bradley et al. (1986), has come a long
way, ultimately yielding at least three pharmacologically distinct receptors (5-HT1B,
5-HT1D and 5-HT7).  Consequently, as proposed by Saxena et al. (1998b), the term
"5-HT1-like receptor" has now become redundant (see also Figure 1.1).
It should be kept in mind that not all responses that were previously ascribed
to an action at these 5-HT1-like receptors have been analysed using the presently
available, selective 5-HT receptor agonists and antagonists.  Therefore, we cannot
categorically exclude the possibility that some responses are mediated by other 5-HT
receptors or even by unknown, novel receptors/mechanisms.  In fact, the
5-HT-induced porcine carotid arteriovenous anastomotic constriction was not
effectively antagonised by GR127935, despite being mediated by 5-HT1-like
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receptors.  This may also be true for the inhibition of plasma protein extravasation in
guinea-pig dura mater (Yu et al., 1997) and contraction of isolated bovine middle
cerebral artery (Roon et al., 1999).
Table 14.1 Efficacy, pharmacokinetics and affinity of sumatriptan, PNU142633, LY334370
and zolmitriptan.
Sumatriptan
100 mg, p.o.
Sumatriptan
6 mg, s.c.
PNU142633
50 mg, p.o.
LY334370
200 mg, p.o.
Zolmitriptan
5 mg, p.o.
Therapeutic
gain
28a, 31b, 33c 53d -8%e 52f 47g
CNS
penetration
Little Little Littleh ? Marked
Cmax
(ng ml-1)
54i 72i ? 388j 10k
295 406 334 288
pKi:
5-HT1B 7.8l 4.8e 6.9m 8.3n
5-HT1D 8.3l 8.3e 6.9m 9.2n
5-HT1F 7.9l ? 8.8m 7.2n
Data taken from: a, Visser et al. (1996c); b, Jackson (1998); c, Goadsby (1998b); d, The
Subcutaneous Sumatriptan International Study Group (1991); e, McCall (1999);
f, Goldstein et al. (1999a); g, Dahlöf et al. (1998); h, McCall, R.B., personal communication;
i, Fowler et al. (1991); j, Pereira et al. (1999).  The authors revealed at the International
Headache Society Meeting at Barcelona, Spain (June 22-26, 1999) that the values listed in
this abstract were 10-fold higher than the actual Cmax values.  The value in the Table has been
derived from the actual Cm x; k, Peck et al. (1998); l, Leysen et al. (1996); m, Johnson et al.
(1997); n, Martin et al. (1997). Therapeutic gain is defined as headache response (decrease in
headache from severe or moderate to mild or none) minus placebo response at 2 hours.
?, Data not available.  CNS, Central nervous system.
14.4 Beyond the second-generation triptans
The results from the present thesis demonstrate that sumatriptan produces
vasoconstriction in the carotid vascular bed.  This cranial vasoconstrictor effect is
exerted on the main capacitance arteries (Table 2.5) as well as arteriovenous
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anastomoses (Table 2.4).  Although sumatriptan displays high affinities at 5-HT1D as
well as 5-HT1F receptors, several lines of pharmacological evidence indicate that the
cranial vasoconstrictor activity of the antimigraine drug is mediated by the 5-HT1B
receptor.  Therefore, assuming that vasoconstriction of dilated cranial blood vessels is
responsible for the therapeutic efficacy of sumatriptan, it is implied that agonist action
at the 5-HT1D and/or 5-HT1F receptor is not required for the antimigraine action.
However, several other mechanisms, which do not seem to be mediated solely by the
5-HT1B receptor, have also been implicated in migraine relief (see Chapter 2). These
mechanisms include inhibition of the trigeminovascular system, either peripherally or
centrally.  Indeed, in an attempt to avoid the 5-HT1B r ceptor-mediated moderate
hypertension and coronary constriction noticed with these drugs, the therapeutic
potential of selective 5-HT1D or 5-HT1F receptor agonists has been explored.
14.4.1 5-HT1D receptor agonists
A series of isochroman-6-carboxamide derivatives, including PNU109291 and
PNU142633, have been described as highly selective 5-HT1D receptor agonists (see
Tables 1.2 and 14.1; Ennis et al., 1998; McCall, 1999).  PNU109291 did not produce
vasoconstriction in human and bovine isolated cerebral arteries (Bouchelet & Hamel,
1999).  Moreover, both compounds are devoid of carotid vasoconstrictor effects in the
anaesthetised cat and do not decrease meningeal artery blood flow or canine coronary
artery diameter (Ennis et al., 1998; McCall, 1999).  Yet, these 5-HT1D receptor
agonists potently inhibit dural plasma protein extravasation in the guinea-pig
(Ennis et al., 1998; McCall, 1999).  Although inhibition of dural plasma protein
extravasation by itself is not predictive of antimigraine activity, the 5-HT1D receptor
seems to be involved in the inhibition of the central component of the
trigeminovascular system (see Chapter 2).  Therefore, selective 5-HT1D receptor
agonists are valuable for probing migraine mechanisms (Ennis et al., 1998).
Notwithstanding, as shown in Table 14.1, the 5-HT1D receptor agonist, PNU142633,
has not proved effective in the treatment of migraine (McCall, 1999), implying that
the 5-HT1D receptor is not involved in antimigraine effects.  PNU109291 is active as
an agonist in the guinea-pig hypothermia model and inhibits c-fo  expression in the
trigeminal nucleus caudalis, suggesting that the compound readily crosses the blood
brain barrier (Waeber et al., 1997; Ennis et al., 1998).  However, it remains to be
established whether PNU142633 (the clinically evaluated compound) is able to gain
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access to the central nervous system.  More importantly, PNU109291 and, especially,
PNU142633 display low intrinsic efficacy compared to 5-HT a  primate 5-HT1D
receptors in GTPg35S binding assays (Pregenzer t al., 1999).  Therefore, at present we
cannot categorically exclude the therapeutic importance of 5-HT1D receptors.
14.4.2 5-HT1F receptor agonists
Two potent 5-HT1F agonists, LY344864 and LY334370 have been described
(Table 14.1).  Both compounds potently inhibit dural plasma protein extravasation
(Johnson et al., 1997; Phebus et al., 1997).  LY344864 is reported to be devoid of
vasoconstrictor activity in human and bovine isolated cerebral blood vessels
(Bouchelet & Hamel, 1999) and in the canine external carotid vasculature (see
Chapter 7; Villalón et al., 1999).  LY334370 has been under clinical evaluation, but
the trials were abandoned because of data from animal toxicology studies.
Nevertheless, the results of this clinical trial suggest that LY334370 is therapeutically
active in acute migraine (Table 14.1; Goldstein et al., 1999a).  However, it remains to
be verified whether the clinically active doses of this compound are devoid of
interaction with the 5-HT1B receptor.  In this context, it is important to note that
LY334370 exhibits only a 10-fold lower affinity at the 5-HT1B r ceptor compared to
sumatriptan (Table 14.1), whereas the Cmaxvalues of therapeutic doses of LY334370
are about 10-fold higher than that of sumatriptan (Pereira et al., 1999).  We recognise
that 5-HT1F receptor stimulation does not mediate cerebral vasoconstriction and that
LY344864 lacks vasoconstrictor effects, but, unfortunately, no information is
available on the possible vasoconstrictor effect of the clinically active 5-HT1F re eptor
agonist, LY334370, in isolated human cranial arteries.
Cohen and co-workers (Cohen et al., 1998) have reported that both LY334370
and LY344864 lack vasoconstrictor activity in the rabbit isolated saphenous vein.
However, it should be noted that a lack of vasoconstrictor activity in the isolated
saphenous vein does not necessarily mean the absence of cranial vasoconstriction.
For example, the antimigraine agent BMS181885 behaves as a silent competitive
antagonist in the canine saphenous vein, yet the drug potently constricts isolated
cephalic blood vessels (Yocca et al., 1997) and the porcine (see Chapter 6;
Saxena et al., 1998a), feline and canine (Yocca et al., 1997) carotid vasculature.
Lastly, no information is available concerning the possible formation of active
metabolites or plasma protein binding.  In any case, the efficacy of LY334370 in
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migraine has no bearing on the therapeutic importance of the 5-HT1B receptor, in view
of poor affinity displayed by the potent antimigraine drugs alniditan (Goldstein et al.,
1996) and IS159 (Chaveau & Delaage, 1997; Dingemanse et al., 1999) at the 5-HT1F
receptor (Leysen et al., 1996).
14.5 Implications for future antimigraine therapy
As discussed above, it appears that the 5-HT1B receptor is the predominant receptor
mediating the therapeutic effects by sumatriptan, although, based on the currently
available information, the role of 5-HT1D and 5-HT1F receptors can neither be
completely discounted nor proven.  In any case, the results presented in this thesis
imply that mainly the 5-HT1B receptor (not the other 5-HT1 receptor subtypes) is
responsible for the sumatriptan-induced cranial vasoconstriction.  Accordingly, it is
tempting to suggest that a direct vascular smooth muscle contraction of dilated
cephalic blood vessels (possibly, including the carotid arteriovenous anastomoses) is
the most important characteristic of acutely-acting antimigraine drugs.  This
suggestion gains weight when considering that: (i) sumatriptan poorly penetrates the
central nervous system; (ii) inhibition of plasma protein extravasation is not predictive
of antimigraine efficacy; and (iii) the 5-HT1B/1D receptor agonists alniditan and IS159,
which have little 5-HT1F receptor affinity, are at least as effective as sumatriptan in
aborting acute migraine attacks (Gold tein et al., 1996; Chaveau & Delaage, 1997;
Dingemanse et al., 1999).  This hypothesis may be challenged by assessing the
antimigraine efficacy of low brain-penetrant, selective 5-HT1B receptor agonists;
unfortunately, such compounds are not yet available.  On the other hand, it is not yet
known whether the integrity of the blood-brain barrier remains intact during migraine
attacks.  It should also be noted that the 5-HT1B r ceptor is widely distributed not only
on vascular smooth muscle, but also within the peripheral and central components of
the trigeminal nerve.
The inhibition of central trigeminal neuronal pathways may be effected by the
more lipophilic triptans, such as zolmitriptan, rizatriptan and eletriptan.  This property
may account for the somewhat higher efficacy observed with these second-gen ration
triptans, zolmitriptan (Dahlöf et al., 1998), rizatriptan (Visser et al., 1996c) and
eletriptan (Jackson, 1998), compared to sumatriptan (see Table 14.1).  On the other
hand, it can also be argued that the higher efficacy with these drugs is mainly due to
their improved pharmacokinetics.  In keeping with the latter is the fact that the highest
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antimigraine efficacy to date is observed with subcutaneous injections of sumatriptan
(Table 14.1).  Moreover, at least one 5-HT1D receptor agonist (PNU142633), which
has been claimed to inhibit the central trigemino-vascular system, is ineffective in
migraine (see Section 14.4.1).
As discussed in Chapter 2, low intensity stimulation of trigeminal afferents
leads to dural vasodilatation, which is inhibited by sumatriptan, at doses devoid of
dural vasoconstriction per se.  This effect, which at least in the rat is mediated by
5-HT1B receptors, could also be involved in the antimigraine effects by triptans.
Perhaps, to achieve maximal antimigraine efficacy, the drugs should be
designed to act via several mechanisms.  A drug, which selectively inhibits
trigemino-vascular system (either central o  peripheral) without cranial
vasoconstriction, may not efficiently abort migraine attack.  However, this remains a
goal worth pursuing.
14.6 Possible mechanisms for future migraine prophylaxis
Although the advances made in the acute treatment of migraine are of major clinical
importance, efforts should also be directed to develop prophylactic drugs that decrease
the frequency of migraine attacks.  Some b-adrenoceptor antagonists, the antiepileptic
drug valproate and several other drugs are used in migraine prophylaxis, but the exact
mechanisms are not well understood (Welch, 1993; Ferrari, 1998).  As discussed
below, some new theories have been put forward, which may be important targets for
future migraine prophylaxis.
14.6.1 Blockade of cranial vasodilatation following cortical spreading depression
The role of cortical spreading depression in migraine (Lauritz n, 1994) is
controversial because of difficulty of demonstrating it clinically.  However, a
promising technique using magnetic resonance imaging, developed by
SmithKline Beecham scientists (Smith et al., 1998), offers new opportunities for
investigating cortical spreading depression in humans.  Meanwhile, animal studies
show that cortical spreading depression can lead to cranial vasodilatation (P rsons,
1998).  Inhibition of this vasodilator response appears to be a novel avenue for
developing antimigraine drugs without vasoconstrictor action pe se.  Indeed,
Chan et al. (1999) have recently reported a series of such compounds, in particular
SB220453, which antagonises cortical spreading depression and blocks plasma protein
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extravasation in rats, but does not interact with any of the known 5-HT receptors.
Moreover, SB220453 blocks carotid vasodilatation in cats induced by trigeminal
ganglion stimulation (Upton et al., 1999) and lacks vasoconstrictor effect on human
isolated coronary artery or saphenous vein (MaassenVanDenBrink et al., 1999b).  It
will be interesting to know whether a drug that lacks vasoconstrictor properties, but
prevents cortical spreading depression and/or the consequent cranial vasodilatation
would be effective in migraine as a prophylactic and/or acute abortive agent.
14.6.2 Cerebral calcium channelopathy
Several investigators have shown that genetic factors are important in migraine
(Russell & Olesen, 1995; Ophoff et al., 1996; Ferrari, 1998).  Thus, mutations in the
a1A subunit of a brain specific P/Q type calcium channel were shown to be involved in
familial hemiplegic migraine (Ophoff et al., 1996) and may also be involved in
non-hemiplegic migraine (T rwindt et al., 1998).  The full understanding of this
calcium channelopathy may ultimately result in the development of migraine-specific
prophylactic drugs.
14.6.3 5-HT7 receptor antagonists
As discussed in this thesis, the main effect induced by 5-HT7 receptor stimulation is
vascular smooth muscle relaxation.  This 5-H 7 receptor-mediated vasorelaxant effect
is also observed in canine (Terrón & Falcón-Neri, 1999) and porcine (Ueno et al.,
1995) isolated cranial blood vessels, as well as in the canine external carotid
vasculature (Villalón et al., 1997a).  Interestingly, several currently used migraine
prophylactic drugs display affinity at the 5-HT7 receptor, such as methysergide
(Herrmann et al., 1977; Silberstein, 1998) and lisuride (Herrmann et al., 1977;
Somerville & Herrmann, 1978; Del Bene et al., 1983). Admittedly, these drugs are
non-selective ligands.  Notwithstanding, it may be argued that 5-HT7
receptor-mediated cranial vasodilatation plays a role in the migraine headache phase.
Consequently, it may be worth assessing the effectiveness of selective 5-HT7 r ceptor
antagonists in the prevention of migraine.
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Chapter 15
Thesis summary
15.1 Summary in English
In Chapter 1 an overview is given about the nomenclature and classification of 5-HT
receptors.  Firstly, the historical aspects of the discovery of 5-HT and the responses
elicited by the ligand have been described, ultimately leading to the classification by
Bradley and colleagues in 1986.  At that time, the 5-HT rec ptors were divided into
three classes, namely 5-HT1-like, 5-HT2 and 5-HT3 receptors, mainly based on
operational differences. With the adoption of structural and transductional
characteristics as additional criteria in 1994, the NC-IUPHAR reclassified 5-HT
receptors into 5-HT1 (5-HT1-like, 5-HT1A, 5-HT1B, 5-HT1D, 5-ht1E and 5-ht1F), 5-HT2
(5-HT2A, 5-HT2B and 5-HT2C), 5-HT3, 5-HT4, recombinant (5-ht5A/5B, 5-ht6, 5-ht7) and
"orphan" receptors.  Based on the latter classification schemes, each of these receptors
has been discussed, updated with the most recent information available.  Particular
emphasis was put on the evolution of the so-called 5-HT1-like receptor, which turned
out to be identical to at least three different receptors, namely 5-HT1B, 5-HT1D and
5-HT7 receptors.
Chapter 2 deals with several aspects of migraine.  Firstly, the epidemiology and
clinical features are shortly described.  Thereafter, an attempt is made, given the
current knowledge about migraine headaches, to explain the pathophysiology of the
disease.  Additionally, pharmacokinetic and pharmacodynamic characteristics of the
acutely-acting antimigraine drug sumatriptan and the new second-generation triptans
are discussed.  Lastly, the pharmacology and relevance of the currently used
experimental models, which are believed to be predictive of therapeutic potential,
have been described in detail.
In Chapter 3, we investigated the selectivity of GR127935 against functional
responses known to be mediated by 5-HT1-like, 5-HT2, 5-HT3, 5-HT4 or 5-HT7
receptors in several in vivo preparations.  GR127935 has recently been introduced as
an experimental tool to antagonise 5-HT1B/1D receptor-mediated functional responses
and indeed exhibits a very high affinity and selectivity for 5-HT1B/1D binding sites.
We show that GR127935 potently antagonises the decreases in total carotid blood
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flow as well as hypotensive responses in the rabbit induced by the 5-HT1-like receptor
agonist sumatriptan.  GR127935 did not modify 5-HT-induced: (i) tachycardia in the
pig (5-HT4 receptor-mediated) and cat (5-HT7 receptor-mediated); (ii) depressor
effects in the rat and cat (5-HT7 receptor-mediated); (iii) von Bezold-Jarisch reflex in
the rat or the early phase of the urinary bladder contraction in the cat (both 5-HT3
receptor-mediated).  In contrast, high doses of GR127935 suppressed 5-HT-induced
pressor responses in the rat and cat and urinary bladder contractions (secondary phase)
in the cat as well as the DOI-induced pressor responses in the rat, which are all
mediated by 5-HT2A receptors.  Lastly, GR127935 produced a methiothepin-resistant
vasoconstriction of porcine carotid arteriovenous anastomoses per e.
In conclusion, we have demonstrated that GR127935 is a potent and selective
5-HT1B/1D receptor antagonist devoid of interactions at 5-HT3, 5-HT4 and 5-HT7
receptors.  However, GR127935 possesses a moderate 5-HT2A receptor blocking
property, which is consistent with its binding profile and seems to display intrinsic
activity in the porcine carotid vascular bed.
In Chapter 4 we have investigated whether GR127935 was able to antagonise the
sumatriptan-induced porcine carotid vascular effects, which were previously shown to
be mediated by 5-HT1-like receptors. In animals pretreated with saline, sumatriptan
reduced the total carotid and arteriovenous anastomotic blood flows in a
dose-dependent manner.  In contrast, sumatriptan increased blood flow to the skin,
ears and fat, although the total capillary fraction was not significantly affected.  These
carotid vasoconstrictor responses to sumatriptan were dose-dependently antagonised
by GR127935.  Taken together, these results led us to conclude that arteriovenous
anastomotic constriction and, possibly, arteriolar dilatation in the skin, ears and fat by
sumatriptan are mediated by 5-HT1B/1D receptors.  Therefore, vascular 5-HT1-like
receptors in the porcine carotid bed appear to be identical to 5-HT1B/1D receptors.
Chapter 5 was devoted to establish the contribution of 5-HT1B/1D receptors in the
constriction of carotid arteriovenous anastomoses elicited by 5-HT (in presence of
5-HT2 receptor blockade), ergotamine and dihydroergotamine (DHE) in anaesthetised
pigs.  It was demonstrated that 5-HT, ergotamine and DHE reduced arteriovenous
anastomotic and increased nutrient blood flows and vascular conductances.  The
vasodilator response to 5-HT, observed mainly in the skin and ear, was much more
Chapter 15
259
prominent than that of the ergot alkaloids.  Treatment with the 5-HT1B/1D receptor
antagonist GR127935 significantly attenuated the effects induced by both ergot
derivatives, whereas the drug only slightly affected the carotid vascular effects by
5-HT.  The results suggest that 5-HT constricts carotid arteriovenous anastomoses
primarily via receptors, which seem to differ from those (5-HT1B/1D) stimulated by
sumatriptan.  The ergot alkaloids produce arteriovenous anastomotic constriction for a
substantial part via 5-HT1B/1D receptors, but also invoke unidentified receptors.  Both
these non-5-HT1B/1D receptors may be targets for the development of novel
antimigraine drugs.
In Chapter 6 we describe the vasoconstrictor effects of some second-generation
antimigraine drugs on porcine carotid arteriovenous anastomoses, an effect that seems
to be of high predictive value for antimigraine activity.  Intravenous administrations of
BMS181885, avitriptan, eletriptan, GMC2021 and alniditan decreased total carotid
blood flow by a selective vasoconstriction of the carotid arteriovenous anastomoses.
The apparent rank order of potency was: alniditan > sumatriptan > avitriptan >
eletriptan > GMC2021, whereas BMS181885 seemed to have a lower intrinsic
activity.  The arteriovenous anastomotic constriction by alniditan, eletriptan and
GMC2021 was potently antagonised by GR127935.  After similar reductions in
carotid blood flow following a single 100 µg kg-1 intravenous dose at 30 min, the
effect of BMS181885 lasted longer than that of sumatriptan.  These results suggest
that the new triptans selectively constrict porcine carotid arteriovenous anastomoses
mainly via 5-HT1B/1D receptors and should be able to abort migraine headaches.  The
latter has indeed been confirmed in initial clinical studies in man.  Lastly, the long-
lasting effect of BMS181885 may reduce the recurrence rate in migraine.
In Chapter 7 we show that intracarotid infusions of the antimigraine drugs
methysergide, ergotamine and DHE produce selective vasoconstriction in the external
carotid bed of vagosympathectomised, anaesthetised dogs, without affecting blood
pressure and heart rate.  Since the above drugs display affinity for several binding
sites, including a-adrenoceptors and several 5-HT1 and 5-HT2 receptor subtypes, this
study has analysed the mechanisms involved in the above responses.  The reductions
in external carotid blood flow (ECBF) by methysergide were abolished and even
reversed to increases in animals pretreated with GR127935.  The reductions in ECBF
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by ergotamine and DHE remained unchanged in animals pretreated with prazosin, but
were partly antagonised in animals pretreated with either GR127935 or yohimbine.
Pretreatment with a combination of GR127935 and yohimbine abolished the responses
to both ergotamine and DHE.  The above doses of antagonists were shown to produce
selective antagonism at their respective receptors. These results suggest that the
external carotid vasoconstrictor responses to methysergide primarily involve
5-HT1B/1D receptors, whereas those to ergotamine and DHE are mediated by 5-HT1B/1D
receptors as well as a2-adrenoceptors.
In Chapter 8, we show results obtained with the newly developed, selective 5-HT1B
(SB224289) or 5-HT1D (BRL15572) receptor antagonists.  In vagosympathectomised
dogs intracarotid infusions of 5-HT and sumatriptan dose- ependently decreased
ECBF, without affecting mean blood pressure or heart rate.  Treatment with the
selective 5-HT1B receptor antagonist SB224289 produced a potent, specific and
dose-dependent blockade of this response, whereas the selective 5-HT1D receptor
antagonist BRL15572 was ineffective.  It is concluded that mainly 5-HT1B, but not
5-HT1D receptors mediate the canine external carotid vasoconstriction by 5-HT and
sumatriptan.
In Chapter 9, we discuss the effects of the selective 5-HT1B (SB224289) and 5-HT1D
(BRL15572) receptor antagonists on the constriction of porcine carotid arteriovenous
anastomoses by sumatriptan.  Since the effects of sumatriptan were antagonised by
SB224289, but not by BRL15572, we concluded that this effect was primarily
mediated by 5-HT1B, but not 5-HT1D receptors.
In Chapter 10 we have further characterised the pharmacological profile of the
receptors involved in the 5-HT-induced late hypotensive response in rats.  It has been
suggested previously that this hypotensive response to 5-HT was mediated by
"5-HT1-like" receptors since this effect is mimicked by 5-CT, is not modified by
cyproheptadine, ketanserin or MDL72222, but it is blocked by methysergide.  Bolus
injections of 5-CT, 5-HT and 5-MeO-T produced dose-d pendent hypotensive
responses with a rank order of agonist potency: 5-CT >> -HT ³ 5-MeO-T with
sumatriptan inactive.  The depressor responses to 5-HT and 5-CT were not attenuated
by GR127935 or equivalent volumes of saline.  In contrast, lisuride, methiothepin,
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mesulergine, metergoline and clozapine dose-dependently antagonised the responses
to 5-HT and 5-CT; the apparent rank order of antagonist potency was: lisuride >
methiothepin ³ mesulergine > clozapine; metergoline displayed variable potencies.
Based upon the above rank order of agonist potency, the blockade by a series of drugs
showing high affinity for the cloned 5-ht7 receptor and the lack of blockade by
GR127935, our results indicate that the 5-HT receptor mediating hypotension in rats is
operationally similar to other putative 5-ht7 receptors mediating vascular and
non-vascular responses (e.g. relaxation of the rabbit femoral vein, canine coronary and
external carotid arteries and guinea-pig il um as well as feline tachycardia). Since
these responses represent functional correlates of the 5-ht7 gene product, the upper
case 5-HT7 receptor appellation is reinforced.
In Chapter 11, we have investigated which vascular beds were responsible for the
5-HT-induced late depressor response in rats, which is mainly mediated by vascular
5-HT7 receptors, as demonstrated in the previous chapter.  In vagosympathectomised,
pentobarbital anaesthetised rats, 5-HT produced a dose-dependent decrease in mean
arterial blood pressure.  This hypotension was accompanied by increases in systemic
vascular conductance, but cardiac output was unaffected.  Exclusively skeletal muscle,
carcass, mesentery/pancreas and adrenal vascular beds contributed to the increase in
total systemic vascular conductance.  Pretreatment with R(+)lisuride abolished all
5-HT-induced systemic and regional haemodynamic effects.  In contrast, pretreatment
with S(-)lisuride or GR127935 did not affect the 5-HT-induced systemic
haemodynamic changes.  The above results suggest that hypotension induced via
5-HT7 receptor activation was exclusively caused by vasodilatation of the systemic
vasculature, confined to skeletal muscle, carcass, mesentery/pancreas and adrenal
vascular beds.  Furthermore, this study shows that blockade of vasorelaxant 5-HT7
receptors by lisuride is stereoselective.
In Chapter 12, we have further characterised the receptors involved in the 5-HT-
induced tachycardia in cats.  It was previously shown that this response was mediated
by 5-HT1-like receptors.  Based upon the rank order of agonist potency (5-CT >>
5-HT > 5-MeO-T >> clozapine), the failure of sumatriptan, indorenate or cisapride to
produce cardioacceleration and the blockade by a series of drugs showing high affinity
for the cloned 5-ht7 receptor, the results indicated that the 5-HT receptor mediating
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tachycardia in the cat was operationally similar to other putative 5-HT7 receptors
mediating vascular and non-vascular responses.  Therefore, this experimental model,
which is not complicated by the presence of other 5-HT receptors, can be utilised to
characterise and develop new drugs with potential agonist and antagonist properties at
functional 5-HT7 receptors.
In Chapter 13, we have tried to establish which 5-HT1 receptor subtypes were
involved in the inhibition of sympathetically-induced vasopressor responses produced
by 5-HT in pithed rats.  Infusions of 5-HT and the 5-HT1 receptor agonists,
8-OH-DPAT (5-HT1A), indorenate (5-HT1A), CP93129 (5-HT1B) and sumatriptan
(5-HT1B/1D), resulted in a dose-dependent inhibition of sympathetically-induced
vasopressor responses.  The sympatho-inhibit ry responses induced by 5-HT,
8-OH-DPAT, indorenate, CP93129 or sumatriptan were analysed before and after
treatment with blocking doses of the putative 5-HT receptor antagonists,
WAY100635 (5-HT1A), cyanopindolol (5-HT1A/1B) or GR127935 (5-HT1B/1D).  After
WAY100635, the responses to 5-HT and indorenate, butno  to 8-OH-DPAT,
CP93129 and sumatriptan, were blocked. After cyanopindolol, the responses to 5-HT,
indorenate and CP93129 were abolished, whilst those to 8-OH-DPAT and sumatriptan
(except at the lowest frequency of stimulation) remained unaltered.  In contrast, after
GR127935, the responses to 5-HT, CP93129 and sumatriptan, but not to 8-OH-DPAT
and indorenate, were abolished.  In additional experiments, the inhibition induced by
5-HT was not modified after 5-HT7 receptor blocking doses of mesulergine.  The
results suggested that the 5-HT1-like receptors, which inhibit the sympathetic
vasopressor outflow in pithed rats, display the pharmacological profile of the 5-HT1A,
5-HT1B and 5-HT1D, but not that of 5-HT7, receptors.
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15.2 Samenvatting in het Nederlands
In Hoofdstuk 1 wordt een overzicht gegeven van de 5-HT r ceptor nomenclatuur en
classificatie.  Begonnen is met een beschrijving van de historische aspecten van de
ontdekking van 5-HT en de responsen geïnduceerd door dit ligand.  Dit heeft
uiteindelijk geleid tot de classificatie volgens Bradley c.s. in 1986.  Op dat moment
waren de 5-HT receptoren ingedeeld in drie klassen, namelijk 5-HT1-achtige, 5-HT2
en 5-HT3 receptoren, hoofdzakelijk gebaseerd op operationele verschillen.  Nadat
structurele en transductionele karakteristieken werden geaccepteerd als additionele
criteria in 1994, heeft de NC-IUPHAR de 5-HT receptoren opnieuw geclassificeerd in
5-HT1 (5-HT1-achtig, 5-HT1A, 5-HT1B, 5-HT1D, 5-ht1E en 5-ht1F), 5-HT2 (5-HT2A,
5-HT2B en 5-HT2C), 5-HT3, 5-HT4, recombinante (5-ht5A/5B, 5-ht6, 5-ht7) en "orphan"
receptoren.  Gebaseerd op deze classificatie schema's, wordt iedere receptor
afzonderlijk bediscussieerd en waarnodig geactualiseerd met de meest recente
informatie.  De nadruk is gelegd op de evolutie van de zogenaamde 5-HT1-achtig
receptor, die uiteindelijk identiek is gebleken aan tenminste drie verschillende
receptoren, namelijk de 5-HT1B, 5-HT1D en 5-HT7 receptor.
In Hoofdstuk 2 worden verschillende aspecten van migraine behandeld.  De
epidemiologie en klinische verschijnselen van migraine zijn kort beschreven.  Verder
is getracht de pathofysiologie van migraine te verklaren, voor zover dit mogelijk is
met de huidige kennis over de aandoening.  Vervolgens worden de farmacokinetische
en farmacodynamische karakteristieken bediscussieerd van het acuut werkende
antimigraine geneesmiddel sumatriptan en de nieuwe, tweede generatie triptannen.
Tenslotte worden de farmacologie en de relevantie beschreven van enkele
experimentele modellen, waarvan aangenomen wordt dat ze van voorspellende waarde
zijn voor therapeutisch potentieel.
In Hoofdstuk 3 is de selectiviteit van GR127935 onderzocht ten opzichte van
5-HT1-achtige, 5-HT2, 5-HT3, 5-HT4 of 5-HT7 receptoren in verschillende
proefdiermodellen.  GR127935 is recent geïntroduceerd als een selectieve 5-HT1B/1D
receptor antagonist en vertoont inderdaad een zeer hoge affiniteit en selectiviteit voor
5-HT1B/1D bindingsplaatsen.  De door de 5-HT1-achtige agonist sumatriptan
geïnduceerde vermindering in halsslagader bloeddoorstroming en bloeddrukdaling in
het konijn werden potent geantagoneerd door GR127935.  GR127935 had geen effect
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op de 5-HT geïnduceerde: (i) tachycardie in het varken (5-HT4 receptor gemedieerd)
en de kat (5-HT7 receptor gemedieerd); (ii) bloeddrukverlagende effecten in de rat en
de kat (5-HT7 receptor gemedieerd); (iii) von Bezold-Jarisch reflex in de rat of de
eerste fase van de urineblaascontractie in de kat (beiden 5-HT3 r ceptor gemedieerd).
Hoge doseringen van GR127935 onderdrukten de 5-HT geïnduceerde
bloeddrukstijgingen in de rat en kat, de tweede fase van de urineblaascontractie in de
kat en de DOI geïnduceerde bloeddrukstijging in de rat; deze responsen worden allen
gemedieerd door 5-HT2A receptoren.  Voorts veroorzaakte GR127935 in het varken
een methiothepine-resistente vasoconstrictie van arterioveneuze anastomoses in het
vaatbed van de halsslagader.  Geconcludeerd wordt dat GR127935 een potente en
selectieve 5-HT1B/1D receptor antagonist is, zonder interacties te vertonen met 5-HT3,
5-HT4 en 5-HT7 receptoren.  Echter, GR127935 bezit een matig 5-HT2A receptor
blokkerende eigenschap, welke overeenkomstig is met het bindingsprofiel. Verder
lijkt GR127935 intrinsieke vasoconstrictieve activiteit te vertonen op craniële
arterioveneuze anastomoses van het varken.
In Hoofdstuk 4 is geanalyseerd of GR127935 in staat is de sumatriptan geïnduceerde
vasculaire effecten in het vaatbed van de carotis arterie van het varken te blokkeren.
Eerder is aangetoond dat het antimigraine geneesmiddel sumatriptan een verlaging
bewerkstelligt van de bloedstroom in de halsslagader, gemedieerd door 5-HT1-achtige
receptoren.  In met fysiologisch zout voorbehandelde dieren, veroorzaakte sumatriptan
een dosis-afhankelijke verlaging van de totale carotis doorbloeding en de bloedstroom
door de craniële arterioveneuze anastomoses.  Anderzijds werden
bloedstroomstijgingen geconstateerd in de huid, oren en vet, hoewel de totale
weefselfractie niet significant veranderde.  Deze effecten werden dosis-afhankelijk
geantagoneerd door GR127935.  Op grond van deze resultaten kan geconcludeerd
worden dat sumatriptan een vasoconstrictie van craniële arterioveneuze anastomoses
en mogelijk ook een vaatverwijding van huid, oor en vet vasculatuur induceert via
5-HT1B/1D receptoren.  De vasculaire 5-HT1-achtige receptoren in het halsslagader
vaatbed van het varken lijken dus identiek te zijn aan 5-HT1B/1D receptoren.
Hoofdstuk 5 is gewijd aan de bestudering van de bijdrage van 5-HT1B/1D receptoren
aan de vasoconstrictie van craniële arterioveneuze anastomoses door 5-HT (in e
aanwezigheid van 5-HT2 receptor blokkade), ergotamine en dihydroergotamine
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(DHE) in genarcotiseerde varkens.  5-HT, ergotamine en DHE verminderden de
doorbloeding en vasculaire conductantie van craniële arterioveneuze anastomoses en
verhoogden de capillaire bloedstroom en vasculaire conductantie.  Het
vaatverwijdende effect van 5-HT, met name geobserveerd in de huid en het oor, was
veel uitgesprokener dan dat van de ergot alkaloïden.  De effecten van de ergot
derivaten werden gedeeltelijk geantagoneerd door GR127935, maar deze antagonist
blokkeerde slechts een klein deel van de 5-HT geïnduceerde respons.  Deze resultaten
suggereren dat 5-HT de arterioveneuze anastomoses voornamelijk contraheert via een
andere receptor en/of mechanisme dan sumatriptan.  De ergot alkaloïden produceren
arterioveneuze anastomose constrictie gedeeltelijk via 5-HT1B/1D receptoren, maar
stimuleren ook receptoren, die op dit moment nog niet gekarakteriseerd zijn.  Deze
non-5-HT1B/1D receptoren kunnen mogelijkheden bieden voor de ontwikkeling van
nieuwe antimigraine geneesmiddelen.
In Hoofstuk 6 wordt het vasconstrictieve effect van enkele tweede generatie
antimigraine farmaca op de craniële arterioveneuze anastomoses in het varken
beschreven.  Het effect in dit proefdiermodel wordt beschouwd van voorspellende
waarde te zijn voor antimigraine effectiviteit.  Intraveneuze toediening van
BMS181885, avitriptan, eletriptan, GMC2021 en alniditan leidde tot een vermindering
van de totale halsslagader bloeddoorstroming, veroorzaakt door een selectieve
vasoconstrictie van de arterioveneuze anastomoses.  De rangorde van potentie was:
alniditan > sumatriptan > avitriptan > eletriptan > GMC2021, terwijl BMS181885 een
lagere intrinsieke activiteit leek te vertonen. De arterioveneuze anastomose constrictie
door alniditan, eletriptan en GMC2021 werd potent geantagoneerd door GR127935.
Na toediening van een enkele dosis, welke na 30 minuten een kwantitatief gelijke
vermindering in arterioveneuze anastomose bloeddoorstroming teweegbracht, hield
het effect van BMS181885 langer aan dan de respons na sumatriptan.  Geconcludeerd
wordt dat de nieuwe triptannen een selectieve constrictie van de craniële
arterioveneuze anastomoses veroorzaken, voornamelijk gemedieerd door 5-HT1B/1D
receptoren.  Deze stoffen zouden dus effectief moeten zijn in de behandeling van
migraine.  Initiële klinische studies in migraine patiënten bevestigen dit.  Bovendien,
zou het lang aanhoudende vasoconstrictieve effect van BMS181885 de snelheid van
opnieuw optreden van een migraine aanval kunnen verminderen.
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In Hoofdstuk 7 wordt beschreven dat direct in de halsslagader van de hond
toegediende doses van de antimigraine geneesmiddelen methysergide, ergotamine en
DHE een selectieve vasoconstrictie in het vaatbed van de externe halsslagader
veroorzaken, zonder de bloeddruk of hartslag te veranderen.  Daar deze
geneesmiddelen affiniteit vertonen voor meerdere bindingsplaatsen, zoals
a-adrenoceptoren, 5-HT1 en 5-HT2 receptor subtypen, zijn de exacte mechanismen
onderzocht die verantwoordelijk zijn voor bovenstaande responsen.  In honden,
voorbehandeld met GR127935, werd de vermindering in bloeddoorstroming in de
externe halsslagader geïnduceerd door methysergide niet alleen compleet
geblokkeerd, maar werd zelfs een verhoging van de bloedstroom geobserveerd.  De
verlaging in halsslagader bloedstroom geïnduceerd door ergotamine en DHE bleef
onveranderd na toediening van prazosine, maar werden gedeeltelijk geblokkeerd na
GR127935 of yohimbine.  De combinatie van GR127935 en yohimbine blokkeerde de
effecten van zowel ergotamine als  DHE compleet.  De doseringen van de gebruikte
antagonisten vertoonden een selectief blokkerend effect.  Deze resultaten tonen aan
dat de responsen in het externe halsslagader vaatbed van de hond door methysergide
voornamelijk gemedieerd zijn door 5-HT1B/1D receptoren, terwijl zowel 5-HT1B/1D
receptoren als 2-adrenoceptoren de effecten van ergotamine en DHE mediëren.
In Hoofdstuk 8 worden de resultaten beschreven van experimenten met de recent
ontwikkelde, selectieve 5-HT1B (SB224289) of 5-HT1D (BRL15572) receptor
antagonisten.  Direct in de halsslagader toegediende doses van 5-HT en sumatriptan
verlaagden dosis-afhankelijk de bloeddoorstroming van de externe halsslagader van
de hond, zonder een effect te hebben op bloeddruk en hartslag.  Dit effect werd dosis
afhankelijk geblokkeerd door SB224289, maar niet door BRL15572.  De conclusie
van deze studie is dat de 5-HT en sumatriptan geïnduceerde vasoconstrictie in het
vaatbed van de externe halsslagader van de hond voornamelijk gemedieerd wordt door
5-HT1B, maar niet door 5-HT1D receptoren.
In Hoofdstuk 9 worden de effecten beschreven van de selectieve 5-HT1B (SB224289)
en 5-HT1D (BRL15572) receptor antagonisten op de sumatriptan geïnduceerde
constrictie van craniële arterioveneuze anastomoses in het varken.  Aangezien deze
effecten werden geantagoneerd door SB224289, maar niet door BRL15572, is
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geconcludeerd dat dit effect gemedieerd wordt door 5-HT1B, maar niet door 5-HT1D
receptoren.
In Hoofdstuk 10 wordt het farmacologisch profiel bestudeerd van de receptoren die
verantwoordelijk zijn voor de 5-HT geïnduceerde late hypotensieve respons in de rat.
Eerder onderzoek heeft aangetoond dat deze respons gemedieerd wordt door
5-HT1-achtige  receptoren, aangezien dit effect werd geïmiteerd door 5-CT, niet werd
geblokkeerd door cyproheptadine, ketanserin of MDL72222, maar wel door
methysergide.  Bolus injecties van 5-CT, 5-HT en 5-MeO-T veroorzaakten dosis-
afhankelijke hypotensieve responsen, met een rangorde van potentie van: 5-CT >>
5-HT ³ 5-MeO-T, terwijl sumatriptan geen activiteit vertoonde.  De
bloeddrukverlagingen door 5-HT en 5-CT werden niet veranderd door GR127935 of
gelijke volumes fysiologisch zout, maar werden wel dosis-afhankelijk geantagoneerd
door lisuride, methiothepin, mesulergine, metergoline en clozapine.  De rangorde van
sterkte van antagonisme was: lisuride > methiothepin ³ mesulergine > clozapine;
metergoline vertoonde variabele potenties.  Gebaseerd op de rangorde van agonist
potentie, de blokkade door een serie van farmaca met hoge affiniteit voor de
recombinante 5-ht7 receptor en de afwezigheid van antagonisme door GR127935,
wordt geconcludeerd dat de 5-HT receptor die de late hypotensieve respons medieert,
operationeel gelijk is aan de 5-ht7 receptor.  Aangezien er nu verschillende functionele
responsen toegeschreven kunnen worden aan de recombinante 5-ht7 receptor, kan de
5-HT7 receptor met hoofdletters geschreven worden.
In Hoofdstuk 11, wordt onderzocht welke vaatbedden verantwoordelijk zijn voor de
5-HT geïnduceerde late hypotensieve respons in de rat.  In hoofdstuk10 is beschreven
dat dit effect voornamelijk gemedieerd wordt door de 5-HT7 receptor.  5-HT
produceerde een dosis-afhankelijke bloeddrukdaling in de genarcotiseerde rat, die
vergezeld ging van een verhoging van de systemische vasculaire conductantie (SVC),
terwijl het hartminuutvolume onveranderd bleef.  De stijging van de SVC was
exclusief gelokaliseerd in skeletspieren, karkas, mesenterium/pancreas en de bijnieren.
Toediening van R(+)lisuride blokkeerde alle 5-HT geïnduceerde systemische en
regionale haemodynamische effecten, terwijl toediening van S(-)lisuride of GR127935
geen antagonisme vertoonden.  De resultaten suggereren dat de 5-HT7 receptor
gemedieerde hypotensie veroorzaakt wordt door een vasodilatatie van de systemische
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vasculatuur, welke zich beperkt tot de vaatbedden van skeletspieren, karkas,
mesenterium/pancreas en bijnieren.  Tenslotte blijkt dat het 5-HT7 receptor
antagonistisch effect van lisuride stereoselectief te zijn.
In Hoofdstuk 12, wordt nader ingegaan op de verdere karakterisering van de
receptoren die de 5-HT geïnduceerde tachycardia in de kat veroorzaken.  Eerder werd
gedemonstreerd dat 5-HT1-achtige receptoren dit effect mediëren.  De rangorde van
agonist potentie (5-CT >> 5-HT > 5-MeO-T >> clozapine), de afwezigheid van
hartslagverhogend effect door sumatriptan, indorenate of cisapride en de blokkade
door stoffen met hoge 5-HT7 receptor affiniteit, wijzen erop de 5-HT geïnduceerde
tachycardie in de kat gemedieerd wordt door 5-HT7 receptoren.  Dit experimentele
model, dat niet gecompliceerd wordt door de aanwezigheid van andere receptoren, is
geschikt voor de karakterisering en ontwikkeling van nieuwe geneesmiddelen met
potentieel agonistische en antagonistische eigenschappen op 5-HT7 receptoren.
In Hoofdstuk 13 wordt onderzocht welke 5-HT1 receptor subtypen een rol spelen bij
de inhibitie van bloeddrukstijgingen geïnduceerd door stimulatie van sympathische
zenuwen in centraal gedenerveerde ratten.  Toediening van 5-HT en de -HT1
agonisten, 8-OH-DPAT (5-HT1A), indorenate (5-HT1A), CP93129 (5-HT1B) en
sumatriptan (5-HT1B/1D), resulteerde in een dosis-afhankelijke inhibitie van
sympathisch geïnduceerde bloeddrukstijgingen.  Deze responsen werden tevens
bestudeerd na infusies van de 5-HT receptor antagonisten, WAY100635 (5-HT1A),
cyanopindolol (5-HT1A/1B) of GR127935 (5-HT1B/1D).  WAY100635 blokkeerde de
5-HT en indorenate geïnduceerde effecten, maar niet die van 8-OH-DPAT, CP93129
en sumatriptan.  Cyanopindolol antagoneerde de responsen opgewekt door 5-HT,
indorenate en CP93129, maar had geen invloed op de responsen na 8-OH-DPAT en
sumatriptan.  De responsen na 5-HT, CP93129 en sumatriptan, maar niet na
8-OH-DPAT en indorenate, werden compleet geblokkeerd door GR127935.  Uit
additionele experimenten bleek verder dat mesulergine niet in staat was de remming
door 5-HT te antagoneren.  Deze resultaten tonen aan dat the 5-HT1-achtige
receptoren, die de sympathische vasopressor activiteit remmen, het farmacologisch
profiel vertonen van zowel 5-HT1A, 5-HT1B als 5-HT1D receptoren, maar niet die van
5-HT7 receptoren.
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16.4 List of abbreviations
5-CT : 5-carboxamidotryptamine
5-HT : 5-hydroxytryptamine; serotonin
5-MeO-T : 5-methoxytryptamine
8-OH-DPAT : 8-hydroxy-2-(di-n-propylamino) tetralin
BIMU8 : endo-N-(8-methyl-8-azabicyclo [3.2.1]oct-3-yl)-2,3-dihydro-(1-methyl)
ethyl-2-oxo-1H-benzimidazole-1-carboxamide
BMS181885: 3-[3-[4-(5-methoxy-4-pyrimidyl)-1-piperazinyl]propyl]-5-(1,2-dioxo-4-
methyl-3-cyclobuten-3-yl) amino-1H-indole trihydrochloride
BRL15572 : 1-(3-chlorophenyl)-4-[3,3-diphenyl (2-(S,R) hydroxypropanyl)
piperazine] hydrochloride
BQ788 : N-cis-2,6-dimethylpiperidinocarbonyl-L-g-methylleucyl-D-1-methoxy-
carbonyltryptophanyl-D-norleucin
BW723C86 : 1-[5-(thienylmethoxy)-1H-3-indoyl] propan-2-amine
CGRP : calcitonin gene-related peptide
CP93129 : 3-(1,2,5,6-tetrahydropyrid-4-yl) pyrrolo [3,2-b] pyrid-5-one
CP99994 : (2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine
CP122288 : 5-methylaminosulphonylmethyl-3-(N-methoxy-pyrrolidin-2R-yl-methyl)-
1H-indole
DAG : diacylglycerol
DOI : (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride
F11356 : 4-[4-(2-[3-(2-aminoethyl)-1H-indol-5-yloxy]-
acetyl]-piperazin-1-yl)-benzonitrile hydrochloride
GMC2021 : 3-[2-(dimethylamino)ethyl]-5-[(trifluoromethyl) sulfonyl] oxy] [1H]
indole oxalate
GR56764 : 3-(2-methylaminoethyl)-1H-indole-5-yl-1H-[1,2,4] triazol-3-yl)methanol
GR82334 : [D-Pro9 [Spiro-g-Lactam] Leu10, Trp11] physalaemin(1-1 )
GR113808 : [1-[2-(methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl-1-methyl-1H-
indole-3-carboxylate
GR127935 : N-[methoxy-3-(4-methyl-1-piperazinyl)phenyl]-2'-methyl-4'-(5-methyl-
1,2,4-oxadiazol-3-yl) [1,1-biphenyl]-4-carboxamide hydrochloride
GR205171 : [(2S, 3S)-2-methoxy-5tetrazol-1yl-benzyl]-(2-phenyl-piperidin-
3-yl)-amine dihydrochloride
IP3 : inositol triphosphate
IS159 : 3-(2-aminoethyl)-5-[acetamidyl-3-(4-hydroxyphenyl)-propionamidyl-
acetamidyl-oxy]-indole
L775606 : 1-(3-[5-(1,2,4-triazol-4-yl)-1H-indol-3-yl] propyl)-4-(2-(3-fluorophenyl)
ethyl) piperazine
L-NAME : NG-nitro-L-arginine methyl ester
LY334370 : 4-fluoro-N-[3-(1-methyl-4piperidinyl)-1H-indol-5-yl]-benzamide
LY344864 : N-[3-(dimethylamino)-2,3,4,9-tetrahydro-1H-carbazol-6yl]-
4-fluorobenzamide
MDL72222 : 1aH,3a,5aH-tropan-3-yl-3,5-dichlorobezoate
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MDL100907: R(+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidine-
methanol
mRNA : messenger ribonucleic acid
NO : nitric oxide
PIP2 : phosphatidyl-inositol 4,5-biphosphate
PNU109291: (s)-3,4-dihydro-1-[2-[4-(4-methoxyphenyl)-1-piperazinyl] ethyl]-N-
methyl-1H-2-benzopyran-6-carboximide
PNU142633: (s)-3,4-dihydro-1-[2-[4-[4-aminocarbonyl) phenyl]-1-piperazinyl] ethyl]-
N-methyl-1H-2-benzopyran-6-carboximide
RO046790 : 4-amino-N-(2,6 bis- methylamino-pyrimidin-4-yl)-benzene sulphonamide
RO600175 : (S)-2-(6-chloro-5-fluoroindol-1-yl)-1-methylethylamine
RO630563 : 4-amino-N-(2,6 bis-methylamino-pyridin-4-yl)-benzene sulphonamide
RP67580 : 2-[1-amino-2-(2-methoxy phenyl) ethyl]-7,7 diphenyl-4
perhydro-isoindolone-(3aR,7aR)
RPR100893: (3aS,4S,7aS)-7,7-diphenyl-4-(2-methoxyphenyl)-2-[(S)-2-
(2-methoxyphenyl) proprionyl] perhydroisoindol-4- l
RS102221 : 8-[5-(5-amino 2,4-dimethoxyphenyl) 5-oxopentyl]-1,3,8-
triazaspiro[4,5]decane-2,4-dione
RU24969 : 5-methoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl-1H-indole-succinate
SB204070 : 1-butyl-4-piperidinylmethyl-8-amino-7-chloro-1-4-benzoioxan-5-
carboxylate
SB204741 : 1-(1-methylindol-5-yl)-3-(3-methylisothiazol-5-yl)-urea
SB206553 : 5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5- tetrahydropyrrolo[2,3-f] indole
SB220453 : (-)-cis-6-acetyl-4S-(3-chloro-4-fluoro-benzoylamino)-3,4-dihydro-
2,2-dimethyl-2H-benzo [b] pyran-3S-ol
SB224289 : 2,3,6,7-tetrahydro-1’methyl-5[2’-methyl-4’(5-methyl-1,2,4-oxadiazol-3-
yl)biphenyl-4-carbonyl] furo [2,3-f] indole-3-spiro-4`-piperidine
hydrochloride
SB242084 : 6-chloro-5-methyl-1-[2-(2-methylpyridyl-3-oxy)-pyrid-5-yl carbamoyl]
indoline
SB258719 : R-3,N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl)propyl]
benzenesulfonamide
SDZ21009 : 4(3-terbutylamino-2-hydroxypropoxy)indol-2-carbonic acid-
isopropylester
SKF-99101H: 3-(2-dimethylaminoethyl)-4-chloro-5-propoxyindole hemifumarate
SR57227 : 4-amino-(6-chloro-2-pyridyl)-1-piperidine hydrochloride
VIP : vasoactive intestinal peptide
WAY100635: N-(2-[4-(2-methoxy-phenyl)-1-piperazinyl]ethyl)-N-(2-pyridinyl)
cyclohexane carboxamide trihydrochloride
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Stellingen behorende bij het proefschrift
5-Hydroxytryptamine Receptors Mediating
Carotid and Systemic Haemodynamic Effects:
the Relation to Acute Antimigraine Therapy
Rotterdam, 27 oktober 1999
Peter de Vries
1. Hoewel eerder toegeschreven aan achtereenvolgens de
5-HT1-like (1986), 5-HT1X (1990), 5-HT1-like ongerelateerd
aan 5-HT1A/1B/1C/1D (1991), 5-HT1D (1996), 5-HT1Da/1Db (1996)
en 5-HT1B/1D (1997) receptor, is het nu duidelijk dat de
5-HT1B receptor de sumatriptan-geïnduceerde craniële
vasoconstrictie medieert (dit proefschrift).
2. In tegenstelling tot sumatriptan, contraheert 5-HT
arterioveneuze anastomosen in het halsslagader vaatbed van
het varken via een op dit moment niet te classificeren receptor
(dit proefschrift).
3. De verbeterde therapeutische effectiviteit van orale
doseringen van tweede generatie triptannen ten opzichte van
sumatriptan wordt verklaard door het verbeterde
farmacokinetische profiel.
4. Affiniteit voor de 5-HT1F receptor is niet noodzakelijk voor
succesvolle antimigraine therapie.
5. There is nothing more horrible than the murder of a beautiful
theory by a brutal gang of facts (François la Rochefoucauld,
1747-1827).
6. Het is jammer dat Goadsby et al. (Ann. Neurol., 1990, 28,
183-187), naast de plasma concentratie van neuropeptiden in
het jugulair veneus bloed tijdens de migraine aanval, niet
gelijktijdig de zuurstof aturatie hebben gemeten.
7. Migraine zit tussen de oren.
8. Personen die hoofdpijn zien als reden voor het afzien van
gemeenschap, zullen nooit ontdekken dat de liefde bedrijven
hoofdpijn kan laten verdwijnen.
9. Als ze er niet is, weet een man pas wat hij mist (De Dijk,
1994).
10. Het definitief gestopt zijn met roken wordt meestal bekend
gemaakt middels een advertentie.
11. Slim en succesvol gaan lang niet altijd samen; vaak moet je
niet nadenken om succesvol te zijn.
12. De recente bevinding van het Centrum voor
Verslavingsonderzoek Utrecht dat studenten meer alcohol
nuttigen dan hun niet-studerende leeftijdsgenoten is net zo
vernieuwend als de conclusie dat pindakaas geen effect heeft
op het draaien van de aarde.
13. 640K ought o be enough for anybody (Bill Gates, 1981).
14. Waar zit die "any" key dan? (FAQ na het vastlopen van de
computer).
15. I am confident that the Republican Party will pick a nominee
that will beat Bill Clinton (Dan Quayle, 1998).
